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ABBREVIATIONS 
(general) 
AA 
AFC 
ALL 
ApoE 
"I-AT 
AP 
AR 
BCIP 
BCP 
BD 
BMH 
BPH 
BSA 
CD 
CFA 
CGG 
CML 
CS 
CSP 
CTL 
DDA 
DTH 
EAE 
EDC 
ELISA 
FCS 
FMDV 
Fmoc 
{3-Gal 
GA 
Gpl20 
hAR 
HEL 
HIV-I 
HRP 
HSA 
HuIgG 
IEF 
IFA 
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Amino acid 
Antibody forming cell 
Acute lymphoblastic leukemia 
Apo-lipoprotein E 
(Xl-antitrypsin 
Alkaline phosphatase 
Androgen honnone receptor 
5-bromo-4-chloro-3-indolyl phosphate 
Branched chain peptide 
B cell determinant 
Bismaleimidohexane 
Benzoic acid para hydroxylase 
Bovine serum albumin 
Cluster of differentiation 
Complete Freund's adjuvant 
Chicken gamma globulin 
Chronic myeloid leukemia 
Circumsporozoite 
Circumsporozoite protein 
Cytolytic T cell lysis 
Dimethyldioctadecylammonium bromide 
Delayed type hypersensitivity 
Experimental autoimmune encephalomyelitis 
l-ethyl-3-(3-dimethylaminopropy l)-carbodiimide 
Enzyme linked immuno-sorbent assay 
Fetal calf serum 
Foot-and-mouth disease vilus 
9-Fluorenylmethoxycarbonyl 
{3-galactosidase 
Glutaraldehyde 
glycoprotein 120 kDa (HIV-I) 
Human androgen receptor 
Hen egg lysozyme 
Human immunodeficiency virus type 1 
Horse radish peroxidase 
Human serum albumin 
Human immunoglobulin G 
Isoelectric focusing 
Incomplete Freund's adjuvant 
IFN-X 
IL-# 
i.p. 
ISCOM 
i. v. 
KLH 
MAbs 
MAP 
MBS 
MHC 
MLA 
NBT 
NK 
OPD 
PAbs 
PBS 
PNP 
PPD 
P3C 
RAM-PO 
RAM-AP 
RI881 
SAF 
s.c. 
SE 
SP 
SPDP 
t-Boc 
TCR 
TD 
Th 
TT 
TFE 
TFA 
WIO 
X-Gal 
Interferon gamma 
Interleukin-# 
Intraperitoneal 
Inullune stimulating complex 
Intravenous 
Keyhole limpet hemocyanin 
Monoclonal antibodies 
Multiple antigen peptide 
m-maleimidobenzoyl-N-hydroxysuccinimide ester 
Major histocompatibility complex 
Monophosphoryl lipid A 
nitroblue tetrazolium 
Natural Killer 
o-phenylendiamine 
Polyclonal antibodies 
Phosphate-buffered saline 
p-Nitrophenylphosphate 
Purified protein derivative (of tuberculin) 
tripalmitoyl-S-glycerylcysteine 
Rabbit anti mouse Ig conjugated with horseradish peroxidase 
Rabbit anti mouse Ig conjugated with alkaline phosphatase 
[17 a-methyl-'Hj methyltrienolone 
Syntex adjuvant formulation 
Subcutaneous 
Staphylococcus enterotoxin 
Synthetic peptide 
N-succinimidyl-3-(2-pyridyldithio)-propionate 
tert ia ry -bu ty I-oxycar bony I 
T cell receptor 
T cell detemlinant 
T helper 
Tetanus toxoid 
Trifluoroethanol 
Trifluoroacitic acid 
Water in oil emulsion 
5-bromo-4-chloro-3-indolyl-galactosidase 
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Componds used in peptide synthesis 
Acm Acetamidomethyl 
Boc Butoxycarbonyl 
Bop Benzotriazole-l-yl-oxy-tris( dimethylamino )-phosphoniumhexafluorophosphate 
2-Br-Z 2-Bromobenzyloxycarbonyl 
Bzl Benzyl 
2-CI-Z 2-Chlorobenzyloxycarbonyl 
DCC N ,N' -Dicyclohexylcarbodiimide 
DCM Dichloromethane 
DIPCDI 
Dnp 
DVB 
Fmoc 
HBTU 
HMP 
HMPB 
HOBt 
HONSu 
HOOBt 
MBHA 
4-MeBzl 
Mts 
OBzl 
ODhbt 
ONp 
ONSu 
OPfp 
OtBu 
PAM 
PEG 
Pmc 
PSA 
PyBOP 
SPPS 
tBu 
TBTU 
TFA 
Tos 
Trt 
t-Boc 
Z 
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Diiso-propylcarbodiimide 
2,4-Dinitrophenyl 
Divinylbenzene 
~-fluoreneylmethyloxycarbonyl 
2-(IH-Benzotriazole-l-yl)-1, 1,3 ,3-tetramethyluronium hexatluorophosphate 
4-(Hydroxymethyl)phenoxymethyl 
4-hydroxymethyl-3-methoxy-phenoxybutyric acid 
l-hydroxybenzotriazole 
N-hydroxysuccinimide 
3-hydrox y-3 ,4-dihydro-1 ,2, 3-benzotriazin-4-one 
Methylbenzylhydrylamine 
4-Methylbenzyl 
Mesitylene-2-sulphonyl 
Benzyloxy 
3-Hydroxy-4-oxo-3 ,4-dihydro-1 ,2,3-benzotriazine ester 
Nitrophenyl ester 
N-hydroxysuccinimide ester 
pentafluorenyl ester 
t-Butoxy 
phenylacetamidomethyl 
Polyethyleneglycol 
2,2,5,7,8-Pentamethylchroman-6-sulphonyl 
Performed symmetrical anhydrides 
Benzotriazole-l-yl-oxy-tris-pyrrolidino-phosphoniumhexatluorophosphate 
Solid phase peptide synthesis 
t-Butyl 
2-(lH-Benzotriazole-l-yl)-1, 1,3 ,3-tetramethyluronium tetratluoroborate 
Trifluoracetic acid 
Tosyl 
Trityl 
tertiair-Butoxycarbonyl 
Benzyloxycarbonyl 
Abbreviations 
AMINO ACID CODES 
One letter Three letter Amino acid 
code code 
A Ala Alanine 
C Cys Cysteine 
D Asp Asparagic acid 
E Glu Glutamic acid 
F Phe Phenylalanine 
G Gly Glycine 
H His Histidine 
I lie Isoleucine 
K Lys Lysine 
L Leu Leucine 
M Met Methionine 
N Asn Asparagine 
P Pro Proline 
Q Gin Glutamine 
R Arg Arginine 
S Ser Serine 
T Tllr Threonine 
V Val Valine 
W Trp Tryptophan 
y Tyr Tyrosine 
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I. INTRODUCTION 
Synthetic peptides are useful tools for the generation of antibodies, The use of antibodies as 
specific reagents in inununochemical assays is widely applied. In this chapter, the application 
of synthetic peptides for the generation of antibodies is described. The different steps that 
lead to the unique reagents, such as the selection of the peptide sequence, the constmction 
of the immunogen, immunization procedures and assays for the selection of the antibodies, 
arc discussed. 
Ll. Antibodies as reagents 
Antibodies can serve as powerful reagents in immunochemical assays for the specific 
detection of many different molecules, termed antigens, Immunochemical detection is rapid, 
simple, cheap and specific, and has the additional advantage that purification of antigens 
from a matrix is not required. Immunochemical detection is not only applied for diagnostics 
in the clinical laboratory, but also, e.g., in the food industry, in health research and therapy. 
Generation of antibodies is carried out in animals by immunization with the antigen. 
The serum contains many different antibodies that are specific for many different antigens. 
Seldom are more than 10% of the circulating antibodies specific for one antigen. Antibodies 
in semm are called polyclollal antibodies (PAbs) since they are secreted by different B 
lymphocyte dones. Each B cell clone secretes a different type of antibody. The use of these 
mixed populations of antibodies may create a variety of different problems in 
inmlUnochemical techniques. With the advent of the hybridoma technique (Kohler and 
Milstein, 1975), production of monoclonal antibodies (MAbs) became available. Hybridomas 
are the result of a somatic cell fusion between a myeloma cell and an antibody-secreting cell. 
Hybridomas can be easily cultured. After selection of those hybridomas with antibody 
secretion of a defined specificity and high affinity for the antigen, cloning of the selected 
hybridoma yields an unlimited production of the monoclonal antibodies. Monoclonal 
antibodies are all identical and possess a unique chosen specificity. 
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Monoclonal antibodies are more time-consuming and costly to prepare than polyclonal 
antibodies. Producing the right set of monoclonal antibodies is often a difficult and laborious 
job. Consideration must be given beforehand to whether monoclonal antibodies are required 
or whether polyclonal antibodies will suffice. 
1.2. Peptides as inlll1unogens 
Antibodies recognize spatial stmctures (epilopes) which may be build up from fragments of 
a larger molecule, termed the antigen. The antigen may be, e.g., a protein. These epitopes 
can interact, in their turn, with the amino acids forming the antigen binding site of the 
antibody. Antibodies may recognize antigenic fragments or sites which are interconnected 
(continuous or linear epitopes) or, on the other hand, widely spaced fragments which may 
form a configuration complementary to an antigen binding site (discontinuous 
epitopes)(Arnon, 1973; Atassi, 1984). Ideally, antibodies will bind to the antigen which was 
used to generate the antibody production. Clearly, the degree of degeneration in reactivity 
(crossreactivity) observed in practice offers the advantage that synthetic structures can be 
used for immunization. These synthetic antigens mimic antigenic stmctures to which 
antibodies can be generated. The antibodies which react with the synthetic structures may 
also crossreact with the native structures from which the synthetic stmctures was derived. 
In the case of proteins, linear epitopes can be mimicked by synthetic peptides (SP). 
With these peptides, antibodies can be raised which recognize the native protein (Atassi, 
1984). There is no strict consensus on what might be the size of an antigenic determinant 
recognizable by antibodies. Sufficient data are available to suggest that short peptides [7-10 
amino acids (AA)] may represent such a determinant (Atassi, 1984; Geysen et aI., 1987). It 
could be shown with lysozyme that up to 16 amino acids can be involved in, or contribute 
to, the interaction of the antibody (17 AA) and a surface loop of the antigen (16 AA) (Amit 
et aI., 1986). In the antibody-antigen complex, these residues form a tightly packed interface 
from which water molecules are excluded. For actual antigen-antibody complexes of 
neuraminidase of influenza vims however, a more flexible interaction was observed (Colman 
et aI., 1987). Binding occurs by an induced-fit mechanism. 
Under certain conditions, application of synthetic peptides provides the first choice 
of approach to the generation of antibodies specific for a certain protein (Table 1): 
(1) Antibodies for application in selective diagnostic test systems need to be able to 
discriminate between molecules which express a high degree of homology. In order to 
generate useful specific reagents, it is most efficient to generate the antibody responses with 
protein fragments or selected peptide sequences as immunogens. These peptides include only 
those parts of a molecule which determine the differences between the structures to be 
discriminated (Boersma et al. 1989a,c; Kleine et aI., 1990; Gerritse et al. 1992; Zegers et 
aI., 1991a,b). 
(2) For the production of highly specific polyclonal reagents by immunization, intact 
proteins or fragments need extensive purification. When purification is not successfully 
achieved or when this results in the denaturation of the antigen, the selection of sequences 
of interest can be based on the primary structure. When the protein product of a gene is not 
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TABLE 1 
Diagnostic antibody production using synthetic peptides 
o To discriminate between the members of a homologous protein family 
Search for sequellces lVith differences 
o To discriminate between variant proteins up to one amino acid difference 
Restricted to the sequence including the substitution 
o To be able to detect a group of homologous proteins 
Search for sequel/ces with complete homology 
o To produce antibodies when a protein can not be suffIciently purified 
Search for antigenic determinants 
o To produce antibodies when a protein is not available but can he predicted from the 
DNA base sequence 
Search for antigenic detenninants 
o To produce antibodies to various domains of a protein; immunodominant determinants 
can thus be avoided 
Search jar domain specific allfigenic sequences 
o To produce antibodies against autologous sequences 
Search for antigellic deterlllillallls and lise appropriate adjuvant 
o To circumvent pathogenic or toxic proteins 
Search for harmless sequences 
o To evaluate sequences for use in synthetic vaccines or vector-based vaccines 
known, the amino acid sequence can be predicted from the DNA base sequence. Synthetic 
peptides thus can be used to elicit native protein-specific antibody responses in these cases 
(Papkoffet aI., 1981; Chomynet aI., 1983; Van Denderen et aI., 1989, 1990; Gerritse et 
aI., 1990). 
(3) Antibodies to mapped determinants are efficient tools in dissecting the function 
of protein stmctural elements (Atassi, 1975; Amit et aI., 1985; Altschuh et aI., 1985; 
Voskuilen et aI., 1987; Zegers et aI., 1991a). 
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TABLE 2 
Strategy for the production of antibodies to synthetic peptides 
o Selection of antigenic sequence 
o Identification of region of interest and limitations in choice 
o Synthesis and purification of peptide 
o Coupling of peptides to a carrier protein 
o Immunization with proper adjuvant in target animal 
o Development of the appropriate assay for evaluation of the anti-native protein reactivy 
o Evaluation of immune response in selUm sample 
o Production and selection of monoclonal antibodies 
o Characterization of the monoclonal antibody in the proper assay 
o Large scale production, purification and labelling if necessary 
(4) Under normal physiological conditions, antibodies directed to autologous 
molecules (i.e" 'self' molecules) are seldom found, Inununization of SP's in a very strong 
adjuvant and via a proper route may result in an antibody response against 'self' molecules 
(Jemmerson and Margoliash, 1979; Jemmerson et a!., 1985; Cooper et a!., 1986), For 
example, immuno-castration (Remy et a!., 1993; Meloen et a!., 1994) or contraceptive 
methods (Aitken et a!., 1993) can thus be achieved, Similarly, experimental auto-immune 
encephalomyelitis (EAE) , an animal model for multiple sclerosis, can be induced with a 
peptide derived from PLP (proteolipid protein)(Tuohy et a!., 1989), 
(5) Pre-selection of immunogenic sites with SP may provide a basis for the more 
efficient engineering of vaccines, Due to limitations in the construction of recombinant or 
synthetic vaccines, it is necessary to include only the most important and representative 
immunogenic sites, which are able to elicit, e,g" neutralizing antibodies (Steward & Howard, 
1987; Zanetti et a!., 1987), Avoidance of pathogenic sequences and of dominant epitopes is 
one major advantage of the peptide strategy, 
The basis for the successful application of the synthetic peptide approach is found in 
the appropriate application of a combination of a multitude of techniques (synthesis, 
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antigenicity calculations, immunochemistry methods (assays like enzyme linked immuno-
sorbent assays (ELISA), dotblot, immunoblot, somatic cell fusion, immunocytochemistry). 
In addition, insight into the interaction of cells in immune responses with respect to 
processing (selection of sequence), presentation (immunization, carrier system etc.) and T-B 
cell interaction is indispensable. In the following sections, the influence these various 
parameters have on the different aspects of applications of peptides will be briefly discussed. 
They affect the generation as well as the analysis of the specificity of monoclonal and 
polyclonal antibodies for diagnostic use (Table 2). 
1.3. Inll11unogenicity 
Exactly what determines the capacity of an antigen or structure to induce an immune 
response (immunogenicity) and to be recognized by an antibody is a subject of discussion 
(Hopp, 1986; Van Regenmortel, 1986, 1989). Two major sets of features determine the 
result of immunizations. 
Firstly. a large number of physical parameters governs the outcome of an antibody 
response to specific parts of a protein. Nevertheless, there are strong indications that almost 
every single peptide sequence (Geysen et aI., 1984, 1985) with only a few exceptions (Briand 
et aI., 1985; Gerritse et aI., 1992) depending on the length, amino acid distribution and the 
method of immunization, can serve to elicit antibody responses, irrespective of its 
localization in the intact protein (Arnon et aI., 1971, Green et al 1982). With overlapping 
synthetic peptides covering about 75 % of influenza hemagglutinin, Lerner and co-workers 
observed that> 90% of the peptides elicited antibodies cross-reactive with the native protein 
(Lerner, 1981; Green et aI., 1982). Also, when short peptide, are utilized for immunization 
anti-peptide responses are generally obtained, although however, the recognition of the native 
protein in these cases is not always warranted (Boersma et aI., 1988a). 
The level of cross-reactivity of anti-peptide antibodies with the antigen from which 
the peptide is derived, depends strongly on the sequence chosen and the micro-environmental 
(Le., in vivo or in assay) conditions. The stmcture of a given antigen is subject to change 
dependent on the micro-environment where the antigen is encountered. Antigen recognition 
in various immunoassays therefore is dependent on the assay and a major source of pitfalls 
(Milstein et aI., 1983; Haaijman et aI., 1984; Boersma et aI., 1988b, 1989b). 
Secondly: after immunization with an intact protein regulatory fine tuning, selection 
and response modulation lead to the production of responses to the immunodominant sites 
only (Van der Drift et aI., 1991; Van Noort et ai, 1990; 1991). Immunogenicity, especially 
with respect to antibody formation, is influenced by the spatial structure of a protein or 
peptide. Immunodominant sites may be formed by linear as well as by discontinuous 
epitopes. Linear epitopes can be mimicked by short peptides or protein fragments. For the 
discontinuous epitopes, intact proteins, combinations of peptides in a tertiary structure or, 
in the case of micro-organisms and viruses, particle-sized antigens are generally required. 
When synthetic epitopes are used to elicit anti-native protein antibodies, the question 
arises whether the affinity for the native antigen will be such that the antibodies elicited 
become useful reagents. The large number of diagnostic anti-peptide antibodies used in many 
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investigations, and in the clinic, makes clear that this is certainly the case. With synthetic 
peptides, monoclonal antibodies and polyclonal antibodies with similar or even better 
affinities for native proteins as generally observed for anti-protein responses could be 
produced (Babraoui et a!., 1986; Laman et a!., 1991), 
PAbs raised with synthetic peptides have the additional advantage of being mono-
specific for the native protein. They lack the common disadvantages of PAbs raised with 
proteins or impure preparations of proteins, such as unwanted crossreactivity with other 
proteins. Crossreactivity of PAbs can cause background problems or false-positive detection 
in immunochemical assays, Peptide-induced PAbs may preclude the need for preparation of 
MAbs, 
In the sections below, the variables will be subsequently discussed which have their 
impact on eliciting and selecting diagnostic antibodies, The steps to be taken in the strategy 
using synthetic peptides to achieve to antibodies applicable in various assays is outlined in 
Table 2, 
II. SEQUENCE SELECTION 
The first step when using peptides for the generation of antibodies specific for a protein will 
be the selection of a peptide sequence. It is obvious that, if free to choose, one will decide 
upon a stretch of the protein which is highly immunogenic. The antigenicity can be predicted 
by taking the weighted average of various physico-chemical parameters of a short sequence 
of amino acids. These parameters will be briefly discussed in this section. In addition, some 
examples of restricted choices will be given. 
ILL Analysis of parameters which determine antigenicity 
The influence of physical parameters on antibody responses can be predicted in part on the 
basis of common sense reasoning. Antigenic sites of intact proteins are accessible to large 
molecules, like antibodies, when exposed on the outside of a protein, Hydrophillic sequences, 
readily soluble in aqueous solutions, are thus most likely to be antigenic, Flexibility might 
enhance the fitting of antigen and antibody (Westhof et a!., 1984; Karplus & Schulz, 1985; 
Fieser et a!., 1987) and hence segmental mobility of the epitope may enhance antigenicity 
(Novotny et a!., 1986), Loops of the protein may protrude from the globular form of a 
protein and as a result of that they may be more readily engaged in binding to a circulating 
antibody (Kyte & Doolittle, 1982), However, it was shown that an antigenic site contained 
one or more highly exposed and accessible critical side chains and one or more largely buried 
and inaccessible critical side chains within the native protein structure. Initial binding of an 
antibody to solvent-exposed critical amino acid residues may promote local side chain 
displacements and thereby allow the participation of other, previously buried, critical residues 
(Getzoff et a!., 1987), 
Various algorithms have been developed on the basis of the aforementioned type of 
reasoning. Averaging of physical and chemical properties of individual amino acids over a 
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certain sequence length (window) leads to a mean value which predicts the behaviour of an 
entire sequence. First, methods were developed to describe the tendency to form secondary 
structures: ,,-helix or f3-sheet or f3-turns (Chou & Fasman, 1978; Garnier et aI., 1978; Hopp 
& \Vaous, 1981; Emini et aI., 1985), Furthermore, to each amino acid a relative value is 
given which represents its ranking in hydrophillic behaviour (Hopp & Woods, 1981, Kyte 
& Doolittle, 1982). Computational methods to attribute helical character to amino acid 
sequences to detect transmemhrane fragments have been developed from hydrophobicity plots 
(Kyte & Doolittle, 1982). When mean hydrophobicity for varying windows was calculated, 
most hydrophobic parts were attributed to transmembrane segments. This method was 
improved hy combining the hydrophobic moment of a helical sequence with its amphiphillic 
character. (Amphiphillic helix: one side along the helix consists of residues with a 
hydrophillic character while the other side along the helix contains residues with a 
hydrophobic character), In this way the "surface seeking" tendency or affinity for the 
membrane interior was computed (Eisenberg et aI., 1984a,b). Normalized hydrophobicity 
values have been specially developed, adapted for the prediction of transmembrane sections 
of proteins which function as membrane spanning transport proteins (Eisenberg ct al., 
1984a,b), The mean value for a number of these physico/chemical parameters, combined in 
an antigenic index, derived from amino acid sequence only gives an estimate of the antigenic 
properties (index) of a protein segment (Wolf et aI., 1988). The outcome of slIch predictions 
is determined to a large extent by the number of amino acids of which the average is taken 
(window size)(Bangham, 1988), Over a short distance, amino acids influence each other. In 
addition, amino acid sequences which, on a linear scale are far distant, may interact by 
forming back folding loops, It is of great importance to take this into account when choosing 
the length of peptides used for immunization (Jacob et aI., 1986; Horiuchi et aI., 1987). High 
(Green et aI., 1982; Niman et aI., 1983) as well as low (Jemmerson, 1987) frequencies of 
responses have been reported dependent on the length of peptides used to elicit the production 
of antibodies, 
The computer prediction leads to a set of putative antigenic sites ('Volf et ai., 1988). 
These predictions of epitopes using an algorithm for the antigenic index of an amino acid 
sequence were successfully applied to a high number of viral and other proteins (Jameson and 
Wolf, 1988; Modrow and Wolf, 1990). 
One should realise that the structural parameters are not the only factors that 
determine the antigenicity of a site on the protein, The function of the protein under 
investigation has to be kept in mind, Participation of functionally active regions of a domain 
in interaction with other molecules, e,g" ligand-receptor interaction or interaction with DNA 
molecules, prevents the binding of antibodies to the protein. Peptides probably can have 
multiple conformations of which only a fraction will mimic the native protein, A selection 
from such a set does not account for immunodominance as will be encountered when intact 
protein is used for immunization. Each species mounts a different antibody response against 
antigens, This means that each species has its own antibody repertoire. Monoclonal 
antibodies can only be produced in certain mouse -or rat- strains due to the histocompatibility 
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of available plasmacytoma fusion lines. These mice and rats however may not cover the 
whole repertoire of antibodies desired. 
In conclusion, selection of peptide sequences can be based on predictions based on 
structural parameters combined with the knowledge of the function of the domains of the 
protein. 
n,2, Restl'icted choices 
If antibodies are required for detecting a protein, it is clear that one chooses a peptide 
sequence for antibody generation which offers the best chance of being highly immunogenic. 
More often, however, antibodies specific for a certain domain of a protein are desired, e.g., 
for studying domain functions, or antibodies against sites of a protein which differ from sites 
in homologous proteins are desired in order to be able to discriminate between those proteins. 
For these selected cases, the peptide approach is extremely valuable. Computer predictions 
for antigenicity are of limited value in these selected cases. 
III, PEPTIDE SYNTHESIS 
Merrifield introduced in 1963 a method for peptide synthesis, based on reactions on a solid 
phase, for which he would receive the Nobel prize (Merrifield, 1963), The solid phase 
peptide synthesis (SPPS) is very suitable for automation, Formation of a peptide bond by 
coupling two amino acids needs on the one hand an activated carboxyl and a protected amino 
group of the N-terminal amino acid and on the other hand a protected carboxyl group of the 
C-tenninal amino acid. The latter is achieved in SPPS by coupling the C-terminal amino acid 
to a functionalized insoluble resin. Functional groups of the side chains of the amino acids 
are also protected but with another type of protection groups than the one used for the Co! 
amino group. After deprotection of the ex amino function, the next amino acid is coupJed. 
\Vhen coupling is complete, all reactants are washed away, leaving a protected dipeptide on 
the resin. The coupling reaction can be checked for completeness by, e.g., the Kaiser test 
(Kaiser et aI., 1970; 1980) which detects unsubstituted li"ee amino groups, Upon detection 
of amino groups, onc can decide (1) to couple again the same amino acid, (2) to acetyl ate 
the amino group by, e.g., acetic anhydride/base or acctylimidazole leaving abrogated 
peptides, (3) to continue with the next amino acid resulting in a part of the peptide molecules 
with a deletion. Following the required number of these cycles, the peptide is detached from 
the resin. The side chain protecting groups are usually simultaneously removed with the 
cleavage of the peptide from the resin. The peptide chain thus grows from the C-terminus 
to the N-terminus. The synthesis scheme is shown in figure 1. 
111.1. Protection groups for Ol amino group 
The tertiail'-butyloxycarbonyl group (t-Boc) is an acid labile group used for protection of the 
Co! amino group of the amino acid, After deprotection with 25% trifluoroacetic acid (TFA), 
the resulting protonated amino group is neutralized using the base diisopropyJethylamine. The 
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H , 
,-------->00 FMOC-N-AA,-RESIN 
Repeat with next 
amino acid (3) 
H,N-AA,-RESIN 
Deprotection & 
washing (I) 
H , 
~N-AA'-OPFP 
H , 
Coupling (2) 
1*-------FMOC-N-(AA, .... AA,-AA,)-RESIN 
Final cleavage 
and deprotection (4) 
L-______ H,N-AA, .... AA,-AAo-CO,H 
free peptide 
Fig. 1. Synthesis scheme for peptides using Fmoc strategy 
side chain protecting groups should resist these acid and base treatments. Barany and 
Merrifield (1977) defined the principle of orthogonality to describe how the nature of 
protective groups should be chosen to arrive at the cleanest end-product. One protective 
function can be removed under conditions in which a second is absolutely stable. Usually 
groups that need strong acidolysis are used for side chain protection in combination with the 
mildly acid labile t-Boe group. Deproteetion and cleavage are achieved by treatment with HF 
or trifluoromethanesulphonic acid. 
A major improvement was the introduction of the a-fluoreneylmethyloxycarbonyl 
group (Fmoe), a base labile protecting group (20 % piperidine is necessary for deprotection) 
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for the ex amino group. This enables a change to complete orthogonality resulting in a 
combination with mild acid labile side chain protection cleavable by TFA. 
In.2. Comparison of t-Boc and Fmoc chemistry 
Peptide synthesis can be carried out in a batchwise or continuous flow manner. In the latter 
the resin is contained in a column through which reagents and solvents are pumped. Local 
high concentrations of reactants are achieved. Recirculation of the reagents improves the 
efficiency of coupling. Only the Fmoc strategy is fully compatible with the continuous flow 
method, which allows for real time spectrophotometric monitoring of the progress of 
coupling and deprotection. 
In the past, the costs of Fmoc reagents did not encourage the usage of the Fmoc 
SPPS. Today, prices are more competitive. Repetitive TFA acidolysis of t-Boc deprotection 
could lead to alteration of sensitive peptide bonds as well as acid catalyzed side reactions. 
In Fmoc strategy, the growing peptide chain is subjected to mild base treatment using 
piperidine during Fmoc group deprotection and TFA is only required for the final cleavage 
and deprotection of peptide resin. Cleavage and deprotection in t-Boe strategy requires the 
use of dangerous HF and expensive laboratory apparatus which is not always readily 
available. 
Recently published results obtained for the synthesis of difficult peptides, for example 
those containing very hydrophobic sequences, demonstrated clearly that Fmoc strategy and 
especially continuous-flow are superior in these cases (Rovero et aI., 1991; Smith et aI., 
1991). 
Forty research groups synthesized the same peptide containing 16 amino acids in a 
sequence with sites for problematic or slow couplings using their own protocols with Fmoc 
or t-Boc chemistry. Crude peptides were compared (Smith et aI., 1991). Over 33% of the 
crude peptide preparations made by using t-Boc chemistry did not contain any of the desired 
peptide and over 44% were unable to achieve greater than 25 % purity. In contrast, 31 % 
of the samples made by using Fmoc chemistry had over 75 % of the desired compound. 
These results proved the superiority of the Fmoc strategy. However, the purity of the best 
peptides made by t-Boc chemistry was comparable with that of the best made by Fmoc 
chemistry. This suggests that, in skilled and experienced hands, either method can give good 
results. 
II1.3. Activation of the carboxyl group 
For peptide bond formation, the carboxyl group of the amino acid requires the activation of 
an electron-withdrawing group. The activated carboxyl group is attacked by the free amino 
function. There are basically four major types of coupling techniques currently employed for 
stepwise introduction of N-ex-protected amino acids in SPPS. Carbodiimides (Fig. 2) have 
been some of the most popular in situ activating reagents in peptide synthesis. The most 
successful coupling reagent, dicyclohexylcarbodiimide (DCC) was introduced by Sheehan and 
Hess (1955). It is a particularly appropriate choice for the apolar environment of polystyrene 
resins. Diiso-propylcarbodiimide (DIPCDI) is used to prevent insoluble acylureas 
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Q-N=C=N-Q DCC 
DIPCDI 
~ C _ /'-. _N.HCI 
N - -N/ "-./ I EDCI 
Fig. 2. Some examples of carhodiimides 
incompatible in column synthesis (Sheehan, 1960). The principal limitation in using 
carbodiimides is the dehydration of Asn and Gin residues. The addition of 1-
hydroxybenzotriazole (HOBt) to the reaction mixture will prevent dehydration and has the 
benefit of acting as a catalyst in speeding up sluggish reactions. Carbodiimides introduce 
racemization at the highly activated carboxyl terminal residue. The racemization can be 
suppressed by the addition of excesses of HOBt, N-hydroxysuccinimide (HONSu), or 3-
hydroxy-3,4-dihydro-l ,2,3-benzotriazin-4-one (HODhbt) (Fig. 3). These acidic nucleophi!es 
reduce the lifetime of reactive intennediates by conversion of the overactivated isoUl'onium 
esters into less reactive and thus more selective active esters. 
Activation through active esters, which have a long tlshelf life", have found 
widespread application in SPPS. Several active esters are described: nitrophenylesters (ONp), 
N-hydroxysuccinimide esters (ONSu), N-hydroxyphtalimide esters, pentafluorenyl esters 
(OPfp), l-hydroxybenzotriazole esters (OBt) and 3-HydroxyA-oxo-3,4-dihydro-l ,2,3-
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HOSt 
o Q N-OH I N 
""" -7 N 
HOOSt 
Q-OH 
o 
HONSu 
Fig. 3. Some examples of additives for suppression of racemization 
benzotriazine esters (ODhbt). OBt esters are easily formed in situ. These OBt esters are not 
isolated. In situ formation has become widely applied because of their ease of use, fast 
reactions (even between sterically hindered amino acids) and their general lack of side 
reactions. For this purpose, generally phosphonium or uranium salts are used which, in the 
presence of a tertiary base, can smoothly convert protected amino acids to a variety of 
activated species. The most commonly employed, Benzotriazole·J·y J·oxy·tris( dimethylamino)· 
phosphoniumhexafluorophosphate (BOP), Benzotriazole·J·yl·oxy·tris·pyrrolidino· 
phosphoniumhexafluorophosphate (PyBOP), 2·(JH·Benzotriazole·j·yl)·j, J ,3,3· 
tetramethyluronium hexafluorophosphate (HBTU) and 2·(jH·Benzotriazole·j·yl)·j, j ,3,3· 
tetramethyluronium tetrafluoroborate (TBTU) generate HOBt esters. OPfp esters are also 
very efficient acylating agents and their chemical structures provide little opportunity for side 
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F 
F F 0 ~ 
A 4' 
R 0 F 
F 
OPfp ester 
Fig. 4, The GPfp-ester 
reactions (Fig. 4). They react somewhat slower than symmetrical anhydrides. The addition 
of HOBt significantly increases the rate of the reaction. OPfp esters are commercially 
available. However Fmoc-Ser(tBu)-Opfp and Fmoc-Thr(tBu)-Opfp do not crystallize and are 
difficult to purify. The ODhbt esters provide suitable alternatives in these cases. A favourable 
property of ODhbt esters is the appearance of a bright yellow colour during acylations which 
can be used to monitor coupling efficiency. 
Preformed symmetrical anhydrides (PSA) have been used by many research groups 
because of their high reactivity. They are generated ill situ using two equivalents of protected 
amino acid and one equivalent of DeC in DeM. The urea formed is removed by filtration. 
PSA are mainly used with t-Boc chemistry. Fmoc-amino acids PSA have some undesirable 
properties. The intermediates formed during PSA generations can undergo rearrangement. 
Some Fmoc amino acids such as Gly, Ala, Cys(ACM), Gln(Mbh) and Asn(Mbh) a.o. are not 
readily soluble in DCM and require DMF for solubilization, but DMF slows down the rate 
of activation. Another drawback is that the use of PSA is quite wasteful, since two 
equivalents of protected amino acids are required to form one equivalent of activated species 
and the latter has to be used in excess. 
111.4. Resins 
The Merrifield resins have been used for more than twenty years for the synthesis of peptides 
and are the standard resins for SPPS of small or medium-sized peptides using the t-Boc 
strategy (Fig. 5). The resin consists of polystyrene beads (200-400 mesh, 1% divinylbenzene) 
functionalized with chloromethyl groups onto which the first amino acid of the peptide is 
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HOCH2-Q- OCH2 --0-RESIN 
A 
CH30 
HOCH2b-OCH2--O- RESIN 
B 
C 
Fig. 5. A). The structure of the Merrifield resin. B). The structure of the Wang resin. C). The Fmoc-Rink handle. 
attached. The use of resins with a phenylacetamidomethyl (PAM) group for the synthesis of 
large peptides has become increasingly popular. This is due in part to the stabilizing effect 
of the PAM function on the ester linkage which helps to reduce losses during acidolysis 
(Merrifield, 1963). 
Both Merrifield and PAM resins are used for production of peptide acids. For peptide amides 
and t-Boc chemistry, alternative resins were developed, such as the MBHA resin (Matsueda 
and Stewart, 1981). The resin consists of polystyrene beads acylated with methylbenzoyl 
chloride to introduce an additional phenyl ring thus being a ketone resin. This intermediate 
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is then reductively aminated to yield MBHA resin. The additional phenyl ring renders the 
peptide-resin linkage labile to HF, giving peptide ami des upon cleavage. 
For Fmoc chemistry, the KA (Kieselguhr/amide) resins were developed, which can 
be used in continuous-flow synthesizers. They are based on a composite of 
polydimethylacrylamide and a inorganic (kieselguhr) support matrix activated with 
ethylenediamine and functionalized with an acid labile linker (4-hydroxymethylphenoxyacetic 
acid). For batch procedures the Wang resin is used throughout, also called the HMP resin 
(Wang, 1973) (Fig. 5). It consists of a polystyrene bead (1 % DVB) onto which a acid-labile 
linker has been attached. Several resins are available for peptide amides based all the acid-
labile (Fmoc)Rink handle (Fig. 5) (Rink, 1987). 
A new range of resins concerns the resins based on tentagel (registered trademark of 
Rapp Polymere; Bayer and Rapp, 1986) which is a polystyrene-polyoxyethylene support. 
They usually consist of a polystyrene backbone to which are attached derivatized 
polyethyleneglycol (PEG) spacers. Advantages of these resins include very favourable 
physicochemical properties, in particular their swelling behaviour. physical stability in flow 
systems and resistance to abrasion and mechanical pressure and improved chemical 
efficiency. High flow rates have been reported to increase the acylation and deprotection 
rates. Nowadays, we apply this resin for our Fmoc peptide synthesis. 
More resins are nowadays available for special applications. For example, for 
production of protected fragments with Fmoc chemistry use can be made of the super acid 
labile 4-hydroxymethyl-3-methoxy-phenoxybutyric acid (HMPB) linker of Riniker 
(Florsheimer and Riniker, 1991). Also for protected peptides made with t-Boc chemistry 
several resins are available. Production of cyclic peptides, peptide libraries and Illultiple 
antigenic peptides find their origin in chemically adapted resins. 
111.5. Protection groups for side chain functions 
A large variety for side chain functions compatible with t-Boc or Fmoc chemistry have been 
described. The most suitable ones are listed in table 3 and ligures 6 and 7. For details with 
respect to strategies of chemical peptide synthesis, deprotection and cleavage protocols the 
reader is referred to the huge amount of literature which exists in this field (Bodanszky and 
Bodanszky, 1984; Atherton and Sheppard, 1989; Stewart and Young, 1984). 
III. 6. Purification 
\Vhen peptides are used as immunogens, the selection of the antibodies specific for native 
protein is performed using the target antigen in the assay in which the antibodies are to be 
applied. In that case, for inununization purposes, the purity of the peptides is of limited 
importance (a purity of 75-90% will be sufficient). For peptides with a lower degree of 
purity coupling methods Illay give odd results since part of the impurities may consist of 
shorter homologous peptides which will, though not all, contribute to coupling results. If, 
on the other hand, peptides are used for screening, then the highest degree of purity should 
be used. 
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TABLE 3 
Recommended protection groups for amino acid side chains 
Amino Acid 
Arginine 
Asparagine 
Aspartic acid 
Cysteine 
Glutamine 
Glutamic acid 
Histidine 
Lysine 
Serine 
Threonine 
Trp 
Tyrosine 
'Vith FUlOe chemistry 
Pmc 
Trt; Tmob 
OIBu 
Trtl; Acm2 
Trt; Tmob 
OtBu 
Trt 
Boc 
IBu 
IBu 
Boc 
tBu 
Recommended for the routine preparation of cysteinyl peptides 
With t-Boc chemistry 
Tos 
OBz! 
4-MeBzI'; Acm' 
OBz! 
Dnp 
2-C!-Z 
Bz! 
Bz! 
Formyl 
2-Br-Z 
2 Stable tll TFA. Can be removed with I1 to form cyclic disult1de peptides in a single step. Has heen used in 
combination with Trt to prepare peptides containing multiple disult1de honds 
3 Generates a cysteinyl peptide on HF treatment 
4 Stahle to HF. Enable peptide to be purit1ed prior to liberation of air sensitive thiol groups 
Apart from incomplete coupling and side reactions during synthesis, the process of 
cleavage and deprotection is always hampered by deleterious side-reactions involving certain 
side-chain protection groups which are liberated as stabile cations reacting with sensitive 
amino acids. Scavengers are added during cleavage to trap the reactive carbonium ions. The 
crude product will exist of a mixture of peptide molecules containing also the desired peptide. 
The concentration of the desired peptide can vary from roughly a few per cent to 90% in a 
cmde preparation depending on the nature of the peptide and sequence length. 
The crude product can be purified by gelfiltration, HPLC, or ion-exchange 
chromatography. HPLC is used most frequently for purification today. Following 
deprotection and cleavage from the resin and subsequent lyophilization of the clUde product 
after ether precipitation, the peptide mixture is dissolved in water with 0.1 % TFA. The 
peptide mixture is separated by reversed pbase HPLC using a C~18 stationary phase and 
eluted with a gradient of acetonitrile and 0.1 % TFA as counter-ion. If a peptide cannot be 
dissolved in water, diluted acetic acid or formic acid or other organic solvents can be tried. 
For acidic peptide, solution in diluted ammonia may be necessary. Sometimes, alternative 
eluants are needed. To confirm the peptide composition, amino acid analysis can be 
performed on the hydrolysed peptide or the mass spectmm can be verified. 
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AMINO PROTECTIVE GROUPS 
Msc: 2-(melhylsulfonyl)elhyloxycarbonyl 
a-elimination 
baselabite 
~ 
Trt: Irilyl 
mild acidolysis 
side chains: Asn/Gln, His, Cys 
Fmoc: 9-fluorenylmelhyloxycarbonyl 
p-elimination 
base labile 
~Oy_ 
o 
Aloe: Allyloxycarbonyl 
allyl Iransfer by Pdo (Ph3 P)4 
Z: benzyloxycarbonyl 
calalytlc hydrogenation 
strong acldolysis 
Boc: letl,-bulyloxycarbonyl 
mild acldolysls 
side chain: Lys 
Fig. 6. Protective groups for amino groups. Some protective groups can also be used for other groups as indicated 
in the figure. 
30 
General Introduction 
CARBOXYL PROTECTIVE GROUPS 
Me: methyl 
used In the conversion to hydrazides 
All: allyl 
allyl transfer by PdO (Ph3 P)4 
Fig. 7. Protective groups for carboxyl groups. 
-CH2 < > 
Bzl: benzyl 
catalytic hydrogenation 
acldalysis 
Bu: lert. ·butyl 
mild acidalysls 
side chains: (Asp/Glu) Ser, Thr, Tyr 
IV. COUPLING OF PEPTIDES TO CARRIERS 
An important clue to the successful use of peptide immunogens is the mode of presentation 
of the selected peptide to the immune system. Using SP, the antigen usually is an assembly 
which consists of a carrier protein, a peptide and bridging coupling reagents. Here, the role 
of these different components in the development of an immune response will be discussed. 
Synthetic antigenic determinants have a wide variety of applications. The actual role 
of a determinant can best be judged from the results of immunizations, Le., the anti-peptide 
antibody responses in sera, the recognition of antigenic determinants by antibodies in various 
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inUllunoassays, each with its typical micro-environmental conditions, and the specificity of 
the MAbs selected. 
For non-immunogenic peptides, (i.e., B cell epitopes only), coupling to a carrier 
protein to provide T cell help is required. This is not a matter of molecular mass since 
immuflogenicity of peptides in general is not increased by homo-polymerization with, e.g., 
glutaraldehyde (Zegers, unpublished results). Polymerization using carbodiimides led to 
encouraging results though in part based on the coupling of T-determinants (Borras-Cuesta 
et aI., 1988). Straightforward covalent elongation with a selected T-cell determinant is an 
alternative option (Hackett et aI., 1985; Francis et aI., 1987b). 
A method was developed for the synthesis of branched peptides (Tam & Zavala, 
1989). This mUltiple antigen peptide method was developed for sensitive detection of anti-
peptide antibodies but, in addition, the multimeric peptides show enhanced immunogenicity 
as compared to free peptides, peptide conjugates or peptides still attached to their solid 
support (Mclean et aI., 1991). A more detailed discussion on multiple antigen peptides is 
given in chapter 10. 
IV.!. Choice of canier 
The properties of a carrier protein determine to a large extent the outcome of immunizations 
with a peptide conjugate. Size, stnlCture, homology with mammalian proteins and relative 
frequency of certain amino acids arc important points to consider. 
Larger proteins (> 60 KDa) are preferred as carriers because they contain a sufficient 
number of functional groups (-NH2, -SH, arginine etc.) for coupling to generate satisfactory 
peptide/protein ratios. In principle most proteins will do if derived from a non-self source. 
However, the more genetically distant a protein is to the animal to be used for immunization 
experiments, the better the chances for immunogenicity. Foreign proteins induce an antibody 
response more easily than proteins which are homologous to 'self' proteins. Keyhole limpet 
haemocyanin (KLH), a large aggregated protein from a gastropod, is therefore often used as 
a carrier protein in mice, rabbits, goats, sheep etc. Other widely used carriers are of bacterial 
origin: tetanus toxoid (TT), purified protein derivative of tuberculin (PPD), and diphtheria 
toxoid. Less efficient in mammals are ovalbumin (OVA) and bovine semm albumin (BSA) 
(Geerligs et aI., 1989), probably due to tolerance to these highly conserved proteins. 
Chicken gamma globulin (CGG) is rather inmmnogcnic in mice, but has a major 
drawback. CGG probably contains a major immunodominant epitope which elicits antibodies 
crossreactive with immunoglobulins (human and mouse)(Boersma et ai., 1992). 
A carrier protein which is very immunogenic may contain immunodominant epitopes 
which render the response to attached peptides negligible (Neurath & Kent, 1985). In 
practice, however, this problem is only very seldom encountered or recognized. It turns out 
that the immunogenicity of the carrier is changed by the coupling of new determinants. 
Apparently a new ranking of inununogenicity of B cell determinants is reached which results 
in antibodies to the newly introduced (peptide) determinants. The size of a carrier is 
important since a larger protein can accommodate more SP. However, coupling of relatively 
large numbers of SP, depending on the protein, can have a negative influence on the 
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properties of a conjugate. Overloading will lead to precipitation and decreased 
immunogenicity (Peeters et aI., 1989). Also crosslinking agents like diazo compounds and 
glutaraldehyde can drastically decrease the solubility and immul10genicity of a carrier-SP 
conjugate. 
Most large aggregated proteins, like KLH (> 600 kDa), have intrinsic adjuvant 
activity. They support long-lasting responses. Consequently, a booster immunization in a 
normal four week time-schedule wil11ead to a state of hyperimmunization. The use of vi IUS 
particles (HbsAg) as a carrier for peptides with a hydrophobic tail that integrates in the outer-
membrane has been proposed as an alternative for both carrier and adjuvant (Neurath et al., 
1989). 
KLH is the most suitable carrier protein because of its properties: a large molecule 
with adjuvant properties, many available groups for coupling and genetically distant from the 
proteins of the recipient. It appeared to possess T cell epitopes which can be bound by MHC 
class II molecules of different animal species. The complexes ofMHC class II molecules and 
T cell epitope, presented hy the antigen presenting cell, are recognizable by their T cells. 
IV.2. Peptide conjugation: possibilities and choices 
A number of relatively simple methods have been developed and evaluated for the coupling 
of labels to peptides and for the coupling of peptides to carrier proteins or fragments (for a 
review see Blair and Ghose, 1983)(Table 4). 
Coupling methods need to be selected carefully. The coupl ing controls the site where 
the peptide is linked, the exposition of C- or N-terminus (orientation), the level of 
deformation by intra-chain coupling, and the level of crosslinking which also may lead to the 
deformation and inaccessibility of the putative epitope. 
Coupling of peptides to carriers, though being an immunological prerequisite, is not 
just connecting the two molecules. The way a peptide is coupled to a protein may introduce 
unexpected new stmctural elements but also may lead to the disappearance of determinants. 
The orientation of the peptide with respect to the carrier backbone influences exposition to 
the environment. Since in the carrier protein all or most amino acids are available, selectivity 
of a coupling method is in part determined by the amino acids present in the SP sequence. 
It will be necessary to avoid the use of certain amino acids for coupling purposes because 
of their important contribution to the antigenicity or stmcture of the peptide or when they 
determine native protein specificity as in mutant and genetic variants of proteins (Zegers et 
aI., 1991b; Gerritse et aI., 1991, 1992). 
For a coupling site of choice additional amino acids (cysteine, arginine) can be 
introduced at the C-or N-terminus of the SP. Addition of a cysteine residue yields a -SH 
group which can be used for coupling and the addition of arginine yields a guanido group 
also usable for coupling. In addition, various methods have been described for the 
introduction of -SH groups for coupling (Blair & Ghose, 1983). The method using N-
succinimidyl-3-(2-pyridyldithio)-propionate (SPDP) (Carlsson et aI., 1978) in this respect is 
probably the most widely used. It can be used to introduce -SH groups in both peptide and 
protein but it may also be used to introduce active -SH in the protein only for coupling to 
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TABLE 4 
Homo- and bifunctional coupling reagents for peptides and proteins 
Reagent Group Amino acid References 
Active -SH -SII eys, Met Traut ct al. (1973) 
Lin et al. (1990) 
Maleimide -Sf! eys, Met O'Sullivan el al. (1979) 
Fujiwara et al. (1988) 
Carbodiimide -eaOH, -NHl Asp, atu, Lys Goodfriend et al. (1964) 
and o:-NH1 Deen et al. (1990) 
eys, Tyr 
N-H ydroxysucci ni mide -NH2 Lys and a-NHl Carlsson et 31. (1978) 
Glyoxal Guanido Arg Atassi (1977) 
Azide Compounds Peptide honds Glazer et al. (1975) 
Aromatic rings Tyr, Trp, His 
-NHl Lys, Arg 
-COOH Gill, Asp 
Glutaraldehyde -NH2 Lys and a-NH2 H:lbeeb et al. (1968); 
-SH and -DB (weak) eys, Tyr, His Claassen and Adler (1988) 
Zegers et al. (1990) 
a peptide cysteine. Introduction of -SH can be monitored spectrophotometrically. Introduction 
of -SH can also be achieved by the reaction of 2-iminothiolane with available -NH2 groups 
(King & Kochoumian, 1978). A peptide that does not contain a sulfydryl group can be 
functionalized during its synthesis at the amino terminus by acylation with S-acetylthioacetic 
acid or the succinimidy1 ester of the latter compound (Duncan et aI., 1983). Treating the 
protected peptide with base, even hydroxylamine, results in the liberation of the sulfydryl 
group. A method was described to introduce -SH via the carboxyl groups of a peptide (Lin 
etal.,1990). 
The advantage of -S-S- bridge coupling mayan other occasions prove to be the weak 
point. -S-S- bridges are relatively unstable under physiological conditions and at low pH. But 
on the other hand the acid lability of -S-S- bridges in conjugates allow dissociation of the 
coupling. In general however, the stability of -S-S- bridged conjugates is sufficiently stable 
to elicit immune responses. 
Most widely used coupling agents are carbodiimides (Goodfriend et aI., 1964; 
Bauminger and Wilchek, 1980; Deen ct aI., 1990), bis-diazo compounds (Glazer ct aI., 
1975), SPDP for introduction of active -SH to produce -S-S- bridges (Carlsson et a!., 1978) 
and compounds including maleiimides and N-hydroxysuccinimides all with a large variation 
in linkers (Liu et aI., 1979, Green et aI., 1982; Briand et a!., 1985) and glutaraldehyde 
(Avrameas, 1969; Korn et a!., 1972; Reichlin, 1980; Zegers et ai., 1990)(see also Table 4). 
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Carbodiimides couple through -COOH and -NH2 groups, which results in at least two 
orientations of the peptide, Acetylation of the peptide leads to preferential coupling at the 
carboxy terminus. 
Homo-bifunctional reagents (SPDP, glutaraldehyde) use the same (-NH2) group both 
in carrier and in peptide. 
In principle, hetero-bifunctional coupling agents can be used in two ways since they 
consist of two different reactive groups connected by an inert linker sequence. Maleimide-N-
hydroxysuccinimide (O'Sullivan et aI., 1979; Ishikawa, 1980; Kitagawa et aI., 1981) and 
maleimide-diazo (Fujiwara et aI., 1988) compounds are mainly used to couple peptides with 
a terminal cysteine to protein -NH2 groups. When a protein is used which is relatively 
cysteine-rich, the method can be used the other way around. For this purpose thyroglobulin 
is a suitable carrier (Ernst et aI., 1989), Introduction of maleimides and -SH separately 
requires two coupling procedures but may have some advantages for specific, covalent acid 
stable linkage of two amino groups. This approach avoids crosslinking and is more specific 
and better controlled than GA coupling, Therefore, the maleimide and -SH respective 
succinimide-derivatives were employed as has been described by Yoshitake et al. (1979), 
Various possibilities of coupling methods using different chemistry exist. The method 
of choice largely depends on the composition and sequence of the peptide and its contribution 
to the function of the protein from which the peptide is derived (see also section IV,5), 
IV,3, Peptide coupling efficiency 
IV, 3, 1, Analysis of coupling ~f!iciel1cy 
Coupling efficiency depends very much on the nature of the coupling method and conditions 
applied, Covalent linkage leads to stable conjugates, 
The chemical stability of coupling agents in general is limited. Especially maleimide 
and N-hydroxysuccinimide based compounds (MBS-type), which are widely used, have 
limited stability due to hydrolysis, Sulfa-variants of these compounds lead to improved 
efficiency and 2-4 times higher yield (Myers et aI., 1989), Though more stable and efficient 
conjugation is obtained with the aromatic linkers in bi-functional coupling agents, for 
immunization purposes the non-aromatic linkers are to be preferred due to their lower 
immunogenicity (peeters et aI., 1989), 
Coupling efficiency is not easy to quantitate, Efficiency can be determined accurately 
only with labelled peptides, Fluorescence, biotin or radio-isotope (I25I,3H) labelling are most 
frequently used. Fluorescence or biotin labelling generally utilizes one amino group per 
peptide and thus may influence the efficiency of the coupling, In addition, steric hindrance 
may be introduced (Von Gliiningen & Schneider, 1989), Incorporation of a unnatural amino 
acid such as norleucine at one of the termini belongs to one of the possibilities to determine 
the coupling ratio. The substitution rate thus can be established from the amino acid 
composition of the conjugate. Other methods rely on the determination of available -SH or 
-NH2 groups before and after coupling (Jones et aJ., 1989; Peeters et aJ., 1989), 
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For short non-labelled peptides substitution can be estimated on the basis of changes 
in relative amino acid frequency after coupling (Briand et aI., 1985). As was shown by Ernst 
et al. (1989) using radioactive labelling ('''I), amino acid frequency determinations for longer 
non-labelled peptides is too inaccurate. 
In an intact protein sequence the immune response pattern is determined by immuno-
dominance rather than by the frequency of a determinant in the protein. Peptides like haptens 
have an intrinsic antigenicity. From investigations using rigid hapten structures it is known 
that over-substitution leads to a decrease in immune responses (Claassen and Van Rooijen, 
1985). Peeters et al. (1989) and Stevens et al. (1981) investigated coupling of peptides to 
Tetanus toxoid (TT) in various ways. Optimal substitution (10-20 SPITT) was about half the 
maximal substitution rate (40-50 SPITT). 
Determination of the peptide to carrier ration in conjugates relies on the eft1cient 
separation of bound and unbound peptides. To achieve this separation. the reaction mixture 
is dialyscd to remove the unbound peptides. \Ve observed that not all unconjugated peptide 
molecules are removed by dialysis. Sometimes, peptide molecules adhere to carrier molecules 
by non-covalent forces forming a so-called "pseudo-conjugate". 
IV. 3. 2. Pseudo-conjugates 
We have repeatedly encountered non-covalent association of pep tides with carriers which 
could not be disrupted using extensive dialysis or mild detergent treatment. Other more 
stringent treatments might not permit discrimination between covalent coupling and high 
affinity binding to the carrier. Pseudo-conjugates did not lead to antibody formation. On the 
basis of these observations, \ve doubt whether chemical evaluation of conjugation is relevant 
since all methods mentioned measure covalent as well as pseudo-conjugates. The quality of 
a conjugate as an inmmnogen cannot be estimated by determining the conjugation efficiency. 
Therefore evaluation of conjugation quality is best performed by the evaluation of immune 
responses (Peeters et aI., 1989, Boersma et aI., 1988a; Deen et aI., 1990; Zegers et 
al. ,1990). 
IV.4. Inullunogenicity of coupling neo-determinants: influence on anti-peptide 
responses 
Homo-bifunctional coupling reagents, glutaraldehyde, carbodiimides and his-diazo compounds 
have all been found to generate coupling agent specific antibodies. Most hetem-bifunctional 
coupling agents include a spacer segment. This segment often functions as a hapten and 
includes immunogenic stlUctures. The length and rigidity of a linker may influence the 
response to the coupled SP (Peeters et aI., 1989; Myers et aI., 1989). In general, aliphatic-
chains will be less immunogenic than linkers with aromatic stmctures. In addition, the 
stlUctures involved in the binding (maleimides, N-hydroxysuccinimide, -SH from activated 
disulfides etc.) with the functional groups of the protein form neo-detenninants which (as in 
the case of acyl-urea adducts formed in carbodiimide coupling) can be highly immunogenic. 
To evaluate for proper antibody responses, screening and immunization in general is 
performed using two conjugates of the same peptide with different carrier proteins and 
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different coupling methods. Even then unwanted antibody responses to neo-determinants can 
be erroneously interpreted as demonstrated by Edwards et al.(l989). 
IV.S. Orientation of a peptide in conjugates and epitope specificity 
Orientation of the peptide in a conjugate may determine to which side of the peptide a 
response will be elicited. Both C- and N-termini are highly represented among immunogenic 
sites of proteins. This is probably influenced by the flexibility of the termini and the 
orientation in the solution. In general this will be !me for peptides as well. According to 
most authors there is no preference for coupling via the N-terminus or C-terminus, However, 
Dyrberg and Oldstone (1986, 1987) showed that for an acta-peptide coupling via the C-
terminus led to better immune responses. Schaaper et al.(1989) applied PEPSCAN 
determinant mapping to evaluate the antisera produced by different coupling agents for either 
terminus. They observed that antibody responses were mainly directed to the non-conjugated 
terminus of a peptide. These findings should be taken into account when antibodies are 
desired against the N- or the C-tenninus of a protein. Coupling of the N- or C-terminal 
peptide of a protein to a carrier protein could best be performed via the terminus of the 
peptide which is situated in the chain of the protein. 
V. IMMUNIZATION 
Immunization requires the introduction of an antigen at a certain site of the hody. The form 
in which the antigen is presented determines the outcome of the response and may be, e.g. 
a purified protein, a vims particle or a constmct in which segments of an antigen are 
sufficiently represented, etc. A large number of parameters influences the result of each 
immunization: a) the site at which the antigen is introduced, b) the vehicle which retains it 
at the chosen localization, c) the type of adjuvant applied, d) the doses of antigen, e) the 
genetic make-up of the recipient, f) genetic distance between recipient and antigen. These 
parameters will be discussed in the following sections. Immunization of peptide conjugates 
results in responses to the peptide, the coupling agent or what remains of it, the carrier 
protein and all combination-determinants. To understand the immune responses to peptide 
conjugates therefore requires differential analysis. 
V.I. A vehicle can deposit lal'ger amounts of antigen at pre-determined sites 
The vehicle to which the antigen is coupled or is dissolved in, determines the localization of 
an antigen. Sepharose beads, pieces of nitrocellulose, aluminium hydroxide gels and oil 
emulsions, a.o" can be used for the purpose of delivery in the peritoneum, under the skin 
or even in the spleen. Some of these vehicles such as alum and oil emulsions have adjuvant 
properties, while others, such as sepharose beads and nitrocellulose are relatively inert in an 
immunological sense. Speco!, a water in oil emulsion, shows a reasonably good performance 
in supporting a good immune response with mild side effects (Bokhout et a1., 1981). 
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Haptens bound to various carrier structures such as proteins and carbohydrate 
polymers readily induce antibody responses (Claassen and Van Rooijen, 1985). This 
suggested that similarly small peptides bound to a polymeric carrier could be used for 
immunization. Fischer et a!. (1989) synthesized peptides according to the Fmoc technique 
which were subsequently immunized as a peptidyl-resin. The immunogenicity of peptides still 
attached to the resin was compared to lree peptides and KLH and OVA conjugates. KLH and 
OVA conjugates performed much better than the same peptide bound to the resin irrespective 
of the co-administration of adjuvant (Freund's) (Fischer et a!., 1989). 
For antibody production against synthetic peptides, not meant as a vaccine, the use 
of a mineral oil can be reconunended. Mineral oils, such as speeol or Freund's complete 
adjuvant, perform, both as a vehicle, and also as an adjuvant (see also section V.4), Since 
peptides by themselves are rather weak immunogens, the antibody response against peptides 
needs immUllopotentiation by adjuvants. Speco! deserves preference above Freund's adjuvant 
since specol provokes less side-effects in animals. 
V.2. Specific routeing of antigen determines localization of antigen 
The site where the antigen is deposited in part determines which lymphoid organs are 
activated and determines to some extent the isotype of the antibodies generated. 
Intraperitoneal (Lp.) and subcutaneous (s.c.) classical immunizations activate mainly the 
spleen and peripheral lymph nodes respectively and result in IgO responses. 
The immunization route is limited by the formulation of the antigen. Insoluble 
antigens cannot be administered intravenously (i. v.). In order to avoid antigen wasting in the 
periphery, the antigen can be applied topically in the spleen, either free or attached to a 
vehicle (nitrocellulose, sepharose beads). Doses 50-100x lower than with intraperitoneal 
immunization could be used on intrasplenic immunization (Spitz, 1986; Hong et a!., 1989). 
Despite the low antigen doses needed, intra-splenic immunization has not found widespread 
application because of major drawbacks. The method is not easy to employ since the spleen 
can easily be damaged and inmmnization is therefore not very reproducible unless in skilled 
hands. In addition, this method is animal-unfriendly. 
Peptides which appear to possess low immunogenicity upon routine Lp. or Lv. 
administration may be given locally to sensitize peripheral lymph node cells. In the mouse, 
immunization in the footpad or subcutaneously in the dorsal flanks may activate regional 
lymph nodes very efficiently when strong adjuvants are applied [Complete Freund's Adjuvant 
(CFA)]. 
Targeting of antigens to certain molecular structures on cells is a form of specific 
routeing of antigen. Enhanced responsiveness has been shown to occur when peptides are 
targeted to surface immunoglobulin or class I molecules (Casten, 1988). For BSA, Lees et 
a!. (1990) showed that targeting with anti-IgD especially led to strong potentiation of 
antibody responses. Immunological targeting to, for example, MHC molecules acts as a 
replacement for the adjuvant in that it targets the antigen and at the same time acts as an 
activation for the antigen presenting cells. To this end, MHC-specific antibodies were applied 
(Carayanniotis et a!., 1988; Carayanniotis & Barber, 1990). Experiments carried out so far 
38 
General Introduction 
with antigen-targeting have shown variable results. The effectiveness corresponds to the 
constlUction of the antigen linked to the targeting molecule. Targeting with anti-IgD led to 
a polyclonal antibody response in the sense that also aspecific B cells are stimulated. 
Conventional immunization using strong, animal-friendly adjuvants can be reconmlended. 
V.3. Scheduling of immunization 
Timing of responses is dependent on the mode of antigen presentation. Slow release of 
antigen from emulsions or crystalline deposits may introduce a delay. 
A general observation with respect to scheduling of inununization schemes is, that it 
proved to be worthwhile to allow a long period (more than four weeks) between the first and 
following immunizations. In these cases booster immunizations evoked higher antibody 
responses. This suggests that in these cases the activation of resting B memory cells is 
synchronized. In some examples we used mice for hybridoma production after a third 
inullunization which was given six months after the second. A high number of specific clones 
were found compared to the number of specific clones found after immunizations with an 
interval of four weeks between booster injections. 
V.4. Adjuvant 
V.4.I. The use of adjuvaul (general) 
Adjuvants are substances that aspecifically potentiate inmllme responses when given 
simultaneously with the antigen. Most applications of peptides are found in experimental 
immunization for antibody production and the testing of the efficacy of peptide vaccines. 
Peptides are thought to be only slightly immunogenic. Adjuvant formulations are needed for 
stimulation of a high antibody response using peptides (Boersma and Claassen, 1995). That 
is why in most experimental protocols the most potent adjuvant, complete Freund's adjuvant 
(CFA), is used. COl\jugates are emulsified in CFA and inmlUnized in experimental animals 
like mice and rabbits. For the production of PAbs however, this has the drawback of the 
contamination with antibodies to bacterial antigens and DNA which are present in CPA. 
Therefore adjuvants without bacterial antigens were developed which in addition provide 
milder treatment for the laboratory animal (Bokhout et aI., 1981; Barteling and Vreeswijk, 
1991). 
The precipitation of peptide conjugates on aluminum hydroxide gels also leads to good 
anti-peptide responses (Geerligs et aI., 1989; Boersma et aI., 1988a, 1989b,c). Comparison 
of results of inununization of conjugates of the same peptide using six different adjuvant 
protocols showed insignificant differences only, when tested for anti-peptide reactivity or 
reactivity to the coupling reagent dependent neo-determinant. Though it has been claimed that 
alum precipitated antigens may sub-optimally stimulate cell mediated inununity, they do elicit 
delayed type hypersensitivity reactions. Until now alum hydroxide gels are the only adjuvants 
generally approved for use in humans and primates (Bamford, 1986; Allison & Gregoriadis, 
1990). A large number of substances (lipid derivatives, liposomes: Tamauguchi et aI., 1983; 
non-ionic block polymers: Zigterman et aI., 1987; Hunter et aI., 1981; virosomes, micelles 
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and the like: Morein & Simons 1985) have been promoted as a promising adjuvant for use 
in vaccine formulations and certainly are worthwhile of being used in the generation of 
diagnostic reagents (Warren et aI., 1986, Geerligs et aI., 1989), 
In most adjuvant formulations, certainly water in oil or double emulsions, antigen 
presentation is influenced by the hydrophobic character of various components of the antigen 
or conjugate, For FMDV vaccine the use of various adjuvant formulations led to a different 
outcome of the vaccine trials (Barteling & Vreeswijk, 1991). Certainly for peptides with 
hydrophobic and hydrophillic regions antigen presentation may be dependent on the vehicle 
and adjuvant formulation chosen (Fieser et ai., 1987). For the generation of diagnostic 
antibodies \ve favour the use of adjuvants, which are relatively mild for experimental animals 
and do not result in crossreacting antibodies, i.e .• water in oil emulsions without the addition 
of micro-organisms. 
V.4.2. Deriv{ltiwtioJl of peptides with integrated adjuvQnticity 
Derivatization of peptides for the purpose of improved immullogenicity is a rapidly 
developing field. Therefore only a few applications are mentioned. Del'ivatization of pep tides 
with hydrophobic tails as proposed by Neurath et al. (1989) may facilitate incorporation into 
liposomes. Derivatization with an aliphatic anchor enabled Neurath and Strick (1987) into 
incorporate synthetic peptides into ISCOM-like stluctures. 
Important for the development of vaccines is the use of purified synthetic bacterial 
cell wall components, muramyl-dipeptides, which can be added to and even synthesized onto 
peptides and protein fragments (Leclerc et aI., 1985). For the priming of villls-specific 
cytotoxic T helper cells, Deres et a!. (1989) prolonged a peptide representing an MHC class-I 
restricted epitope of intluenza nucleoprotein (AA 147-158) by covalent linkage to a 
tripalmitoyl-S-glycerylcysteinyl-seryl-serine (Jung and Bessler, 1995). This type of integrated 
adjuvanticity is most promising. Such lipopcptide-antigen conjugates have a number of 
advantages, They remain stable in heat, light and solvent. They are fully biodegradable, No 
toxic side-effects have been seen thus far. 
VI. CHARACTERIZATION OF POLYCLONAL AND MONOCLONAL 
ANTIBODIES 
The antibody responses elicited with synthetic peptides should he evaluated in time after each 
administration of the antigen. In this section, methods for the assignment of the antibodies 
are described. In addition, it will be emphasized that the choice of the evaluation method 
implies the reactivity of the antibodies found. 
VI.I. Performance characteristics of antibodies are assay specific 
As has been discussed (Haaijman et aI., 1988), MAbs tend to show a specific, assay 
dependent, recognition pattern towards the antigen to which they are directed. The assay 
conditions exert their influence not only on the antigen but also on the diagnostic antibody. 
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This phenomenon is regularly encountered even in routine diagnostics. ehoy et al. (1988) 
using antibodies specific for Trichinella spirafis, demonstrated assay dependent variation in 
the results of eight different immuno-assays tested for the detection of Trichinella spirafis 
antigens. This indicates, that antibody selection has to be performed in the assay, or under 
the conditions, in which the antibody should to be applied. 
In the past we produced a large number of specific MAbs for various antigens. For 
each antigen only a few proved to be multi-assay applicable. The general rule, however, is 
that the specific antibodies perform well only under certain assay conditions. This could 
mean that selection of MAbs in ELISA may preclude finding antibodies that perform 
optimally on, e.g., fixed tissues. In the case of the selection of antibodies produced upon 
inullunization with peptides, the initial selection may be performed on conjugates of the 
peptide in ELISA. In that case, conjugates of the peptide are used which are prepared with 
a different carrier and different coupling agent than those used for inullunization. It is 
assumed that in such conjugates a peptide will show various possible conformations. Some 
of these may mimic the conformation which is found in the assay of choice. With selected 
anti-peptide antibodies one may proceed to the more specific antigen detection methods for 
which the antibodies were produced (Zegers et 'II., 1991a). The scheme for a standard 
strategy of the synthetic peptide approach including performance analysis is represented in 
Table 2. A feature that is incorporated in all assays (ELISA, immunoblotting, 
immunocytochemistry) is the specificity control of native protein and individual determinants 
by inhibition with the antigen or the peptide (with the relevant antigen and with an irrelevant 
antigen as a negative control), respectively. These inllibition assays are usually performed 
as a pre-incubation of the antibody with various concentrations of the appropriate antigen 
before application ill assay. A true competition between free and bound antigen ill assay can 
be performed as an alternative. 
VI.2. Assay dependent conformation of the antigen 
The conformation of the antigen is dependent on its actual micro-environment and treatment 
before and during the assay. In ELISA systems the antigen adheres to the plastic surface of 
a microtiter plate. This may introduce some conformational stress which may result in a 
deformation of an epitope present in the antigen as it was used for immunization. 
Similarly, the treatment of proteins in biochemical methods for detection and analysis 
results in different levels of denaturation and therefore different conformations of a protein. 
For instance, when a protein is treated with SDS it loses most of its conformation. 
VI.3. Analysis of anti-peptide antibody responses in "ariolls assays 
VI.3.]. ELISA 
Antisera elicited with a carrier-peptide conjugate may contain antibodies directed to the 
peptide, the carrier, the coupling reagent, and neo-determinants. The search will be for 
antibodies that cross react strongly with the native protein. Proper screening procedures allow 
discrimination between the specificities mentioned. Free peptides are used for detection as 
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well as the conjugates of these peptides made with a different protein carrier and a different 
coupling agent than those used for the conjugate applied for immunization. This procedure 
allows discrimination between the various immunogenic determinants. Antibody responses 
are analysed in a direct ELISA procedure on plates with a coating of peptides, peptide 
conjugates and the native antigen, or, alternatively, in an indirect or in a capture ELISA 
with, e.g., antibodies that capture the native antigen. In competition assays, competition 
between the peptide and the native antigen can be analysed. 
Capture and competition ELISA are most sensitive. Competition is preferred when 
denaturation of the antigen is expected by the direct coating procedure, Titration is needed 
of all reagents used for coating as well as for detection for proper evaluation of the antibody 
specificity. The orientation of peptides in conjugates used for immunization and for response 
analysis may definitely cause confusion in the interpretation of resu Its (Boersma et aI., 1992). 
The orientation of the peptide in the conjugate used for inmlUnization may be different from 
the orientation of the peptide in the conjugate used for screening or even from the free 
peptide adhered to the plastic surface. Elicited antibodies may not recognize the peptide in 
the assay system, but, by contrast, they can bind to peptides free in solution. 
According to some authors peptides shorter than 15 amino acids do not bind to plastic 
surfaces (Briand et aI., 1985). In our experience all umnodified peptides can be coated 
directly when the proper conditions are applied (see Chapter 12). Peptides which have been 
acetylated or peptides with an amide terminus will show a binding behaviour to plastic which 
is pH dependant. Variation in buffer pH can provide suitable conditions for ELISA assays. 
In addition, peptides can be coated to polystyrene plates using glutaraldehyde pre-activation 
(Klasen et a1., 1983). This however may lead to antigen presentation in assay with 
preferential exposure of the non-coupled site. The advantage of the application of covalent 
coating is that more stringent conditions can be used in the assay, such as the use of urea 
(Klasen et aI., 1983). Similarly coupling of antigens with carbodiimides can be used for in 
assay antigen presentation. Other methods include indirect coating through poly-L-lysine (see 
Chapter 12) or copolymers of lysine and alanine (Hobbs, 1989). 
Also other ways of presenting peptides, e.g., coated beads etc. applied in ELISA 
format have been developed (Modrow et aI., 1989). 
Vl.3.2. Btottillg to lIitrocel/utose or otller ",uppom 
Sensitive direct immuno-blotting assays such as have been described by Radl et a!. (1988) 
and Boersma et a!. (1989b) are easy and rapidly performed assays for the detection of 
antibody specificity. The procedure performed with the strips of nitrocellulose is similar to 
that in ELISA. The amount of antigen needed is extremely low. Antigen detection limits are 
in the ng order. Dilutions of ascites fluid of 1:50.000 are sufficient for detection. Adsorption 
onto nitrocellulose may introduce an assay characteristic recognition pattern as any other 
assay. 
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VI.4. PEPSCAN: epitope mapping as the counterpart of anti-peptide antibodies 
Synthetic peptides selected according to various (theoretical) criteria may lead to the 
generation of specific antibodies. By their very nature, it is known to which site these 
antibodies are directed. Vice versa, peptides can be used for the screening for antigenic 
epitopes along the entire sequence of a protein. This concept was first implemented by the 
group of Leach (Smithet aI., 1977; Hurrell et aI., 1978). Using the same support for peptide 
synthesis and RIA, they showed that, in principle, it was feasible to delineate antigenic 
determinants. On a solid support, short overlapping peptide sequences were synthesized 
together representing an entire protein sequence. Subsequently, antibodies generated to the 
protein were tested for binding to these peptides using an RIA-like approach. In this manner 
antigenic sequences were detected. This method has been refined and made available for 
large scale applications (over 400 peptides per protein) by Geysen et al. (1984, 1985) and 
Meloen and Barteling (1986). 
Peptides of characteristically 8-9 amino acids spanning the entire protein were used 
to demonstrate interaction between antibodies and synthetic peptide sequences. In this 
PEPSCAN method, the antigenicity scan is performed as in ELISA. At present, 2000 
peptides can be tested daily in ELISA, while a batch of 3000 pin-bound peptides can be 
produced in 4-6 weeks. A major advantage is the reusability of the pin-bound peptides for 
screening. Following an ELISA, bound antibodies are eluted from the peptides using SDS 
and (3-mercaptoethanol. Synthesis of peptides to paperdiscs allowing screening of multiple 
antisera simultaneously has been described by van 't Hof et al. (1993). 
The drawbacks of the PEPSCAN method are that with short sequences (hexamers) 
in combination with the ELISA type of system extremely low binding affinities can be 
determined of which the physiological relevance is questionable. In addition, the method of 
synthesis does not allow for a control of the integrity of the peptide sequences on the solid 
support during synthesis. The density of the peptides OIl the rods may interfere with antibody 
binding. This means that a negative PEPSCAN remains inconclusive (Geysen et aI., 1987), 
whereas a positive signal has to be confirmed using longer peptides (nonamers). According 
to Geysen et al. (1985) the binding of antibodies to peptides derived from distant segments 
of a protein is an indication that even discontinuous determinants can be detected using the 
PEPSCAN method. On the other hand all synthetic peptides antigenic ally may be 
discontinuous since not all amino acids in a peptide necessarily contribute to the antibody 
binding (Geysen et aI., 1987). 
The PEPSCAN method can also be used for the detection and mapping of T cell 
epitopes by applying a proliferation assay rather than the ELISA (Van der Zee et aI., 1989). 
Peptides must be cleaved off from the solid support. The method has been refined (Schaaper 
et aI., 1992) 
The PEPSCAN method can be used for selecting immunogenic sequences in a 
practical approach, instead of selection based on theoretical considerations, for the purpose 
of, e.g., vaccine development. Exact determination of the epitope in a peptide to which the 
selected antibody binds is possible. 
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Chapter 2 
I. INTRODUCTION TO EXPERIMENTAL WORK 
The aim of the studies presented in this thesis was to investigate and optimise the parameters 
which playa role in the generation of antibodies using synthetic peptides. The most important 
parameters are: a) selection of the peptide sequence that is going to be used for immunization 
and which represents a part of the protein against which antibodies are desired; b) the 
synthesis chemistry; c) the constmction of the immunogen: choice of the carrier or 
incorporation of intrinsic T cell epitopes, choice of coupling chemistry which influences the 
orientation of the peptide to the carrier; d) the immunization protocol which influences both 
the level of the inunune response and the affinity of the antibodies; e) the evaluation method 
of the antibody response; f) the method used for the selection of the hybridomas. 
Eliciting antibodies with part of the amino acid sequence instead of with the entire 
protein is an alternative if the protein of choice is pathogenic, lethal or not available. In 
addition, antibodies specific for a pre-selected site of the protein can only be generated by 
using peptides. The success of the generation of specific antibodies using synthetic peptides 
heavily depends on the careful application of the different steps that control the method. The 
peptide method therefore often fails, since the steps are carried out without the proper 
considerations. It was our intention to carefully investigate these steps and combine them to 
formulate a strategy. 
Two different proteins were chosen for which site-specific antibodies were desired and 
for which antibodies could not be obtained using classical inmmnization with the entire 
protein. The human androgen receptor was chosen because of its known homology \vith other 
steroid receptors and as an example of a protein which was not available, but the amino acid 
sequence could be predicted from the eDNA sequence. Human IX)-antitrypsin Z was studied 
as an example of a protein with a single amino acid substitution resulting in dramatically 
altered biological properties. Although model systems, antibodies against both proteins could 
be employed directly in a clinical research setting. The generation and characterization of 
antibodies specit1c for these two proteins, with the aid of synthetic peptides, serves as a 
model system to optimise the parameters that govern the specificity of the selected antibodies 
and is described in part I and part II. 
In chapter 1, the strategy followed for eliciting and selecting antibodies using 
synthetic peptides is outlined. The different factors, which have a decisive impact on the 
successful generation of the desired antibodies, are introduced and discussed briefly. This 
chapter is quite comprehensive and is also meant to be a concise review and guideline for 
those entering the field of antibody generation using peptides. 
Efficient coupling of a synthetic determinant to a carrier protein is generally a 
prerequisite for adequate antigen presentation to the immune system. A new method for 
conjugation of a peptide to a carrier protein using glutaraldehyde as coupling reagent is 
described in chapter 3. The advantage of this method lies in controlled coupling of the 
peptide in a convenient two-step dialysis procedure preventing the formation of homodimers 
of the peptide and preventing crosslinking of carrier protein molecules. 
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In part I, the generation and characterization of antibodies, specific for a protein for 
which the amino acid sequence was not known, but could be predicted from the eDNA 
sequence, are described. The human androgen receptor is a member of a protein family of 
steroid receptor showing considerable homology. Immunization with a peptide sequence 
derived from the androgen receptor, which avoids homology with sequences from the other 
steroid receptors, may lead to antibodies specific for the androgen receptor provided that the 
proper choices in the entire process are made. The selection of the epitope in such a case is 
clUcial for success. An example of epitope selection is given in chapter 4 describing the 
generation of monoclonal antibodies which afe specific for the different domains of the 
human androgen receptor and do not crossreact with the other steroid receptors. These 
antibodies have opened a wide field of possibilities for studying the function, localization and 
regulatory mechanisms (of the domains) of the receptor in biochemistry and histochemistry. 
In addition, these antibodies offer the possibility of investigating prognosis and behaviour of 
prostatic tumours under honnonal therapy, 
In part II, the generation of antibodies, which are able to distinguish proteins with 
only one amino acid difference, are described, In such a case, one is restricted to a fixed 
localized sequence of the protein: the substitution site, Exact delineation of the peptide 
sequence then becomes very impmtant. Flanking sequences of the substitution site strongly 
influence the immunogenicity and may therefore be decisive in obtaining the proper 
antibodies. Immunodominant nanking sequences, e,g., may prevent the generation of 
antibodies directed to the substitution site, An overview of the strength and limitation of the 
usage of peptides for single amino acid specificity is given in chapter 5, In chapter 6 and 7 
and partly in chapter 5, the generation and application of monoclonal antibodies for the 
detection of genetic variants of ai-antitrypsin is described, Antibodies specific for the Z-
variant of ai-antitrypsin (a Glul -l2 ~ Lys substitution) offer the possibility of easily and 
rapidly detecting carriers early in life. Z homozygous individuals develop lung emphysema 
at an cady age. \Vith eady detection, preventive life-style measures and/or specific therapy 
can be given. The generation and selection of antibodies which specifically recognize variants 
of ai-antitrypsin offer an unique model system to investigate the factors involved. In these 
chapters, the importance of sequence selection, construction of the immunogen, route and 
timing of immunization, selection assays for monoclonal antibodies and accessibility of the 
epitope in ai-antitrypsin is emphasized. 
In part III, the use of synthetic T cell epitopes in a hybrid constlUct as an alternative 
to a peptide-carrier complex is discussed. A synthetic T cell epitope may be advantageous 
for use in a synthetic vaccine. In addition, also for antibody production, synthetic T cell 
epitopes may deserve preference over the use of a carrier protein, e,g" when a selected 
epitope is a weak immunogen. Immunodominance from the carrier protein can be 
circumvented in this way, Chapter 8 gives an overview of all the parameters involved with 
T cell epilope selection and the relative localization wilh respect to the B cell epitope for 
inducing proper B cell-epitope specific antibody responses, In literature there is some 
confusion as to whether covalent linkage between a T and a B cell determinant is necessary 
for an antibody response against the B cell epilope. A covalent linkage between a T and a 
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B cell epitope is a requirement for achieving cognate B-T cell interaction, yielding a memory 
antibody response, as shown in chapter 9. An alternative format for a peptide constmct 
consists of a branched poly-lysine core to which linear epitopes are synthesized, These 
multiple antigen peptides proved to be very suitable as antigens in various immuno-assays. 
In literature, they were initially proposed as immunogenic with every B cell epitope 
sequence. We show in chapter 10 their usage as immunogen and that incorporation of a T 
cell determinant into a multiple antigen peptide constmct is essential for induction of 
antibodies with a high affinity for the native protein. 
A general discussion on the use of peptides as antigens is given in chapter 11. Besides 
epitope selection, selection assays for screening hybddomas proved to be decisive for the 
outcome of the specificity of the monoclonal antibodies. Straightforward instmctions on the 
usage of peptide antigens, abstracted from the experience with synthetic peptides, are given. 
A detailed description of the methods lIsed is given in chapter 12. 
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Chapter 3 
An improved conjugation method for controlled covalent 
coupling of synthetic peptides to proteins using 
glutaraldehyde in a dialysis method 
Journal of Immunological Methods, 130 (1990) 195-200 
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AN IMPROVED CONJUGATION METHOD FOR CONTROLLED COVALENT 
COUPLING OF SYNTHETIC PEPTIDES TO PROTEINS USING 
GLUTARALDEHYDE IN A DIALYSIS METHOD 
Netty Zegers, Koen Gerritse, Carla Deeo, Wim Boersma and Eric Claassen 
Deparlmellt of I11Uf//mofogy. Medical Biological Laboratory TNO, 
P.O. Box 45, 2280 AA Rij,m'ijk, 17Je Net/lerlands 
Key words: Synthetic peptide; Conjugation; Glutaraldehyde two-step reaction 
Abbreviations: KLH, keyhole limpet hemocyanin; MBS, succinimidyl m-maleimidobenzoate; 
EDC, l-ethyl-3-(3-dimethylaminopropyl)carbodiimide); SP, synthetic peptide; BSA, bovine 
selUlll albumin; GA, glutaraldehyde. 
SUMMARY 
Controlled and efficient conjugation of synthetic peptides to proteins, for use in immunization 
or in assay procedures, is a prerequisite for the immunological applications of synthetic 
peptides. This study describes a new method of conjugating synthetic peptides to proteins in 
such a way that no homopolymers of synthetic peptides or proteins occur. To achieve this, 
the protein is first activated with glutaraldehyde and subsequently excess glutaraldehyde is 
removed. Then coupling of the synthetic peptide to the activated protein occurs while 
subsequently the surplus reactive glutaraldehyde groups on the protein are blocked with 
lysine. Excess free peptide and lysine is then removed by dialysis. This improvement not 
only results in better defined conjugates when compared to classical glutaraldehyde coupling, 
but also in the consumption of smaller amounts of synthetic peptide during conjugate 
formation. When used for immunization we obtained similar and sometimes even better 
responses with the glutaraldehyde based conjugates than with succinimidyl (MBS) conjugates 
of the same peptides. The performance of the modified conjugates in ELISA procedures, 
immunization and inmlUnocytochemistry suggests that they are superior to conjugates formed 
by classical glutaraldehyde coupling. 
INTRODUCTION 
Synthetic peptides (SP) have become important tools in the production of antibodies (cf., Van 
Regenmortel, 1989). They are used when there is no purified protein available (Van Laar et 
a!., 1989), when the amino acid sequence is unknown but can be predicted on the basis of 
the DNA sequence (Van Denderen et a!., 1989) and when there is a strong homology 
hetween proteins that differ only in one or a few amino acids (Boersma et a!., 1989). In most 
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cases SP are too short to be immunogenic and coupling to a carrier protein, which can 
provide T cell help, is a necessary prerequisite for antibody production. A broad range of 
coupling reagents that make use of different kinds of functional groups, can be used. For 
immunization and screening of anti-peptide antibody responses two different and independent 
methods of conjugation are required. Two conjugates, of which the one used for detection 
must be different from the one used for immunization, must be available, in order to evaluate 
the immune response in, e.g., ELISA. This permits discrimination between the specific 
peptide response and the response against the coupling (neo)-determinant which has been 
introduced. Alternative procedures to the maleimide-based reagents and carbodiimide methods 
become available. 
Richards and Knowles (1968) first proposed glutaraldehyde as a protein cross-linking 
reagent. Avrameas (1969) demonstrated the conservation of immunological and enzymatic 
activity of different enzymes coupled to proteins with the aid of glutaraldehyde in a one-step 
reaction. It is this one-step reaction that is used for the conjugation of SP to proteins by many 
investigators. A major drawback of this method is the crosslinking of pep tides in an 
uncharacterized way, with the formation of homopolymers. The method is inefficient since 
SP are able to cross-link to each other and great excess SP must be added to the carrier 
protein to ensure that enough peptide molecules are coupled to the carrier. 
We report here an alternative conjugation method making use of a two-step-reaction 
with glutaraldehyde, which produces peptide carrier conjugates without the formation of 
homopolymers of either component. 
MATERIALS AND METHODS 
Peptide synthesis, purification and characterization 
Peptides (SPEKI3, SPEKI4, SPEKI5, SP13 and SP68) were synthesized essentially as 
described by Merrifield (1963) with I-Boc protected amino acids usiog a Biosearch Sam II 
automatic peptide synthesizer. Deprotection was performed using hydrogen fluoride. Peptides 
(SP59, SP60, SP61, SP66) were synthesized on RapidAmide resin beads using F-moc 
protected amino acids (Ramps System, Dupont, Medical Products, U.S.A.), and deprotected 
with piperidine. Elongation was controlled at each step (Kaiser et aI., 1970, 1980). Final 
deprotection and cleavage lVas performed using a mixture of trifluoroacetic acid (TFA), 
phenol, and ethane-dithiol followed by precipitation and filtration from diethyl ether. Tertiary 
butyl protection groups were removed using mercuric (II) acetate. 
Peptides were purified as described in detail by Van Denderen et al. (1989). Amino 
acid analyses were performed using the method described by Janssen et al. (1986). Free thiol 
groups were determined using DTNB (5' ,5'-dithiobis(2-nitro-benzoic acid) according to 
Ellman (1959). 
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TABLE I 
Antibody responses a in BALB/c mice immunized with various peptides conjugated using 
GA or MBS to a KLH carrier 
GA MBS 
SPEK13 NH,-KA VLTIDKKGTEAASAC + 
SPEK14 NH,-KAVLTIDEKGTEAASACA + + 
SPEK15 NH,-KLSKA VHKA VLTIDKKC + 
SP59 NH,-CQQQEA VSEGSSSGRAREASG + + 
SP60 NH,-EGSSSGRAREASGAPTSSKDNYC + + 
SP61 NH,-EDTAEYSPFKGGYTKGLEGEC + + 
SP66 NH,-CVQVPKILSGKVKPIYFHTQ + Ndb 
SP13 NH,-APPVAGGPSVC + + 
SP68 NH,-TKAKRRVVQREKRA VGIGALC + + 
J Qualitative expression of serum antibody responses in ELISA. 
~ Not determined. 
Synthetic peptides 
The sequences of the peptides are given in Table l. SP 13 is derived from HulgG2 (Boersma 
et a!., 1988). SP59, SP60, SP61 and SP66 were from the human androgen receptor (Van 
Laar et a!., 1989). SPEKI3, SPEK14 and SPEK15 were from human "I-antitrypsin. SP68 
is a peptide from gpl20 of the human immunodeficiency vims type 1 (HIV-l). 
Coupling methods 
Gilitaraidehyde 
The (carrier) protein was dialysed at a concentration of 10 mg·ml·lagainst 200 ml 0.2% 
glutaraldehyde (GA, 'Baker' grade 25% in H20, J.T. Baker Chemicals, Deventer, The 
Netherlands) in PBS (0.01 M phosphate-buffered saline, pH 7.2) for 16 h at 4°C. The 
activated (carrier) protein was then dialysed against PBS (three times in 500 ml for several 
hours), to remove excess GA, and transferred to a reaction vessel. The peptide (10 mg'ml' 
in distilled water) was added to the GA activated carrier in a molar ratio of 100 molar 
equivalents and the mixture stirred for 16 h at 4°C. The remaining active GA groups were 
blocked by 0.2 M Iysine-HCI (0.1 m!) during a 2 h incubation. The excess peptide and lysine 
molecules were removed by dialysis. 
MBS 
Essentially the method as described by Van Denderen et a!. (1989) was used. Briefly, MBS 
(succinimidyl m-maleimidobenzoate) was dissolved in dimethylformamide (20 mg·ml). MBS 
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wa:'> added in three equal portions at 5 min intervals using a molar ratio of 200 to 1, relative 
to the (carrier) protein (10 mg·ml·'in PBS). Excess MBS was removed over a PD·IO column 
(Pharmacia). Finally the peptide (10 mg·ml·')was added in 100 times molar excess and 
incuhated for at least 1 h at room temperature. 
EDC· 
The modified method described by Deen et al. (1990) was used. Briefly, the carrier protein 
(10 mg·mi), EDC (l·ethyl·3·(3·dimethylaminopropyl) carbodiimide, 200 mg··mi) and the 
peptide (10 mg-mlj were dissolved in 0.5 M N·methyl·imidazole pH 6.0 (Aldrich, M5, 
083-4, B!1Issel, Belgium). The peptide was added to the carrier to give a 100 times molar 
excess. After the addition of EDC (protein: EDC ratio of 100: I) the mixture was stirred for 
30 min at room temperature followed by dialysis against PBS. 
Immunization 
Conjugates (25 Ilg) of the different peptides and keyhole limpet hemocyanin (KLH) 
(Calbiochem, 374811, San Diego, CA, U.S.A.) emulsified in Specol (Bokhout et aI., 1981), 
were injected intraperitoneally into groups of three or four 12-week-old BALB/c female mice 
and boosted after 5 weeks with the same dose of conjugates. 7 days after each immunization 
a blood sample was taken from the tail vein. 
Imnnmoassays 
ELISA procedures were performed essentially as described by Deen et al. (1990). PVC 
microtiter plates (Titertek, 77·172·05) were coated overnight with protein or peptide (50 ~I 
of 5 ~g·ml·'in PBS) at 4"C and blocked with 0.5% gelatin in PBS. Sera were incubated for 
I h at different dilutions in 0.1 % gelatin and 0.05 % Tween 20 in PBS. Goat anti·mouse IgG 
conjugated to alkaline phosphatase (KPL) was used as second antibody, and p-nitrophenyl 
phosphate (I mg·ml·')in 0.01 M diethanolamine + I mM MgCI, (pH 9.8) was used as 
substrate. Immunoprecipitation was performed as described by Van Laar et al. (1989). All 
of the values were corrected by subtraction of the pre-immune semm background. 
RESULTS 
Coupling of SP to carriers 
All peptides (Table I) were coupled with either GA or MBS to KLH and with EDC to BSA 
(for ELISA). The activation of the KLH with GA using the dialysis method did not result in 
any significant degree of cross-linking. The solution of activated KLH did not contain 
precipitates. After conjugation the resulting solutions remained clear. After storage in the 
freezer for several months the GA conjugate still showed no precipitation. 
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Fig. 1. Serum antibody responses to unconjugated SP61 determined in direct ELISA, Mice were immunized twicc 
with KLH-MBS-SP61 conjugates (Ief!) or KLH-GA-SP61 conjugates (right), SP61 was coated directly to a 96-weJl 
plate. The initial serum dilution was 11100. Results are shown for three (MOS) or four (GA) individual mice. 
Polyclonal sera against cOljjugates produced with GA and MBS 
Mice, three or four per group, were immunized with 25 I'g of the peptide conjugates coupled 
with GA or MBS to KLH. The antibody response in the sera was measured in a direct 
ELISA. The specific response to the relevant peptide was assayed. The peptide was coated 
directly to the plate or indirectly when coupled to a non-relevant protein (BSA) through a 
carbodiimide coupling using EDe. This was in order to be able to discriminate between the 
antipeptide and coupling agent specific responses. Table I shows the results of analyses of 
the sera from the different groups. Sera from mice immunized with the peptide conjugates 
coupled with MBS gave a positive response to the free peptide coat as well as to the coating 
of peptide in the BSA conjugate. Seven out of nine mice immunized with GA coupled 
conjugates gave a positive response both to the peptide and to the SP-BSA conjugate. 
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Fig. 2, Serum antibody responses to SP61 presented in BSA-(EDC)-SP61 COIUug.1tes. Datil obtained using an ELISA 
procedure (see materials and methods section) to assay the same sera as used in Fig. 1. BSA-(EDC)-SP61 was 
directly coated to a 96-well PVC plate. The initial serum dilution was 1/100. Results are shown for three (MBS) or 
four (GA) indivkltlal mice. 
Reaction of polyclonal anti-SP61 se .. a with SP61 
The antibody responses to SP61 are shown as a representative example in more detail (Fig. 
I). The antibodies elicited with KLH-MBS-SP61 conjugate (three animals) were compared 
to those elicited with KLH-GA-SP6l conjugate (four animals). At lower serum dilutions (l 
and 2) the responses to SP61, coated directly to the plate, were similar. However, the 
amount of SP specific antibodies in the sera elicited with the GA based conjugates was much 
lower at higher serum dilutions (3 and 4) when compared with the MBS based conjugates. 
Reaction of polyclonal anti-SP61 se .. a with SP61 conjugate 
Recognition of SP61, present in a conjugate with EDC coupled BSA, by antibodies elicited 
with KLH-GA-SP61 was compared with recognition by antibodies generated with 
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Fig. 3. Serum antibody responses to the native protein of tile human androgen receptor were determined by agarose 
immulloprecipitation. The results obtained using the same sera as in Fig. I are shown. The initial serum dilution was 
1150. Note serum dilutions are tenfold. The amount of radioactive hormone was expressed as desintegrations per 
minute (DPM). 
KLH-MBS-SP61. As shown in Fig. 2 the responses were similar for all semm dilutions. 
Responses generated with GA based conjugates were comparable to the response obtained 
with the sera generated with MBS coupled conjugates to the free peptide coated directly to 
the plate. Thus the conformation of the peptide in the BSA-EDC conjugate resembled the 
conformation in both the KLH-GA and the KLH-MBS conjugates. 
Reaction of polyclonal sera with androgen receptor 
Antibodies directed against the native protein (the human androgen receptor) were detected 
in an iml11uIloprecipitation assay. The results are shown in Fig. 3. The antibody responses 
towards the native protein in sera from mice immunized with both the GA and the MBS 
conjugate were similar at lower serum dilutions (1 and 2), At higher selUm dilutions (higher 
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than 115000) it was obvious that the sera elicited with KLH-GA-SP61 gave a native protein 
specific response, whereas the signal had disappeared in sera from the mice immunized with 
the MBS conjugate. It should be noted that "log serial dilutions were used in the 
immunoprecipitatioll assay whereas in the ELISA 210g serial dilutions were used. 
DISCUSSION 
In this study we have shown that a novel two-step dialysis method with GA as a coupling 
agent for covalent linkage of SP to carrier proteins is a very efficient method for the 
production of immunogenic SP~carrier conjugates. Apart from the advantage of conjugation 
with lower amounts of SP in comparison with the classic method, and the absence of 
homopolymcrs of SP or carrier, we also found a larger proportion of antibodies against SP61 
crossreacting with the native protein when this new method was used. 
For both immunization and assay purposes it may be necessary to couple SP to 
proteins and this can be done by making use of several functional groups on either molecule. 
The functional groups most frequently used are amino, carboxyl and thiol groups. EDC is 
a heterobifunctional reagent that couples an amino group with a carboxyl group to form a 
peptide bond (Goodfriend et aI., 1964; Deen et aI., 1990). MBS (Boersma et aI., 1988), 
MHS (succinimidyl-6-(N-maleimido)-n-hexanoate) and SMCC (succinimidyl-4-( N-maleimi-
do-methyl)-cyclo-hexane-l-carboxylate) (Peeters et aI., 1989) are widely used when all amino 
group and a thiol group are available. When cysteine has a confomlational role in the 
sequence, it is preferable to avoid coupling via this cysteine. 
Glutaraldehyde is a homobifunctional reagent that couples two proteins or peptides 
via amino groups. The one step GA method often fails to evoke peptide specific antibodies 
because of inefficient conjugation (i.e., unwanted polymerization or even precipitation during 
coupling) and it is for this reason that one resorts to a more defined method. We have 
previously described a two-step GA dialysis method (Claassen and Adler, 1988; modified 
after Boersma, 1984) for the conjugation of a polyclonal antiserum to an enzyme (alkaline 
phosphatase) and this conjugate has proven to be of value in innnunocytochemistry. 
In the present study peptide specific responses were obtained with seven out of nine 
peptides, derived from different proteins. This indicates that selective use of GA leads to 
efficient SP coupling. In two cases (SPEK13 and SPEKI5) it was not possible to raise 
antibodies to these peptides. A striking feature of these two SP was the fact that they were 
the only examples with two adjacent lysines (see Table I). 
Two or more lysine residues in the peptide do not need to be inhibitive for elicitating 
antibody responses as shown in peptides 61, 66, 68 and SPEKI4. It is a remarkable feature 
that SPEK14 differs from SPEK13 only in one amino acid and yet this small variation results 
in a different response. It should be noted, however, that this difference involves a lysine 
which is probably part of the epitope against which the antibodies are directed. 
As has been shown by Schaaper et al. (1989) and Boersma et al. (1988) antibodies 
are elicited particularly against that part of the SP most distant from the coupling site. 
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Different orientations of the peptide relative to the carrier, as may be the case when the 
sequence has one or more Iysines, could be a very useful feature. Thus, at least one of the 
several possible orientations, resulting from GA conjugation, mimics the epitope in the native 
protein. 
As can be seen from the results with SP61 a higher antipeptide response does not 
always correlate with an enhanced response to the native protein. Indeed the opposite seems 
to hold true in this case. The sera elicited with the GA conjugates have a higher titer against 
the native protein than sera elicited with the MBS conjugate (Fig. 3) in spite of a weaker 
response against the peptide (Fig. 1). The responses to the peptide presented in a protein 
conjugate were similar. This suggests that conjugation eft1cacy should always be tested in an 
assay specific way, i.e., with the native protein as described in the case of EDe conjugation 
(Deen et ai., 1990). 
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Chapter 4 
Epitope prediction and confirmation for the human 
androgen receptor: Generation of monoclonal antibodies for 
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SUMMARY 
The human androgen receptor (hAR) is an important regulatory protein particularly in male 
sexual differentiation. The investigation of hAR functionality has been hampered by the lack 
of AR specific monoclonal antibodies recognizing the functional domains of the receptor. 
Therefore production of high affinity mono-specific polyclonal (PAbs) and monoclonal 
antibodies (MAbs) directed to the hAR was initiated following the synthetic peptide (SP) 
strategy. Five hAR specific peptides were selected on the basis of their predicted antigenic 
properties avoiding homology with other steroid hormone receptors. Peptide specific 
polyclonal antisera were obtained following selected immunization protocols. Mono-specific 
polyc\onal antibody responses were elicited to all peptide, in mice and rabbits. 
Crossreactivity of the peptide specific antisera with the native hAR in various biochemical 
assays was observed with two out of five peptides. Peptide SP61 (hAR residues 301-320) was 
used for the generation of site-directed MAbs specific for the hAR. Specificity for the hAR 
was established by immunoprecipitation, immune-complex density gradient centrifugation and 
immunohistochemistry on human prostate tissue sections. The multi-assay performance of the 
selected high affinity antibodies proved the usefulness of the straight forward peptide 
approach and opens a wide field of possible biochemical and physiological investigations into 
questions related to androgen action. 
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INTRODUCTION 
Androgens playa major role in male sexual differentiation and they are essential for prostate 
gland development. They also playa role in ounour genesis in the human prostate. Most 
human prostatic tumours are at least initially androgen dependent. Androgens exert their 
action via binding to the intracellular androgen receptor. The activated androgen receptor 
(AR) subsequently modulates specific gene transcription by interaction with cis-acting 
hormone responsive elements present in target genes. Steroid hormone receptors consist of 
three domains: the N-terminal part, which might be involved in the regulation of gene 
transcription, a DNA binding domain, and a steroid-binding domain at the C-tenninus [1,2]. 
Recently the cDNA sequence of the human androgen receptor (hAR) was elucidated [3,4]. 
This information provided a basis for the production of new tools to study the hAR system. 
Since a considerable homology with other steroid receptors (progesterone, oestrogen and 
glucocorticoid receptors) exists and in addition the purification of a sufficient amount of the 
protein was not obtained, we decided to use the synthetic peptide (SP) approach to generate 
site specific, hAR specific, polyclonal and monoclonal antibodies (MAbs). Especially the 
availability of hAR specific antibodies directed to the different parts of the molecule: the 
N-terminal regulating part and the DNA and steroid binding domains could be very helpful 
for immuno-aftlnity purification of the receptor. Furthermore, site specific antibodies would 
facilitate detailed investigation of the AR structure, distribution and its physico-chemical 
properties. Specific antibodies open new possibilities for histochemical localization of the 
receptor in tissue sections, for diagnostic purposes and to monitor, e.g., AR expression 
during endocrine therapy for prostatic cancer. 
In previous studies, it was shown that when a protein is not available for 
immunization, for instance for reasons of purification, but the DNA sequence has been 
determined, synthetic pep tides (SPs) become very important tools to generate specific 
antibodies [5,6]. The use of SPs allowed us to circumvent the difficulty in generating specific 
antibodies when there exists a strong homology in a family of proteins [7]. SPs are frequently 
applied in model studies of antigenicity [8-14]. Furthermore, SPs are used to assign the 
importance of certain amino acid residues (in replacement studies) with respect to the 
function of a protein domain [15]. SPs may become important as specific subunits in the 
production of vaccines [16,17]. 
As the antigenic determinants of the hAR were not known, putative continuous 
epitopes were selected on the basis of theoretical considerations. In this report, we describe 
the selection and synthesis of the peptides and the immunization and screening procedures 
to evoke hAR specific monoclonal and polyclonal specific antibodies. We show that the 
MAbs are widely applicable in various biochemical and histochemical techniques and that 
they do not crossreact with other steroid receptors. These properties make them useful 
diagnostic tools. 
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MATERIALS AND METHODS 
Peptide synthesis, purification and characterization 
Peptides (SP59, SP60, SP61, SP65 and SP66) were synthesized on RapidAmide resin beads 
using Fmoc protected amino acids (Dupont, U.S.A.) following the procedure as described 
for the RAMPS System (Dupont, Medical Prod., Biotechnology Syst., U.S.A.). Piperidine 
was used for deprotection. Elongation was checked each step [18]; the method described by 
Kaiser et al. [19] was used in case of a proline. Final deprotection and cleavage was 
performed using a mixture of trifluoroacetic acid, phenol, and ethanedithiol followed by 
precipitation and filtration from diethyl ether. Mercuric (II) acetate was used to deprotect the 
peptides containing cysteine with a tertiary butyl protection group. Cysteine containing 
peptides were reduced with fi-mercaptoethanol for I h at pH 8. This procedure also allows 
to restore the N to 0 migration in case of serine or threonine. Peptides were purified using 
liquid chromatography on G-15 Sephadex (Pharmacia) in 5% acetic acid. Fractions were 
analyzed on a Beckman Ultrosphere 5 lUll reversed-phase CI8 column using a gradient of 
acetonitrile with 0.1 % trifluoroacetic acid. Fractions with the same major compound and with 
a high purity were pooled and lyophilized twice. Amino acid analyses were performed to 
confirm the peptide composition of the hydrolysed peptide using pre-column derivatization 
of the amino acids [20]. The amount of free thiol groups was determined using DTNB 
(5' ,5' -dithiobis(2-nitrobenzoic acid)) [21]. 
Coupling methods 
All peptides were coupled to immunogenic carrier proteins to enhance antigen presentation 
(ill vivo) or to be used in screening (antigen presentation ill assay) [12]. 
Glutaraldehyde 
Essentially the method described by Zegers et al. [14] was applied. The (carrier) protein was 
dialysed at a concentration of 10 mg-ml-'against 200 ml 0.2% glutaraldehyde (GA) CBaker' 
grade 25% in H20, J.T. Baker Chemicals, Deventer, Holland) in 0.01 M phosphate-buffered 
saline, pH 7.2 (PBS) for 16 h at 4'C. The activated (carrier) protein was then dialysed 
against PBS (three times in 500 ml for several hours) to remove excess GA and transferred 
to a reaction vessel. The peptide (10 mg'ml-' in distilled water) was added to the GA 
activated carrier in a molar ratio of 100 molal' equivalents. The mixture was stirred for 16 
h at 4'C. Remaining active GA groups were blocked by 0.1 ml Iysine-HCI (0.2 M) during 
a 2 h incubation. The excess peptide and lysine molecules were removed by dialysis. 
MBS 
III-Maleimidobenzoyl-N-hydroxysuccinimide (MBS) ester (Pierce 22310, Rockford, IL. 
U.S.A.) coupling, conjugating -NH, and -SH groups, was performed as described earlier 
[12]. The MBS was dissolved in dimethylformamide at a concentration of 20 mg'ml- I To 
the (carrier) protein (10 mg'ml-'in PBS) MBS was added in a molar ratio of200:1, in three 
equal portions at 5 min intervals. After incubation for another 20 min at 4(1C, under stirring, 
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the mixture was centrifuged to remove any insoluble salts. The supernatant was purified over 
a PD-IO gel filtration column (Phannacia, Sweden) to remove excess MBS. To the 
MBS-activated protein the peptide (10 mg·rul) was added in 100-times molar excess and 
incubated for I h at room temperature. The conjugate was then purified by dialysis against 
PBS. 
EDC 
For l-ethyl-3(3-dimethylaminopropyl)carbodiimide (EDC; Sigma E-7750, St Louis, MO, 
U.S.A.), conjugating -COOH and -NH2 groups, the modified method as described earlier 
[13) was used. Briefly, the carrier protein (10 mg'm,I), EDC (200 mg·ml,l) and the peptide 
(10 mg-ml'l) were dissolved in 0.5 M N-methylimidazole pH 6.0 (Aldrich, M5, 083-4, 
Btussels, Belgium). The peptide was added to the carrier in a 100 molar excess. After 
addition of EDC (molar ratio protein/EDC is 1: 100) the mixture was stirred for 30 min at 
room temperattlre followed by dialysis against PBS. 
Conjugates of peptides and proteins for screening were made with bovine serum 
albumin (BSA) and for immunization purposes with keyhole limpet hemocyanin (KLH, 
Calbiochem, 374811, San Diego, CA, U.S.A.). The conjugates were produced with the aid 
of various coupling agents (MBS, GA or EDC) and were designated as, e.g., 
KLH-MBS-SPxx or BSA-EDC-SPxx. 
Immunization 
Rabbits (Flemish Giant random bred, MBL-TNO, Rijswijk, The Netherlands) were injected 
subcutaneously three times at 4 week intervals, with 250 I'g of the conjugate. First 
immunization and booster conjugates were emulsified in Freund's complete adjuvant. For the 
third immunization the conjugate was emulsified in incomplete Freund's adjuvant. Serum was 
analyzed 14 days after each immunization in ELISA or inmmnoprecipitation reaction 
followed by sucrose density gradient centrifugation [22). Pre-immune sera of the same rabbits 
served as (negative) controls. 
Conjugates of the peptide and KLH were emulsified in Specol [23], and 25 I'g was 
injected intraperitoneally into groups of four (12-week-old female BALB/c) mice. The mice 
were boosted after 5 weeks with the same dose of conjugates and adjuvant. Seven days after 
each immunization a blood sample was taken from the tail vein, The serum was assayed in 
a direct ELISA (in which the antigen was coated directly to the plate by passive adsorption) 
or in an immunoprecipitation assay, 
ELISA 
PVC-microliter plates (Titertek, 77-172-05 highly activated, Flow Laboratories, Irvine, 
U.K.) were coated overnight at 4'C with 50 1'1 PBS containing 51'g-ml,1 protein, peptide or 
alternatively the peptide conjugated to BSA (not used for immunization) with a reagent not 
used in the inmlUnogen. Plates were blocked with 0.5% gelatin in PBS during a 30 minute 
incubation at room temperature. Sera were diluted in 0.1 % gelatin and 0.05% tween-20 in 
PBS and incubated for 1 h. Alkaline phosphatase conjugated to goat-anti-mouse IgG or 
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swine-anti-rabbit Ig (Kirkegaard and Perry Laboratories, MD, U.S.A.) were used. 
p-nitrophenyl phosphate (I mg·ml·i)in 10 mM diethanolamine + I mM MgCl, at pH 9.8 
was used as substrate. After 30 min the absorbance was read at 405 nm in a Titertek 
Multiskan reader (Flow Laboratories, Irvine, U.K.) against normal mouse semm or 
pre-immune rabbit serum responses as a blank. The titre in the ELISA was chosen arbitrarily 
as that dilution which gave an absorbance of 1.0 after 30 min of incubation. A direct ELISA 
was used to determine the isotype of the MAbs with specific 
rabbit-anti-mouse-immunoglobulin-subclass anti-sera (Miles Laboratories, Kankakee, IL, 
U.S.A.). 
Inmmllopl'ecipitation 
The response to the native androgen receptor was analyzed in an immunoprecipitation assay. 
Sera were incubated at different dilutions for 2 h at 4'C in roller tubes with anti-mouse-lgG 
conjugated to agarose (Sigma). After centrifugation and washing of the pellet with PBS, 25 
1'1 of a nuclear extract from LNCaP cells (a human cell line of a lymph node carcinoma of 
the prostate) [24] in which the receptor was labelled with [17,,-methyl-3H]methyltrienolone 
([3H]RI881, a synthetic androgen, NEN-Dupont, Dreieich, F.R.G.), was added. 
Subsequently 400 1'1 PBS was added and the mixture was incubated for 2 h at 4'C while 
rotating [22]. After centrifugation and washing of the pellet, the sample was assayed for the 
amount of radioactivity. Values are given corrected for background. 
Sucrose gradient centrifugation 
Essentially the method described by De Boer et a!. [25] was followed. Briefly, 50 ml of 
[JH]RI881-labelled nuclear extract (0.15 M NaCI) from LNCaP cells was incubated for 6 
hat 4'C with antiserum or RPMI 1640 culture medium (Flow, Irvine, U.K.) supplemented 
with 7.5% FCS and 1% NMS as a control and subsequently layered on 10-30% SUCrose 
gradients in the presence of 0.15 M NaCI and centrifugated for 20 h at 370 000 x g at 4"C. 
Monoclonal antibodies 
Cell fusion was perfOlmed essentially as described by Haaijman et al. [26]. Briefly, a spleen 
cell suspension was prepared 4 days after the second boost. Spleen cells and SP2/0 cells in 
logarithmic growth were fused at a ratio of 5:1 in 40% poly(ethylene glycol) 4000 (Merck, 
Darmstadt, F.R.G.) + 5% DMSO in PBS. The fused cells (IO'/well in 0.2 ml) were cultured 
in RPMI 1640 selection medium, containing 1 /lg'ml-1azaserine and 0.1 mM hypoxanthine, 
15% FCS, 2 mM glutamine, 0.1 mg·ml·istreptomycin, 100 E'ml-i penicillin, 1 mM sodium 
pyruvate, and 5'10-5 M fi-mercaptoethanol. After I week of culture the azaserine was 
discontinued and the FCS concentration was lowered to 10%. Selected cell cultures were 
subcloned by limiting dilution at a density of 0.5 cells/well. 
BALBlc mice were injected intraperitoneally with 0.5 Illi pristane (2,6,10,14-tet1'3-
methylpentadecane 96%, Ega-chemie, Steinheim, F.R.G.). Seven days later the mice were 
injected with 106 monoclonal hybridoma cells in 0.25 ml PBS. Ascites fluid was collected 
under anaesthesia. 
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Immunohistochemistry 
Samples of prostatic tissue with glandular hyperplasia were removed from prostatectomy 
specimens immediately after surgery, snap-frozen by immersion in cooled isopentane (-150") 
and stored in liquid nitrogen. Immunohistochemistry was performed on cryostat sections of 
5 I'm thickness using the method described by Ruizeveld de Winter et ai, [27], After fixation 
and rehydration, the slides were incubated overnight with appropriate dilutions of MAbs in 
PBS (pH 7,8) at 4'c' After several washing steps the reactivity was visualized using 
horseradish peroxidase conjugated to rabbit-ant i-mouse immunoglobulin (DAKO, Denmark) 
diluted 1:100 in PBS containing 5% non-immune human serum and 5% non-immune rabbit 
serum. Diaminobenzidine and hydrogen peroxide were used as substrate. Control slides were 
incubated with pre-immune sera or PBS. 
RESULTS 
Peptide selection 
The amino acid sequence of the human androgen receptor [3,4] was used to select stretches 
of about 20 amino acids, with a high antigenicity index [28,29] with the aid of a computer 
prediction program (Genetics Computer Group, Wisconson; [30]), This selection was based 
on analysis of primary and secondary structure parameters such as hydrophilic character, 
protein surface probability and expected flexibility [31-36], Preferable sequences including 
putative "turn" sequences were selected based on earlier experiences. The cut-off places in 
sequences were chosen in such a way that amino- and carboxy-termini had a relatively high 
hydrophilicity index, Because of a strong homology between the hAR and other steroid 
hormone receptors, peptides were chosen such that amino acid sequences similar to those in 
other steroid hormone receptors, like progesterone-, oestrogen- and glucocorticoid receptors, 
were avoided [37-41], 
The selected peptide sequences were matched with protein sequences in the protein 
sequence database PIR (Protein Identification Resource, National Biomedical Research 
Foundation, Washington, D,C" U,S,A,) to determine whether the selected sequences showed 
homology with proteins stored in the database. Even when a mismatch of ten residues (50% 
homology) in the peptide sequence was allowed, we did not find similar peptide sequences 
from putative crossreactive (human) proteins except the hAR fragment itself. 
The position of the five selected peptides is shaded in Fig, 1. An extra cysteine (at 
the N-terminus for SP59 and SP66, at the C-terminus for the other peptides) was added for 
coupling purposes, SP59, SP60 and SP61 are situated in the N-terminal domain and SP65 
and SP66 in the steroid binding domain of the protein (Table 1), 
Generation of Illonospecific polyclonal antibodies 
Each peptide conjugated to KLH with MBS was injected in two rabbits, SP59 was also 
coupled to KLH with glutaraldehyde, Therefore one rabbit was immunized with 
KLH-MBS-SP59 and one rabbit with KLH-GA-SP59, 
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Fig. 1. Physical parameters of the androgen receptor protein predicted on the basis of the amino acid sequence 
deduced from the DNA sequence. In this plol hydrophilicity data are calculated according to Kyle and Doolittle [34J. 
CF: Chou and Fassman (1978), GOR: Garnier, Osguthorpe and Robson (1978). See Materials and Methods section. 
After the second boost, sera from all rabbits as tested in ELISA gave a positive 
response to the coating of free peptide as well as to the same peptide in a BSA conjugate 
(Fig, 2), The response towards SP65 was low compared to the response to other peptides, 
Pre-immune sera of rabbits did not show any response to the peptides, SPs immunized in 
mice gave essentially similar polyclonal responses as observed in rabbits, All responses were 
read against non-immune semm as a blank. 
Effect of conjugation on antibody responses ill mice 
At higher serum dilutions, the reactivity of antibodies to SP61 was much lower in sera of 
mice immunized with conjugates of SP61 prepared with glutaraldehyde (KLH-GA-SP61) than 
was determined after KLH-MBS-SP61 immunization (Fig, 3, right), The responses towards 
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TABLE I 
Selected amino acid sequences of the human androgen receptor 
SP Residues Sequence 
SP59 (AA194-213) ~QQQEAVSEGSSSGRAREASG 
SP60 (AA201-222) EGSSSGRAREASGAPTSSKDNY~ 
SP61 (AA301-320) EDTAEYSPFKGGYTKGLEGE~ 
SP65 (AA834-853) KELDRIIACKRKNPTSCSRR~ 
SP66 (AA899-917) ~VQVPKILSGKVKPIYFHTQ 
Underlined ,Qrsteine was not a part of the hAR sequence, hut was added at one of the termini of the peptides for 
coupting purposes. 
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Fig. 2. Response to peptide and conjugate. Reactivity of antibodies in rabbit sera with free peptide or with the 
peptide conjugated to BSA via EDC determined in ELISA. Rabbits were immunized twice with KLH-MBS-SP 
conjugates. The serum dilution was 1: 500. Results arc shown as the mean value with standard bars for two rabbits. 
Coatings are: peptide, striped bars; BSA-peptide. solid bars. 
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Fig. 3. Reactivity of antibodies in mouse sera with free SP61 (right) and BSA-EDC-SP61 (left) in ELISA. Mice were 
immunized twice with KLH-MBS-SP61 or with KLH-GA-SP61. The initial serum dilution was 1:100. Results are 
shown as the mean value with standard deviation bars for three (MBS) Of four (GA) mice. The response to the free 
peptide differs significantly for the two last dilutions (P < 0.05 and P < 0.01 respectively for a final dilution 1: 
400 and 1: 800) 
SP61 conjugated with EDC to BSA were similar for both groups (Fig. 3, Jeft). Sera from 
these mice did not react with other peptides or with BSA. In Fig. 4, the responses towards 
the human androgen receptor of the sera elicited with the GA and the MBS based 
KLH-conjugates of SP61, as measured in an immuno precipitation assay, are shown. At 
higher serum dilutions (higher then 1: 5000), the sera from the mice immunized with 
KLH-GA-SP61 still gave a native protein specific response, while for the sera elicited with 
MBS conjugate the signal has disappeared. 
Recognition of the native protein 
The hAR specific antibody response in the rabbit and mouse anti-sera was demonstrated for 
the peptide SP61 and for SP60 with rabbit sera only, in several independent techniques: 
sucrose gradient density centrifugation, immunoprecipitation, Western blotting and 
immunohistochemistry (data not shown). 
Generation of monoclonal antibodies 
Groups of three or four mice were innnunized with KLH-MBS-SP61 and KLH-GA-SP61. 
Two different conjugates were used in order to present the peptide in various orientations to 
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Fig. 4. Reactivity with androgen receptor. The reactivity of antibodies in mouse sera with hAR~sleroid complex using 
immuno-agarosc precipitation. Mice were immunized twice with KLH-MBS-SP61 or KLH-GA-SP61, Results are 
shown for I010g serial dilutions of the sera with an initial serum dilution of 1: 50. The mean value with standard 
deviation bars for three (MBS) or four (GA) mice are given. Solid line represents glutaraldehyde and the dotted line 
represents MB5. 
the immune system [12,42]. Spleen cells of mice immunized with KLH-GA-SP61 were used 
for cell fusion. The first fusion was highly efficient as all the wells (768) contained 
proliferating hybridomas. SP61 specific antibody producing clones were identified in a 
primary selection in ELISA. Anti-SP61 responses were found in 107 out of 768 wells. A 
second selection was performed in immunoprecipitation and gave 15 positive anti hAR 
clones. Seven wells containing clones with the highest reactivity were selected for 
subcloning. Three out of seven lost their activity during subcioning, Four monoclonal cell 
lines, F39.3.1, F39.4.1, F39.S.1 and F39.6.2, derived from different wells in the original 
96-well fusion plates, were selected for ascites production, 
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Fig. 5. Titration curve of MAbs to SP61 in a direct ELISA. The titre was expressed as the dilution at which the 
absorbance is 1.0 after 30 min of incubation. The initial ascites dilution was I: 100 (point 0). 0, F39.3.1; +, 
F39.4.1; 0, P39.5.1; 6., F39.6,2; and v, background. 
Characterization of hAR specific monoclonal antibodies 
ImmUlloprecipitafiOlI 
Specificity for the human androgen receptor was detennined by assaying the crossreactive 
response to other hormone receptors (progesterone, oestrogen and glucocorticoid receptors) 
in immuno precipitation assays. The four MAbs showed a positive response with the hAR 
only. The selected MAbs crossreacted with rat AR and calf AR in ill1ll1unoprecipitation and 
Western blots. In a comparison of the reactivity of the four anti,AR MAbs, in the agarase 
precipitation assay, the highest titre was obtained with F39.4.1 ascites (Fig. 5; Table II). 
Ascites fluid F39.4.1 could be diluted ten times more than both ascites F39.5.1 and F39.6.2. 
The affinity of MAb F39.3.1 for hAR is very low, the titre being lower than 1:100. 
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TABLE II 
Properties of hAR specific monoclonal antibodies 
MAb Isotype hAR SP61 Sedimentation Immullo-histo-
titrea titreb rate constant\' chemistryd 
P39.3.1 Ig02b" < I: 100 1:918 4.5S 
P39.4.1 IgOI K 1:13000 1: 12800 6.5S + 
P39.5.1 IgOI K 1:1300 1:18100 6.5S 
P39.6.2 Ig02b K 1:600 1:7900 6.5S 
The titre is expressed as the dilution al which the antihody binding to the !tAR-steroid complex is 50% of 
maximum, determined in immuno agarose precipitation. 
The titre is expressed as the dilution at which the absorbance is 1.0 after 30 min of incuhation with substrate 
at 25"C determined hy ELISA 
Complex formation of antihody binding to RI88I-bAR induces a shin in sedimentation constant 
Only F39.4.1. gave strong immunostaining (+) in sections of hyperplastic prostatic tissue. The other MAbs 
were negative (-). Detailed information in Fig. 7 and in the text. 
Anti-hAR MAb P39.4.1 in this assay crossreacted with the rat-AR (not shown) but the 
affinity as judged from titration curves might be a factor ten lower than observed for the 
bAR. 
To precipitate 25 fmol hAR, 0.13 I'g MAb P39.4.1 was needed. The concentration 
of IgO was established by measurement of the total protein concentration and from scanning 
agarose gels to assign the proportion of total protein of the IgO band. 
ELISA 
The curves of MAbs P39.4.1 and P39.6.2 (Pig. 5) with SP61 at comparable protein 
concentrations showed a steep slope in a direct ELISA. The slope ofMAb P39.5.1 decreased 
more slowly and showed a prozone effect at lower dilutions. This might indicate that the 
affinity ofP39.5.1 for SP61 is lower than the affinity of P39.4.1 and P39.6.2. The affinity 
of P39.3.1 for SP61 is very low as can be derived from both the slope and the titre (Table 
II). 
The isotype of the MAbs (Table II) was determined in a direct ELISA. Both P39.4.1 
and P39.5.1 were IgOiK and the MAbs P39.3.1 and P39.6.2 were Ig02bK. 
Antigen-antibody complex j0I111atioll 
Formation of antibody-receptor complexes was analyzed by sucrose density gradient 
centrifugation. In Fig. 6 the precipitation of the androgen receptor in presence Of absence of 
the MAbs is shown. Por MAbs P39.4.I, P39.5.1, and P39.6.2 the buoyant density of the 
steroid-hAR complex in a sucrose gradient shifted approx. frolU 4.6S to 6.5S due to the 
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Fig. 6. Complex formation of selected MAbs with the hAR. Complexes were demonstrated by a shift in the 
sedimentation profile of the [JH]R1881-1abeUed hAR. Appropriate antibody dilutions were established in separated 
titration experiments. Sedimentation profiles in 10-30% sucrose gradients of [ll-l]R1881-labelled hAR in LNCaP 
nuclear extracts incubated with (A) MAb F39.3,1 (0); (B) MAb F39.4.1 (CD); (C) MAb F39.5.1 (0); (D) MAb 
F39.6.2 (e); or without antiserum (0). The total volume was 100/11 in which the ascites dilution was 1:100. MAbs 
F39.4. 1, F39.S.1 and F39.6.2 show a characteristic sedimentation shift. With MAh F39.3.1 there is an interference 
of the MAb with the sedimentation properties of the receptor not characteristic for immune-complex formation. 
binding of the antibody to the complex. For MAb F39.3.1 the shift was less pronounced, 
only broadening of the 4.6S peak was seen (Fig. 6A). 
ImmUllohislochemistlY 
Supernatants from 15 cell cultures (tested positive in immunoprecipitation) of anti-SP61 
specific MAbs were applied for the indirect immuno-enzymatic staining of human prostate 
tissue sections. Only MAb F39.4.1 gave strong staining in immuno-histochemistry. Fig. 7 
shows hyperplastic prostatic glands surrounded by stromal cells. A strong and specific 
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Fig 7. Top panel: low-power magnification of hyperplastic prostatic tissue imnmnostained with F39.4.1. Prominent 
nuclear staining of prostatic glands and a large proportion of stromal cells. No nuclear counlerstaining ( x 100). 
Lower panel: hyperplastic prostatic gland immunoslained with F39.4.1. Intense nuclear staining of secretory 
epithelial cells lining the glands. Variahle staining of stromal nuclei. The basal cells do not show reactivity with 
F39.4.1. No nuclear counterstaining (x 250). 
83 
Chapter 4 
immunostaining of the nuclei of secretory epithelial cells and some of the stromal cells is 
obtained using the anti-SP61 MAbs, 
DISCUSSION 
In this study we demonstrate, that the synthetic peptide strategy leads to the generation of 
highly specific and desirable reagents that could not be produced following classical 
approaches, Human androgen receptor antibodies were produced with: known determinant 
specificity, high affinity and multi-assay performance, The properties of the high affinity 
hAR specific poly- and monoclonal antibodies are summarized in Table II. Calculation and 
prediction of putative antigenic sites of the AR to which the MAbs are directed was based 
on the amino acid sequence derived from the eDNA sequence. Peptides were selected by 
exclusion of sequences with a large homology with other steroid receptors (oestrogen, 
progesterone, glucocorticoid) and selection of putative immunogenic peptides, based on the 
prediction of the antigenicity index. This approach is limited to prediction of continuous 
linear epitopes, against which antibodies can be evoked with synthetic peptides, We elicited 
a peptide specific response to all peptides selected with a computer algoritluu, In two out of 
five cases antibodies crossreacted with the intact hAR, These two peptides, SP60 and SP61 
are both located in the same N-terminal domain of the protein, MAbs were only developed 
with the peptide that generated the highest response, This N-terminal domain of the hAR 
showed a relatively low degree of homology (approx, 80%) with N-terminal sequence of the 
rat AR as compared to the homology observed in the DNA binding domain and the 
steroid-binding domain [46], Homology of hAR with the rabbit AR is not known, but the 
DNA sequence as present in the hAR may be conserved in rabbits as well. For SP61 17 out 
of 20 amino acids are homologous in human and rat androgen receptors, A putative high 
degree of homology between hAR and rabbit AR did not prevent the generation of specific 
hAR antibodies, This can be explained by the fact, that the receptor in general is not or only 
to a limited degree exposed to the immune system. 
Peptides SP65 and SP66 are hydrophilic stretches derived from the C-terminal steroid 
binding domain, Anti-SP65 and anti-SP66 antibodies were not crossreactive with the hAR 
as shown with immuno-precipitation and in immuno-histochemistry. Apart from exposed 
sites, hinges and protein edge strands, the hydrophilic stretches in a protein may have a 
function in protein-protein, protein DNA-RNA or protein-steroid interactions. The reason for 
anti-SP65 and SP66 antibodies being not crossreactivc with the hAR might originate in either 
a difference in 3D structure of the peptide or in the assay systems applied, The sera were 
screened for the presence of hAR specific antibodies with agarose immuno precipitation. In 
this assay the hAR is complexed first with a labelled steroid analogue (['H1R1881) and 
subsequently the antisera are added. It cannot be excluded that the putative antigenic sites of 
the hAR are shielded and/or drastically changed by the steroid binding, such that the 
antibodies cannot recognize the altered hAR, It is also possible that only denatured hAR may 
be recognized by anti SP65 or anti SP66 antibodies. However, this is unlikely since the 
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immuno-precipitation method and the sucrose gradient centrifugation method applied make 
use of soluble hAR extracted with 0.15 M. NaCI without any detergents and only mild 
fixation was used for immullo-chemistry. 
Pour MAbs with different isotype (IgGlK (2 x) and IgG2bK (2 x» and with different 
affinity for the hAR (varying from moderate to high) were isolated in one fusion after 
immunization with SP61. The MAbs obtained are site specific for AA30I-320 situated in the 
N-terminal part of the hAR. Anti-SP61 MAbs show a broad applicability as was shown in 
our performance testing namely in inmml1o-histochemistry, in immul1oblotting assays and in 
immuno-precipitation assays. MAb P39.4.1 has the highest affinity for the hAR (0.0052 
I'glfmol hAR) (Table II) hut not the highest affinity for SP61. MAb P39.5.1 has the highest 
affinity for SP61 but hAR binding is moderate (Table II; Pig. 5). Differences in isotype are 
wellcome since this enables double staining studies in immunohistochemistry with different 
second step (anti-isotype) conjugates, MAbs with low affinity can also be used, e.g., in 
competition studies. 
PAbs against a synthetic peptide of 15 amino acids at the N-terminal end of the DNA 
binding region of the rat AR, that do recognize the ratAR in immunohistochemistry have 
been described [43,44]. Chang et a!. [45] produced PAbs and MAbs obtained after 
immunization with B-galactosidase fusion proteins of fragments of the hAR (A: AA331-572 
and B: AA 544-822). One of the MAbs raised with the fragment A fusion protein has the 
highest affinity, and precipitates an amount of 25 fmol AR with 4 I'g monoclonal antibody. 
In contrast, only 0.13 I'g was needed for MAb P39.4.1 (this paper) for precipitation of a 
similar amount of AR. Although non-identical assay conditions could have affected these data 
it suggests, however, that MAb P39.4.1 has a velY high affinity for hAR. 
In the present study we have shown, that the strategy using synthetic peptides for 
MAb production may lead to qualitative and quantitative results, that otherwise only could 
be obtained at the expense of considerably greater effort, e.g., production of purified fusion 
proteins. Especially the properties of the hAR: instability, large, not available in purified 
form made it a good candidate for this type of approach. 
Excellent site specific performance of the mono-specific polyclonal antibodies as well 
as for the monoclonal antibodies was demonstrated in different biochemical assays: 
immunoprecipitation, sucrose density gradient centrifugation and im1Uuno-histochemistry. The 
antibodies probably recognize the native hAR in immuno-precipitation since the extraction 
method applied only uses 0.15 M NaCI without use of detergents and only mild fixation was 
used for tissue sections in inmmno-histochemistry. The MAbs have high affinity for hAR 
(ascites P39.4.1 still effective at 1: 13000 dilution) and they crossreact with the homologous 
rat AR and bovine AR. 
The hAR-specific antibodies produced are reactive with the N-tenninal part of the 
receptor and are supposed not to interfere with DNA- and steroid-binding and allowing, 
therefore, biochemical and cell-biological investigations at the molecular level. Furthermore, 
the immuno-histo-cytochemistry at light microscopic and electron-microscopic level should 
enable now the generation of data on expression of the receptor during growth and 
development as well as in malignant processes. 
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I. INTRODUCTION 
Synthetic peptides are nowadays very potent tools for a broad spectrum of applications in 
biological research. Anderer and Schlumberger (1965) used a synthetic peptide derived from 
the C-terminal end of the tobacco mosaic virus coat protein for raising native protein-specific 
and virus neutralizing antibodies. In the 1970s, more investigators elicited antibodies against 
identified antigenic epitopes from proteins with synthetic peptides (Arnon et aI., 1969, 1971; 
Feamy et aI., 1971; Langbeheim et aI., 1976). In that decade, it was a common belief that 
the production of antisera with peptides against native proteins required the prior 
identification of antigenic determinants, After demonstration of the possibility to produce 
antibodies against peptides which were chosen based on knowledge only of the nucleotide 
sequence from which the amino acid sequence was derived (Walter et aI., 1980), an ever-
faster moving production of antibodies using synthetic peptides started, By then, synthetic 
peptides also became favorite tools for vast fields of research, such as mapping proteins for 
antigenic determinants and T cell determinants, ligand specificity of numerous cellular and 
nuclear receptors, probes for determining protein structure, immunomodulation, vaccines, 
autoimmunity, biochemical mechanisms and more, Peptides are used for investigation of 
peptide-MHC interaction, Sequence analogs can mimic or inhibit protein function, Dramatic 
changes with peptide analogs were observed in agonist-antagonist character. 
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Many inheritable diseases arc the result of a mutant protein, often with substitution 
of only a single amino acid, which may lead to dramatic changes in protein stlUcture and 
function. Tracking carriers with such protein disorders may be a matter of life and death. 
VilUS mutants can be screened with variant- specific monoclonal antibodies (MAbs), 
Synthetic peptides are indispensable for the production of MAbs with single amino acid 
specificity. These MAbs are important tools for detection of protein variants. In addition, 
synthetic peptides are also very useful for induction of antibodies which can discriminate 
between individual members of a protein family sharing a high degree of homology, e.g., 
hormone receptors. These antibodies may contribute to the investigation of regulatory 
mechanisms. 
In this chapter, we will discuss the single amino acid specificity of antibodies and the 
use of peptides as probes to prove single amino acid specificity in biochemical reactions, 
illustrated with examples from the literature and from work of our own group. A detailed 
description of the generation of MAbs specific for one amino acid will be given in Section 
VI. Peptide sequences will be given in a single letter code for amino acids, otherwise the 
three letter code for amino acids will be used. 
II. DETECTION OF VIRUS MUTANTS 
Retrovimses show a large mutation frequency, which occurs during reversed transcription 
or replication. Mutations are the result of various factors. Reversed transcriptase lacks 
exollucleolytic (proofreading) activity and the error rate is 104 per generation. DNA 
polymerase from the host works more accurately with an error rate of 10'5. The error rate 
for polymerase II is not known, but it probably will not be different from reversed 
transcriptase. Major rearrangements of sequences, a high frequency of genetic recombination 
together with the ability of oncogene capture of the virus genome, contribute further to the 
high mutation rate. The human immunodeficiency virus (HIV) , a retrovirus, is a striking 
example. Proteins from HIV show extensive variation among isolates, which are expressed 
in the primary amino acid sequence. These variants may have different biological activity 
(replication rate, cell tropism, and syncytia induction), which may be related to sequence and 
to the stmctural differences in the surface proteins. The third variable domain (V3 domain) 
of HIV-l external glycoprotein gpl20 evokes a major fraction of neutralizing antibodies 
during a natural infection. Several studies using MAbs have confirmed the role of the V3 
domain in viral infectivity. The V3 domain is therefore considered to be important for 
candidate vaccines. Polyclonal and monoclonal antibodies directed against preselected 
epitopes of the V3 domain may be useful reagents to characterize structure-function 
relationships of viral proteins. Such antibodies may be used to probe epitopes that can be 
included in candidate vaccines for induction of neutralizing antibodies. In addition, variant-
specific antibodies may have valuable diagnostic and therapeutic application. 
We used synthetic peptides to generate rabbit polyclonal antibodies (PAbs) and murine 
MAbs against relatively conserved sequences li'om IIIB and MN variants of HIV -I (Laman 
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et aI., 1992). The two variants both contain the inmlUnodominant sequence GPGRAF. In the 
flanking sequences some differences exist: a few amino acid substitutions and one deletion 
of two amino acids (IIIB variant: IRIQRGPGRAFVTIG; MN variant: 
KRIHIGPGRAFYTTK). A IIIB derived peptide overlapping the tip of the V3 domain, 
IRIQRGPGRAFVTIG, was used to generate MAbs. Two MAbs neutralized IIIB but not MN 
and inhibited syncytium formation induced by IIIB. The MAbs showed high affinity for 
gpl20 with ~s of 6.8 *10-11 M and 1.6 • /0-10 M respectively. PEPSCAN analysis mapped 
the binding site to the sequence IRIQRGPGR. In addition, two non-neutralizing MAbs were 
raised with peptides derived from the N- and C-terminal side of the loop. A similar MN 
derived peptide was used to produce a rabbit PAb. This PAb inhibited syncytium formation 
induced by HIV-I IIIB and four field isolates. These findings showed that variant-specific 
and HIV -I neutralizing antibodies can be obtained with synthetic peptides and that high 
affinity anti-peptide MAbs can be generated. Moreover, the PAbs generated through single 
peptide immunization crossreacted with four different viral strains (field isolates) which 
indicate major implications for vaccine development. 
Another application of variant-specific synthetic peptides was developed in our group 
(Laman et aI., 1991). Peptides derived from the neutralizing epitope of gp41 of HIV-l 
(residues 586-608) were conjugated to the enzyme alkaline phosphatase. These enzyme-
peptide conjugates may be used for detection of the epitope specificity of antibody forming 
cells in tissue biopsies, e.g., lymph nodes, from mv infected individuals. Cryostat sections 
of lymph nodes were incubated with these conjugates. Enzyme-peptide conjugates bound by 
antigen-specific antibodies present in antibody forming cells stained with an appropriate 
substrate. In addition, the antibody subclass isotype (IgGI, IgG2, IgG3, IgM, IgE or IgA) 
and the specificity of the antibody forming cell could simultaneously be demonstrated in 
double staining experiments using peptide-alkaline phosphatase conjugates (using a blue 
substrate) together with isotype-specific antibody-peroxidase conjugates (using a red 
substrate) incubation. Violet stained (blue + red) cells thus produce peptide-specific 
antibodies with the isotype under study. Blue stained cells produce peptide-specific antibody 
with a different isotype, and red cells visualize antibodies directed against different antigens. 
This method allows correlation of ill vivo function of B cells with lymph node pathology, 
clinical stage of the disease and serological data after HIV infection. 
III. IMMUNODETECTION OF GENETIC VARIANTS OF PROTEINS 
Nowadays more than 4000 inherited disorders are known. New molecular techniques have 
accelerated the discovery of the molecular defects of the disease. Partly thanks to the Human 
Genome Project, the genes causing these diseases are tracked. In the last decade, the genes 
for cystic fibrosis (Rommens et aI., 1989; Riordan et aI., 1989; Kerem et aI., 1989), 
neurofibromatosis (Wallace et aI., 1990), Duchenne's muscular dystrophy (Monaco et aI., 
1986), Huntington's disease (The Huntington's Research Group, 1993) and others have been 
located. Some of the disorders are listed in Table I. (For an exhaustive review, see Cooper 
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Disorder 
Hemophilia A 
Hemophilia B 
Hemoglobinopnthies (thalassemias) 
Familia1 hyperjipoproteinemia 
Inherited c:mphysema 
Seven: combined immunodeficiency 
Duchennc muscul1lf dystrophy 
Becker muscular dystrophy 
Cystic fibrosis 
Neurofibromatosis 
Huntington's dis= 
Phcnylk<:lonuria 
Protein 
{Factor VIII) 
{Factor D..l 
Hemoglobin 
Apo-E 
Ct,-Antitrypsin 
Adenosine deaminase 
Dystrophin complex 
CFTR protem 
NFl gene product 
(chromosome 17) 
ITlS gene product 
Phenylalanine bydro),:ylase 
TABLE 1 
Some inherited disorders 
o,,~ 
Deletion 
Nonsense mutations 
Deletion 
Point mutation 
Point mutation 
Point mutation 
Point m ulation 
Point mutation 
Point mumtion 
Deletion 
Point mutation 
Point mutation 
Deletion 
3 Base deletion 
Point mutation 
Point mutation 
Point mutation 
Point mutation 
Point m utntions 
fu~~ 
Deletions 
Point mutltious 
fu~ru 
Point mutltious. 
deletions. inserts 
Location 
Several exons 
$everaJ eXODS 
SeveraJ C"ODS 
Arg'''_His 
ArgI_~Ser 
Arg"_Gln 
Asp"......cly 
Arg"'_Cys 
Glu"""_Lys 
Argl"_Gln 
I..eu-'''"'_Arg 
.::.Phe'" 
Gly""_X 
Gly''' ..... Asp 
Arg""'_X 
Asn"''' ..... Lys 
Sevcrnl, rare 
Incidence 
1 : 1 0000 males 
1 :30000 males 
1 :600 certnin ethnic groups 
1:500 
1:3500 
"", 
1:3500 (m:..les) 
1:35000 
1:2500 (Caucnsians) 
Sevcrnl exons 1:3500 
Sevcrnl exons 
Leu->Pro; Arg ..... :>top 
Multiple GIn 1:10000 
1:10000 
Reference, 
Furic and Furie, 19&5 
Furic and Furic. 19S5 
Furic and Furic. 19&8 
Weisgrober ct aI., 19S::! 
Bollen et :iI .• 1983: C=ell et :iI .• 1982 
V:iIerio et:iI~ 19&3; Orkin et :iI,. 1983 
Bonthron e! :iI .• 1985 
V:..Ierio et :..I .• 1986 
Monneo et :..I., 1986; Koenig c! :..I., 1987 
Erv<l5ti et aJ .. 1990 
Rommens et aI .• 1989; Riordan et al.. 1989 
Kerem et aI .• 1989 
Ng et aI~ 1991 
De;m et aJ_. 1990 
Wallace et aI .• 1990 
Viskochil et aI., 1990 
c.twthon et al.. 1990 
Gusella et aI_ 1983; 
Huntington's Res. Group, 1993 
Woo et :iI., 1983; Dilella et aI., 1986n., 
19S6b 
b 
a g" 
"" ~ ~. 
~ 
<:i ;;,-
s· 
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and Schmidtke, 1991, 1992.) The majority of the inherited disorders are caused by a 
mutation in the DNA sequence, by deletion of a single base or of part of the DNA sequence, 
or by alternative splicing. Point mutations may lead to a single amino acid substitution or to 
an aberrant protein product if the mutation is a nonsense mutation. Even single amino acid 
substitutions in the protein product may have dramatic effects, e.g., the Glu342~Lys 
substitution in O:'cantitrypsin predisposes the variant homozygous carriers for risk of 
developing lung emphysema at a relatively young age or the Arg158~Cys substitution in 
apolipoprotein E (Apo-E) which leads to hyperiipoproteinemia. Especially for these two 
examples, preventive lifestyle measures like no smoking and avoiding areas with smog (ar 
antitrypsin) or a low fat diet (Apo-E) delay onset and severity of the disease. 
With development of lifestyle advices and new therapeutic approaches, e.g., 
replacement therapy and gene therapy, reliable and simple diagnostic assays for tracking 
variant carriers at risk become very important. Though polymerase chain reaction assays are 
now broadly applied for screening mutated genes, they are rather expensive, time consuming 
and not fully reliable. For some disorders, diagnosis eady in pregnancy is required, 
especially when a severe disease develops very early in life. But for other inherited diseases, 
which can be restored or delayed by therapy or certain lifestyle measures, postnatal screening 
may be chosen. In that case, diagnostic assays based on antibodies are simpler and cheaper. 
For specific diseases, these variant protein products may even be detected in serum by 
monoclonal antibodies specific for the variant amino acid region of the protein. The 
monoclonal antibodies required can be obtained by immunizing animals with synthetic 
peptides which contain the variant region. They have been developed in our laboratory for 
Apo-E variants (Gerritse et aI., 1992) and for "'I-antitrypsin variants (Zegers et aI., 1991). 
A detailed description of raising variant-specific antibodies for ~1-antitrypsin will be given 
in Section VI. 
Though most valuable for single amino acid substitutions, the synthetic peptide 
approach can be applied for deletions also, especially when a single amino acid has been 
deleted (rare), but also when a part of the sequence has been deleted. A nice demonstration 
thereof has been described by Ris-Stalpers et al. (1990). An aberrant form of the human 
androgen receptor, missing 41 amino acids in the N-terminal region caused by a point 
mutation abolishing normal RNA splicing at the exon4/intron4 boundalY leading to a 
disturbed male sexual differentiation and development in an individual with a 46,XY 
karyotype but a female habitus, could not be detected with a monoclonal antibody specific 
for the N-telminal region of the human androgen receptor. 
Another demonstration of the powerful technique of the synthetic peptide approach 
was the elicitation of antibodies specific for tumor-specific ber-abl joining regions in chronic 
myeloid leukemia (CML) as well as in acute lymphoblastic leukemias (ALL). The reciprocal 
translocation between chromosome 9 and chromosome 22 as observed in CML and ALL 
results in a 22q- chromosome, the so-called Philadelphia chromosome. The translocation 
events create on the Philadelphia chromosome a fusion between two genes: ber and abl. 
Depending on the localization of the breakpoint in the ber gene, different chimeric ber-abl 
genes are generated, each encoding their own tumor-specific protein. The amino acid 
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sequences at the point of the junction represent unique tumor-specific detelTIlinants. Since the 
fusion of the ber and abl genes occurs within a coding triplet, a newly generated amino acid 
emerges. For example, the b2a2 fusion protein has the sequence INKEE'ALQRP in the 
junctional region and the b3a2 fusion protein has the sequence KQSSK' ALQRP in the 
junctional region. The first four residues are from the second (b2) or third (b3) exon of the 
ber gene, respectively, and the last five residues are from the second exon (a2) of the abl 
gene. These sequences are not unique for the individual with cells with a Philadelphia 
chromosome, since they are also present in cells expressing the normal ber and abl gene 
encoded proteins. The residues marked with an asterisk (E and K), however, are newly 
formed. The junctional regions are the aimed detelminants for raising specific diagnostic 
antibodies. Detection of these tumor-specific proteins has a strong clinical signiticance. We 
therefore immunized rabbits and mice with peptides spanning these junctional regions. 
Antibodies thus raised were site specific and could discriminate, using a protein kinase cell 
assay, between the different Philadelphia proteins in various CML and ALL cell lines and 
in blood samples of patients (van Denderen et aI., 1989, 1990, 1992, 1994). 
IV. VARIATION OF AMINO ACID SUBSTITUTION 
In this section we will describe examples of investigations with synthetic peptides for which 
substitution of single residues has been applied. The reader is also directed to the chapters 
2 and 3 on PEPSCAN methods. Peptide sequence variation is widely employed in various 
biochemical research topics. 
IV,1. Modulation of ligand function 
A synthetic peptide derived from hen egg-white lysozyme (HEL) (1-18) and an analogous 
peptide in which Phe at position 3 is substituted by Tyr are both immunogenic in (C57BIIl 0 
x DBAJ2)Fl mice. In the parent C57B1/6 mice, genetically non-responders to HEL, the 
analogous peptide itself (Tyr') induces anti-peptide antibodies that also bind to the wild-type 
peptide (phe'), whereas the Wild-type peptide itself is not immunogenic. Thus, a single amino 
acid substitution of aromatic amino acids - Phe is a non-polar and Tyr is a polar residue -
in a peptide may convert the peptide from silent to immunogenic or virtually a non-responder 
mouse strain into a responder one (Sette et ai., 1986). 
Amino acid substitution in a synthetic peptide substrate may convert selective activity 
from agonistic to antagonistic or vice versa, or may convert the substrate susceptible for 
another receptor, as will be clear from the following examples. Substance P 
(RPKPQQFFGLM-(NH,» is an undecapeptide that acts as a neurotransmitter. It is part of 
a family known as tachykinins. Three main types of tachykinin receptors have been suggested 
to exist in the periphery: SP-P, SP-E and SP-N receptors. The hexapeptide [pGIU']SP6-11 is 
equipotent with the undecapeptide in SP-P systems. Substitution of Pro for Gly' in 
[pGlu6]SP 6-11 discriminates between two receptor subtypes in the same tissue preparation 
(Laufer et ai., 1986). 
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Replacement of Pro' in the bradykinin sequence with D-Phe is the essential change 
used to convert kinin analogs into antagonists, The mechanism likely depends, at least in 
part, on the aromatic and basic character of the peptide (Lawrence et aI., 1989). The impact 
of aromatic and basic amino acids was also demonstrated with analogs of bombesin (Saeed 
et aI., 1989). His12 was replaced by several residues. Replacement of His12 by Phe resuIted 
in an agonist with a lOO-fold decrease in activity. Substitution by D-Phe yielded an 
antagonist, but with a lO'-fold decrease of affinity. Substitution by a larger and more 
hydrophobic residue, D-{J-naphtylalanine, produced an analog with complete loss of 
antagonist activity. On the other hand, substitution by a more basic hydrophillic group but 
with similar size to D-Phe, D-pyridyJalanine, Of D_Arg12 (basic residue) generated very weak 
agonists. D_Trp12 converted the analog inactive, and D-Tyr12 rendered a very weak 
antagonist, 100-fold less potent than the D_Phe12 analog. 
Wild-type and mutant synthetic peptides conjugates were used as signal peptides of 
the SV-40 large T antigen to assay their binding to proteins of rat liver nuclei on Western 
blots. Proteins of 140 and 55 kD were exclusively recognized by wild-type peptide conjugates 
and less efficiently by conjugates of a mutant peptide which differed by a single amino acid 
from the wild-type (Wolff et aI., 1988; Finlay et aI., 1989; Meier and Blobel, 1990). 
Specific amino acid sequences have been suggested to serve as nuclear transport signals. 
Most of these sequences consist of a stretch of basic amino acids preceded by a Pro or Gly. 
Replacement of Lys l28 of the SV-40 large T antigen by any amino acid but Arg completely 
abolished its nuclear targeting ability and conferred cytoplasmic localization. The stretch of 
basic amino acids (Lys or Arg) was thus found to be a prerequisite for the transport signal 
sequence. 
A peptide (ASQKRPSQRHG) derived from myelin basic protein (AA 1-11), which 
is involved in the induction of experimental autoimmune encephalomyelitis (EAE), with a 
single amino acid substitution (Lys4 -> Ala') appeared to show completely different 
characteristics than the normal peptide. The mutant peptide (Ala') binds to MHC class II 
molecules and stimulates encephalitogenic T cells in vitro better than the normal peptide. It 
is non-immunogenic and non-encephalitogenic ill vivo in (PL/JxSJL)Fl mice and prevents 
EAE when administered before, at the time of immunization with the normal peptide or near 
the time of disease onset (Smilek et a!., 1991). Thus, a change of charge (from positive to 
neutral) at position 4 in this peptide likely confers a different character to the peptide: from 
disease inductive to disease suppressive. 
Actin polymerization can be inhibited by small synthetic peptides LKHAET and 
LKKTET. Substitution of the third position (His or Lys, both positively charged amino acids) 
by a Glu (a negatively charged polar amino acid) modulated the action from G-actin to F-
actin (Vancompernolle et a!., 1992). 
IV .2. Analysis of protein structure 
Synthetic peptides were used to investigate the stmcture of two adjacent zinc finger domains 
of the yeast transcription factor ADRI. These peptides readily bound zinc in a tetrahedral 
stmcture, while the mutant peptide containing a deletion for a single amino acid did not. 
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CyslH, CYS I37, His150 and His 155 are part of the metal binding site in the second zinc finger 
I3'KPYPQGLQNRCFTRRDLLIRHAQKIHSGNU". The residues between Cys l37 and His"o 
form a loop. Deletion of one residue, Asn''', prevents the folding of the peptide into a zinc 
finger domain. Ligand spacing is thus a major factor for zinc finger folding and has been 
revealed by use of a peptide analog (parraga et a!., 1990). 
The influence of the flanking amino acid sequence on the O-glycosylation of a single 
threonine was investigated in vitro by examining a series of 52 related peptide substrates 
(O'Connell et a!., 1992). Each residue of the parent peptide (derived from the human Von 
WiIlebrand factor) was substituted with different amino acids. Substitution of any amino acid 
tested at position +3, -3 and -2 relative to the threonine markedly decreased O-glycosylation, 
as did the presence of a charged residue at position -1. The substitutions of amino acids at 
the other positions of the peptide substrate had little effect. 
Single amino acid variation was applied to investigate sequence-stmcture and 
stmcture-function relationships in proteins by various investigators. An elegant study was 
carried out with peptide analogs from myohemerythrin (Getzoff et a!., 1987). The antibody 
binding determinants of myohemerythrin (MHr) were mapped using 113 overlapping 
hexapeptide homologs of the MHr sequence. The roles of individual side chains in each 
determinant were characterized by measuring the reactivities of antisera with sets of 120 
peptides that included all possible analogs (replacement nets) differing in sequence from the 
parent peptide by replacement of a single amino acid residue. Such a replacement net study 
made it possible to assign each residue of a peptide to one of the following four categories: 
essential, selected, partially replaceable or generally replaceable. It was shown that each 
antigenic site contained one or more highly exposed and accessible critical side chains and 
one or more largely buried and inaccessible critical side chains within the native protein 
structure. Antibody binding was analyzed combined with three-dimensional crystallographic 
stmcture determination. With these techniques, it was found that initial binding of an 
antibody to solvent-exposed critical amino acid residues may promote local side chain 
displacements and thereby allow the participation of other, previously buried, critical 
residues. 
Single amino acid deletions at position 19, 20, 21 or 22 in the C-telminal part of the 
a-helical region (residues 9-22) of salmon calcitonin did not greatly affect either the 
conformational (measured by circular dichroism) or the biological properties of this protein 
(Epand et a!., 1988). The amphipathic character of this region was kept despite single amino 
acid deletions. 
Ni et a!. (1989) used nuclear magnetic resonance (NMR) to study the structural basis 
for the bleeding disorder caused by the single mutation of Gly" to Val" in the Aa-chain of 
human fibrinogen. VaP' was found to disrupt the type II {3-turn involving Glu" and Gly" in 
normal protein. The positions of Glyl3 and Gly" were also displaced in this mutant protein. 
This altered geometry presumably affects the positioning of Arg 16-Glyl7 bond in the active 
site of thrombin. As a result, the cleavage of the Arg16_Glyl7 peptide bond in the mutant 
peptide by thrombin is much slower than the cleavage of the same bond in normal peptides. 
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IV .3. Optimalization of ligand sequences 
Pharmacological industries need to improve and to optimize therapeutic agents. Especially 
for peptides, used as substrates, improvement of their affinity for receptor binding is rather 
easy. Each residue is subsequently replaced by one of the coded or non-coded amino acids. 
and the mutant peptides are assayed for their biological activity and are compared with the 
original peptide and previous versions of mutant peptides. 
For aprotinin, the Kunitz trypsin inhibitor from bovine mast cells, a series of 
homologs have been prepared by use of peptide-chemical procedures to modulate the 
inhibitory specificity. LysiS at the PI position of its reactive site was replaced by any other 
amino acid. Especially, Val 15 aprotinin was the most powerful inhibitor in the series for 
leucocyte elastase, having a dissociation constant which ranks among the smallest values 
reported for protein inhibitors of this proteinase. Thus, this mutant of aprotinin may be 
beneficial in the treatment of human diseases which are associated with the destmctive 
potential of leukocyte elastase. Aprotinin itself is an excellent inhibitor of trypsin due to the 
positively charged side chain of its PI, but a relatively weak inhibitor for chymotrypsin and 
shows no detectable inhibition with leukocyte elastase. This investigation demonstrated the 
individual contribution of a single residue to the inhibition of a particular target proteinase 
and enabled specific inhibitors to be designed (Tschesche et aI., 1987). 
Six analogs, single amino acid modifications, of the highly o-opoid receptor selective, 
conformationally restricted. cyclic peptide [D-Pen2. D-Pen5) enkephalin were evaluated for 
opoid activity in rat brain receptor binding and mouse vas deferens (MDV) smooth muscle 
assays. The enkephalin peptide, Tyr-D-Pen-Gly-Phe-D-Pen. contains two D-Pen residues 
(penicillamine, containing a thiol group in the side chain) which are cyclized via a disulfide 
bond. The N-terminus was modified by substitution of Tyr by N.N-diallyltyrosine and 
resulted in a very low potency, low affinity agonist despite apparent overall conformational 
similarity with the original peptide. The low affinity could probably be attributed to a local 
effect of the diallyl substitution. Modification of the carboxy terminal group from a 
carboxylic acid to a carboxamide resulted in reduction in a-receptor selectivity due to 
enhanced Ii-receptor affinity, Substitution of GlyJ with sarcosine or substitution of Phe4 with 
D-Phe or phenylglycine all lead to drastic losses of binding affinity and MDV potency. 
Particularly noteworthy was the high a-receptor affinity. potency and selectivity for the 
analog in which Gly3 was replaced by a-aminoisobutyric acid, This analog displayed a quite 
different conformation than the original peptide (Haaseth et al.. 1990). This example 
demonstrates the effects found by replacement of amino acids by non-coded amino acids. 
A peptide, which was 2000-fold more reactive with a transmission blocking 
monoclonal antibody against PlaslIlodium jalcipal'll/tl Pjs25 than the peptide derived from the 
25 leD surface protein. could be obtained by subsequent amino acid substitution (van 
Amerongen et al.. 1992). The reactivity of the MAb with the peptide sequence LDTSNPVKT 
(derived from the surface protein of P. jaicipa/'ulll) was low. The improved peptide with the 
sequence FDDTDPIKK resulted from the amino acid variation. 
Besides the examples mentioned above, also other investigations on substrate 
selectivity and optimalization have been frequently described. Only the subjects of these 
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studies will be mentioned here. Lottenberg et ai. (1986) described the amino acid variations 
at different positions PI-P4 of peptide substrates for factor Xa. Ho et ai. (1988) studied the 
effects of substitutions in {3-endorphin on analgesic potency. An increase of antagonistic 
activity of parathyroid hormone analog was found by replacement studies by Goldman et at. 
(1988). Prorok and Lawrence (1989) studied the influence of amino acid insertions to peptide 
substrates for the cAMP-dependent protein kinase. 
V. ANTIBODY SPECIFICITY 
Poly- and monoclonal anti-peptide antibodies with a unique fine specificity for even single 
amino acids are applicable to distinguish members of a protein family with high homology 
or even to discriminate between variant proteins differing in only a single point mutation. 
Here we review some results from the literature. 
A monoclonal antibody against hemoglobin S was produced with a synthetic peptide 
derived from the N-terminal {3-chain of hemoglobin S, where the single amino acid difference 
between hemoglobins A and S occurs. Hemoglobin A contains the sequence VHLTPEEY and 
the S variant contains the sequence VHLTPYEK. The negatively charged glutamine has been 
replaced by the neutral valine, and two residues downstream a second change in charge has 
occurred: valine has been replaced by the positively charged lysine. With this MAb, one 
heterozygotic AS cell in a mixture with one million AA cells could be detected. (Jeru;en et 
aI., 1985). 
In human cells, the ras protein family cor ~nt'i of several members including normal 
(proto-oncogene) and mutant (oncogene) forms, TIL .llUtant forms which result from somatic 
mutations of the normal ras genes appear to be responsible for the loss of normal growth 
control. The mutant form typically contains a single amino acid change at position 12. 
Antibodies were raised against the ras gene product p21. Anti-p2l Ser l2 (Ser is polar, nOI1-
charged) was raised with synthetic peptides and recognized only v-Ki-ras protein, but not v-
Ha-ras protein (containing Arg12, polar, positive charge) nor the normal ras protein 
containing Gly (neutral) at position 12. Micro-injection of antibodies specific for Ser!2 of the 
oncogenic v-Ki-ras protein into cells transfOlmed by this protein caused a transient reversion 
of the cells to a normal phenotype (Feramisco et aI., 1985). 
Also Clark et ai. (1985) raised polyclonal anti-peptide antibodies against the ras gene 
product p21. These antibodies distinguished the normal p21, containing glycine at amino acid 
position 12, from the oncogenic form with serine at position 12. This remarkable specificity 
was achieved by affinity purification. The polyclonal antibodies were adsorbed to a column 
to which a Gly!2-containing peptide was attached and the flow-through was subsequently 
adsorbed to the Ser12-containing peptide column. 
Schoofs et ai. (1988) raised antibodies against a synthetic peptide corresponding to 
the carboxy terminal 24 amino acids (305CPKYVKQNTLKLA TGMRNVPEKQTJ28) of the 
heavy chain of the hemagglutinin molecule of influenza virus A/X-31 (H3). This peptide 
represents a region of the hemagglutinin molecule which is buried in the molecule. When 
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intact vinls or protein was used as the immunogen, no antibodies against this region were 
found. The peptide appeared to possess three antigenic sites, identified with polyclonal mouse 
anti-peptide sera in a PEPSCAN. Subsequently, two monoclonal antibodies Were selected 
with the 305-328 peptide. One MAb was found to be specific for the most inununodominant 
epitope of the peptide 314LKLAT3I8. In a "replacement set" PEPSCAN, it was shown that all 
five amino acids are essential for the interaction and most probably are contact residues. In 
addition, no amino acid substitutions were allowed at either site of the epitope. The MAb 
was highly specific for the H3 viros subtype and did not bind to the H2 SUbtype. Subtype H3 
differs from subtype H2 at position 315 (Lys vs Val), which is included in the 314LKLAT318 
epitope. A second MAb recognized the 312NVPEKQT318 epilope of which NJ21, E315 and Q327 
using PEPSCAN technology were implicated as contact residues. This study elegantly shows 
that for influenza virus subtypes, in which the subtype-specific residues are buried in the 
protein or alternatively are not immunogenic, subtype-specific monoclonal antibodies can 
only be developed with the help of synthetic peptides. 
Antibodies specific for the VPl protein type 0 foot-aod-mouth disease virus were 
raised with a synthetic peptide comprising residues 141-160. This region contains a highly 
conserved RGD (145-147) sequence which contributes to neutralizing antibody binding sites. 
Anti-peptide antibodies neutralized a wider range of type 0 variant isolates than the anti-
virion semIll. Elongation of this peptide at the amino terminus reduced the number of 0-
variant strains which could be neutralized by the anti-peptide sera. Selected substitutions of 
a single amino acid at position 148 altered the specificity of the raised antibodies. In 
particular, the Leu-Ser substitution induced antibodies which neutralized both type 0 
(Leu l48) and type A (Serl48) virus-equally (Parry et aI., 1989). 
Polyclonal site-specific antibodies were raised to synthetic peptides with a length of 
12 to 13 amino acids representing HLA-DQw7 and -DQw8 allelic sequences, differing only 
by one amino acid in position 57 being Asp and Ala, respectively. This position is the least 
conserved one. The difference investigated is substantial, being a negatively charged Asp and 
a neutral Ala. These peptide-specific PAbs distinguished single amino acid substitutions in 
HLA-DQ {l-chain alleles associated with insulin-dependent diabetes (Atar et aI., 1989). 
Immunological discrimination between human apolipoprotein E2 (Arg 158-Cys) and 
E3 isoforms differing in amino acids was described (Gerritse et aI., 1992). A monoclonal 
antibody was selected aftcr using a panel of several variant-specific peptides. The peptide 
sequences used were homologous to human Apo-E2 and in all but one amino acid 
homologous to the murine Apo-E2. The mouse immune system appeared to be tolerant to 
most of the selected sequences. Immunization with only one of the peptides (AA 154-172) 
evoked an anti-protein-specific response despite a low predicted antigenicity index. This study 
clearly showed the utmost frontiers of the peptide approach. 
The foregoing examples all demonstrate the possibility and usefulness of raising 
variant-specific antibodies with the restriction that the suhstitution has a major impact on the 
protein, in general implying a change of charge. These examples have been summarized to 
indicate the limits of the presently available peptide technology. In addition, another example 
will be extensively described in the next section including all important aspects to be taken 
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into consideration when generating site directed monoclonal antibodies which can 
discriminate between proteins differing in a single amino acid residue. 
VI. RAISING MONOCLONAL ANTIBODIES SPECIFIC FOR GENETIC 
VARIANTS OF ",-ANTITRYPSIN 
Human ai-antitrypsin is a selUm protease inhibitor which inhibits mainly neutrophil elastase 
in the lungs. Nowadays more than 70 different isoforms of the protease inhibitor are known, 
most of them being point mutations in the DNA sequence leading to amino acid substitutions. 
Severe ai-antitrypsin deficiency results from a single amino acid substitution (GluJ42~Lys) 
in the molecule which causes ai-antitrypsin accumulation in the liver where it is synthesized. 
The change of charge from negative to positive in the Z molecule induces an alteration in the 
three-dimensional stmcture of the Z variant protein which, as a consequence, also showed 
a reduced activity, 
Homozygous carriers with the Z type substitution (GluH2~Lys) are at risk to develop 
lung emphysema at a relative young age. Also, heterozygous carriers with the SZ phenotype 
may be at risk. Early detection of such carriers offers the possibility to prescribe lifestyle 
measures, which delay the disease, or to start with replacement therapy. Presently applied 
methods for detection of variants are not suitable for routine screel1ing since they are difficult 
to interpret. Simple assays based on monoclonal antibodies, raised using synthetic peptides, 
which can distinguish between the Z and S variant and the normal M protein, have been 
developed. 
For this purpose, we synthesized several pep tides (Table 2) with different length and 
various overlapping sequences derived from the M and the Z ai-antitrypsin. Peptides mostly 
contain only a B cell determinant and are therefore not immunogenic themselves. Hence, 
peptides were coupled to keyhole limpet hemocyanin (KLH) as a carrier to provide T cell 
determinants with the bifunctional heterogenous coupling agent m-maleimidobenzoyl-N-
hydroxysuccinimide ester (MBS) via a Cys added at one of the termini or via their functional 
amino or carboxyl groups with glutaraldehyde (GA) (Zegers et aI., 1990) or a carbodiimide, 
(EDC: l-ethyl-3-(3-dimethylaminopropyl)carbodiimide) (Deen et a!., 1990). Balb/C mice 
were immunized i.p. or s.c. with the peptide-KLH conjugates or with free peptides both 
given with an adjuvant. 
We earlier showed that also short peptides of about ten amino acids may induce native 
protein- specific antibodies (van Denderen et a!., 1989, 1990). Short peptides (10-12 amino 
acids) (SPEK1A, SPEK1B and SPEK3) derived from the 342 region of ",-antitrypsin in 
general did not elicit antibodies cross-reactive with the native protein. Based on our present 
experience and also on that of other investigators (Partidos and Steward, 1992), longer 
peptides of about 15 to 25 amino acids readily lead to protein-specific antibodies of higher 
affinity. Elongated peptides (SPEKll to SPEKI5) derived from ",-antitrypsin with various 
positions of the substituted amino acid were more successful in raising {XI-antitrypsin 
antibodies. 
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TABLE 2 
Peptides used to elicit anti (XI-antitrypsin variant-specific antibodies 
SPEKIA 'CVLTIDi¥KGTE 342 position in Z-variant (AA 337-346) 
SPEKIB 'CVLTID);KGTEA 342 position in M-variant (AA 337-347) 
SPEK3 'CHKA VLTIDK!< 342 position in Z-variant (AA 334-343) 
SPEKll KLSKA VHKA VLTIDli\KC' 342 position in M-variant (AA 328-343) 
SPEKl2 'CKLSKA VHKA VLTIDK!< 342 position in Z-variant (AA 328-343) 
SPEKl3 KA VLTIDE,KGTEAAGAC' 342 position in Z-variant (AA 335-350) 
SPEKl4 KA VLTIDIlKGTEAAGAC' 342 position in M-variant (AA 335-350) 
SPEKl5 KLSKA VHKA VLTIDK!<C' 342 position in Z-variant (AA 328-343) 
MOUSE KA VLTIDEIGTEAAA V Homologous sequence of mouse 
fYI-antitrypsin 
Variant-specific residues have been underlined and in rcoline. Terminal cysteine residues with';; super!(Cripl are added 
to the aI-antitrypsin sequence for Ihiol coupling possibility. Mouse-specific residues have been underlined (Latimer 
et aI., 1990). 
SPEKll (derived from the M variant) is almost completely homologous with the 
mouse "'I-antitrypsin. A Thr (mouse) in stead of a Lys (human) at position 343 at the 
carboxy terminus of the peptide is the only difference. Immunization of Balb/C mice with 
SPEKll induced only weak "I-antitrypsin-specific antibody responses. The complementary 
Z derived peptide SPEKI5, with two residues different from the mouse sequence, induced 
stronger cxt-antitrypsin-specific responses, The polyclonal antibodies were not able, however, 
to discriminate between the M and the Z type. SPEK12, which was conjugated to a carrier 
protein with the distal end compared to SPEKI5, also did not result in Z-specific antibodies. 
Subsequently, we synthesized peptides SPEKl3 and SPEKl4 with the substitutions 
in the middle of the peptides and in addition two extra residues different from the mouse 
sequence at the carboxy terminus. Immunization, either Lp. or s.c., with KLH-MBS 
conjugates of the peptides induced polyclonal antibodies specific for "'I-antitrypsin (Tahle 3). 
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Free peptides only induced a peptide-specific response after s.c. immunization, but failed to 
induce protein-specific responses. KLH-MBS-SPEKI4 even raised antibodies specific for the 
M variant which did not recognize the Z variant; KLH-MBS-SPEK13 induced polyclonal 
antibodies which also recognize the M variant, but with lower specificity or affinity than the 
Z variant. 
Conjugates made by coupling with EDC or with glutaraldehyde failed to induce 
peptide- or protein- specific antibodies. These coupling reagents make use of amino groups 
(EDC or glutaraldehyde) or carboxyl groups (EDC). Peptides SPEK13 , SPEK14 and SPEK15 
possess several residues with these functional groups (Lys, Asp, Glu and end groups). The 
peptides probably will be conjugated to the carrier at more than one site. This probably will 
TABLE 3 
Antibody responses after immunization with various conjugates via different routes 
ELlS A Coating 
Inununization Route Free SP Oi,AT(M) Oi,AT(Z) 
Free SPEK 13 i.p. 
KLH-MBS-SPEK 13 i.p. +++ + + 
KLH-EDC-SPEK 13 i.p. 
KLH-GA-SPEK 13 i.p. 
Free SPEK 13 s.C, ++ + 
KLH-MBS-SPEK 13 S.c, ++ + 
Free SPEK 14 i.p. 
KLH-MBS-SPEK 14 i.p. +++ ++ 
KLH·EDC·SPEK 14 i.p. 
KLH·GA·SPEK 14 i.p. + 
Free SPEK 14 s,c, ++ 
KLH·MBS·SPEK 14 S,c, +++ ++ 
Free SPEK 15 i.p. 
KLH·MBS·SPEK 15 i.p. +++ ++ + 
KLH·EDC·SPEK 15 i.p. 
KLH·GA·SPEK 15 Lp. 
Free SPEK 15 s,c, + 
KLH·MBS·SPEK 15 s,c, +++ + + 
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TABLE 4 
Specificity of anti-human ai-antitrypsin monoclonal antibodies 
ELlS A 
MAb lsotype SPEK13 SPEK14 c¥cAT(Z) c¥,-AT(M) 
F43.8.1 [gGl K + + 
F46.4.1 [gGl K + + + + 
FSO.2.1 [gG2b K + + 
FSO.3.1 [gGl K + + 
FSO.4.1 [gG2a K + + 
modify the specific epitope to such an extent that antibody recognition of the free peptides 
or of the native protein will be hampered. 
Variant-specific monoclonal antibodies were selected after immunization of mice with 
KLH-MBS-SPEKI3 or KLH-MBS-SPEK14. The reaction pattern of the MAbs is shown in 
Table 4. Three classes of MAbs were obtained. MAbs FSO.2.1, FSO.3.1 and FS0.4.1 
specifically recognize only the Z variant of ",-antittypsin. MAb F46.4.1 recognizes all 
variants of Q'cantitrypsin, and MAb F43.8.1 recognizes all variants except the Z variant. 
With the combination' of these MAbs, it is possible to discriminate between hetero- or 
homozygous Z carriers in different assays. 
The selected MAbs have a high affinity for ",-antitrypsin in ELISA systems in which 
the protein is coated and also for O:'I-antitrypsin variants in immunoblots after isoelectric 
focusing (Zegers et aI., 1991). Subsequently, a sandwich ELISA was designed with a 
polyclonal antibody to capture different variants of ai-antitrypsin combined with our selected 
variant-specific MAbs for rapid and facile discrimination between homo- or heterozygous Z 
carriers. However, commercially available polyclonal antibodies interfered with the binding 
of our variant-specific MAbs. We therefore raised poJyclonal antibodies in rabbits using an 
immune complex of ai-antitrypsin and polyclonal rabbit Abs specific for ai-antitrypsin 
(Sigma, St. Louis, MO). After absorbing these polyelonal antibodies to human serum 
albumin, they were suitable for use as capture antibodies in a sandwich ELISA (Zegers et 
aI., 1993). 
MAb F43.8.1 had a very low affinity for native ",-antitrypsin in the sandwich 
ELISA, and it was not possible to detect all offered samples. The MAbs were selected in an 
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mildly denatured antigens 
M'1M1M1S SS M3Z ZZ M1M1M1S SS M3Z ZZ 
Fig. 1. Comparison of native and denatured ai-antitrypsin variant-specific detection with a capture ELISA. Human 
plasma samples with known ai-antitrypsin phenotype were diluted 1:50. Samples were denatured by heating at 56°C 
for 30 minutes (right panel) or used in native form (left panel). Variants were captured by variant-specific MAbs: 
non-Z-specific F43.4.1 (solid bars), all variant-specific F46.4.1 (cross-hatched bars) or Z-specific F50.4.1 (F50.2.1 
was used for the right panel) (striped bars). Captured antigens were detected with a polyclonaI rabbit serum W9104 
specific for ai-antitrypsin ami a second antibody specific for rabbit Ig conjugated to alkaline phosphatase. Reactivity 
was measured after 45 minutes for the right panel and after 90 minutes for the left paneL 
ELISA with antigen coated to the surface of a plate. The MAbs therefore readily recognized, 
to some extent, denatured antigen coated to a plastic surface or coated onto nitrocellulose. 
In addition, MAbs F46.4.1 and FSO.2.1 also recognized "'I,antitrypsin in solution, but MAb 
F43.8.1 had a much lower affinity for "",antitrypsin in solution. When the diluted human 
plasma samples were mildly denatured by heating at S6°C for 30 minutes, MAb F43.8.1. 
could detect non,Z "",antitrypsin in all samples (Fig. I). Also MAbs F46.4.1 and FSO.2.1 
could still readily detect the captured and denatured ",[,antitrypsin. A dipstick method, based 
on the sandwich ELISA, was also quite suitable to distinguish homo- or heterozygous Z 
carriers (Fig. 2). 
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Fig. 2. ai-Antitrypsin variant-specitic detection with a capture dipstick. Human plasma samples with known 
ai-antitrypsin phenotype were diluted 1 :50, Samples were denatured by heating at 56°C for 30 minutes. Variants 
were captured by variant-specific MAbs spotted onto nitrocellulose (1 Itl of a 2 mg.ml"l solution): non-Z-spccit1c 
F43.4.1 (upper dots), all variant-specific F46.4.1 (middle dots) or Z-spccific FSO.2.1 (lower dots). Captured antigens 
were detected wilh MAb F91.3.2 specific for ai-antitrypsin conjugated to {1-galactosidase. X-Gal was used as 
~uhstrate to yield a clear blue spot. 
Another set of peptides (Table 5) was synthesized encompassing the substitution of 
the S variant of ",-antitrypsin (Olu 264~ Val). Mice were immunized with free peptides or 
with KLH conjugates made with MBS. With short peptides SP 138 and SP 139, no peptide-
or protein-specific antibody response was found. Elongation of SP138 with three residues at 
either end, SP136, introduced solubility problems, and therefore the conjugation procedure 
was not effective. The homologous SP137 (M variant) was soluble and KLH-MBS-SPI37 
induced peptide- and ",-antitrypsin (M)-specific antibodies. 
Elongation of SP138 to SP190 with three residues only at the N-terminal side resulted 
in a soluble peptide. SP190 was coupled to KLH or N-terminally extended with a well-known 
T cell epitope (Hackett et aI., 1985) telmed SP191. Both KLH-MBS-SPI90 and free SPI91 
or KLH-MBS-SP191 raised ",-antitrypsin-specilic antibodies. These polyclonal antibodies 
recognized, however, both the M and the S variant. Monoclonal antibodies resulting from 
these immunizations also could not discriminate between the S and the M variant. Inhibition 
ELISAs with peptides SP136, SP137, SP138, SP139 and SP190 indicated that the dominant 
MAb binding site probably is the DEOK sequence. This Hnding corresponds with a computer 
prediction algorithm program (Jameson and Wolf, 1988; Wolf et aI., 1988) in which the 
sequence DEOK was found to be a stretch with a high antigenicity index (Table 6) as 
compared to the rest of the sequence. Especially for the S variant, the sequence LQHLVNE 
has a much m.ore lower antigenicity index compared to the homologous sequence LQHLENE 
of the M variant. 
SP256, with the deletion of the immunodominant sequence DEOK, was conjugated 
to KLH with MBS and injected in mice, We also synthesized the corresponding multiple 
antigen peptide (Tam, 1988), MAP255, 8 linear peptide sequences with aN-terminal 
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TABLE 5 
Peptides used to elicit S or M variant-specific antibodies 
Mouse D.QGKMQHLEQILSKEL Homologous mouse acanti-
trypsin sequence 
SP136 DEGKLQHLYNELTHDIC' S variant AA 256-271 
SPI37 DEGKLQHL~NELTHDIC' M variant AA 256-271 
SP138 KLQHLYNELTC' S variant AA 259-268 
SP139 KLQHL~NELTC' M variant AA 259-268 
SP190 C'DEGKLQHLYNELT S variant AA 256-268 
SP191 FERFEIFPKE- T cell epitope + 
DEGKLQHLYNELTC' S variant AA 256-268 
MAP190 (DEGKLQHLYNELT),-core S variant AA 256-268 
MAP191 (FERFEIFPKE- T cell epitope + 
DEGKLQHLYNELT),-core S variant AA 256-268 
MAP250 (DEGKLQHLYNELTHDI),~core S variant AA 256-271 
MAP251 (FERFEIFPKE- T cell epitope + 
DEGKLQHLYNELTHDI),-core S variant AA 256-271 
MAP255 (FERFEIFPKE- T cell epitope + 
LQHLYNELTHDI)8-core S variant AA 260-271 
SP256 LQHLYNELTHDIC' S variant AA 260-271 
Variant-sped fie residues are underlined. Terminal cysteine residues with >;0 superscript are added to the acantitrypsin 
sequence for thiol coupling possibility. MAP peptides are multiple antigen peptides (8 peptide sequences per 
molecule) branched 10 a core of 7 lysine residues according to Tam el aI., 1988. The T cell epitope used for N-
terminal extension of pep tides was derived from influenza virus hemagglutinin (Hackett el aI., 1985). Mouse-specific 
residues have been underlined (Latimer et aI., 1990). 
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TABLE 6 
Antigenicity index for Ci -antitrypsin M and S variant , 
Residue Amino I M I s I number acid 
250 A -0.600 -0.600 
251 I -0.600 -0.600 
252 F -0.600 -0.600 
253 F -0.600 -0.600 
254 L -0.600 -0.600 
255 P 0.250 0.250 
256 D 1.300 1.300 
257 E 1.300 1.300 
258 G 1.300 1.300 
259 K 0.900 0.900 
260 L 0.750 0.600 
261 Q 0.750 -0.300 
262 H 0.750 0.300 
263 L 0.750 0.300 
264 ElY 0.900 0.300 
265 N 0.900 -0.300 
266 E 0.900 -0.300 
267 L 0.750 0.750 
268 T 0.600 0.600 
269 H -0.300 -0.300 
270 D -0.600 -0.600 
271 I 0.300 0.300 
272 I -0.300 -0.300 
273 T -0.600 -0.600 
274 K -0.600 -0.600 
275 F 0.450 0.450 
276 L 0.900 0.900 
277 E 0.900 0.900 
The antigenicity index was calculated according to Jameson and Wolf (1988). 
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TABLE 7 
Antigenicity index for a!~antitrypsin M and Z variant 
Residue Amino M Z 
number acid 
330 S ~0.450 ~0.450 
331 K 0.450 0.450 
332 A 0.450 0.450 
333 V 0.600 0.600 
334 H ~0.300 ~0.300 
335 K ~0.600 ~0.600 
336 A ~0.600 ~0.600 
337 V ~0.600 ~0.600 
338 L ~0.600 ~0.600 
339 T ~0.600 ~Q.600 
340 I 0.000 0.000 
341 D 0.900 0.900 
342 ElK 1.100 0.900 
343 K 1.100 0.900 
344 G 1.100 0.900 
345 T 0.900 0.900 
346 E 0.750 0.750 
347 A ~0.300 ~0.300 
348 A ~0.300 ~0.300 
349 G ~0.600 ~0.600 
350 A ~0.600 ~0.600 
351 M ~0.600 ~0.600 
352 F ~0.600 ~O.600 
353 L -0.600 ~0_600 
354 E ~O.600 ~0.600 
355 A ~0.600 ~0.600 
356 I ~0.600 ~0.600 
357 P ~0.600 ~0.600 
The antigenicity index was calculated according to Jameson and Wolf (1988). 
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extension of the T cell determinant branched to a core of 7 lysine residues. MAP255 was 
also used for immunization. In ELISA, a peptide-specific response was found, but not an 
(X,-antitrypsin-specific response. We may conclude from these results that the sequence 
LQHLVNELTHDI has a low intrinsic immunogenicity and is too short to mimic the stmcn,re 
of native cxl-antitrypsin. 
The experiments described in this section nicely demonstrate the attractiveness and 
the pitfalls of the peptide strategy for generating variant-specific antibodies. In these cases, 
one is constrained to a limited possibility of peptide sequence choice. To raise Z- specific 
antibodies, it was needed to carefully select the peptide sequences. Several overlapping 
peptides had to be tested. It proved to be essential to locate the substituted amino acid in the 
middle of the peptide (SPEK13). Also for this region the predicted immunogenicity 
corresponds with the findings. The residues surrounding the variant-specific amino acids have 
a higher predicted antigenicity than the preceding sequence (Table 7). If this part of the 
sequence is situated, however, adjacent to the coupling site, then the steric hindrance 
probably prevails over the immunogenicity. SPEKl5 apparently is a less antigenic sequence. 
Also the mode of coupling of the peptide to a carrier protein is of importance. Only with 
conjugates made with MBS were (¥\-antitrypsin-specific antibodies produced. 
Sometimes peptides are not soluble in aqueous buffers and in DMF or DMSO which 
cause troubles with conjugation procedures. To overcome this problem, linear extension of 
the peptide with a T cell epitope or synthesis of a branched peptide may be advantageous. 
For some applications with MAbs generated with synthetic peptides, it is necessary to make 
the binding site of the protein for the antibody more accessible by denaturing the protein. 
Direct selection of MAbs in a sandwich ELISA instead of only selection on PVC surface 
coated protein will probably yield MAbs which have a higher affinity for the native protein 
in solution. Denaturing the protein may not be necessary. Until now, we did not succeed in 
generating S variant-specific antibodies, mainly due to the low antigenicity of the val'iant-
spednc domain and the immunodominant preceding DEGK sequence, 
Experiments based on these considerations led to the production of variant-specific 
monoclonal antibodies which can discriminate between proteins with only one amino acid 
different in various immuno-assays. 
VII. CONCLUSION 
Synthetic pep tides have proven to be essential means for investigational purposes in a 
numerous number of disciplines. Single amino acid specificity is encountered Variant-specific 
residues are underlined. Terminal cysteine residues with * superscript are added to the 
"I-antitrypsin sequence for thiol coupling possibility. MAP peptides are multiple antigen 
peptides (8 peptide sequences per molecule) branched to a core of 7 lysine residues according 
to Tam et aI., 1988. The T cell epitope used for N-terminal extension of peptides was 
derived from influenza virus hemagglutinin (Hackett et aI., 1985). Mouse-specific residues 
have been underlined (Latimer et aI., 1990). 
with a large number of functionally diverse biological molecules. With well chosen sequences 
in synthetic peptides, the specificity of these molecules can be investigated and the function 
of ligands can be mimicked or inhibited. 
MAbs which are single amino acid specific in general can only be produced with the 
aid of synthetic peptides. These MAbs are extremely useful for early, fast, reliable and cheap 
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detection of variant proteins, e.g., genetic variants or virus mutants. In order to generate 
variant-specific MAbs, a number of aspects should be carefully taken into account, such as 
peptide length, sequence, orientation relative to a carrier, coupling mode procedures, carrier, 
Band T cell epitope selection, immunization scheme and formulation and finally selection 
methods. In the example described, important aspects were highlighted. This example can 
serve as a guideline for production of other variant-specinc MAbs in the future. 
ABBREVIATIONS 
AA Amino acid 
ALL Acute lymphoblastic leukemia 
Apo-E Apolipoprotein E 
alAT ai-Antitrypsin 
CML Chronic myeloid leukemia 
EAE Experimental autoimmune encephalomyelitis 
EDC 1-Ethy 1-3-(3-dimethy laminopropyl)carbod iimide 
ELISA Enzyme-linked immunosorbent assay 
HEL Hen egg-white lysozyme 
HIV Human immunodeficiency virus 
i.p. Intraperitoneal 
i. v. Intravenous 
KLH Keyhole limpet hemocyanin 
MAb Monoclonal antibody 
MBS m-Maleimidobenzoyl-N-hydroxysuccinimide ester 
MHC Major histocompatibility complex 
MHr Myohemerythrin 
PAb Polyclonal antibody 
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DETECTION OF GENETIC VARIANTS OF urANTITRYPSIN 
WITH SITE-SPECIFIC MONOCLONAL ANTIBODmS 
Netty D. Zegers, Eric Claassen, Koen Gerritse, Carla Deen and Wim I.A. Boersma 
T.N.D. Medical Biological LobaraIDl)" P.O. Box 45, 2280 AA Rijswijk, the Netherlallds 
Additional Keyphrases: heritable disorders - emphysema - synthetic peptides - enzyme-linked 
immunosorbent assay 
Abbreviations ",-AT, ",-antitrypsin; ELISA, enzyme-linked immunosorbent assay; KLH, 
keyhole limpet hemocyanin; MBS; m-maleimidobenzoylsuccinimide ester; IEF, isoelectric 
focusing; MAb(s), monoclonal antibody(ies); PBS, phosphate-buffered saline; and BSA, 
bovine serum albumin. 
SUMMARY 
The serum protein "l-antittypsin (",-AT) serves as the major inhibitor of neutrophil elastase. 
The most common allele of the ai-AT gene is designated as PiM , The Z mutation is a 
single-base substitution of the normal M allele, causing a Glu~Lys change at position 342 
in the molecule. The ZZ phenotype is associated with a severe deficiency of ai-AT, sentm 
concentrations of the protein being 10% of normal. Individuals with an ai-AT deficiency are 
at an increased risk of developing emphysema. To generate antibodies that specifically detect 
the 342 position in the context of the flanking sequences, we synthesized several peptides that 
included the 342 position for both the M and the Z variant. Immunization with variant-speci-
fle peptide-carrier conjugates elicited ai-AT variant-specific responses, as determined in a 
direct enzyme-linked immunoassay. Monoclonal antibodies (MAbs) were selected with 
different specificity for the 342 region: MAbs F43 recognize only the "I-AT sequence with 
341Glu, i.e., all variant proteins that are non-Z, either from hetero- or homozygous 
individuals; MAbs F50 recognize only the sequence with 341Lys, i.e., all Z-variant proteins 
in ZZ or heterozygous individuals; MAbs F46 recognize ai-AT with either 341Lys or 342Glu, 
all variant proteins with sequences as in the peptides used. Z homo- and heterozygotes were 
detected with our MAbs in a rapid and simple immunoblot assay. Other variants (M, S, and 
F) can also be assigned on the basis of the electrophoretic pattern. This sensitive detection 
method is very easy, rapid, and straightforward and provides a powerful tool for diagnosis 
of the ai-AT deficiencies, allowing early treatment (augmentation of ai-AT) and proper 
advice on lifestyle practices. 
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INTRODUCTION 
<x,-Antitrypsin (<x,-AT) is a serum protein that inhibits several proteases, primarily neutrophil 
elastase (EC 3.4,21.37) (1),' The most common allele of the <x,-AT gene is designated Pi", 
The Z-allele, Piz, a genetic variant of O:'I-AT, contains a single mutation such that a lysine 
instead of a glutamic acid is encoded at position 342 (2,3), The Z-gene represents 1-2% of 
<x,-AT haplotypes in individuals of Northern European descent, 
The ZZ phenotype is associated with a severe deficiency of (Xl-AT, resulting in serum 
concentrations of the protein only 10% of normal (normal = 2-4 giL), This deficiency is 
basically a decreased production of ai-AT rather than production of a variant with decreased 
activity as a result of the amino substitution, Individuals with an aI-AT deficiency are at an 
increased risk of developing emphysema (4). Carriers are at risk for lung disease when the 
o:cAT concentration in serum is less than :=:::35% of normal. Moreover, :=::: 15% of neonates 
with the ZZ phenotype develop hepatitis and are more likely to develop cirrhosis as adults, 
There is also an association between O:'I-AT deficiency and various immune-mediated 
diseases, e.g., rheumatoid arthritis, anterior uveitis, systemic lupus erythematosus, and 
asthma (5), 
Cigarette smoking, air pollution, and other situations leading to airway irritation 
contribute to a severe clinical course. Preventive lifestyle measures, e.g., non-smoking 
behaviour, are advised. Several clinical trials with substitution therapy with recombinant 
DNA-produced <x,-AT have been initiated recently (for an overview, see Crystal, 6), Based 
on statistical calculations of the incidence of the Piz allele, it is likely that a cohort of patients 
with clinically unrecognized ai-AT deficiency exists. Because they are probably hidden, via 
a false diagnosis, in the group of patients with asthma or chronic aspecific respiratory 
diseases, they probably will not receive proper therapy. For obvious reasons of early 
diagnosis, easy screening of the population for (he presence of the Z <x,-AT phenotype could 
be very helpful. <x,-AT is not phenotyped in all patients with chronic aspecific respiratory 
diseases, let alone in the whole population, because of the specialized character of the current 
detection methods for the different variants. 
Current (XI-AT phenotyping is intricate, being based on analysis of complex isoelectric 
focusing (IEF) patterns to be read only by skilled personnel. Site-specific monoclonal 
antibodies (MAbs) would be of great value in straightforward detection assays, The 
generation of Z- or M-specific antibodies has been hampered because purified (XI-AT from 
MM or ZZ origin injected into animals does not generate antibodies specific for the 342 
region. Thus an alternative approach is needed. 
In our hands, synthetic peptides have been very powerful tools for evoking 
site-specific antibodies that cross-react with the native protein, They have been applied (e,g,) 
when no purified protein was available (7), when the amino acid sequence was unknown but 
could be predicted on the basis of the DNA sequence (8, 9), and when proteins were strongly 
homologous, differing in only a few amino acids (10), 
We synthesized several synthetic peptides that contain the 342 position for both the 
M and the Z variant. Immunization of mice with peptide-carrier protein conjugates evoked 
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an antibody response in Sel11111 that was specific for the variant protein, as detected in 
enzyme- linked immunosorbent assays (ELISA). After fusion of immune spleen cells with 
SPZIO myeloma cells, we selected several MAbs that were specific for the 342 region with 
either glutamic acid or lysine at this position. 
Based on the use of these antibodies, a rapid, sensitive screening method that can 
easily be applied on a large scale has been developed. By using this immunoblot assay with 
IEF gels, one can detect homo- or heterozygous carriers for the Z-allele. Because application 
of blotting techniques has been rapidly advancing in clinical diagnostic laboratories, we 
envisage a quick introduction of our assay. 
MATERIALS AND METHODS 
",-AT(M) was obtained from Sigma Chemical Co., St. Louis, MO. ",-AT(Z) was purified 
from 20 mL of plasma from a ZZ donor by use of an immuno-affinity column. Purified 
rabbit IgO directed against "cAT (Sigma) was coupled to 5 mL of AffigeI"HZ (Bio-Rad 
Labs., Richmond, CAl according to the manufacturer's protocol. The ",-AT protein bound 
to the column was eluted with 0.1 mollL glycine buffer pH 3.0. 
Phenotyped human sera was obtained from Dr. RR. Frantz (State University of Leiden, The 
Netherlands) and Dr. J.H. Kramps (Academic Hospital, Leiden, The Netherlands). 
Peptide synthesis 
We synthesized peptides by using a Sam II automatic peptide synthesizer (Biosearch, San 
Rafael, CAl according to the solid-phase synthesis method with tert-butyloxycarbonyl 
(t-Boc)-protected amino acids as described before (8). 
Conjugates 
Conjugates of peptides and proteins for immunization were made with keyhole limpet 
hemocyanin (KLH; Calbiochem, San Diego, CAl with the aid of m-maleimidobenzoyl-
succinimide ester (MBS) (11). Briefly, MBS was dissolved in dimethylfOlmamide (20 giL), 
then added in three equal portions at 5-min intervals at a molar ratio of 200 to 1, relative to 
that of the carrier protein, 10 giL in phosphate-buffered saline (PBS; 10 mmol of phosphate 
and 150 mmol of NaCI per liter, pH 7.2). Excess MBS was removed by passage through a 
PD-I0 column (Pharmacia, Uppsala, Sweden). Finally, the peptide (10 giL) was added in 
100-fold molar excess and incubated for at least I h at room temperature. Conjugates for 
screening consisted of bovine serum albumin (BSA) and peptide, coupled by using a different 
reagent (a carbodiimide) (12) from the one used for immunization. 
Immunization 
Conjugates (25 I'g) of the different peptides to KLH emulsified in "specol" (a water-in-oil 
suspension) (13) were injected intraperitoneally into groups of four 12-week-old female 
BALB/c mice. The mice were given booster injections after five weeks with the same dose 
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of antigen in specol. Serum antibody responses were analyzed by ELISA seven days after 
each immunization. 
ELISA 
We coated poly(vinyl chloride) microtiter plates (highly activated, Titertek; Flow Labs., 
Irvine·, Scotland) with 50 J.<L of protein, peptide, or peptide coIliugate (5 mg/L) in PBS 
overnight at 4"C and subsequently blocked the remaining binding sites with gelatin, 5 giL in 
PBS, during a 30-min incubation at room temperature. Sera were incubated for 1 h at various 
dilutions in a solution of 1 g of gelatin and 0.5 mL of Tween 20 per liter of PBS. Goat IgG 
directed against mouse JgG conjugated to alkaline phosphatase (Kirkegaard & Perry Labs., 
Gaithersburg, MD) at a 500-fold dilution in the gelatin-Tween 20 solution was incubated for 
I h at room temperature to detect the bound antibodies to the coated antigen. p-Nitrophenyl 
phosphate in, per liter, 10 mmol of diethanolamine and 1 mmol of MgCI" pH 9.8, was used 
as substrate. The absorbance was read after 30 min at 405 nm against the signal from 
nonimmune mouse selUm as a blank. 
The specific antibody response was assayed on a coating of the peptide; on a coating 
of the peptide conjugated to BSA, a protein that was not used for immunization but was 
coupled with the aid of another reagent; and on coatings of the purified M and Z variants of 
(XI-AT protein. 
Monoclonal antibodies 
A spleen cell suspension was prepared four days after the second booster injections. Spleen 
cells and SP2/o cells were washed twice with serum-free RPMI 1640 (Boehringer Mannheim, 
Mannheim, F.R.G.). Spleen cells and SP2/0 cells were fused at a ratio of 5:1 in a reagent 
containing 400 giL of Polyethylene Glycol 4000 (Merck, Darmstadt, F.R.G.) and 50 mL of 
dimethyl sulfoxide per liter of PBS. We resuspended the fused cells in selection medium and 
cultured 10' cells/well in a 96-well plate (total volume 0.2 mLi well). The selection medium 
contained, per liter, 5.7 /lmol of azaserine and 0.1 mmol of hypoxanthine supplemented with 
150 mL of fetal calf serum, 2 nllnol of glutamine, 69 /lmol of streptomycin, 100 int. 
units/mL of penicillin, 1 mmol of sodium pyruvate, and 50 J.<mol of B-mercaptoethanol in 
RPMI 1640. After one week of culture, we omitted the azaserine and decreased the fetal calf 
serum to 100 mLlI.. Half the volume of the supernate was replaced by culture medium twice 
a week. Selected positive wells were subcloned by limiting dilution at a cell density of 0.5 
cell/well. 
BALB/c mice were injected intraperitoneally with 10' monoclonal hybridoma cells in 0.25 
111L of PBS. Ascites fluid was collected under anesthesia. 
IEF blotting 
Samples of human sera (I /lL undiluted) were transferred to the middle of an IEF gel, pH 
4-6.5. We used the protocol and system from the Phast SystemR (pharmacia). Immediately 
after gel electrophoresis, we blotted the protein bands by diffusion onto pre-wetted (with 
Tris/methanol/glycine, pH 8.3) O.I-i,m-thick cellulose-nitrate membrane (PH79; Schleicher 
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TABLE I 
Sequence of Synthetic Peptides 
SPEKI3 KA VLTIDKKGTEAAGAC' Positions 33S-3S0 Z-variant 
SPEKI4 KA VLTIDEKGTEAAGAC' Positions 33S-3S0 M-variant 
'A C-terminal cysteine was added to the sequence for coupling through the Ihiol group with MBS to KLII, 
and Schuell GmbH, Dassel, F.R.G.) at room temperature for at least 3 h or overnight. The 
cellulose-nitrate membrane was developed according to the ELISA protocol, but with 
S-bromoA-chloro-3-indolylphosphate (Sigma), 16S mg/L, and nitroblue tetrazolium (Sigma), 
330 mg/L, as substrate and stain, respectively. After blocking the unoccupied binding sites 
on the membrane, and between incubations with antiserum, we washed the blots three times 
with Tween 20, O.S mLiL in PBS, for S min. Finally, we rinsed the blots in distilled water 
and dried them between tissues. 
RESULTS 
Generation of Monoclonal Antibodies 
We synthesized peptides from both the M and the Z variant (Table I). An extra cysteine was 
added to the sequence for coupling purposes. Peptides were conjugated to KLH with MBS. 
Mice were injected intra peritoneally with peptide conjugates. All antigens were immunized 
with the aid of specol, a mineral oil, as adjuvant. Immune responses were measured by 
ELISA on coatings of free synthetic peptides, or of conjugates of synthetic peptide and BSA, 
",-AT(M), or ",-AT(Z) after the first booster immunization. 
The KLH-MBS conjugates of the peptides induced high antibody responses to the specific 
peptides. A cross-reacting antibody response to "I-AT(M), but not to ",-AT(Z), was elicited 
with KLH-MBS-SPEKI4. InmlUnization with KLH-MBS-SPEK13 gave an anti "c 
AT(Z)-specific response (data not shown). 
We fused myeloma cells with the spleen cells from mice immunized with the KLH-MBS-
SPEKI4. For non-Z-specific "cAT, we selected Mabs F43.8.1, F43.17.1, and F43.20.1 
after subcloning. 
In two subsequent experiments, we fused with myeloma cells the spleen cells from 
mice immunized with KLH-MBS-SPEK13. MAbs F46.1.3, F46.3.1, and F46.4.I, being anti-
"c AT(Z + non-Z)-specific, were selected after subcloning. We selected "cAT(Z)-specific 
MAbs FSO.1.3, FSO.2.1, FSO.3.1, and FS0.4.1 in a second fusion experiment. 
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TABLE 2 
Specificity of Monoclonal Antibodies' 
ELlS A 
MAb Isotype' SPEK13 SPEK14 acAT(Z) ",-AT(M)' 
F43.8.1 IgGl K + + 
F43.17.l IgGI K + + 
F43.20.1 IgGl K + + + 
F46.3.l IgGl K + + + + 
F46.4.1 IgGl K + + + + 
F50.1.3 IgGl K + + 
F50.2.1 IgG2b K + + 
F50.3.1 IgGI K + + 
F50.4.1 IgG2a K + + 
a Assayed in a direct ELISA with coating of pep tides or proteins. +, a positive signal (with A.fill >0.2 read against 
a hlank after 30 min of incuhation with substrate); -, a negative result (1\05 <0.01). 
hMAbs were assayed (about 1:50 000 dilution) on coatings of pep tides in ELISA, with rabbit antibodies directed to 
different isotypes of mouse Ig. To make visible the bound rabbit antibodies, we used swine IgG directed to rabbit 
JgG conjugated to alkaline phosphatase, with p-nilrophcnyl phosphate as substrate. 
'The MAbs have been assayed on al-AT(M) coating, but from the blots from isoelectric focusing gels, it appeared 
thai all variants except the Z variant were recognized by MAbs marked with + in the column headed by acAT(M). 
Specificity of the MAbs 
The reactivities of the MAbs with peptides and proteins were measured in an ELISA. Table 
2 shows results for a 1000-fold dilution of ascites fluid. MAbs F43.8.1, F43.17.1, and 
F43.20.1 recognized SPEK14 and t>,-AT(M) in the ELISA; MAbs F46.3.1 and F46.4.1 
recognized SPEKI3, SPEKI4, ".-AT(Z), and t>,-AT(M); and MAbs F50.1.3, F50.2.1, 
F50.3.1, and F50.4.1 appeared to be specific for SPEK13 and a,-AT(Z). 
Titration of the MAb F43 series, F46 series, and F50 series in the ELISA was performed 
on a coating of purified ",-AT(M) and a.-AT(Z). The initial dilution of the MAbs (ascites 
fluid) was 1000-fold, after which log, serial dilutions were made (Figure I). The titer of 
MAbs was arbitrarily chosen as the dilution of ascites fluid that gave an absorbance (A.IOS) 
of 0.5 after 30 min of incubation with substrate. MAbs F43 showed a high reactivity with 
al-AT(M), with titers between 1:32000 and 1:128000, and no reactivity with t>,-AT(Z). 
MAbs F46 showed a titer of 1:64 000 to t>,-AT(M) and 1:32000 to a,-AT(Z). MAbs F50 
showed a lower reactivity pattern with ",-AT(Z), compared with the signal of the F43 and 
F46 series to a,-AT(M). MAb F50.4.1 showed the greatest reactivity with a,-AT(Z), with 
a titer of 1: 16 000. The MAbs F50 series did not react with ".-AT(M). 
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Fig. 1. Reactivity of MAbs with IXl-AT(M) and IXI-AT(Z) in ELISA. (A) Reactivity of MAbs P43 series with 
a,-AT(1vI) and IXI-AT(Z). A log1 serial dilution of the MAbs was made. The first mark indicates a lOOO-fold dilution, 
the second nlark a 2000-fold dilution, and so on. The MAbs were assayed on coatings of purified aeAT. (B) 
Reactivity of MAbs F46 series. (q Reactivity of }"IAbs F5D series 
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Fig. 2. Immulloblots from isoelectric focusing gels for human plasma with different aI-AT phenotypes. The blots 
were developed with (top) non-Z-specific MAb F43.8.1 (diluted SOO-fold), recognizing (Ill-AT sequences with 342Glu; 
(middle) MAb F46.4.1 (SOO-fold dilution), which reacts with all aI-AT variants e41Glu and J-IlLys); and (bottom) 
Z-specific MAb FSOA.I (SOO-foId dilution) (342Lys). + and -, anodal and cathodal electrodes, respectively 
125 
Chapter 6 
The isotype of the MAbs was determined in an ELISA with use of rabbit antisera that 
were specific for mouse immunoglobulin subclasses (Table 2). 
Immunoblotting 
The different variants of ai-AT, as they occurred in human sera or plasma, could be detected 
in immunoblots for IEF gels (Figure 2). MAbs F46.3.1 and F46.4.1 all gave visible bands 
from reaction with all different variants of ai-AT, Because of variation in glycosyJation, the 
(XI-AT from one genotype shows multiple bands, and the pattern is characteristic of the 
phenotype. MAbs F43.8.1, F43.17.1, and F43.20.1 recognized all bands except the bands 
from the Z phenotype. From the difference between MAbs F43 and F46, we could detect 
homo- or heterozygous carriers for Q',-AT(Z). A direct evidence for the Z-positive sera was 
the visible band in an immunoblot with MAbs FSO.1.3, FSO.2.1, FSO.3.1, or FSO.4.l. 
Figure 2 shows a representative example for each of the three groups of MAbs. 
We did not detect any bands from sera from 27 homozygous ZZ carriers in an 
inununoblot developed with MAb F43.8.l (data not shown). The bands of these 27 ZZ sera 
were clearly visible after reaction with MAb FS0.4.1 (data not shown). These experiments 
demonstrated the reproducible specificity of the MAbs, which can distinguish the two variants 
of the 342 position of (XI-AT. 
Assay Sensitivity 
To show the sensitivity for (Xl-AT in immunoblots, we made log2 serial dilutions of human 
serum in PBS, then transferred 1l'L of undiluted or diluted human serum to an IEF gel. The 
protein bands were blotted to cellulose nitrate and were visible after reaction with MAb 
FS0.4.1 (Z-specific) and with F46.4.1 (Z-specific and non-Z-specific) (Figure 3). The sample 
of human semm, which contained 0.36 mg of (XI-AT(Z) per milliliter, could be detected until 
an eightfold dilution with the Z-specific MAb FSO.4.1. The nonnal range of (XI-AT 
concentration in human selUm is 2-4 giL and the mean value for (XI-AT(Z) is 0.2-0.4 giL. 
About SO ng of "I-AT(Z) (0.04S giL) is the detection limit in this immunoblot assay with 
FSO.4.l. With MAb F46.4.1, a 64-fold dilution was still detectable, which contained S ng 
of "I-AT(Z) (0.004S giL) on the gel. 
DISCUSSION 
We developed several MAbs that are specific for either (XI-AT(Z) or non-Z "'I-AT and that 
do not show unwanted cross-reactivity with the proteins assayed. These MAbs, with different 
isotypes and various affinities for ai-AT, were raised against variant-specific synthetic 
peptides. Specificity for the variant-type native protein was established in an ELISA and 
verified in an immunoblot from lEF gels. Application of the combination of MAbs FS0.4.1, 
F43.8.1, and F46.4.1 allowed us to detect respectively all the "I-AT Z variants, i.e., those 
with 342Lys homozygous and heterozygous; all non-Z 34'Glu variants that have the same 342 
position sequence as M variants; and the M and Z cross-reactive sequences around the 342 
position ("'Glu and J4'Lys). Having antibodies available with different reactivity patterns and 
isotypes could be very advantageous for competition studies or in double-labelling studies in 
histocytochemistry. 
126 
Deteetioll of Variant Proteins 
1 2 3 4 5 6 7 8 
+ 
-
A 
+ 
Bl 
Fig, 3, Immunoblots from IEF gels for human plasma with ZZ phenotype of <Xl-AT: I IlL of plasma serially diluted 
with PBS, Lane I, undiluted plasma, Subsequent lanes contain the serially diluted (log1) samples, Blot A was 
developed with MAb F46,4,1 (specific for all aI-AT variants) diluted SOO-fold, Blot B was developed with the 
Z-specific MAb F50,4, 1, diluted 500-fold, Anodes and cathodes designated as in Fig, 2 
We were able to assign the phenotype of the ",-AT in human donor sera by 
immunoblotting from IEF gels. The Z phenotype could be detected very easily with MAbs 
of the FSO series in particular. Analysis of 27 typed ZZ sera from two different laboratories 
with our immunoblot method allowed us to calculate a detection limit of SO ng for ",-AT(Z) 
with MAb FSO.4.1. This is sufficient to detect homozygous Z carriers, for which the mean 
",-AT concentration in serum is about 0.2-0.4 giL, only 10% of normal. We applied 1 ilL 
of serum onto the IEF gel and this appeared to contain saturating amounts of ",-AT(Z) to 
be detected. In case of doubt, it is possible, with the Phast System, to apply threefold more 
sample at different places of the gel or even ninefold more sample if a different applicator 
is used. The detection limit for ",-AT(Z) in the immunoblot system is lO-fold more sensitive 
(S ng) with MAb F46.4.1. 
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Heterozygous Z carriers of "I-AT could be detected with a second blot developed with the 
MAb F43 series (to make visible the additional bands) or with the MAb F46 series (to make 
visible the complete set of "I-AT bands). Because all variants of "I-AT except "I-AT(Z) 
share the same sequence of amino acids as in SPEK14, all bands of (XI-AT except the ones 
from "cAT(Z) should be detectable with MAb F43 series. To date, only a few of the major 
types of "I-AT - MIMI (n = 7), MIZ (n = I), SS (n = I), M3Z (n = 1), MIS (n = I), 
M2M2 (n = I), and ZZ (n = 27) - have been examined. We did not observe differential 
staining for MI, M2, M3, S, or Z with MAb F46 series, although staining depends on the 
concentration of (XI-AT in serum. The same is tlUe for MAb F43. All protein bands from all 
variants of "I-AT thus far analyzed are detected with MAb F46 series. 
The inmlUIloblotting method is reproducible and so far has not produced any 
false-positive or false-negative results. This approach confirms that antipeptide antisera can 
be very powerful reagents by being very specific. Because the MAbs described were raised 
with synthetic peptides and were first selected with variant-specific synthetic peptides, the 
selected MAb can react with only proteins that contain the sequence of the peptide used for 
immunization. Human serum albumin, transferrin, immunoglobulins, and human proteins 
thus far listed in a protein sequence databank (Protein Identification Resource, National 
Biomedical Research Foundation, Washington, DC) did not contain the sequence contained 
in SPEKI3 or SPEKI4, even when a mismatch of eight residues (out of 16) was allowed. 
We show here the specificity of the MAbs that react with a variant protein only that differs 
in only one amino acid. Recently, we showed the specificity of an antipeptide MAb that 
could differentiate between the human androgen receptor and other homologous steroid 
receptors (7). We also selected a human IgG2-specific antipeptide antibody that showed no 
reactivity with human IgGI, IgG3, or IgG4 (14). These examples and the present data 
illustrate the unique power of antipeptide antisera. 
We expect that our immunoblot method will be very useful for the routine laboratory 
to screen patients with chronic obstructive lung disease. Until now, only very specialized 
persons, usually only found in university hospitals, could interpret the IEF pattern and assign 
the phenotype of homozygous or, even more difficult, heterozygous carriers of lXcAT Z 
variants. However, the method we describe here can be performed and interpreted rapidly 
and easily by every laboratory technician. This method may therefore become useful at least 
as an independent secondary confirmatory procedure. Also for differential diagnosis of 
neonatal jaundice, often seen in ZZ carriers, the immunoblot method may have great value 
because of its simplicity and rapidity. Application of blotting techniques are used more and 
more in the routine clinical laboratories. Especially, chromatographic procedures carried out 
with miniature electrophoretic systems (Phast System) are very rapid and easy. They mostly 
are provided with a simple blotting system. Carriers who are hetero- or homozygous for the 
Z allele may be detected in every hospital laboratory among patients with chronic obstmctive 
lung disease by using miniature electrophoretic systems, combined with immunoblotting for 
variant-specific antibodies. 
Current procedures are based on polyclonal antisera directed to lXI-AT, and typing is 
based on the banding pattern. However, variant~specific polyclonal antibodies are not easy 
to produce because they have to recognize a difference of only one amino acid. Monoclonal 
antibodies, however, are very advantageous over polyclonal antibodies in being reproducible 
reagents, always containing the same constant specificity and affinity. 
Some other "I-AT alleles have been associated with pulmonary disease: e.g., the S allele, 
when it occurs in the homozygous state or heterozygous with the Z allele; the null alleles 
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(heterozygous with other deficiency alleles or homozygous), which result in either no 
expression of {XI-AT or expression of unstable tmncated ai-AT which is not detectable in 
semm; and some rafe deficiency alleles (15) such as Mheerlen, Mmaltoll' Mprocida.Mnkllioon. Mmineral 
springs' Plowelll and Z;rugsburg, when they occur in the heterozygous state with the Z allele. Because 
a panel of variant-specific antibodies might become very helpful in screening programs for 
"I-AT deficiency, an S-variant-specific antibody is currently being developed in our 
laboratory via the same synthetic peptide strategy. 
In Northern Europe, the frequency of homozygous Z-carriers is about I in 2000. 
Homo- and heterozygous carriers of M, S, and Z alleles constitute > 98 % of the population 
in Northern Europe. The other 2 % exists of hetero- or homozygous carriers of alleles that 
have not been associated with pulmonary diseases, e.g., the F, I, and P alleles. Null allele 
products cannot be detected in selUm at all and are therefore found only by familybased 
screening in combination with DNA sequencing techniques. Rare deficiency alleles are 
detected from their deviant banding pattern in IEF or li'om DNA sequencing. But for the 
more common deficiency phenotypes (MS, SS, SZ, and ZZ), the variant-specific antibodies 
may be a welcome supplementary tool in "I-AT typing. 
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variants of aI-antitrypsin specific for one single amino 
acid using synthetic peptides: importance of conjugation of 
synthetic determinants 
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GENERATION AND SELECTION OF MONOCLONAL ANTIBODIES TO 
VARlANTS OF aI-ANTITRYPSIN SPECIFIC FOR ONE SINGLE AMINO ACID 
USING SYNTHETIC PEPTJI)ES: 
IMPORTANCE OF CONJUGATION OF SYNTHETIC DETERMINANTS 
Netty D. Zegers, Conny van Holten, Eric Claassen and \Vim 1. A, Boersma 
TNO ~'1edical Biological Laboratory, dept. Immunology and l'\'fedica\ tvlicrobiology 
P,O. Box 45, 2280 AA Rijswijk, The Netherlands 
J. INTRODUCTION 
a)-Antitrypsin (aI-AT) is a serum protein that serves as the major inhibitor of neutrophil 
elastase. The Z mutation is a single base substitution in the normal M allele causing a GLU 
to L YS change at position 342 in the molecule. The ZZ phenotype is associated with a 
severe deficiency of aI-AT with serum levels 10% of normal. Individuals with an ai-AT 
deficiency are at an increased risk of deVeloping lung emphysema. Antibodies that 
specifically can detect the 342 position would be very hclptltl for reasons of early diagnosis. 
Pointmutations, however, are not readily detected by polyclonal antibodies and in addition 
the sequence that includes the mutation may not be located in an antigenic site of the 
protein. MAbs were therefore generated using synthetic peptides. 
II. RESULTS AND DISCUSSION 
\Ve synthesized several synthetic peptides whieh include the 342 position for both the IvI 
and the Z variant. After conjugation of pcptides to a carrier protein KLH with different 
coupling agents (MBS, EDC and glutaraldehyde), we found a protein specific response, 
detected in a direct EL1SA, after immunization with the ivIBS conjugate only. 
Location of the position of the mutant specific amino acid in the peptide appeared to be of 
importance with respect to the sequence of the B cell determinant which was recognized 
on the peptide. Position distal of the coupling site leads to readily recognition of the 
determilH1Ilt. 
In addition, the method applied for selection of the specific hybridomas was a crucial and 
point in the whole process. Following fusion of stimulated spleen cells with myeloma cells, 
we selected several MAbs specific for the 342 region with either glutamic acid or lysine 
at this position . .iv1Ab F43.8.1 (lVI-variant specific) was selected in an ELISA with the 
antigen coated to the plate. The affinity for a.l-AT in solution as used in a capture ELISA 
(fig 1) is low compared to (Xl-AT adsorbed to an ELISA plate. Thus, when antibodies are 
selected with particular methods, then these antibodies do not necessarily have to recognize 
the samc protein prcsented in a different method. 
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Polyclonal rabbit antibodies (PAbs) spcci/ic for ai-AT shield or change the 342-region of 
o.l~AT. Using these PAbs as capture antibodies, we obtained MAb's which probably 
recognized a sequence situated N~terminal of the 342 position in al~AT. 
The selected MAb F46.4.1 recognizes all variants and is not specific for the variant 0. 1-
AT(Z). However, when we first incubated MAb's to be selected with variant a,-AT(Z) and 
then transferred the mix to the wells coated with rabbit PAbs anti ai-AT for the sandwich 
ELISA, we obtained Z-specific MAbs FSOA.l. These experiments underline the importance 
of the selection strategy in the production of MAbs. Development of polyclonal and 
monoclonal capture antibodies, which do not prevent binding of the variant specific MAbs, 
is at present in progress. 
\Ve demonstrated that it is possible to raise specific antibodies against strongly homologous 
proteins that differ only in one amino acid. \Ve developed an immuno-blot assay using IEF 
gels in which it is possible to detect homo- or heterozygous carriers for the Z-allele [1] with 
MAb FSOA.I in combination with MAb F43.S.1 or MAb F46A.1. Our method applying 
immunoblotting is simple, sensitive and specific. The selected MAbs can also be used as 
capture antibodies in a sandwich ELISA for rapid detection of Z carriers. The synthetic 
peptide approach has shown to offer perspectives in the development of diagnostic assays 
with site specific MAbs that could discriminate between strong homologous proteins. 
III. REFERENCES 
I. Zegers NO, Claassen E, Gerritse K, Deen C, and Boersma WJA. Clin. Chem. 37:1606, 1991. 
133 
Chapter 7 
1.50 ,--------------------- --~ 
F43.8.1 F46.4.1 F50.4. 1 
w 1.00 () 
Z 
« 
m 
([ 
0 (f) 
" 
m 
« 0.50 
~. f) 
0.00 ~ - L 
2 3 4 2 3 4 2 3 4 
TITRES 
Fig. 1. Detection of ai-AT variants in a capture ELISA. Non-Z a)-AT specific MAb F43.8.\ (left), ai-AT specific 
MAb F46.4, 1 (middle) and Z ai-AT specific Mab F50A.I were used as capture antibodies. 2Log serial dilutions 
(initial dilution 1:50) of human sera with the MIMI D, ~·:121\'12 +, MIS 0, SS l!., M3Z 0 and ZZ v phenotype 
were incubated for 1 hour and subsequently detected with ((I-AT specific polyclonai rabbit semm, swine anti rabbit 
Jg conjugated to alkaline phosphatase and p-nitrophcnylphosphatc as substrate. 
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I. INTRODUCTION 
Synthetic peptides are valuable tools to raise antibodies crossreactive with the native proteins 
from which the sequences were derived. Most randomly chosen short peptides consist of a 
B cell determinant which, by definition, does not induce an epitope-specific inUliune response 
by itself. Introduction of a T cell epitope is necessary to offer T cell help and memory for 
a humoral immune response. A T cell determinant can activate specific T cells to synthesize 
certain Iymphokines necessary for T and B cell activation, interaction and proliferation. The 
T cell determinant needs to be presented to T cells bound in the groove of an MHC molecule 
at the cell surface of antigen presenting cells. The peptide-MHC complex is recognized by 
the T cell receptor (TCR) at the T cell. Therefore, a T cell determinant contains at least two 
domains: one which binds to the groove of the MHC molecule and one for interaction with 
the TCR. In peptide immunization, the T cell epitope is usually supplied by a carrier protein 
to which synthetic peptides are covalently coupled. Alternatively, a short synthetic 
determinant with a distinct sequence motif which can be presented by MHC class II to T cells 
can be linked directly to a B cell epitope. 
Milich et al. (/986) were among the first to demonstrate that a synthetic peptide 
immunogen, encompassing one T cell epitope and one B cell epitope, could be used to raise 
anti-native protein antibodies. These epitopes were non-overlapping peptide bond linked 
determinants situated in the same region of the pre-S(2) protein of hepatitis B surface antigen. 
With constmcts of a similar synthetic peptide containing a T cell determinant of the circum-
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sporozoite protein of the Plasmodium faldpaftlln and a major B cell determinant from the 
same protein covalently linked with MBS, it was possible to elicit high-titer antibodies against 
the B cell epitope (Good et aI., 1987). Hybrid constructs of T and B cell determinants 
derived from different proteins made by linear synthesis (Francis et aI., 1987a; Cox et aI., 
1988; Sinigaglia et aI., 1988; Borras-Cuesta et aI., 1987; Palker et aI., 1989) or linked via 
glutaraldehyde (Leclerc et aI., 1987; Jolivet et aI., 1990) induced antibodies against the B 
cell determinant of the hybrid peptides which were crossreactive with the native protein. This 
proved that the anti-B cell determinant responses also may be elicited with foreign helper T 
cell determinants. 
An immunogen consisting of only one B cell epitope and one T cell epitope may be 
advantageous over a large carrier-hapten complex immunogen. Since the number of antigenic 
sites in the peptide immunogen is restricted, implicating the lack of antigenic competition, 
such a construct may be useful to produce antibodies against weakly immunogenic regions 
of a large protein. Also immunodominance resulting from the carrier protein could be 
circumvented. 
Here, we wilJ describe some aspects concerning the use of T cell determinants for 
MHC class II presentation to T cells to raise high-titer native protein specific antibodies. 
II. SELECTION OF T CELL EPITOPES 
Dependent on the specific application of a synthetic antigen to be used for immunization, the 
choice of a T cell epitope sequence for incorporation in a synthetic antigen is more or less 
fixed. For vaccines, T cell determinants have to be derived from the pathogen sequence, 
since a pathogen-specific memory response is needed at the time a pathogen enters the body. 
Identification of strong T cell epitope fragments in protein sequences is therefore of 
importance. These T cell determinants preferably should be promiscuous, i.e., suitable for 
stimulation of multiple MHC haplotypes. A vaccine constructed with such a promiscuous T 
cell determinant then is active in a major part of the population. 
To raise protein-specific antibodies applicable for research or diagnostic purposes, it 
is important to select a T cell detelminant that is dominant in the target animal and restricted 
for the target animal's MHC class II haplotype. In this case, the T cell epilope sequence may 
be derived from any other protein than the protein from which the B cell epilope is derived. 
A limited number of known T helper cell determinants for use in different strains of mice 
is listed in Table 1. 
A number of methods have been proposed for prediction of T cell determinants and 
are described in detail elsewhere in this edition (Chapters 1-6). A brief summary is made in 
this paragraph. Prediction only is possible if the exact amino acid sequence of this protein 
is known. On the other hand, T cell epitopes can be assigned in a more pragmatic approach 
by using T cell stimulation assays with protein fragments (see below). It may be clear that 
only linear T cell epitopes can be predicted this way. 
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i\1HC AA residues 
Hen egg lysozyme 
H-2' 46-61 
H_2J 20-35 
H_2J 116-129 
H-2~ 74-90 
I-I-2~ 30-53 
H-2~ 81-96 
I_El 1-18 
I-N 51-61 
I-N 112-129 
H_2J 108-120 
H_2J 105-129 
Ovalbumin 
H_2J 323-339 
Sperm whale myoglobin 
H-21. 26-40 
102-118 
136-146 
Pigeon cytochrome c 
I_El 95-104 
~ Repressor protein 
I-N; I_El 12-26 
12-26 
TABLE 1 
Murine MHC restricted T cell epitopes 
Sequence 
NTDGSTDYGlLQINSR 
YRGYSLGNWVCAAKFE 
KGTDVQAWIRGCRL 
NLCNIPCSALLSSDlTA 
CAAKFESNFNTQATNRNTDGSTDY 
CSALLSSDlTASVNCAK 
KVFGRCELAAAMKRHGLD 
TDYGILQINSR 
RNRCKGTDVQAWlRGCRL 
WVAWRNRCKGTDV 
MNAWVAWRNRCKGTDVQA WIRGCRL 
ISQAVHAAHAEINEAGR 
QDlLlRLFKSHPETL 
KYLEFISEAIIHVLHSR 
ELFRKDlAAKY 
LlAYLKQATAK 
LEDARRLKAIYEKKK 
LEDARRLKAIYEKKK 
Influenza hemagglutinin protein (AIPR8/48) 
H_2J 111-119 FERFEIFPK 
I-N 129-140 NoVTAACSHEGK 
Plasmodium j(llcipanllll circumSpOIOzoite coal protein 
I-A' 365-380 NANPNANPNANPNANP 
Promiscuous 378-398 DlEKKIAKMEKASSVFNVVMS 
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T Cell Epilopes 
T cells recognize peptide fragments presented in a groove of the MHC class II 
molecules at the cell surface of antigen presenting cells. These peptide fragments which 
originate from processing of a protein by an antigen presenting cell are usually 8-12 residues 
in length. T cells recognize only the primary and secondary stmcture of the protein, but not 
the tertiary structure of the native protein. As a result, prediction of T cell recognition sites 
can be based on secondary structure and the amino acid sequence of the native protein. 
Therefore, most theoretical prediction methods are merely based on the feasibility of peptide 
binding in the groove of the MHC 1110lecule, ignoriog the interaction with the TCR. 
By analyzing functionally recognized T helper determinants, the hypothesis was 
formulated that T cell detelminants tend to be amphipatic helices, ~- helices with 
hydrophobic residues on one side and hydrophilic residues on the other side along the helix 
(DeLisi and Berzofsky, 1985; Berkower et aI., 1986; Spouge et aI., 1987). Based on this 
hypothesis, an algorithm called AMPHI was developed for predicting such T cell 
determinants (Margalit et aI., 1987). The computer program identifies regions that tend to 
form amphipatic helices by scoring both the strength of hydrophobic moments as a function 
of the periodicity, within seven amino acids, and the lengths of positive segments. 
An alternative method was developed by the group of Humphreys (Elliott et aI., 1987; 
Stille et aI., 1987). They demonstrated that the strip-of-helix hydrophobicity index (SOHHI) 
(mean hydrophobicity of residues at positions II, II +4, II + 7, 11+ 11, etc.) identified T cell-
presented epitopes, presumably on the basis of quantifying the cooperativity among 
hydrophobic residues in such longitudinal hydrophobic strips. Based on the SOHHl, they 
developed the strip-of-helix hydrophobicity algorithm (SOHHA). The degree ofhydrophilicity 
of the non-hydrophobic side of the helix was not relevant to the selection of the T cell-
presented epitope. The algorithm was proposed to select both class I and class II restricted 
epitopes (Reyes et aI., 1988). 
A third method for selection of T cell determinants was the method developed by 
Rothbard and Taylor (1988). They formulated an algorithm based on the motif (charged or 
Gly)-(hydrophobic)-(hydrophobic)-(hydrophobic or Pro)-(polar or Gly). The motif was 
postulated on the basis of analysis of functional T cell epitopes. Sette et a!. postulated a 
similar motif for interaction of peptides with I-A" or I_Ed (Sette et aI., 1987, 1988, 1989a, 
1989", 1989c). For I-Ed, the motif IVas composed of three basic residues. The first basic 
residue was found either in positions I, 2 or 3. The other basic residues were found in 
position 4 and 6, whereas position 5 was usually occupied by a non-charged or somewhat 
hydrophobic amino acid. Using this motif based method, they predicted three overlapping 
I-Ed binding sites in dynOlphin, an opioid peptide. The peptide 1-13 of dynorphin IVas found 
to bind with more than a lO-fold higher affinity than other good I-E' binding peptides (Sette 
et aI., 1990). 
The efficacy of three methods for predicting T cell epitopes (AMPHl, SOHHA and 
the motif of Rothbard and Taylor) was evaluated (Reyes et aI., 1990). By comparing 
functional T cell determinants and predicted sequences, the SOHHA methods scored higher 
in terms of overlap (ratio predicted over experimental sequence residues ~O.5), sensitivity 
(correct predictions/number of reported T cell-presented sequences) and efficiency (correct 
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predictions/number of predictions}. However, it is not clear which methods were used for 
tracing the known T cell detelminants involved in this analysis (Reyes et a!., 1990). The T 
cell epitopes used in this study for comparison with predicted sequences were from the 
literature communicated by multiple researchers which have used a variety of functional 
assays. The number and sequence of the experimentally determined known T cell epitopes 
is dependent on the assays and strains of mice used (Gammon et a!., 1991). More extensive, 
precise, experimental localization of T cell epitopes may thus alter the outcome of the 
comparison of the three methods. 
Prediction of T cell determinants does not allow for MHC polymorphisms. Many 
known T cell determinants are MHC restricted. Moreover, predicted sequences, capable of 
binding to MHC molecules, are not always immunogenic because of a deficient T cell 
repertoire. For these reasons, some investigators favor the empirical approach for localization 
of T cell determinants, Analysis of a protein is carried out by stimulation of protein primed 
T cells with overlapping peptides. The most comprehensive method uses the PEPSCAN 
strategy initially developed by Geysen et a!. (1984) and since then many times improved and 
refined (van der Zee et a!., 1989). The advantage of the PEPSCAN method using peptide 
synthesis onto pins is the possibility of synthesizing a high number of different peptides. 
Scanning a protein sequence in single amino acid steps with a series of sequential peptides 
allows exact localization of the T cell determinants present in the protein. Complete scanning 
of lysozyme using this method for three strains of mice with different haplotypes showed 
markedly different T cell determinants for the strains used (Gammon et a!., 1991). 
An alternative functional method for tracing MHC class II restricted T cell 
determinants was developed in our laboratory (van Noort and van der Drift, 1989). This 
method is of major importance when the amino acid sequence of the protein is not known, 
but it is also applicable for known sequences. The protein is mildly digested by cathepsin D, 
a Iysosomallendosomal enzyme involved with cellular antigen processing. Subsequently, the 
fragments are separated and used in a T cell stimulation assay. Using this method, several 
proteins were analyzed for the presence ofT cell determinants (van Noort et al., 1991; Boots 
et a!., 1991; Boog et a!., 1993). Cathepsin D recognizes a certain motif of eight residues as 
substrate for digestion. Retrospectively, based on experimental data, the motif (hydrophobic)-
(Leu)-(hydrophobic)-(charged, polar or small)-(hydrophobic)-(hydrophobic)-(charged, polar 
or small)-(hydrophobic) was postulated (Van Noort and Van der Drift, 1989; see also 
Chapter 7 in this edition). In 50% of all sequences cleaved, a Leu residue is found at position 
PI (the residue prior to the scissile bond). The N- terminus of a processed T cell determinant 
is located adjacent to the cleavage site formed by cathepsin D. T cell determinants may be 
predicted in this way on the basis of the cathepsin D substrate motif. 
Fundamental questions about the length of the T cell determinant are difficult to 
answer (see also the following paragraphs). For MHC class II with an open peptide binding 
groove, a variety of peptide lengths can be found, but the minimal length appeared to be 
8-10 amino acids (Brown et aI., 1993; Rudensky et a!., 1991; Chicz et a!., 1993). 
In conclusion, it is clear that present prediction methods are not fully efficient due to 
the fact that they are based on peptide-MHC interaction. For a functional T cell determinant, 
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the interaction of this complex with the TCR is highly important. This interaction is, 
however, hard to predict. Selection of T cell determinants in a functional assay is most 
efficient, with the advantage that the target animal of choice can be involved. Especially for 
application in vaccines, experimental determination of useful sequences appears to be the 
method of choice. 
III. T CELL EPITOPE RESTRICTION 
Prediction methods for T cell epitopes do not take MHC polymorphism into account. Apart 
from MHC restricted T cell determinants (see Table 1), numerous promiscuous T cell 
determinants, capable of binding to different MHC haplotypes, were described also. Milich 
et a!. (1988) demonstrated that two different MHC class II restricted T cell determinants 
combined with a B cell determinant incorporated in one constlUct yielded an immunogen 
which was capable of eliciting B cell detenninant-specific antibodies in mouse strains with 
different MHC haplotypes (Table 2). 
TABLE 2 
Antibody responses to peptide constructs with MHC restricted T cell epilopes 
Construct 
TD'(l)·BD 
TD'(2)·BO 
TD~(3)-nD 
TO'(4)·BD 
TD'(5)·BD 
TDh-TD~-BD 
TD~-BD 
Anti-DO antibodies 
in mice with 
MHC haplotype 
x;y 
k;b 
k;b 
k; b 
k;b 
k; b 
b; k 
k; d 
b; d; f; k; q; r; s 
x and y can be any haplotype. 
Remarks 
BD=TD in H_2h mice 
Also Abs to TDh and TD~ 
New H_2J TD possibly formed 
in conjunctional sequence 
References 
Milich et aI., 1988 
Rzepc'Ykelal .,I990 
Londofioetal.,l9W 
Sinigaglia et aI., 1988 
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High-titer NANP-specific antibodies could be raised in both H_2b and H-2k mice after 
immunization with hybrid two~component peptides consisting of the NANP repeat from the 
immunodominant surface antigen of circumsporozoite protein (CSP) from Plasmodium 
ja/ciparufI/ and five different epitopes (T cell detelminants) of the merozoite surface antigen 
2 (MSA2) of P. ja/ciparlillll,JJ.:zepczyk et a!., 1990). The NANP repeat itself is poorly 
immunogenic in H-2b mice only (DelGuidice et a!., 1986; Good et a!., 1987). Even in studies 
using the (NANP), repeat coupled to a carrier protein, only a low level of anti-(NANP)[ was 
induced. This study also confirms the finding that genetic restriction can be overcome by 
addition of the proper epitope. A more striking finding was that the simple addition of a 
cysteine to the N-terminus of the peptide (NANP), markedly enhanced the immunogenicity 
in H_2b mice and generated antibodies in the nonnally non-responder H-2k mice. By 
introducing a Cys, dimers could possibly be formed, which could account for better T cell 
stimulation (see also paragraph on multiple copies), or a new T cell epitope could be formed 
in the junctional sequence of the dimer. There appeared to be some proof for the formation 
of dimers, since blocking the free -SH group renders the peptide non-immunogenic. 
Enhanced immunogenicity after the addition of a cysteine residue was reported for poliovirus 
peptides, hepatitis B surface Ag peptides and foot-and-mouth disease vilUspeptides (Ferguson 
et aI., 1985; Dreesman et aI., 1982; Brown et aI., 1984; Francis et aI., 1987b). 
The action of different MHC class II restricted T cell epitopes together in one hybrid 
peptide construct was explored in studies described by Londono et a!. (1990). They 
synthesized a tri-component peptide composed of (1) an H-2b restricted tandemly repeated 
tetrapeptide sequence (NANP) from the immunodominant surface antigen of circumsporozoite 
protein (CSP) from PlasmodiufI/ ja/cipal'llfl/, (2) an H-2' restricted T helper cell epitope 
(referred to as Th2R) from the non-repetitive part of the CSP sequence, and (3) a pure B cell 
determinant from P. ja/ciparlifl/ liver stage Ag, the LSA, a 17 residue repeat sequence. 
Special attention was paid to the connection of the three sequences to obtain a reciprocal 
reinforcement of the helical potentials of the Th2R and LSA helical components. With this 
tri-component peptide (NPNA)4N-Th2R-LSA", high and long lasting levels of antibodies 
were raised to all three components after a single immunization without adjuvant in mice with 
H_2b (B6 and BIO mice), H_2k (BIOBR and C3HiHe mice) and also H_2d<b (F1(BALBicxB6) 
mice) background, but not in H_2d mice (Table 2). The experiments indicated that each 
sequence containing an active T helper site induced antibodies against itself and helped 
antibody production to neighboring sequences, overcoming the genetic restriction of the 
immune response to the latter. Surprisingly, a di-hybrid peptide Th2R-LSA" induced 
antibodies recognizing the LSA sequence in H-2d mice in addition to antibodies against Th2R 
and LSA in H-2' mice. A newly formed H_2d epitope may be formed in the overlapping 
portion of the hybrid peptide. This H_2d epitope was, however, not active in the tri-
component peptide. Some hypotheses were proposed for this phenomenon. First, the NPNA 
repeats could induce in H_2d mice a specific T cell mediated suppression of the antibody 
response against the rest of the determinants in the tri-component hybrid. Possible 
suppression in H-2d mice might be overcome by conjugating the tri-component peptide to 
carrier proteins. Other explanations for the differences in the priming capacity between the 
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hybrids include differences at the level of the cognate interaction between T and B cells, 
differences in antigen processing and presentation or major alterations in the tri-hybrid 
peptide of the predicted <x-helix secondary stmcture of Th2R-LSA17 • These experiments 
clearly demonstrate the necessity to carefully explore all possible actions of the constituting 
components of a hybrid constmct. 
Sinigaglia et al. (1988) localized a promiscuous T cell detelminant in the CSP of the 
malaria parasite P. ja/ciparulll (residues 378-398 made with two Cys~Ala substitutions to 
prevent formation of a disulphide) which is recognized in association with most mouse and 
human MHC class II molecules. In mice with different genetic backgrounds (haplotypes b, 
d, f, k, q, I' and s), antibody titers specific for (NANP)J were raised with a synthetic hybrid 
peptide composed of the (NANP)J sequence, which is a B cell determinant, and the T cell 
determinant AA 378-398. The elicited antibodies were also crossreactive with sporozoites. 
T cell clones from eight non-immune human donors with different haplotypes (DR1, DR2, 
DR4, DRS, DRw6, DR7 and DR9) were derived upon ill vitro stimulation with that T cell 
determinant. Such a promiscuous T cell determinant may be valuable for incorporation in a 
synthetic anti-malaria vaccine, since individuals with different MHC class II alleles would 
respond to such a vaccine, 
In a study performed by Su and Caldwell (1992), a chimeric peptide composed of a 
T helper and a B cell determinant of the Chlamydia frachomafis major outer membrane 
protein induced antibodies in strains of mice with different H-2 haplotypes. The peptide 
sequence used as the T cell determinant was rather long (25 residues) and might therefore 
contain more than one T cell determinant. The antibodies all recognized the B cell 
determinant regardless the strain of mice used, but neutralizing antibodies were only found 
in some strains. The fine specificity of the antibodies as determined with the PEPSCAN 
method (Geysen et aI., 1984, 1987) did not appear to be MHC related, since both 
neutralizing and non-neutralizing antibodies were detected in strains of the same MHC 
haplotype. The difference in fine specificity may be a B cell related phenomenon, such as 
a "hole" in the B cell repertoire, or differences in genes that control the production of 
antibody to the epitope. 
In conclusion, MHC restriction to a certain synthetic construct may be overcome by 
incorporating a T cell epitope with the proper MHC restriction (Milich et aI., 1988; 
Rzepczyk et aI., 1990; Londono et aI., 1990) or a promiscuous T cell epitope (Sinigaglia et 
aI., 1988; Su and Caldwell, 1992). Special attention should be paid to the conjunctional site 
of two components, since new T cell epitopes may be formed or existing T cell epitopes may 
be lost (see also the following sections). 
IV. INFLUENCE OF CHAIN ELONGATION ON T CELL EPITOPES 
Ample evidence for the positive influence of elongated T helper cell detenninants concerning 
T cell and antibody responses has been collected in several studies. 
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Childerstone et al. (1990) determined the minimal peptide sequence from the N-
terminal region of a 3800 MW streptococcal antigen (residues 6-15) that stimulated T cells, 
Elongation of this T cell epitope with six residues (to residues 1-16) enhanced the 
proliferative T cell response roughly with a factor 2, These results were confirmed in a study 
in which an extended peptide was made to increase the amphipathic score of a T cell 
determinant, residues 26-40 from sperm whale myoglobin (Kim et aI., 1990), These latter 
elongated peptide (residues 24-42) induced proliferation of specific T cell clones at a 30-fold 
lower concentration than the short peptide. 
Ertl et al. (1991) showed that even very short peptides of 3-5 amino acids from the 
immunodominant region of the viral nucleoprotein of rabies virus (AA 404-418) were able 
to stimulate a T cell clone generated with intact rabies virus, They tested a series of peptides 
varying in length (3-32 amino acids long), The ability of peptides to induce a response was 
inversely correlated with their lengths, Short peptides had to be used at 10' times higher 
concentrations as compared to the long peptides (15 or 32 amino acids long), The specificity 
of the T cell response, however, was directly correlated to the length of the peptides, The 
response to 15 amino acids long peptides showed a high degree of specificity and the 
response to 3 to 5 amino acid long peptides showed a high degree of degeneration 
(flexibility), The long as well as the short peptides had to be presented in association with 
the same MHC class II haplotype (I-E') , 
In contrast to the studies described above, truncation of the N-terminus with one or 
two amino acids (Ser or Ser-Asp) of a minimal class I cytotoxic T lymphocyte (CTL) epitope 
(SDYEGRLI) from the nucleoprotein of influenza A/PR resulted in a higher binding affinity 
for a class I molecule than the epitope (Cossins et aI., 1993), The minimal CTL epitope was 
determined in a functional 51Cr release assay for recognition of a nested series of peptides 
by a specific class I restricted CTL clone in the presence of target cells. The relative binding 
affinities were measured using an indirect funclional competition assay, Briefly, a suboptimal 
epitope (IEGGWTGMIDGW) and varying concentrations of competing peptides were 
incubated with specific (for IEGGWTGMI) effector cells and labeled target cells and 
subsequently 51Cr release was measured. The N-terminal tnmcated peptides showed a higher 
inhibition of lysis than the minimal CTL epitope. The truncated peptides could not be 
recognized, however, by a class I restricted eTL clone, This study emphasizes the 
importance of choosing the proper functional read-out system when assigning the 
consequences of an engineered peptide construct on immune responses. 
Differential effects of chain elongation of T cell epitopes on the specificity of the 
antibody response in the mouse appeared to be strain related (partidos and Steward, 1992c), 
A peptide sequence derived from the fusion protein of measles virus (residues 240-252, 
GDINKVLEKLGYS(C)) induced both T and B cell reactivity in several strains of mice 
(C57BLl6, CBA, All and TO), but it elicited no reactivity in BALBlc and SWR mice, 
Elongation of this peptide sequence with six amino acids (GGDLLG(C» at the C-terminus 
showed both positive and negative effects. Extension was based on the presence of residues 
of moderate hydrophilicity, flexibility and protrusion index along with the presence of a {3-
turn. A cysteine residue at the carboxyl end of each peptide was introduced to increase 
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immunogenicity (Francis et aI., 1987b). The elongated peptide did induce an antibody 
response in BALBlc and SWR mice, but the Band T cell responsiveness disappeared in 
C57BL!6 mice. In addition, the antibody response was significantly higher after immu-
nization with the elongated peptide than with the shorter one. 
Using a major innnunogenic T cell determinant of pigeon cytochrome c (residues 
92-103), it was reported that N-terminal extension of the minimally required 12 to 23 
residues (stepwise addition of one amino acid was carried out) maximatly stimulated 
cytochrome c-specific T cell hybridomas (Srinivasan et aI., 1993). The elongated peptide had 
the ability to bind directly to MHC class II molecules and did not require processing. Even 
the addition of a second T cell epitope of tetanus toxoid to the cytochrome c sequence, which 
resulted in a peptide of 51 residues, further enhanced stimulation of cytochrome c-specific 
T cells without processing. Thus, regions of the antigenic peptide which lie outside the 
proposed peptide binding groove of the class II molecule can influence presentation ill vitro 
and subsequently the stimulation of specific T cells. 
Elucidation of the structure of the MHC class I (Bjorkman et aI., 1987) and class II 
molecules (Brown et aI., 1993) together with binding studies revealed some striking 
differences between the two MHC classes apart from similarities. The class I peptide-binding 
groove is blocked at either end, implicating that only peptides with restricted size (8-10 
residues) can bind. The class II binding groove is open at both ends and allows binding of 
a peptide which may stick out at both ends of the groove. Peptides varying in size (13-25 
residues) could be extracted from class II molecules (Rudensky et aI., 1991; Chicz et aI., 
1993). 
In conclusion, interpretation of the results discussed with respect to determination of 
T cell epitope length is hampered, since in only a few experiments was the exact optimum 
T epitope determined. Elongation of T cell determinants may have a dual effect. On the one 
hand, increased stability of a helix as a result of a longer peptide chain may enhance peptide 
binding to class II binding. The composition of the sequences used for elongation is, of 
course, of importance in achieving a helix conformation. This is not the case for class I 
molecules, since the length of the bound peptide is fixed. On the other hand, elongation may 
more effectively result in an enhanced immune response in animals with a different MHC 
haplotype than with a shorter TD. Keeping this in mind, extension of a T cell determinant 
probably will be most effective for class II determinants. Elongation of T cell epilopes 
positively influences the strength of the immune response and may influence the restriction 
pattern to MHC binding. 
V. POSITIONING OF T CELL EPITOPES IN CHIMERIC PROTEINS 
Different combinations of a T cell determinant (residues 65-85) and a B cell determinant 
(residues 422-436), both derived from the mycobacterial 65-kD protein, were used to study 
whether it was possible to stimulate the antibody response against a poor immunogenic B cell 
determinant (BD) by coupling this determinant to a potent T cell detelminant (TD) (Cox et 
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aI., 1988). The orientation of the two detelminants proved to have a profound effect on the 
magnitude and specificity of the antibody response. Only the BD-TD construct and not the 
TD-BD construct elicited antibodies specific for the B cell determinant (Table 3). Strikingly, 
both tested hybrid peptides stimulated T cell proliferation equally well. The TO monomer 
as well as the hybrid peptides (TD-BD and BD-TD) induced TO specific antibodies. The 
extent of the TD-specific antibody response was substantially decreased after immunization 
with the TD-BD construct. The TO, in monomer and hybrid, has a well-defined IX- helical 
structure. The proline residue at the N-telminus of the B cell determinant is likely to disturb 
the IX-helical nature of the hybrid TD-BD construct, resulting in an abrogated BD-specific 
antibody response in case of the TO-BO. The role of the proline at the N-terminus of the 
BD-TD construct is not important for the secondary stmcture of the constmct, and antibodies 
specific for the B cell detelminant can be elicited. 
TABLE 3 
Antibody responses elicited with hybrid TO-BD construcls 
ImJllunogen Anti-TO Anti-EO Remarks References 
TD-BD + Proline at N- Cox el aI., 1988 
BD-TD + + terminus BD 
TD-BD + Golvano el aI., 1990 
ED-TO + 
TD-BO + Linear Levely el aI., 1990 
BD-TD + Linker (EMH coupling) 
TD-BD + Partidos et aI., 19923 
BD-TD + Appeared to be slrain 
related Pmudos el aI., 1992b 
(151-174)-(133-143) + Milich el aI., 1990 
=TD-BD 
133-174 + 
=BD-TD 
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In another study, described by Golvano et al. (1990), combinations of two T cell 
detcllllinants and two B cell detelminants in hybrid constmcts were evaluated for their ability 
to raise antibody responses. It was demonstrated that TD-BD constructs elicited antibodies 
specific for the B cell determinant and no, or low levels of, antibodies specific for the T cell 
determinant. Contrary to this, the BD-TD constructs induced antibodies specifically directed 
against the T cell determinant and not, or only at a low level, against the B cell determinant. 
It was hypothesized that enzymatic processing of the constructs by antigen presenting cells 
probably might be responsible for the difference in antibody responses, The lysine or arginine 
at the C-terminus of the T cell determinant may provide a cleavage site for certain proteases. 
Such a site is not present in the BD-TD constmcts; here, the lysine or arginine is at the C-
terminus of the complete construct. 
Levely et al. (1990) compared a linearly synthesized constmct yielding a TD-BD 
configuration with a construct in which the T cell and the B cell determinant were chemically 
coupled to each other via their tC1TIlinai cysteines with the linker bismaleimidohexane yielding 
a BD-(linker)-TD constmct. The TD-BD construct elicited BD-specific antibodies, but with 
the BD-(linker)-TD construct TD-specific antibodies were found only, Proliferative responses 
were similar for both constlUcts. The orientation of the TD appeared to detennine the 
specificity of the antibody response. However, it is not quite clear whether this is due to the 
method used for coupling of the determinants or a mere consequence of the polarity of the 
hybrid peptide, 
The importance of the mutual orientation of T and B cell determinants in one hybrid 
constlUct on the antibody response induced with such constructs was confirmed by Partidos 
et al. (1992a), Synthetic constructs were used with a T cell determinant (residues 288-302) 
and a B cell determinant (residues 404-414) from the F protein of measles vims, Chimeric 
peptides in which the T cell epitope was synthesized to the N-terminus of a B cell epitope 
induced primarily antibodies which recognized the B cell determinant. In contrast, 
localization of the T cell epitope at the C-terminus of a B cell epitope induced antibodies 
preferentially reactive with the T cell epitope, In a later study, it was found that positioning 
of the T cell epitope was strain related (Partidos et aI., 1992b), In TO mice (H-2'), the N-
terminal orientation of the T cell epitope with respect to the B cell epitope was the most 
effective, whereas in eBA mice (B_2\.:) the C-terminal orientation was the best in inducing 
high levels of antibodies specific for the B cell epitope, This may reflect differences in 
processing and presentation of the chimeras by the two mouse strains. The strain dependency 
was previously reported in a study using multiple antigen peptides with epitopes from the P. 
Ja/cipartllll circumsporozoite (Munesinghe et aI., 1991), 
Both the orientation of the T and B cell determinants and the context of the T cell site 
within the larger composite peptide was found to influence both antibody fine specificity and 
T cell fine specificity (Milich et aI., 1990), A hybrid peptide consisting of the dominant T 
cell determinant of the pre-S(2) region of the hepatitis B surface antigen (residues 151-174) 
positioned N-terminally to a dominant B cell determinant (residues 133-143) from the same 
protein yielded an effective pre-S(2) synthetic immunogen (151-174)-(133-143) = TD-BD, 
Antibody and T cell responses obtained with this hybrid construct were compared with the 
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responses obtained with a linear peptide li'om the native sequence (residues 133-174) in 
several strains of mice with different MHC class II haplotypes. The 133-174 peptide induced 
anti-peptide antibodies in all strains, but these antibodies were not crossreactive with the 
native protein. The level of antibodies specific for the 156-174 peptide (a minor antibody site 
after immunization with HBsAg) was significantly higher than the levels of antibodies 
specific for the 120-145 peptide, which contains two dominant group-specific pre-S(2) 
antibody sites 133-139 and 137-143. Strikingly, reversion of the T and B cell determinants 
induced a qualitatively different immune response. The (151-174)-(133-143) constmct 
(=TD-BD) generated antibodies primarily specific for the 133-143 sequence. Above all, 
these antibodies recognized the native HBsAg protein, A low level of antibodies specific for 
the 156-174 region was found. Also T cell responses of lymph node cells from mice primed 
with one of the pep tides qualitatively differed. Two overlapping T cell epitopes, 156-170 and 
161-174, were found in the 151-174 region. The 133-174 primed T cells recognized the 
156-170 site, but not the 161-174 site. Conversely, (151-174)-(133-143) primed T cells 
preferentially recognized the 161-174 site, and the 156-170 site was less well recognized. 
In addition, it was observed that differences in T celJ specificity OCCUlTed after elongation 
or shortening of the T cell determinant (148-174,156-174, 161-174). 
Lowenadler et al. (1992) investigated how individual Band T cell epitopes are 
functionally linked to each other in a multi-determinant fusion protein. They constructed 
fusion proteins with two different B cell determinants derived from different proteins (Table 
4). The two B cell determinants were separated by one, two or four copies of a dominant T 
cell epitope (ovalbumin residues 323-339) (Shimonkevitz et aI., 1984; Buus et aI., 1987) 
dominant in H-2" mice (BALB/c). A peptide spacer (an IgG binding peptide) was positioned 
upstream or downstream of the T cell epitopes. The immunological relationship between T 
and B cell epitopes was examined by measuring specific T cell activation and antibody 
responses in animals inmlUnized with chimeric peptides containing the inserts in varying 
numbers (1, 2 and 4 copies). The antibody responses against B cell determinants at the amino 
and the carboxy terminus, respectively, were differently influenced by the molecular 
localization of the inserted Th determinant (Table 4). All fusion proteins containing the Th 
epitopes induced antibody production against the B cell determinant at the amino terminal end 
irrespective of the positioning of the T cell determinants. Only a very weak antibody 
response was observed against the B cell determinant at the carboxy terminus after 
immunization with fusion proteins with single or multiple copies of the T cell determinant 
in the adjacent position. Similar results were obtained with constmcts containing one or two 
copies of the T cell determinant in a distal position. This B cell detemlinant proved to be a 
minor epitope in these constmcts. However, four copies of the T cell deterJ1llnant in a distal 
position markedly enhanced the antibody response. The authors concluded that specific T cell 
help for antibody production was more effective when the T cell determinants were placed 
in a distal position. Furthermore, a fusion protein containing four copies of the ovalbumin 
(OVA) T cell determinant effectively elicited T cell help for high levels of antibody produc-
tion against both B cell determinants examined, showing that activated Th cells recognizing 
a single epitope sillluitaneously provide help for distinct sets of B cells specific for widely 
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TABLE 4 
Antibody responses elicited with fusion proteins 
Iml1mllogen 
BD I-spacer-TD-BD2 
BD l-spacer-(TD),-BD2 
BD l-spacer-(TD)4-BD2 
BD 1-TD-spacer-BD2 
BD 1-(TD),-spacer-BD2 
BD 1-(TD),-spacer-BD2 
From Lowenadler et al. (1992). 
Anti-BD! 
+++ 
+++ 
++++ 
++ 
+++ 
++++ 
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Anti-BD2 
+ 
± 
+++ 
spaced epitopes within a protein. Only the influence of inserting a spacer between the T cell 
determinant and the B cell determinant was investigated in these experiments, They did not 
investigate the influence of positioning the T cell determinant(s) N- or C-terminally of the 
same B cell determinant. 
The examples above (Table 3) demonstrate that in most cases the antibodies are 
elicited against the C-terminal part of the hybrid constructs. The investigation of Cox et a1. 
(1988) is an exception. With the TD-BD constmct, TD-specific antibodies were found in 
their study. It was hypothesized that the conformation of the constmct might playa role in 
directing an antibody response. The a-helical conformation in the TD-BD construct is 
disturbed by a proline situated at the N-terminus of the BD. Altered antigen processing 
and/or presentation may be the result. Differences in antigen processing and presentation 
were also assumed for the strain dependant antibody response, as was observed by Partidos 
et al. (1992b). Strikingly, the T cell proliferation was similar for both orientations of a 
hybrid constmct (Cox et aI., 1988; Levely et aI., 1990). 
In conclusion, a light preference for the N-tenninal position of a TD seems to exist. 
No generals rules can be applied, however, for the best localization of a TD in a hybrid 
(TDIBD) constmct with the aim of optimal BD-specific responses. Once again, to date, 
experimental testing of all possible combinations is the best approach in designing 
immunogenic constmcts. 
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VI. IMMUNODOMINANCE 
Despite the ability of each MHC molecule to bind many different pep tides, the T cell 
response after immunization with a whole protein is directed to a few and often only to onc 
of the processed peptide determinants (Roy et a!., 1989). Several mechanisms might explain 
this observed inmlUllodominance of certain T cell determinants: (a) the relative availability 
of the antigenic determinants after processing (Gammon et a!., 1987; Adorini et a!., 1988b); 
(b) the relative affinity of their binding to MHC molecules (Buus et a!., 1987); (c) 
competition at the levels of antigen processing, binding and presentation among different 
determinants restricted to the same or different MHC molecules (Guillet et al., 1987; Adorini 
et a!., 1988b); (d) the frequency in the individual's peripheral T cell repertoire of clones that 
can be stimulated by each determinant class II complex (Schaeffer et a!., 1989; Adorini et 
a!., 1988b; Galronon et a!., 1990; Perkins et a!., 1991b); (e) regulatory mechanisms such as 
suppression (Sercarz and Krzych, 1991). 
Elongation of a selected T cell detennillant with a sequence representing, e.g., a B 
cell determinant may strongly influence stmctural and physicochemical features of the T cell 
determinant with altered antigen presentation as a result. Immunodominance of a newly 
formed T cell determinant may emerge from such combined sequences (Bhardwaj et at., 
1992). In fact, it is often seen that in chimeric peptides an overlapping new TD is formed 
(Perkins et a!., 1991a; Wang et a!., 1992a, 1992b). This newly formed junctional T cell 
determinant of a hybrid peptide was found to be inununodominant in several strains of mice 
with a different H-2 haplotype (Wang et a!., 1992b). They also found that chimeric peptides 
did not require processing (Perkins et aI., 1991a; Wang et a!., 1992a; Bhardwaj et a!., 
1992), and hence, the enhanced immunogenicity of certain determinants may be due to 
competition for stimulation of T ceJls superimposed upon a hierarchy of competitive binding 
among diffel'cnt TD sequences of the complete peptides into the groove of the MHC 
molecule. When a peptide spanning the sequence of the overlapping new TD was covalently 
linked to a different previously defined TD, antigenicity of the immunodominant junctional 
region was silenced and a new epitope assumed ioul1unodominance (Wang et al.. 1992b). The 
immunodominant epitope is determined by complex interactions among the epitopes, which 
most likely depend on the stmctural conformation of the composite peptide. 
For MHC class II, there seems to be a preference for binding of longer peptides at 
a central position rather than at either end. To avoid central binding, a hybrid peptide of 51 
residues, composed of two known (a-helical peptides) T ceil determinants joined by a {3- turn 
to allow stable association of the a-helical peptides, was constmcted (Srinivasan et at., 
1993). This long peptide construct retained ils ability to trigger a T cell response specific for 
one of the original T cell determinants. Therefore, conjunctions may be constructed keeping 
the two separated T cell determinants functional with the constraint that the stmctural units 
are taken into account. 
Smolenski et a!. (1990) found that several peptides from different proteins could 
compete in vitro for presented antigen binding sites on antigen presenting cells with processed 
cytochrome c. The cytochrome c- specific T cell response could be blocked in an MHC 
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unrestricted manner. They speculated that peptides may be bound to APC stmctures other 
than MHC class II molecules prior to the association with MHC class II. In addition, an 
important role in the inununodominance phenomenon may be attributed to the MHC class 
II associated invariant chain Ii. Recently, it was demonstrated that particular epitopes derived 
from hen egg lysozyme (HEL) could be preferentially presented probably due to Ii 
modulation (Momburg et aI., 1993). Maybe the Ii is the APC stmcture speculated about by 
Smolenski and co-workers. 
These studies demonstrate the so far unpredictable effect of flanking sequences on 
peptide recognition. Induced changes in peptide conformation, which either promote or 
inhibit appropriate interaction with the class II molecule or the TCR, may be the cause of this 
effect. Newly formed immunodominant T cell epitopes in the junction of a TD and BD are 
highly undesirable for application in vaccines. As demonstrated by Srinivasan et al. (1993), 
this effect can be avoided by keeping the stmctural units (a-helical peptides) intact. Keeping 
these investigations in mind, it is highly recommended that elongation of a selected T cell 
determinant with other T cell detelminants or a B cell determinant with the aim to construct 
a strong and/or promiscuous immunogen should be accompanied by a thorough investigation 
into the effect on T cell determinant usage in the system under study. 
VII. INFLUENCE OF MULTIPLE COPIES OF T CELL EPITOPES 
Many investigators have demonstrated the beneficial effect of inserting multiple copies of a 
T cell epitope in a synthetic immunogen for raising a proper antibody response (Leclerc et 
aI., 1987; Borras-Cuesta et aI., 1988; Cox et aI., 1988; LOwenadler et aI., 1990; Munesinghe 
et aI., 1991; L6wenadler et aI., 1992; Partidos et aI., 1992b). The mechanisms responsible 
for this property could be multiple and were the subject of many studies. 
Linear homopolymers of peptides (the monomers consisted of ordy a B cell 
determinant or the B cell determinant was extended N-terminally with a T cell determinant), 
made by using a carbodiimide coupling with side chain protected peptides, were used to study 
immunogenicity (Borras-Cuesta et aI., 1988). Two different B cell determinants were used. 
Three of the four polymers showed enhanced antibody responses. The generation of a new 
T cell epitope in the junction of the monomers was suggested by the investigators. They used 
several prediction methods to validate their assumption. One method (DeLisi and Berzofsky, 
1985) indeed predicted a new T cell determinant for two of the three polymer peptides that 
showed an enhanced immunogenicity. With anolher method (Margalit et aI., 1987), a 
predicted reinforced amphipathic pattern was found for all three polymer peptides, but lhis 
method could not predict a new T cell determinant. 
Also, fusion proteins containing multiple copies of the major antigenic determinant 
of foot-and-mouth disease vims were shown to have enhanced immunogenicity (Broekhuijsen 
et aI., 1987). 
LOwenadler et al (1992) constmcted fusion proteins with lwo different B cell 
determinants derived from different proteins. The two B cell determinants were separated by 
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one, two or four copies of a dominant T cell epitope. A peptide spacer was positioned 
upstream or downstream of the T cell epitopes (see Table 4). Multiple copies of the T cell 
determinant in any position led to increased levels of antibody production against the N-
terminal B cell epitope, confimling earlier findings of a stoichiometric relationship between 
T and B cell epitopes in B cell activation (L6wenadler et aI., 1990). Four copies of the T cell 
determinant in a distal position improved the poor antibody response to the C-terminal B cell 
determinant. Lymph node cells of BALB/c mice primed with the different chimeric fusion 
proteins proliferated, in vitro, to a similar extent in response to a synthetic peptide containing 
the T cell epitope and thus did not reveal any differences in priming efllciencies of the 
various constructs. T cell activation was also examined by measuring IL-2 production by a 
T cell hybridoma specific for the T helper determinant used in their constmcts. The level of 
IL-2 production by this T cell line was correlated to the number of T cell epitopes in the 
fusion peptide. Furthermore, there was an absolute requirement for uptake and processing 
of the constmcts since fixed antigen presenting cells failed to trigger IL-2 production. In 
contrast, presentation of the isolated synthetic T cell peptide was only partially inhibited in 
fixed antigen presenting cells. To exclnde the possibility that any newly formed T cell 
epitope in the junction of two fused sequences contributed to T cell activation, the 
proliferative response to a junctional peptide spanning six amino acids on either side of the 
fusion point was examined. Lymph node cells of mice primed with any of the constructs did 
not recognize the junctional peptide. 
These experiments demonstrate the stoichiometric relationship between the number 
of copies of T cell determinants and antibody production which proved to be based on an 
increased level of IL-2 production rather than on an enhanced T cell proliferation. The 
results, however, were obtained from in vitro proliferation data. It is not clear whether these 
conclusions are also valid under physiological conditions. The absolute numbers of specific 
T cells after immunization with the different constmcts were not determined. On the other 
hand, the increase in antibody production also may be the result of increased T cell cytokine 
production rather than the expansion of specific Th cells by proliferation, since, ill vivo, 
proteins with multiple copies of a T cell determinant may trigger increased production of 
other cytokines, e.g., IL-4, that are important in regulating B cell activity. Indeed, it was 
shown by Evavold and Allen (1991) that antigen recognition may result in IL-4 production 
by T cells even in the absence of proliferation. 
Sette et al. (1990) incorporated the core region crncial for class II binding in multiple 
copies in the same peptide ("reiterative motif") and measured the binding capacity of this 
peptide for purified MHC class II molecules. They showed that the relative binding capacity 
increased a factor of 27.7 for the reiterative motif VHAAHA VHAAHA VHA derived from 
the I-Ad restricted T cell determinant of ovalbumin (AA 323-339) ISQA VHAAHAEINEAGR 
(Sette et al., 1987). This binding remained I-Ad specific, because the relative binding capacity 
for I-Ed was less than 1 % of the binding capacity for I-Ad When the peptide spacer EIN (AA 
333-335) was inserted between two copies of the core motif, the relative binding capacity 
for I-A" decreased to 1.6. In contrast, positioning the peptide spacer EIN at the end of two 
copies of the core motif yielded a binding capacity of24.8. It may be questioned if two core 
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motifs subsequently repeated arc sufficient for maximum binding capacity, Similar results 
were obtained with the I-E' restricted T cell determinant from HEL (AA 105-120) and the 
I_Ed restricted T cell determinant from the A-repressor protein (AA 12-26). These data 
showing enhanced binding capacity of the reiterative motif support the hypothesis that 
cooperative stabilization of peptide secondary structures is favorable for class II binding. 
Insertion of the tri-peptide spacer prevented the stabilization, but placing the spacer C-
terminally of the two copies did not influence the stabilization. Since it was known from 
earlier studies (Sette et at., 1989b) that a Val ~ Ala substitution at position 327 did not affect 
the binding of the peptide to I-A', the analog reiterative motif peptide composed of only two 
amino acids (AHAAHAAHAAHAAHAA) was tested for I-Ad binding. This peptide even 
appeared to bind very strongly to I-A' with an enhanced relative ilinding capacity of 34. 
The OVA reiterative core peptide (VHAAHAVHAAHA VHA) also inhibited antigen 
presentation to an OVA-specific T cell line of the complete natural T cell determinant by 
fixed antigen presenting cells. This suggests MHC binding at the same site which is involved 
in T cell activation. Reiterative core motifs do not directly stimulate T cells since a part of 
the complete natural T cell epitope is missing, 
Naturally occurring clustered class II binding sites have been identified. This implies 
a possible role for reiterative-like stmctures in the generation of immunodominant regions. 
Three overlapping I-Ed motifs have been found in dynorphin AA 1-13 (Sette et aI., 1989b). 
The 327-332 OVA core motif is inlllediately preceded by another I-A' motif321-326. Other 
examples are the influenza virus hemagglutinin 121-146 region (two apparent I-A" sites (Sette 
et aI., 1989a); the HEL 105-129 region (two apparent I-Ed sites) (AdOl'ini et aI., 1988a); the 
pigeon cytochrome c 81-104 region (two apparent I-E' sites)(Carbone et aI., 1987); the 
staphylococcal nuclease 1-40 region (at least two independent I_Ek sites)(Schaeffer et aI., 
1989); and in some regions of the VP1, VP2 and VP3 capsid proteins of human rhinovirus 
(Hastings et aI., 1993). 
We think that for an estimate of the practical implications, these findings should be 
further investigated ill vivo by analyzing qualitatively and quantitatively the antibody response 
after immunization of mice with peptide constructs composed of either (a) the complete 
natural T cell determinant, or (b) the repeated core motif extended with the necessary 
flanking sequence to obtain a complete T cell determinant, and both (a) and (b) combined 
with a B cell detenninant. 
Elongation of a T cell epitope sequence may increase the amphipatic score in a 
predictive algorithm (AMPHI) or may enhance the T cell response as measured in a 
proliferation assay (Ert! at aI., 1991; Kim et aI., 1990). These results are further extended 
evidence for increased conformational stability of the elongated T cell epitope and therefore 
for increased efficiency. 
Using a multiple antigen peptide containing four copies of tandemly arranged T and 
B cell epitopes. from the repeat region of the P. Jalciparum circumsporozoite protein, 
optimal antibody responses were obtained (Munesinghe et aI., 1991). 
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Both the level of specific antibodies and the affinity for the B cell determinant of these 
antibodies were enhanced after immunization with hybrid peptide constructs containing a 
double copy of a T cell determinant located at the N- or C-terminus of a B cell determinant 
as compared to constructs with a single copy of the T cell determinant (Partidos et aI., 
1992b). In these constructs, the Band T cell detenninants were separated by a gly-gly 
dipeptide spacer. In this study, position of the T cell determinant at the N-terminus of the 
B cell determinant appeared to be more advantageous in terms of affinity. 
The examples above demonstrate that multiple copies of a T cell determinant may lead 
to an increase of the immune response, which could be both quantitatively higher and 
qualitatively better in terms of affinity, Several mechanisms can contribute to this phenom-
enon. An increased conformational stability of the T cell detenninant as a result of 
cooperative action of multiple copies within one molecule may lead to a higher binding 
constant between the MHC molecule and the T cell determinant. In addition, new potential 
T cell epitopes may be generated in the junction of the monomers. A stoichiometric 
relationship between copy number of T cell epitopes and the number of MHC molecules 
which are occupied with a Th peptide exposed at the cell membrane of the antigen presenting 
cell may lead to a more efficient activation of T cells at higher T iB cell epitope ratios. It is 
also conceivable that the level of IL-2 production andior of other cytokines increases upon 
antigen presentation of a constmct with multiple copies of a T cell epitope with more 
efficient activation of antibody fOlming cells as a consequence. 
VIII. INFLUENCE OF COUPLING MODES ON T CELL EPITOPES 
Linear constmcts consisting of a selected T cell determinant and a B cell determinant can be 
made by linear synthesis. A linearly synthesized hybrid peptide often consists of more than 
30 residues. An alternative method may be linking the two determinants after synthesizing 
them separately. This latter method offers the advantage of the combination of a stock of a 
well documented T cell determinant with various B cell detenninants. A large batch of the 
T cell determinant ensures a constant quality when comparing different B cell determinants 
in hybrid constructs. Another advantage is that it is then possible to synthesize shorter 
peptides, since efficiency of peptide synthesis gradually decreases with length. 
Coupling of the two detelminants via their N-terminal amino group, their C-tcrminal 
carboxyl group or via a functional group of one of their amino acids, however, may influence 
the epilope orientation and the secondalY structure of the composed peptides or may alter the 
immunogenic epitope. Examples from the literature making use of different coupling methods 
resulting in both effective or useless constructs will be discussed. 
One of the first experiments using peptide constructs, which encompass both a T cell 
and a B cell determinant, made by covalent coupling via a linker, was described by Good et 
al. (1987). They coupled a predicted and subsequently proven T cell determinant from the 
malaria circumsporozoite protein via its C-terminal cysteine with the aid of MBS to the N-
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terminal amino group of the NP(NANP)I,NA peptide, a B cell determinant from the same 
protein. This construct elicited high-titer antibodies specific for NP(NANP)I,NP. However, 
in their experiments, they did not differentiate between the antibody response specifically 
directed to the T cell determinant or B cell determinant, nor did they analyze the 
functionality of the elicited antibodies in a neutralization assay. Nevertheless, this study is 
the first proof of the ability of a synthetic construct made by conjugation via a linker to elicit 
B cell determinant-specific antibodies. 
Co-polymers of a B and a T cell determinant derived from different proteins, made 
by glutaraldehyde, elicited B cell determinant-specific antibodies (Leclerc et aI., 1987). In 
a study performed by Jolivet et al. (1990), co-polymers of four different peptides of which 
at least one of the peptides represented a T cell determinant were made by glutaraldehyde. 
The polyvalent synthetic peptides induced antibodies directed against each of the four 
component peptides in outbred guinea pigs. Linkage via glutaraldehyde makes use of amino 
groups. Only one of the foUl' peptides contained several Iysines scattered through the whole 
sequence. But despite linkage via the lysine residues which may destroy the epitope, and 
despite random orientation of this peptide antibody. induction against this epitope was not 
prevented. 
In a study from Levely et al. (1990), two methods of construction of hybrid peptides 
were compared. They linearly synthesized a peptide composed of a T cell determinant, at the 
N-terminal side of a B cell determinant both derived from proteins from the respiratory 
syncytial virus separated by a gly-gly spacer. These determinants were also chemically 
conjugated by means of a natural N-terminally located cysteine in the T cell determinant and 
an added N-terminal cysteine in the B cell determinant. The cysteines were coupled by the 
homo-bifunctional linker bismaleimidohexane (BMH). The chimeric peptides induced 
different specific antibody responses. Also, the free T cell determinant induced peptide-
specific antibodies. The antibodies found after immunization with the linearly synthesized 
hybrid peptide were mainly directed to the B cell determinant, while the antibodies found 
after immunization with the chemically constructed peptides were principally directed against 
the T cell determinant. The consequences are discussed in Section V. 
Similar results were found in experiments performed in our laboratory (Zegers et a1., 
1993). We constructed hybrid peptides by linear synthesis and by different chemical 
conjugation. The T and B cell determinants were coupled by the homo-bifunctional linker 
BMH or by the hetero-bifunctional linker MBS. Additional cysteines were incorporated in 
the sequences of the determinants for coupling purposes. The cysteine was placed C-
terminally in the T cell determinant and C- or N-terminally in two different B cell 
determinants. First, with MBS conjugation, the thiol group of the B cell determinant was 
blocked with ethylmaleimide. After reaction of MBS with one of the amino groups of the B 
cell determinant, the T ceJI determinant was coupled. After immunization with these different 
constlUcts, only T cell determinant- specific antibodies were found with the chemical 
constructed peptides, while both T- and B cell determinant-specific antibodies were found 
with the linearly synthesized peptides. 
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Several explanations can be given why in this case we did not find B cell determinant-
specific antibodies with chemically linked constructs. First, chemical modification of the B 
cell determinant, introduced during coupling procedures, might have altered or destroyed the 
immunogenic determinant. We therefore analyzed the antibody response in an enzyme-linked 
inununosorbent assay on isolated chemically modified B cell determinants. However, 
antibodies specific for a modified B cell epitope were not found. Previously, high-titer anti-
bodies specific for the B cell determinant were elicited with conjugates of keyhole limpet 
hemocyanine (KLH) and the B cell determinants made by coupling with MBS. For these B 
cell determinants, the thiol group of an added cysteine to the B cell epitope was used. Thus, 
chemical crosslinking using thiol groups did not destroy immunogenicity by itself. However, 
antibodies specific for the B cell determinant could not be raised with a KLH conjugate made 
by coupling with glutaraldehyde. We then concluded that lysine residues in this specific B 
cell detelminant are important for immunogenicity and therefore should not be used for 
coupling (Zegers et aI., 1990). Second, antigen processing or presentation also may have 
impaired the antibody response against the B cell determinant after immunization with chemi-
cally linked constmcts. It is conceivable that these TO-specific antibodies are elicited by the 
free TO molecules still present in the preparation of the hybrid constmct. On the other hand, 
the chemically conjugated constmct might not be processed properly which impairs binding 
of TD to MHC molecules. Antigen presentation is thus hampered, resulting in the absence 
of BD-specific antibodies. Several investigators have proposed that adjacent sequences may 
alter the conformation of an epitope, resulting in significant altered antigen processing or 
changes in T cell recognition (perkins et aI., 1991a; Wang et aI., 1992a, 1992b; Kim and 
Jang, 1992). 
As appears from the examples above, in appropriate designed experiments, chemically 
coupled TD-BD constmcts may lead to the induction of BD-specific antibodies (Good et aI., 
1987; Leclerc et aI., 1987; Jolivet et aI., 1990). Glutaraldehyde 01' MBS are the linkers of 
choice. However, these coupling reagents did not appear to be useful if amino groups of 
residues present in the sequence of the BD were used for coupling (Zegers et aI., 1993). 
Conjugation with BMH did not yield constmcts which elicited BD-specific antibodies (Levely 
et aI., 1990; Zegers et aI., 1993). 
IX. IS COVALENT COUPLING OF T AND B CELL EPITOPES NECESSARY? 
In order to obtain an optimal humoral immune response, Band T cells must cooperate in 
close conjunction (Kupfer et aI., 1986; Vitetta et aI., 1987; Noelle and Snow, 1990; Clark 
and Ledbetter, 1994). The cognate interaction between helper T and B cells involves the T 
cell receptor which recognizes the antigen presented in association with MHC class II 
molecules at the cell surface of B cells. Also, the CD3 and the CD4 molecules are associated 
with this complex. Besides this cognate interaction, second co-stimulatory signals between 
T and B cells are necessalY for activation of B cells to differentiate and proliferate. CD28 
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and B7 interaction plays a major role, and recently, the interaction between gp39 (activated 
T helper cells) and CD40 (B cells) was described (Noelle et a!., 1992). Moreover, certain 
lymphokines produced by activated T cells are essential factors involved in antibody 
production. Lymphokines are active only in high local concentrations and are therefore 
optimally inductive only within short distances from their production site. Bartlett et a!. 
(1989) showed ill vitro that "bystander" B cells were less frequently induced into cell cycle 
than B cells in contact with T cells. Moreover, the B cells in physical contact with T cells 
had a higher RNA content and were larger than the bystander B cells present in the same 
cultures. Entry of B cells into the GI phase appeared to be antigen and T cell contact 
dependant, but not lymphokine dependant. Lymphokines were needed for cycle progression 
to S phase. Several other reports support the view that conjunction of Band T cells is 
required for B cell triggering (Kupfer et a!., 1986; Vitetta et a!., 1987; Noelle et a!., 1983; 
Krusemeier and Snow, 1987), There are, however, also reports which describe lymphokine 
induced polyclonal B cell cycle entry in an MHC unrestricted manner and subsequent 
progression to S phase for 20% of the B cells (Leclercq et a!., 1984, 1986; Defranco et a!., 
1984). A fraction of these cells differentiates and produces Ig, although at a lower rate than 
terminally differentiated plasma cells (Leclercq et a!., 1986). 
B cell activation via CD40 is required for specific antibody production and can also 
he induced ill vitro, besides through T cell interaction, by a soluble recombinant gp39 or by 
an anti-CD40 antibody in the presence of cytokines (Hollenbaugh et a!., 1992; Gascan et a!., 
1991; Nonoyama et a!., 1993). Also, ill vivo, the involvement of CD40-gp39 interaction was 
established to be essential for thymus dependent humoral immunity in our own laboratory 
(Van den Eertwegh et a!., 1993). 
Minimal requirements for antibody production to peptide antigens were defined in a 
study by Goodman-Snitkoff et a!. (1990, 1991). They crosslinked a T cell as well as a B cell 
epitope to a hydrophobic anchor and complexed these epitopes into the phospholipid bilayer 
of liposomes resulting in a multivalent configuration. These immunogens were able to induce 
production of antibodies specific for the B cell epitope. Liposomes with a linear peptide 
comprising a T and a B cell determinant also induce B cell determinant-specific antibodies. 
These data suggest that Th epitopes do not have to be covalently linked to the B cell epitope 
to be active, but that intrastructural help is equal to intramolecular help. 
Recently, some papers were published describing antibody production specific for B 
cell determinants after inununization with mixed uncoupled T and B cell detelminants 
(Sa robe et a!., 1991; Partidos et ai., 1992d; Shaw et ai., 1993). This antibody production can 
only be explained by assuming direct binding (or after internalization) of the T cell 
determinant to class II molecules of the B cell having recognized the B cell determinant. 
Direct binding to MHC class II molecules could take place by competition of the T cell 
determinant with a (sell) peptide that is already present in the cleft of the MHC class II 
molecule. To accomplish this, the affinity of the T cell determinant for the class II molecule 
should be much higher than the affinity of the peptide bound in the MHC molecule. 
Stimulation via this pathway is probably very inefficient. A (locally) velY high concentration 
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of the Th peptides is thus required. Binding of the TD to the class II molecule after 
internalization by the B cell favors the hypothesis of intermolecularlintrastlUctural help (Lake 
and Mitchison, 1976; Milich et aI., 1987; Goodman-Snitkoff et aI., 1990,1991). In the 
studies which describe co-immunization of the TD and the BD in a mixture, the peptides 
were emulsified in (complete) Freund's adjuvant. Both the TD and the BD peptide should 
be entrapped in the same micro-droplet to give intrastructural help. Evidence for the 
assumption of simultaneous presence of both T and B cell determinants in one droplet came 
from the study of Partidos et al. (l992d). B cell-specific antibodies only were detected after 
immunization with both BD and TD peptides mixed in the Freund's adjuvant emulsion. Intra-
peritoneal immunization of the TD combined with subcutaneous immunization of the BD at 
the same moment did not result in BD-specific antibodies. The possibility of associated, non-
covalently bound TD-BD complex formation cannot be excluded. Co-immunization of a poor 
immunogenic peptide from the malaria circumsporozoite protein together with keyhole limpet 
hemocyanin raised peptide-specific antibodies (Good et aI., 1988). In contrast to this finding, 
we observed that "pseudo conjugates", formed by non-specific adherence of peptides to 
carrier molecules, were not able to elicit a peptide-specific antibody response (Deen et at., 
1990). Similarly, immunization with a mixture of the nucleocapsid (strong immunogen) of 
the hepatitis B virus with envelope antigen (not immunogenic) of the virus did not result in 
anti-envelope antigen-specific antibodies, whereas a particle (virion) encompassing both 
proteins did (Milich et aI., 1987). These effects can hardly be explained as the result of 
bystander help as suggested by Partidos et al. (1992d) since only a small proportion of the 
B cells can be activated via this pathway (Bartlett et aI., 1989). Moreover, the level and 
affinity of the antibodies to the B cell epitopes following immunization with mixed, non-
covalently bound TD and BD peptides was lower than that obtained following immunization 
with an analogous chimeric TD-BD constlUct (Shaw et aI., 1993). 
In our laboratory, we were not successful in applying co-immunization with TD and 
BD peptides (Zegers et aI., 1993). Our experiments indicated that induction of BD-specific 
antibodies with a mixture of free TD and BD peptides is certainly not possible with all 
combinations of T and B cell determinants. In contrast, a covalent bond between T cell and 
B cell determinants in general is required to induce high affinity anti-BD antibodies 
crossreactive with the native protein. 
From the investigations described above, it is clear that for efficient antigen 
presentation and subsequent antibody production, a cognate interaction between Band T cells 
is required. This will assure antigen-specific T cell help resulting in a specific memory 
response. To accomplish this, a covalently bound TD-BD construct, or a Iiposome, a virion 
or another particulate structure with both a TD and a BD built in to give intrastructural help, 
is the most applicated and relatively effective manner. Also, a water-in- oil emulsion, in 
which a TD and BD are mixed, will be appropriate, if the TD and BD are entrapped in the 
same micro-droplet to give intrastructural help. However, entrapping in the same droplet is 
a chance process and will be less efficient. This might have caused the affinity and titer of 
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the antibodies raised with the mixed TD and BD to be lower than that obtained with a 
covalently bound TD-BD constmct. 
Taken together, to obtain a high level of BD-specific antibodies with a high affinity 
and crossreactivc with the native protein, a covalently bound BD-TD constmct should be 
used for immunization. 
X. CONCLUDING REMARKS 
Coupling of B cell determinants to carrier proteins may serve several goals. The carrier 
protein provides T cell help to anti-peptide antibodY fomling cells. Processing of a carrier-
peptide conjugate by the antigen presenting cells generates different T cell determinants 
which can stimulate different T cells. The immullogenicity of a peptide-carrier may thus be 
increased by stimulating a larger T cell pool. Also through the size of a carrier-peptide 
conjugate, the capture by phagocytes may be increased. 
On the other hand, it may be advantageous to work with a simple and precisely 
defined immunogenic construct. Using a rather small peptide containing one or several (the 
same or different) copies of a well selected T cell determinant and a B cell determinant for 
inununization provides the ability to manipulate the specificity, level and affinity of the 
immune response. Moreover, immunodominance of TDs from a carrier protein can be 
excluded when only TD-BD constructs are used for immunization. Especially for vaccines, 
such an approach offers the possibility to inmmnize with strong acting T cell determinants 
with a broad MHC haplotype spectrum. Cryptic T cell determinants hidden in a pathogen-
derived native protein are circumvented in this way. In addition, it is highly desirable to 
stimulate pathogen-specific T celJs for vaccine applications. 
Selection of T cell determinants on the basis of prediction methods is not fully 
efficient. The action of a selected T cell determinant should be defined in a functional assay 
with cells from the target animal. For vaccine applications, it is recommended that a promis-
cuous T cell epitope is chosen, certainly for outbred populations and human use. 
A light preference for the N-terminal position of a TD in a construct exists, since the 
antibody response is directed to the C-terminal part of a construct. However, this is not a 
general rule, since processing of a construct and antigen presentation largely depends on the 
sequence of the overlapping junction between the two determinants. In animals, this is strain 
dependent. Special attention, therefore, should be paid to the conjunctional site of the two 
components. New T cell epitopes may emerge, which is not advantageous since such a newly 
formed TD is not pathogen or protein derived and alternatively existing T cell epitopes may 
be lost. This effect can be avoided by keeping the stmctural units (a-helices) intact, e.g., 
separated by a helix breaker. 
Chain elongation of a TD may increase the stability of a helix and, as a result, may 
enhance peptide binding to MHC class II molecules. Higher titers of antibodies were reported 
with a broader MHC restriction spectrum. On the other hand, the response in an animal with 
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a certain MHC haplotype may disappear. Also in this respect, special attention should be 
paid to the TD and BD junction. 
Multiple copies of the TD may often lead to an enhancement of the immune response. 
An increased conformational stability of the TD favors binding to an MHC molecule. 
Processing of- the constructs yields morc molecules of the TD. A stoichiometric relationship 
between the copy number of TDs and the number of MHC molecules occupied with a TD 
and exposed at the cell membrane of the antigen presenting cell may lead to a more efficient 
activation of T cells. In addition, the level of Il-2 production may enhance upon better T cell 
activation with the more efficient activation of antibody cells as an effect. 
Chemical coupling of a TD and a BD with linkers not always results in an efficient 
immunogen. Dependent on the availability of functional groups in the TD and BD, random 
orientation of the determinants may be generated. This may be disastrous for the immuno-
genicity. We arc of the opinion that linear constructs with a natural peptide bond are most 
appropriate. This may be accomplished by lineal' synthesis, which becomes more difficult, 
however, with increasing length of the sequence, Condensation of fully protected fragments 
offers an alternative synthesis method. 
In general, it is a prerequisite for an efficient immunogen to build the TD and BD in 
one constmct or in a structural unit, such as a Iiposome 01' another particulate stmcture, 
Antibody production was reported upon immunization with just a mixture of free TD and 
BD, but the affinity and titer of the antibodies raised were lower than those obtained with a 
covalently bound TD-BD constlUCt. 
It is clear that careful analysis should be made of the structural influences of all 
components in designing immunogenic constructs. As shown above, many factors may play 
an important role. Just adding two sequences in one constl11ct generally does not always lead 
to an optimally active immunogen. The construct which has been found most appropriate on 
the basis of theoretical choices still needs confirmation of the putative superiority in a 
functional assay where it is compared to alternative simple constmcts. 
ABBREVIATIONS 
AA Amino acid 
BD B cell determinant 
BMH Bismaleimidohexane 
CSP Circumsporozoite protein 
CTL Cytotoxic T lymphocyte 
HEL Hen egg lysozyme 
KLH Keyhole limpet hemocyanin 
MBS m-Maleimidobenzoyl-succinimide ester 
MHC Major histocompatibility complex 
OVA Ovalbumin 
TCR T cell receptor 
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TD T cell determinant 
Th T helper 
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PEPTIDE-INDUCED MEMORY (IGG) RESPONSE, CROSS-REACTIVE WITH 
NATIVE PROTEINS, REQUIRES COVALENT LINKAGE OF A SPECIFIC B 
CELL EPITOPE WITH A T CELL EPITOPE 
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Abbreviations: TD: T cell determinant; BD: B cell determinant; MBS: m-Maleimidobenzoyl 
succinimide ester; Q:'cAT: lXcantitrypsin 
SUMMARY 
In order to raise antibodies synthetic peptides are often coupled to a carrier protein to provide 
the necessary T cell determinants, Alternatively, a short synthetic determinant with a distinct 
sequence motif which can be presented by major histocompatibility complex (MHC) class II 
to T cells, can be linked directly to a B cell epitope. Recently, it has been suggested that 
covalent linkage between a class II-presentable T helper peptide and a B cell epitope is not 
required to induce antibodies against a B cell determinant (Sarobe et al., Eur. j, llt/mul/ol. 
1991. 21: 1555). Therefore, we investigated the ability of an H-2d-restricted T cell 
determinant (AA 111-120 FERFEIFPKEK) from the influenza virus hemagglutinin, to 
support B cell responses to different proven B cell determinant peptides. derived from human 
<Xl-antitrypsin. Antibodies against B cell epitopes crossreactive with native <Xl-antitrypsin 
could be raised only when these B epitope peptides were covalently coupled to the T cell 
determinant through a peptide bond. No antibodies were raised against the B cell epitope 
when the free peptides (T and B cell epitopes) were just mixed or when the T cell epitope 
was conjugated via m-maleimidobenzoyl succinimide ester or bis-maleimidohexane to the B 
cell determinant. Antibodies against the T cell determinant were raised in all cases, 
regardless of the mode of presentation: just mixed with or covalently coupled to the B cell 
determinant. The results indicate that a covalent bond between T cell and B cell determinants 
in general is needed to induce anti B cell determinant antibodies cross-reactive with the native 
protein. 
170 
T Cell Epilopes 
I. INTRODUCTION 
Most randomly chosen short peptides consist of a B cell determinant only, which, by 
definition, does not induce an epitope-specific immune response by itself. In that case, a T 
cell epitope is necessary to offer T cell help and memory for a humoral immune response. 
The T cell epitope is usually supplied by a carrier protein to which synthetic peptides are 
covalently conjugated. Using this approach, we successfully raised various antibodies 
cross-reactive with native proteins [1-3]. The methodology of chemical conjugation, with 
respect to the amino acid composition and orientation of the epitope used, proved to be of 
crucial importance [4-6]. 
Milich et al. [7] were among the first to demonstrate that a synthetic peptide, 
encompassing one T cell epitope and one B cell epitope, could be used to raise anti-native 
protein antibodies. With constructs of a similar synthetic hybrid peptide containing a T cell 
determinant and a B cell determinant from the same protein covalently linked with 
m-maleimidobenzoyl succinimide ester (MBS), it was possible to elicit high-titer antibodies 
against the native protein [8]. Hybrid constructs of T and B cell determinants derived from 
different proteins, made by linear synthesis [9, lO] or linked via glutaraldehyde [IIJ, induced 
antibodies against the B cell determinant. 
Recently, Sarobe et al. [12J described the induction of antibodies against a peptide 
hapten which does not require covalent linkage between the hapten and a class II-presentable 
T helper peptide. The current dogma, however, states that haptens and small peptides are 
poor immunogens to which antibody responses can be elicited only by coupling them to 
larger carrier proteins (for excellent review see [13]). We used the promising approach 
described by Sarobe et al. [121 to raise antibodies against genetic variants of "I-antit,ypsin 
("I-AT). Results presented in this report indicate that a covalent linkage between the T cell 
peptide and the B cell peptide as a mle is necessary. 
II. MATERIALS AND METHODS 
ILL Pcptides used for immunization and evaluation 
SP 149 (FERFEIFPKEKC) is a well-described T cell determinant (TD) from the influenza 
virus hemagglutinin [14J. SPEK15 (LSKA VHKAVLTIDKKC) is a peptide sequence derived 
from the genetic Z variant of "I-AT (residues 329-343) and SPI90 (CDEGKLQHLVNELT) 
is a peptide sequence derived from the S variant of "I-AT (residues 256-268). Both SPEKI5 
and SPI90 are B cell determinants (BD). SPEK15A (FERFEIF-
PKEKLSKAVHKAVLTIDKKC) and SP191 (FERFElFPKEKDEGKLQHLVNELTC) are 
hybrid peptide sequences of SP149) with SPEKI5 or SPI90, respectively, and therefore 
include at least one T cell epitope and one B cell epitope. Peptides were N- or C-terminally 
elongated with an extra cysteine for coupling purposes. 
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II.2. Peptide synthesis and coupling 
Peptides were synthesized as free acids by the solid-phase method of Merrifield [15] using 
t-boc chemistry for peptides SPEK15 and SPEK15A as described elsewhere [1] or using 
Fmoc chemistry [16] for peptides SP149, SP190 and SPI91 on an automated Milligen 9050 
Continuous Flow Synthesizer (Millipore Co. Milford, MA). The cleaved and deprotected 
peptides were purified by gel filtration and analyzed as described before [1]. 
SP149 (TD) was covalently linked via MBS, by its C-terminal Cys to SPEKl5 or 
SP190, representing B cell epitopes. Thiol groups in SPEK15 (C terminal) and SP190 (N 
terminal) were protected with ethylmaleimide. Remaining free thiol groups were measured 
with Ellman's reagent [17]. Equimolar amounts of MBS, 100 mM in dimethyl formamide 
(DMF) , were allowed to react with the protected peptides and subsequently, SPl49 was 
added in equimoiar amounts to both reaction mixtures. Alternatively, peptides were 
covalently linked via their terminal-situated cysteines with 1,6 bismaleimidohexane (BMH). 
SPl49 and SPEKl5 were mixed in equimolar amounts. Subsequently, BMH dissolved in 
DMF was added at a concentration 1.5 times that of the total amount of free thiol groups. 
Coupling reduced the measurable amounts of free thiol groups by 90%. Statistically one third 
of the conjugates consists of the combination SPI49-BMH-SPEK15. SP149 and SPl90 were 
coupled under the same conditions as those described above. Conjugation of peptides and 
keyhole limpet hemocyanin (KLH) was carried out as described elsewhere [2]. 
II.3. Peptide modification 
Thiol groups of SPEK15 and SPl90 were blocked with ethylmaleimide in equimolar 
amounts. One of the five amino groups in SPEK15 and one of the two amino groups in 
SPl90 were modified with MBS by adding MBS in equimolar amounts to the peptides. The 
maleimide moiety of MBS was blocked by addition of equimolar amounts of cysteine. 
11.4. Immunization and evaluation 
Groups of three 12-week-old female BALB/c mice were immunized by Lp. injection of 200 
1'1 of an emulsion of 90 1'1 peptide solution in water and 110 1'1 "specol" (a mineral oil 
adjuvant [18]) containing 30 I'g of each peptide used. Parallel groups were immunized with 
a mixture of peptides emulsified in complete Freund's adjuvant, Mice were given booster 
injections afler 4 and 8 weeks with the same dose of antigen. For the groups administered 
with Freund's adjuvant, the booster injections were given in incomplete Freund's adjuvant. 
ELISA was carried out as described before [2]. 
III. RESULTS 
III. I. Antibody l'esponse l'aised with peptide-cal'l'iel' innnullogens 
First, we raised peptide- and native protein-specific antibodies with KLH-MBS-SPEKI5 and 
KLH-MBS-SPI90 (Table 1). Single B cell determinants (SPEK15 or SP190) did not elicit 
peptide specific responses. 
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SPEK15A 
SP149-MBS·SPEKI5 
SP149 + SPEKl5 Speeo] 
SP149 + SPEK15 Freunds 
KLH_MBS-SPEK15b 
SP191 
SP149-MBS-SP190 
SP149 + SPl90 Specol 
SP149 + SPl90 Freunds 
KLH·MBs..SP190b 
TABLE 1 
Relative levels of specific IgG reactivity in sera as determined in ELISA 
SPI49 
(TO-BD) 0.847 ± 0.158 
(TO-MBS-BD) 0.689 ± 0.261 
(TO + BD) 0.420 ± 0.248 
(TO + BD) 0.010 ± 0.088 
nd 
(TO-BD) 0.233 ± 0.243 
(TD-MBS-BD) 0.391 ± 0.320 
(TD + BD) 0.050 ± 0.320 
(TD + BD) 0.235 ± 0.342 
nd 
SPEK15A 
USI ± 0.145 
0.666 ± 0.345 
0.556 ± 0.331 
0.156 ± 0.117 
nd 
nd 
nd 
nd 
nd 
nd 
SPEK15 
0.705 ± 0.002 
o ± 0.002 
0.002 ± 0.005 
o ± 0.005 
0.314 ± 0.113 
nd 
nd 
nd 
nd 
nd 
COATING 
SP191 
nd" 
nd 
nd 
nd 
nd 
1.557 ± 0.023 
0.791 ± 0.456 
0.131 ± 0.007 
0.536 ± 0.527 
nd 
SP190 O!l-AT 
nd 0.728 ± 0.193 
nd o ± 0.004 
nd 0.035 ± 0.039 
nd 0.002 ± 0.004 
nd 0.184 ± 0.119 
0.251 ± 0.131 0.567 ± 0.065 
o ± 0.007 o ± 0.005 
0.031 ± 0.027 0.011 ± 0.021 
o ± 0.017 0.041 ± 0.036 
0.586 ± 0.182 0.573 ± 0.294 
a) not determined; b) Inununizations with K1..H conjugates and EUSA evaluation were carried out in a separate study; TD: T-cell determinant: BD: B-cell detenninant. The values in this 
table represent the average absorbances for sera of three mice ± standard deviation taken after the second booster immunization and diluted I :400. With this dilution. plateau levels were not 
obtained (compare Fig. 1). 
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III.2. IgM and IgG antibody responses raised with peptide constructs 
Four groups were immunized with (I) the TD-BD constlUct, (II) the TD-MBS-BD constlUct, 
(III) TD + BD mixed in specol and (IV) TD + BD mixed in Freund's adjuvant. The 
sequence SPEK15 was used as BD. At 5 days after the first immunization, both IgM and IgO 
responses were low to SP149 (TD), SPEK15A (TD-BD), SPEK15 (BD) and <x,-AT (native 
protein) and remained low for 28 days (data not shown). Seven days after a booster 
immunization, IgM responses in sera from an groups against the different antigens were low 
when compared to IgO responses (data not shown). 
Since the anti-native protein responses were still relatively low after the second 
immunization, it was decided to boost the reaction a second time. Fourteen days later, the 
IgO antibody response to SPEK15A (TD-BD) after immunization with SPEK15A (TD-BD) 
was higher than the antibody responses after immunization with the other TD and BD 
combinations (Fig. lA). The antibody response against SPEKI5A after immunization with 
SPEK15A (TD-BD) probably is composed of the antibody response against the TD SP149 
and the antibody response against the BD SPEKI5, since the addition of the titration curves 
of the responses against TD and against BD is similar to the titration curve against TD-BD. 
The IgG antibodies in the sera of mice immunized with SPEK15A cross-reacted with the 
native protein <x,-AT (Fig. ID). The immune responses against SPEK15A (TD-BD) elicited 
with the immunogens II to IV were directed only against the TD SP149. ELISA for the sera 
of these groups showed similar curves for SPEK15A and SP149; no contribution from the 
immune responses against the BD SPEK15 was added to the response against SP149 (see Fig. 
1B and C). Only a response against SP149 (TD) was detected with mixtures of TD and BD. 
111,3. Comparison of antibody responses from mice immunized with different BD 
Constructs with SP190 as BD were immunized in four groups of m.ice as for SPEK15. 
Responses were essentially similar to the IgG and IgM responses after immunizations with 
SPEK15 (BD) constlUcts (data not shown). In sera from mice immunized with TD + BD 
mixtures or with TD-MBS-BD (with SPEK15 or SP190 as BD), no responses were found 
directed against the B cell determinants or against the native protein (c¥l-AT). In these sera, 
only an antibody response against the TD could be found. In sera from mice immunized with 
linearly synthesized TD-BD peptides, antibody responses against the B cell determinants and 
against <Xl-AT were detected (Table I). 
11I.4. Role of chemical modification of B cell determinants 
Since amino groups of SPEK15 and SP 190 were used for linkage to the thiol group of 
SP149, the epitope of peptides SPEK15 and SPI90 may be modified such that antibodies 
raised with these chemically linked constlUcts do not recognize the BD in the antigens used 
in ELISA (SPEKI5, SP190 and <Xl-AT). Responses (Ig total) against modified BD were 
compared with responses against BD and TD for SPEK15 as BD (Fig. 2). Similar results 
were obtained with SP 190 as BD (not shown). In sera from mice immunized with 
SP149-MBS-SPEKI5 or SPI49-MBS-SPI90 no antibodies were found against modified BD. 
Only antibodies against the TD in the TD-BD or TD-MBS-BD constlUcts were detected. 
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Fig, 1. Titration ofJgG antibodies in serum 14 days after the third immunization determined in ELISA. Groups of 
three mice were immunized with SPEK15A II, with SP149-MB8-SPEK15 0, wilh SP149 mixed with SPEK15 in 
speeo! e, with SP149 mixed with SPEK15 in complete Freund's adjuvant 0, Serum IgO responses against 
SPEK15A (A) against SPEKi5 (B), against SP149 (C) and against aI-AT (0) are shown. Mean responses with 
standard error bars of groups of three mice using log2 serial dilution of serum with initial dilution 1 :50 arc shown. 
We investigated whether it was possible to raise antibodies against the BD applying 
an alternative coupling method, TD and BD were chemically linked via their terminal thiol 
groups from cysteine with BMH, With these coru;tmcts, TD-BMH-BD, with SPEKl5 and 
SP190 as BD, mice were inununized twice with a 4-week interval. The antibody response 
was evaluated in ELISA in sera taken 7 days after the second immunization, Only antibodies 
against the TD were found but not against the BD, modified BD and ai-AT (results not 
shown), 
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Fig. 2. Titration of antihodies (1g) in serum 14 days after the third immunization determined in ELISA. Serum 
responses raised with SP149-MBS~SPEK15 arc shown. A log! serial dilution of serum with initial dilution I: 100 was 
made. The mean responses with error bars of three mice arc shown. SPEKi5 II, SPEK15A D, with 
SP149-MBS-SPEK15 ., with SPEK15 modified 0 were used as coating antigens in ELISA. 
IV. DISCUSSION 
As an alternative for a carrier protein, a synthetic T cell determinant (TD) which can be 
linearly synthesized to a B cell determinant (BD) was applied. We tried to verify another 
more simple alternative reported by Sarobe et al. [12] who just mixed a TD and a BD to 
raise anti-BD antibodies. This strategy offers a major advantage over the other m.cthods 
mentioned, since coupling is time consuming. a coupling site must be introduced in the BD 
and, moreover, neodeterminants may be introduced. We used this attractive approach to raise 
anti-ai-AT antibodies. Proven BD [5, 6] were synthesized linearly to a well described TD 
[14]. These BD, and TD were also chemically conjugated. In addition, BD and TD were 
mixed and immunized according to Sa robe et al. [12]. Using our immunization protocols, 
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all IgM titers were negligible for all groups. IgG antibodies which were cross-reactive with 
the BD and the native protein "'I-AT were induced only with linearly synthesized TD-BD 
peptides and with KLH-bound peptides. The TD appeared to include a BD which in all 
modes of presentation, linearly synthesized, chemically coupled or mixed TD and BD, leads 
to anti-TD antibodies. This, in addition, formed a huit-in-control for proper immunization. 
With chemically (via MBS or BMH) linked TD-BD constmcts, no humoral antibody 
responses were found cross-reactive with the BD Of the native protein. Several interpretations 
might explain why we did not find anti-BD directed antibodies with chemically linked 
constructs: (a) chemical modification of the BD, (b) no conjugation between TD and BD, or 
(c) altered antigen processing or presentation, 
Considering (a), previously, the BD SPEK15 and SP190 conjugated to KLH with 
MBS elicited high-titer anti-peptide antisera which were cross-reactive with (Xl-AT. This 
proved that chemical cross-linking of these BD with MBS did not prevent immunogenicity 
by itself. For production of the KLH conjugate, the thiol group of SPEK15 was used for 
coupling as in the TD-BMH-BD conjugate. For coupling TD and BD with MBS, one of the 
amino groups of the BD was used, resulting in multiple constmcts of different orientation. 
The immunogenic BD configuration might have been destroyed, Similar experience was 
encountered in the comparison between conjugates of KLH and several peptides coupled with 
MBS or with glutaraldehyde [5]. The immune response against SPEK15 totally disappeared 
when the glutaraldehyde conjugate was used as immunogen. Glutaraldehyde also uses amino 
groups for coupling. We concluded that lysine residues are extremely important for the 
immunogenicity of SPEKI5. To analyze whether chemical modification of the BD generated 
during the coupling procedure might have elicited antibodies which only recognized the 
modified BD and not the unmodified BD, we measured the reactivity against modified BD 
in ELISA. This turned out to be negative. 
Considering (b) above, linkage of TD and BD was checked by measuring free thiol 
groups in the construct combined with elution patterns of HPLC chromatograms. It could be 
estimated that over 50 % of the added BD was coupled to the TD with MBS. From 
remaining free thiol groups, it could be concluded that 90 % of the peptides were conjugated 
with BMH. Assuming random linkage between peptides, about one third of all conjugates 
may be expected to represent heteroconjugates. From other experiments [4], we learned that 
a dose of 10 I'g (i. e .. one third of 30 I'g) should be sufficient to induce a proper immune 
response, though it is lower than the dose given for the linearly synthesized BD-TD. In 
addition, antibodies cross-reactive with the TD were found after immunization with BMH-
coupled constructs proving that the dose was sufficient. 
Though it has been reported that chemical coupling of BD and TD [8, Il] could 
induce a memory immune response against the BD, our selected BD and TD did not induce 
antibody responses against the BD when chemically linked. Our results are consistent with 
a report [19] which showed that immune responses generated with a linearly synthesized 
TD-BD peptide are predominantly directed against the BD, whereas the BD-TD construct, 
chemically linked via BMH, elicited antibodies against the TD. In our study. there is no 
difference between responses to the chemically linked TD-BD or BD-TD construct when used 
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for immunization. Both constructs did not elicit antibodies against the BD. Thus, orientation 
of the TD in this case does not seem to be the only limiting factor as has been suggested by 
others [10, 20-22]. 
Considering (c), antigen processing, competition for MHC binding and hampered 
recognition by the T cell receptor: a Ilholel! in the repertoire may influence an immune 
response. Several investigators [23-25] have proposed that adjacent sequences may alter the 
conformation of an epitope resulting in significant altered antigen processing Of changes in 
T cell recognition, For our chemically linked TD-BD constructs, altered conformation 
relative to linear synthesized TD-BD peptide may also account for the lack of antibody 
responses against the BD. 
Though it has been reported that mixtures of free TD and BD [12] could induce a 
memory immune response against the ED, our experiments indicated that this is certainly not 
true for all combinations of T and B cell epitopes. Current views on the generation of a 
memory immune response recently stated that TD and BD must be localized in the same 
molecule [13, 26]. Peptides used in the studies by Sarobe et al. [12] might have associated 
to form a strong complex allowing antigen processing and recognition and subsequently 
cognate T and B cell interactions to elicit a humoral immune response. However, in previous 
studies [4]. we found that "pseudo conjugates", nonspecific adherence of peptides to carrier 
molecules, were not able to elicit an immune response in contrast with peptides coupled to 
the same carrier molecules with carbodiimide. 
Taken together, our results indicate that in order to induce a high-titer anti-peptide 
immune response, the peptide must be provided with a T cell epitope by covalent coupling 
to a carrier protein or by a peptide bond between TD and BD. 
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I. INTRODUCTION 
A new approach to generate anti-peptide antibodies has been initially developed by the group 
of Tam and colleages (Posnett et a!., 1988; Tam, 1988). A branched core of lysine residues 
was constlUcted by making use of the c¥ and € amino groups of lysine. Subsequently, multiple 
copies of the peptide epitope of choice could be synthesized onto all arms of the core. The 
resulting stmcture has been called multiple antigen peptide (MAP) (Fig. 1). 
Two categories of MAP application can be distinguished: (i) as a highly efficient 
immunogen and (ii) as an efficient antigen for detection in immunoassays. The MAP 
approach for inununization purposes offers several advantages over the conventional carrier-
peptide constlUCt. It is a construct of intermediate molecular mass with a defined orientation 
of the peptide. Most of the molecule (may be more than 90%) consists of the peptide antigen 
in contrast to the carrier-peptide conjugate, where the peptide in general is only part of the 
construct. Ad i. First, probable immunodominant determinants or even suppressor 
determinants of the carrier protein can be circumvented by applying a MAP. Second, 
purification is rather easy, and, dependent on the peptide sequence chosen, the constlUct can 
be used directly for immunization without coupling to a carrier protein. Third, the peptide 
dose of the administered MAP is exactly known, in contrast with the peptide dose 
administered as a peptide-carrier conjugate. In addition, the dendritic peptide chains on the 
MAP are probably mobile, which may contribute to enhanced immunogenicity. These 
characteristics make the MAP extremely useful for application as immunogen or as a syn-
thetic vaccine. 
Ad ii. MAPs were also shown to be very useful as antigens in solid phase 
immunoassays. Coating of MAPs to polymer surfaces leads to more efficient epitope 
exposition than is obtained with free monomeric peptides and thus are very effective for 
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Fig. 1. Schematic drawing of a multiple antigen peptide. To the functional groups of the resin, the first amino acid 
(lJ-Ala as an internal standard amino acid) is coupled, and, subsequently, a Lys with two Fllloc protecting groups 
fOf the a and c amino groups is coupled. After removing the Fmoc groups, two Lys residues can be coupled. This 
step can be repealed several times, untillhe branching of choice has been reached: the core. Four and eight branched 
cores are applied most frequently, The selected peptide is then synthesized onto tlte arms of the core. Here, two 
MAP molecules on a resin bead are shown. 
sensitive detection in ELISA (Tam and Zavala, 1989; Habluetzell et aI., 1991; Marsden et 
aI., 1992; Marguerite et aI., 1992). 
Here, we will discuss the MAP immunogen propel1ies only. 
II. ALTERNATIVE SYNTHESIS 
The basic design of a MAP allows alternative synthesis to offer investigators highly flexible 
possibilities to explore various abilities of the MAP approach for inununization purposes. By 
making use of two different protecting groups (Pmoc and tHoc) for lysine at the last level of 
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branching, two different peptide synthesis routes can be applied, Thus, two different peptides 
can be synthesized onto the core, (Tam and Lu, 1989), 
Chemical coupling of a purified peptide with a N,or C-telminal cysteine and a 
chloroacetylated oligomeric lysine core matrix was described as an alternative for 
construction of the MAP (Lu et aI., 1991), This method offers the advantage to study the 
influence of orientation of the peptide to the lysine core, It was found that antibodies raised 
with these MAPs were mainly directed against the distal (and most flexible) part, opposite 
of the conjugation site, of the peptide (Lu et aI., 1991), 
Drijfllout and Bloemhoff (1991) described a similar coupling method: the addition of 
a protected branched lysine core to a functionalized peptide, The lysine core is kept protected 
by N,(S'acetylmercaptoacetyl)'glutamyl residues, Removal of the S'acetyl groups just prior 
to the coupling procedure yields thiol functions which can be used for coupling to, e,g" S, 
(Npys),cysteinyl peptides, 
Virtually the same approach was followed by Baleux and Dubois (1992), Both the 
lysine core and the peptide antigen were provided with S,(Npys),cysteine, Conjugation was 
carried out by removal of the Npys group of the lysine core with dithiothreitol and 
subsequent addition of the S,(NPys) peptide, 
Coupling of a fully protected peptide, which contained a T cell determinant (TD), and 
a protected MAP, containing peptides with a B cell determinant (BD), proved to be an 
effective method for fragment condensation (Mclean et aI., 1992), The TD peptide can be 
synthesized in bulk in advance and thus does not require repetitive synthesis of the TD each 
time a di'epitope MAP is synthesized, 
III, MAPS AS IMMUNOGENS 
An octameric MAP was found to be highly immunogenic in mice (Balb/c) and rabbits in the 
first study carried out with MAPs, The peptide (14 residues) was derived from the human 
T cell antigen receptor {3-chain constant region. The antibodies which were raised reacted 
with the peptide in its monomeric form as well as in its octameric form and with the intact 
i3,chain protein (Posnett et aI., 1988), The antibodies were mainly directed against the N, 
terminal residues of the peptide, No antibodies against the core were detected, The subclass 
distribution of the subsequently generated monoclonal antibodies was predominantly IgG1 
and, to a lesser extent, IgA and IgG2a, which the authors attribute to the T cell dependent 
nature of the antigen, The authors did not demonstrate that the selected peptide sequence with 
which the MAP was constructed itself contained a T cell determinant, nor was it investigated 
whether a new T cell determinant had been formed upon assembly of epitopes by synthesis 
of the MAP, It is also conceivable that repeating epitopes on the same molecule may cause 
crosslinking of antigen,specific immunoglobulin receptors on B cells and thus behave as a 
relatively T cell independent immunogen which can induce isotype switching, However, 
known T cell independent immunogens as lipopolysaccharide (LPS) or ficoll activate B cells 
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to synthesize predominantly IgG3 besides IgG 1. Posnett and colleagues did not investigate 
the IgG3-speciftc response. 
In a subsequent study, five out of six different MAPs with octameric branched 
peptides derived from different proteins were highly immunogenic. The antibodies which 
were induced crossreacted with the native proteins (Tam, 1988). For one determinant 
investigated the analogous carrier-SP conjugate induced substantial lower levels of antibodies 
than was observed with the MAP construct. 
Co-workers of Marsden compared the efficacy of six different MAPs with 
conventional carrier-peptide conjugates of the same peptide sequences as immunogens 
(McLean et aI., 1991). The titers of sera from rabbits immunized with branched peptides 
were higher than those immunized with carrier-peptide conjugates. These findings are 
confirmed by others (Wang et aI., 1991). However, Briand et al. (1992) have tested several 
peptides sequences, as a carrier-peptide conjugate or as a MAP, in immunization studies. 
They found that three out of four MAPs were immunogenic, but, most importantly, only one 
out of these four MAPs raised antibodies crossreactive with the native protein. It appeared 
that immunization with two MAPs, in which the sequence of the peptides was derived from 
the C-telminus of a protein, did not result in protein-specific antibodies. The orientation of 
the determinants with respect to the core matrix may have played a major role. From this, 
we tend to conclude that there is no advantage in using MAPs with respect to the generation 
of anti-native protein antibodies with synthetic immunogens. 
With the (NANP)lO repeat of Plasmodillmjalciparum circumsporozoite protein, it was 
demonstrated that a MAP construct with 4 branches could overcome genetic MHC 
restriction. The linear (NANP)lO peptide is only immunogenic in H_2b mice (DelGuidice et 
aI., 1986; Good et aI., 1987), while with the (NANP)wMAP construct IgG antibodies were 
raised in various mouse strains with different MHC background (Pessi et aI., 1991). 
However, MAP constructs with the repeat of other malaria parasites (P. vivax and P. 
berghel) did not overcome genetic MHC restriction. It is difficult to explain the finding that 
the MAP-(NANP)lO construct overcame MHC restriction, since it seems a favorable 
exception. The authors speculated on three hypotheses. (i) A MAP might bind to MHC class 
II molecules as a multivalent ligand. However, it was shown that not all MAPs could 
overcome MHC restriction, thus this may only be found with special combinations of MAPs 
sequences and MHC haplotypes. (ii) (NANP)-specific B cells are activated with a MAP 
independently ofT cell help through Ig crosslinking. However, IgG antibodies were observed 
and proliferation of lymph node cells from immunized mice was observed. (iii) A MAP 
follows different proteolytic pathways, as compared to linear peptides, leading to products 
that bind with higher affinity to Ia molecules. In addition, we think that it is conceivable that 
new T cell determinants may be formed in the MAP with the (NANP)lO sequence. 
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IV. INCORPORATION OF A T CELL DETERMINANT 
Enhancement of the antibody response by addition of a TD peptide in a MAP has been 
reported (Tam et aI., 1990; Munesinghe et aI., 1991; Mclean et aI., 1992; Nardelli et aI., 
1992a). 
It was investigated whether incorporation of a TD in an essentially non-immunogenic 
BD-MAP would result in an immunogenic construct. MAPs containing 4 or 8 copies of aT 
cell detelminant combined with 0, 1, 4 or 8 copies of a B cell determinant were compared 
for their efficacy to raise (neutralizing) antibodies (Tam et aI., 1990). Also, the 
complementary MAPs in which the TD and BD were mutually exchanged (4 or 8 copies of 
the B cell determinant combined with 0, 1,4 or 8 copies of the T cell determinant) were syn-
thesized and inununized. Moreover I in the same study the effect of orientation of the 
determinants [(BD-TD)4, (BD-TD)" (TD-BD)4 or (TD-BDls] on the antibody response was 
investigated. The BD (residues 93-108, repeat domain) and the TD (residues 265-276) were 
derived from the circumsporozoite protein (CS) of P. berghei. The BD monomer and the 4 
and 8 branched MAPs containing either the BD or the TD alone did not induce antibodies 
in mice. The BD-TD monomer induced only a velY low level of CS-specific antibodies. In 
this study, 4 or 8 branched MAPs containing linearly synthesized tandem arrayed BD-TD or 
TD-BD peptides induced high levels of recombinant CS-specific antibodies and protected 
mice from challenge (50-80% protection). The (BD-TD)4-MAP scored highest followed by 
(TD-BD)4-MAP or (TD-BD),-MAP and (BD-TD),-MAP. This study showed that 
incorporation of a T cell detelminant in a MAP indeed rendered the construct immunogenic 
as compared to the MAPs that only contained the BD. Four branches appeared to be 
sufficient, if not optimal, for eliciting a high inmmne response in case a TD is incorporated. 
After mapping the P. berg"ei circumsporozoite protein for T cell helper activity, 
Migliorini et al. (1993) chose two apparent T cell determinants (residues 20-39 and 57-70) 
for constructing multiple antigen peptide constructs comprising only one of the T cell 
determinants or one of the T cell determinants co-linearly synthesized to a tandem repeat of 
B cell determinant of the CS protein. Mice immunized with one of the T-B constructs were 
protected after a challenge with infective sporozoites and a high level of B cell determinant-
specific antibodies could be detected. Strikingly, also mice immunized with a MAP construct 
comprising only the 57-70 T cell epitope were protected, while peptide-specific antibodies 
were not found. These latter results indicate that protection can be obtained either by effector 
T cells or by high levels of antibodies. Thus, a double mechanism of protection can be 
acquired by a synthetic peptide vaccine. With evaluation of the antigen-specific antibody 
response alone, protection against infection after challenge with a pathogen may be missed. 
We have investigated the effect of incorporation of a T cell determinant on the 
antibody response either in a linear peptide or in a MAP. The immunogens were compared 
with the linear peptide conjugated to a carrier protein, keyhole limpet hemocyanin (KLH). 
We determined whether or not a T cell dependent antibody response intrinsically is formed 
by a MAP without a TD sequence. The T cell responses were assessed in an in vitro 
proliferation assay after priming ill vivo with the different immunogens. 
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Peptide Character 
SP149 TD 
SP190 BD 
SPl91 'fD-BD 
SP215 TD and BD 
Sequence 
FERFEIFPKEKC' 
TABLE 1 
Peptide sequences 
C'DEGKLQHLVNELT 
FERFElFPKEKDEGKLQHLVNELTC' 
DKTVERKCCVECPPCPAPPVA 
*' An extra cysteine was added to the sequences for coupling purposes. 
TO: T cell determinant; DO: B cell determinant. 
T Cell Epitopes 
Derived rrom 
TD from influenza (AA 111-120) 
aI-Antitrypsin (AA 256-268) 
TO + AA 256-268 from tXl-antitrypsin 
Human IgG2 (hinge) (AA 95-115) 
The peptides used for this study are listed in Table 1. Peptide SP190, a pure B cell 
determinant, was derived from the human S-variant of ",-antitrypsin (residues 256-268). 
SP191 contained the sequence of SP190 which was N-terminally elongated with a TD from 
the influenza virus hemagglutinin (residue 111-120) (Hackett et aI., 1985; Zegers et aI., 
1993). A third peptide, SP215, was derived from human IgG2 (residues 95-115) and 
contained an intrinsic TD and BD (Boersma et aI., 1989). Peptides SP190 and SP191 were 
coupled to KLH via an extra added cysteine, and SP215 was coupled via EDC (using 
carboxyl and amino groups). These peptides were used for immunization in mice (BALB/c) 
as free peptide, MAPs or conjugated to KLH. Sera were analyzed for specific antibodies in 
ELISA. 
From Fig. 2, it is clear that SP190 (BD) is not immunogenic. The KLH-SP190 
conjugate induced peptide-specific antibodies which were crossreactive with ~lAT as 
expected. When SP190 was offered as a branched peptide (MAP), peptide-specific antibodies 
were detected and these antibodies were also reactive with the ",AT protein in ELISA. The 
level of protein- specific antibodies raised with the MAP was lower than the level raised with 
the KLH-SPI90 conjugate. It can be concluded from these results that a non-immunogenic 
peptide can be made immunogenic by offering it as a MAP or as a carrier-peptide conjugate. 
From Fig. 3, it is clearly seen that incorporation of a TD renders the peptide 
immunogenic, though the antibody response induced with the free TD-BD peptide (SP191) 
is low as compared to the antibody responses induced with the MAP or the conjugate 
including the same sequences. Incorporation of a TD in a MAP therefore specifically 
enhanced the protein- specific antibody response. The level of the ",AT-specific antibody 
response after immunization with MAP191 is similar to the response after immunization with 
the KLH-SP191 conjugate. 
SP215 is immunogenic and induces peptide- specific antibodies crossreactive with the 
native protein (Fig. 4). Conjugation of this peptide with EDC to a carrier protein decreased 
the protein-specific response, probably due to modification of the epitope by the coupling 
procedure, Also with a conjugate made by coupling via the cysteines, protein-specific anti 
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Fig. 2. Comparison of the specific reactivity of mouse sera after immunization with different peptide constructs 
containing a B cell determinant peptide. Mice were immunized twice with a 4 week interval with the linear peptide 
SP190 (upper graph), with a carrier-peptide construct KLH-MBS-SP190 (middle graph), or with a branched peptide 
MAP190 (lower graph), One week after the second immunization, sera were analyzed in ELISA for reactivity with 
linear peptides [SP190 and SP191, or the T cell determinant (TD)] , with branched peptides [MAP190 and MAP191], 
or with the native protein ai-antitrypsin [ATM). Mean serum responses of three mice with standard deviation are 
shown. See Table 1 for sequences and character of peptides. 
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Fig. 3, Comparison of the specific reactivity of mouse sera after immunization with different peptide constructs 
containing a B and a T cell determinant peptide. Mice were immunized twice (4 week interval) with the linear 
peptide SP191 (upper graph), wilh a carrier-peptide construct KLI-I-MBS-SP191 (middle graph), or with a branched 
peptide MAP191 (lower graph). Serum immune responses were analyzed in ELISA as described for Pig. 2. 
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Fig. 4. Comparison of the specific reactivity of mouse sera after immunization with different peptide constructs 
containing a B cell and a T cell determinant peptide. Mice were immunized twice (4 week interval) with the linear 
peptide SP215 (upper graph), with a carrier-peptide construct KLH-EDC-SP215 (middle graph), or with a branched 
peptide MAP2IS (lower graph), One week after the second immunization, sera were analyzed in ELISA for 
reactivity with the linear peptides, SP215, with branched peptide MAP215, or with the native protein human IgG2, 
See Table I for sequences and character of peptides. 
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bodies were not found (not shown). For this peptide. with many functional groups available 
for coupling, the MAP approach seems the most appropriate one. Indeed, high levels of 
protein-specific antibodies were raised with MAP215. 
Lymph node cell proliferation assays were performed after in vivo priming with the 
immunogens. Most obviously. in vitro restimulation with a peptide or a MAP, which contains 
a TD, induced a specific enhancement of the proliferation (Fig. 5). Especially, the 
stimulation indices for restimulation with SP191, MAP191 or SP215 of cells primed with 
SPI91, MAP191, SP215 or MAP215 were of the same order of magnitude as after 
restimulation with concanavalin A, a polyclonal mitogen (not shown). No proliferation was 
seen with SPI90 and MAPI90 (both contain only a BD) restimulation of cells primed with 
SP190 (BD), MAP190 (BD), SPI91 (TD-BD) or MAPI91 (TD-BD). 
We found subclass distribution patterns (IgGl, IgG2a, IgG2b, IgG3) which were more 
or less similar for all immunogens used (data not shown), The only apparent difference 
observed was that the level ofBD-specific IgG2b antibodies elicited with MAP190 (BD) was 
higher as compared to MAP191 (TD-BD). Also the ratio IgG2b/IgGl was higher after 
immunization with MAP190 than that found with the other immunogens. It remains to be 
demonstrated whether a MAP without a TD in the peptide sequence can behave as a T cell 
independent immunogen capable of inducing isotype switching. 
We showed that for strong and native protein-specific responses incorporation of a 
TD into a MAP can be an advantage. For the sequences used in our study, a MAP with only 
a BD did not stimulate T cells ill vitro in a proliferation assay. Despite the absence of T cell 
activation, specific IgG antibodies (predominantly IgG2b and IgGl) could be detected. The 
antigen presentation as well as the B cell activation mechanism by MAPs still remains to be 
elucidated. In the present case, for a peptide which contained several residues sensitive to 
moditlcation during coupling procedures, the MAP approach is most appropriate. 
V. MAPS AS VACCINES 
Major advantages of synthetic peptide vaccines are the avoidance of any pathogenic sequence 
which is present in the pathogen in its natural or attenuated form and the safe production of 
the vaccine. Furthermore, the immune response with MAP is directed only against the 
selected protective peptide sequence. MAPs are expected to be extremely useful for 
application as vaccines, since they present a multivalent construct with high potential 
immunogenicity. A MAP is of advantage, as compared to conjugation of a peptide to a 
carrier protein which is needed for immunogenicity, in that the immune response mounted 
against the carrier protein as is observed with a conventional carrier-peptide constmct can 
be avoided. With a MAP, the immunodominant B cel! determinant, relevant for elicitation 
of protective antibodies, together with efficient promiscuous T helper or cytotoxic T cell 
determinants, can be selected. 
Several investigators explored the application of MAPs as vaccines in model studies. 
Mice could be protected from infection with rodent malaria after immunization with a MAP 
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Fig. 5. Proliferation ofslimulaled lymph node cells primed in vivo with a linear peptide or with a MAP. Proliferation 
of stimulated lymph node cells primed with (Upper graph) SP190 or MAP190, (Middle graph» SPl91 or (J~ower 
graph) MAP191. SP215 or MAP2t5. Cells were restimulated ill vitro with different antigens (Y~axjs). The mean 
stimulation index with standard deviation for three mice is shown on the X-axis after lH~Tdr incorporation and is 
calculated by dividing the Cplll in cultures with antigen by the cpm in cultures without antigen. A stimulation index 
greater than 2 is significant. 
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containing a BD and a TD of the circumsporozoite protein of the parasite (Tam et aI., 1990; 
Zavala and Chai, 1990; de Oliveira et aI., 1994). 
Neutralizing antibodies against the HlY·I were elicited in guinea pigs after 
immunization with a MAP containing a rather long sequence (33 amino acids) from the third 
variable (Y3) loop of gp120. The antibody response exceeded the response found with a 
peptide·bovine semm albumin conjugate prepared with glutaraldehyde with a factor 100. 
Moreover, the antibody response persisted more than 3.5 years (Wang et aI., 1991). 
Putative vaccines with intrinsic adjuvant properties were constructed by linking 
tripalmitoyl·S·glycerylcysteine (P3C) to a MAP with a peptide sequence from the Y3 loop 
of gpl20 from HIY·I which includes a neutralizing B cell epitope, T helper and T·cytotoxic 
epitopes (Defoort et aI., 1992; Nardelli et aI., 1992b). The lipophilic membrane·anchoring 
group (P3C) can be used for inclusion in liposomes. Such complexes induced specific HIY·I 
neutralizing antibodies and elicited cytotoxic T lymphocytes. Even with a single 
administration of the P3C-MAP construct without incorporation in a tiposome, the same 
responses were obtained (Nardelli and Tam, 1994), demonstrating the promising potential 
use of MAPs as vaccines. 
VI. CONCLUDING REMARKS 
MAPs offer a very useful alternative for conventional immunogens (linear peptides and 
peptide·carrier conjugates), provided that a TD is incorporated in the peptide sequence or that 
a TD is formed by the sequences in the constmct. Since a MAP is a spatial stmcture, 
conformational determinants also may be formed. MAPS are very tlexible in use by various 
optional synthesis possibilities, In general, the specific antibody response raised with MAPs 
is higher than the antibody response raised with linear peptides and comparable with or even 
superior over the antibody response with peptide-carrier conjugate. Moreover, carrier-specific 
antibodies, immunodominant determinants of the carrier and carrier induced epitope 
suppression may be prevented by the use of MAPs, which is another important advantage for 
application in vaccine development. 
In case the amino acid sequence of an antigen contains residues which are important 
for immunogenicity and of which side chains are sensitive to coupling reagents, coupling 
should be avoided. MAPs then offer an excellent alternative. Besides antibody production, 
T effector cell mediated protection also can be obtained by applying a MAP as vaccine 
including a TD. 
From several studies it has become clear that a MAP with four arms of branching is 
sufficient to induce an optimal immune response. 
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ABBREVIATIONS 
""AT 
BD 
CS 
EDC 
ELISA 
Fmoc 
KLH 
LPS 
MAP 
MBS 
P3C 
t-Boc 
TD 
",,-Antitrypsin 
B cell determinant 
Circumsporozoite 
1-Ethyl-3-(3-dimethylaminopropyl)carbodi imide 
Enzyme-linked immunosorbent assay 
9-Fluorenylmethoxycarbonyl 
Keyhole limpet hemocyanin 
Lipopolysaccharide 
Multiple antigen peptides 
m-Maleimidobenzoyl-succinil11ideester 
Tripalmitoyl-S-glycerylcysteine 
t-Butoxycarbonyl 
T cell determinant 
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I. 
Detection of proteins using immuno-chemical assays is specific, reliable, simple, convenient, 
cheap and rapid. Furthermore, a lot of samples can be assayed simultaneously, this in 
contrast with -many other, more conventional, biochemical assays, Specific antibodies arc 
needed for immuno-chemical assays and have to be elicited in animals upon immunization 
with the protein of interest. Sometimes a protein is not available for immunization for 
different reasons (see chapter 1) or cannot be used because the protein is toxic or pathogenic. 
Immunization with part of the protein syntheticaUy made is an alternative. Such synthetic 
peptides also offer the possibility for eliciting antibodies specific for proteins which are 
homologous to other proteins. The most optim.al sequence, i.e., the part with the most 
mismatches to the homologous proteins, can then be selected for immunization. For some 
investigations domain-specific antibodies are a requirement. It is apparent that synthetic 
peptides are the most appropriate reagents for eliciting antibodies. It was the aim of the 
investigations presented in this thesis to develop a successful strategy for arriving at 
applicable antibodies with high affinity for the native protein. To realize the generation of 
antibodies, two model proteins were chosen, each with its own characteristics and reasons 
for applying the synthetic peptide approach. The first protein against which antibodies were 
desired, the human androgen receptor, had not been isolated before and the amino acid 
sequence was predicted from the DNA sequence. In addition, a considerable homology exists 
with other steroid receptors. The antibodies had to be applicable in various immuno-assays, 
such as ELISA, \Vestern blotting, immuno-precipitation, or in histochemical procedures. The 
second protein, a variant of ai-antitrypsin, differs in only one amino acid from the normal 
ai-antitrypsin. It is obvious, that only antibodies specific for the substitution site can 
distinguish between the different variants. In these cases one is thus restricted in the choice 
of the synthetic peptide sequence. 
Using inununizations with peptides, we were able to generate highly specific 
diagnostic antibodies, applicable in various immuno-chemical assays, with a high affinity for 
the different domains of the human androgen receptor and for the most important variant of 
ai-antitrypsin. The generation, evaluation and applications of the antibodies will be discussed 
in view of the different parameters which have their impact on the complete route to success 
using the peptide strategy. 
Based on our observations of more than 300 different peptide sequences derived from 
numerous proteins, suggestions will be given for the various steps in the route of the peptide 
strategy application (Table 1), meant for those who enter this field of research. 
II, SEQUENCE SELECTION 
The selection of the sequence to be used for the immunogen is the first and most important 
step in the generation of anti-peptide antibodies. The choice of the sequence is seldom a 
totally free one. Restriction to certain regions of the protein is often dictated by homology 
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Strategy for the production of antibodies to synthetic peptides 
o Selection of antigenic sequence 
on the basis of physical and chemical structure parameters of the protein 
Immunugenicity: Hydrophillic > hydrophobic sequences 
Surface probability 
Fragment flexibility 
Secondary structure (a-helix> (j-sheet) 
Tertiary stmcture 
Results in : Antigenic index 
o Identification of region of interest and limitations in choice 
Localization of mutations 
Check for homology within protein families 
Glycosylation or modification sites 
o Check for homology with extracellular andlor selUm proteins 
o Synthesis and purification of peptide 
o Derivatization 
To improve illllllunogenicity 
To include adjuvanticity 
To include reporter molecule 
o Coupling of peptides to a carrier protein 
To incorporate a T cell determinant 
o Immunization with proper adjuvant in target animal 
Mostly 2 administrations with well selected time interval are needed 
Discussioll 
o Development of the appropriate assay for evaluation of the anti-native protein reactivy 
Sometimes this step can only be carried out after induction of antibodies. This mean!) after the nelOt step. 
o Evaluation of inmlUne response in semfll sample 
Determination of anti-conjugate reactivity to check for proper immunization 
Determination of anti-peptide reactivity 
Determination of anti-carrier reactivity 
Determination of antkoupling determinant reactivity 
Determination of anti-native protein crossreactivity in appropriate assay 
Determination of specificity of the antibodies. Note: absence of specificity in a polyclonal serum is not 
necessarily a problem, since specific antibodies Illay be present in the mixture 
o Production and selection of monoclonal antibodies 
Selection with the assay in which the monoclonal antibody is going to be used. Preselection in ELISA with 
a peptide coating is possible in order to screen a huge number of clones. 
o Characterization of the monoclonal antibody in the proper assay 
Reactivity with native protein (inhibition assay) and specificity 
lsotype 
o Large scale production, purification and labelling if necessary 
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with other proteins. For instance, selection of a homologous peptide will generate family-
specific antibodies which readily recognise shared epitopes. Alternatively, selection of 
heterozygous peptides will result in antibodies which arc uniquely spedne for a single 
member of the entire family. One should realise, however, that selection of a member-
specific sequence can result in unwanted family-specific antibodies. Even restriction to a 
single position in a protein may be encountered. Thorough knowledge of the protein in 
relation to its characteristics such as stlUcture, function and relationships with other proteins 
may substantially increase the rate of success. For example, structures which have a function 
in the binding of ligands often represent protein invaginations (hormone or DNA-binding 
pockets) which are difficult to reach for the relatively large antibodies (Novotny et aI., 1986). 
In contrast, structures which form extensions of proteins such as zinc fingers or the V3 loop 
of the HIV-! might offer better accessibility. Searching for matches with other protein 
sequences in data bases and subsequently taking this information into account may prevent 
disappointments afterwards, e.g., unwanted crossreactions. Besides information about 
intrinsic characteristics of the protein, computer algorithms for prediction of antigenic 
sequences may provide additional help with varying success as we showed before (Zegers 
et aI., 1991a, 1991b; Gerritse et aI., 1990; Kleine et aI., 1990; van Denderen et aI., 1990, 
1992, 1994; Boersma et aI., 1989a). 
As has been critically reviewed by Van Regenmortel & Daney de Marcillac (1988) 
none of the present computative methods for the selection of antigenic determinants leads to 
a satisfactory success rate in prediction of antigenic sites. It was demonstrated on the basis 
of a retrospective statistical analysis that segmental mobility (Karplus & Schulz, 1985) and 
hydrophillicity prediction algorithms led to the highest level of correct predictions of known 
epitopes. The lowest level of correct predictions was obtained using the method based on the 
relative frequency of specific amino acids in known determinants (Welling et aI., 1985). 
However, the analysis of Van Regenmortel and Daney de Marcillac (1988) is based on 
literature data from a variety of different methods to assess antigenicity: e.g., (a). Some 
polyclonal antisera generated with the intact protein or fragments were subsequently tested 
for cross-reactivity with peptides. The outcome of this type of test system is influenced by 
the way the peptide is presented in the assay (free peptide, conjugated, bound to plastic 
surfaces, competition with labelled peptide etc.), (b). By inhibition assay using peptides of 
the binding to the native protein, (c). The data obtained by the PEPSCAN method. In this 
evaluation (Van Regenmortel & Daney de Marcillac, 1988) only the correct prediction was 
taken into account of known determinants of well-studied model proteins. These however 
represent only the laboratory animal selection of all possible antigenic sites. For a correct 
evaluation the ratio of the antibodies directed against the protein (peptide mimicking the 
protein structure under assay conditions) as a proportion of all anti-peptide antibodies 
(antigenicity of the peptide per se) might have given a more realistic estimate of the 
correctness of the various predictions. 
We observed that only a proportion of the anti-peptide antibodies were crossreactive 
with the native protein. A peptide can adopt various conformations as well as in the 
immunogenic construct and in assay conditions dependent on the micro-environment. Only 
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one of these conformations resembles the conformation of the epitope in the native protein. 
And a proportion of these crossreactive antibodies are multi-assay applicable (Zegers et aI., 
1991b; Boersma et aI., 1989b). Similar observations were reported by Jemmerson (1987) for 
antibodies elicited using peptides from horse cytochrome-c. Parry et al. (1988) demonstrated 
for the foot-and-mouth disease vims (FMDV) that guinea pig anti-peptide sera raised to a 
synthetic peptide of the AA 141-160 of FMDV, showed cross-reactivity with the vims 
particle dependent on the mode of peptide-presentation. About 60-70% of the activity in the 
sera was directed to the peptides only. Intact vims absorbed out 30-40% of the specific 
activity. This was irrespective of whether the peptide was immunized free or conjugated with 
KLH. 
Short peptides (10 AA) are not always immunogenic or only yield peptide-specific 
antibodies not cross reactive with the native protein. Though we earlier showed that short 
peptides may induce protein-specific antibodies (Van Denderen et aI., 1989, 1990), longer 
peptides of about 15 to 25 amino acids readily lead to native protein-specific antibodies of 
higher affinity. The explanation for these findings may again be found in the multiple 
conformations a longer peptide can adopt relative to the possibilities of a short peptide. 
Another explanation may be that the short peptide has too few contact residues for the IgM 
molecule on the surface of the B cell which initially bind the immunogen. 
We suggested that, in general, short peptides tend to elicit antibodies which recognize 
the denatured form of the protein only (Boersma et aI., 1988). Application of short peptides 
therefore may be of advantage for the elicitation of antibodies to be used in assays where the 
antigen is encountered in denatured form, e.g., in SDS-PAAGE, fixed tissue specimens etc. 
(Van Denderen et aI., 1989, 1990). In contrast, Dyson et al. (1985) showed that an 
immunogenic nona-peptide which showed a preferential conformation in aqueous solutions 
elicited anti-native antibodies to hemagglutinin of influenza vilUs. Ultrastructural analysis 
showed that longer peptides indeed tend to mimic the native three dimensional stmctme of 
a protein much better since these peptides maintain a specific space-filling stmcture (Horiuchi 
et aI., 1987). 
Some, more general, recommendations for sequence selection are: Try to avoid 
"difficult sequences" to synthesize, e.g., sterically hindered amino acids such as IIe-IIe, Leu-
lIe. Choose termini in such a way that they are relatively highly hydrophillic. Avoid residues 
such as Trp, His, Met, Tyr and Cys since they are sensitive to side reactions and/or 
oxidation during deprotection procedures. However, Cys is often incorporated for coupling 
purposes and aromatic residues may be advantageous for immunogenic reasons. Avoid 
synthesizing hydrophobic sequences or sequences that readily form iJ-sheet stlUctures since 
solubility problems may arise. Choose the terminal sequences in such a way that they 
preferably contain hydrophillic residues. Include functional groups at one of the termini 
designed for coupling to a carrier protein by means of a proper amino acid residue for 
example. Avoid localization in the middle of the peptide sequence of residues of which the 
side chain might be involved (but not desired) in coupling procedures necessary for 
conjugation to a carrier protein. Localization of the substituted residue in the centre of the 
peptide sequence is most successful for generating variant-specific antibodies. Try to avoid 
201 
Chapter 11 
including immunodominant sequences as predicted with computer algorithms if site-directed 
antibodies are desired specific for a substituted residue. 
Of course not all recommendations can be strictly followed and a compromise should 
be made. Fortunately, even in cases where selection choices were not fully optimal, 
appropriate antibodies could be found thanks to a flexible and partly degenerated immune 
system, 
Computer algorithms for prediction of the antigenicity surely are helpful in the 
selection of putative immunogenic sequences. Crossreaction of the antibodies with the native 
protein induced with such selected peptides, however, is not guaranteed (van Regenmortel 
and Pellequer, 1994). But even if protein-specific antibodies should be elicited upon 
immunization with a peptide, they are just a fraction of the peptide-specific antibodies. 
In conclusion, we show that several factors in the selection of sequences playa role 
and that from our experience the following rules can be proposed: 
search for antigenicity according to the computer predictions 
exclude sequences which are homologous to other proteins by searching data bases 
take into account other characteristics of the protein sequences, such as function and 
structure, that highly improve the success rate. 
incorporate useful coupling sites and avoid troublesome amino acids, with regard to 
synthesis as well as coupling aspects. 
select a sequence of at least 15 residues. The maximum number of residues is 
determined by the costs of the synthesis and the difficulty of synthesis which increase 
with the length of a peptide. 
locate the epitope in the centre of the peptide sequence or at the distal end from the 
coupling site. 
chose hydrophillic residues at the termini of the peptide for improving the solubility 
and, as a consequence, the efficiency of conjugation of the peptide and the carrier 
protein. 
Together all these considerations will generally lead to the successful selection of the peptide 
sequence. 
III. SYNTHESIS AND PURIFICATION 
Synthesis of peptides is an intricate task despite the completely automatic synthesizers 
commercially available nowadays. It demands high investments in terms of money, 
knowledge and skill. Though synthesis seems a routine job, it definitely is not. Many 
protocols for protection, activation, coupling, deprotection and cleavage chemistry as well 
as for the kinetics of the reactions are available together with a wide range of reagents. These 
are all confusing to new researchers. If synthesis is a difficult job, the purification of peptides 
still is much more demanding. Already for a decapeptide, 2010 different sequences are 
possible, this is more than 1013 . All these sequences have their own characteristics which 
make it infeasible to work with one standard protocol for purification. 
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For immunization it is not necessary to achieve the highest purity, but the more pure 
a preparation is, the more homogenic the antibody response will be. It is conceivable, e.g., 
that a side-product in the preparation wil1 be immunodominant which is not desired. For 
evaluation purposes, the peptides should be of the highest purity. 
Many suppliers are nowadays offering custom-made peptides at reasonable prices and 
one can buy peptides with various grades of purity. Only if more than about a hundred 
peptide sequences per year are needed, could it be worthwhile to think of a synthesis unit 
with a teelmician trained well for the job. 
IV. CONSTRUCTION OF THE IMMUNOGEN 
IV.I. Free peptides 
Immunization with free peptides in general does not lead to antibody responses, since most 
peptides selected with prediction algorithms for antigenicity only contain a B cell 
determinant. 
According to some authors the success rate is unexpectedly high while using antigenic 
peptides an of sufficient length, ± 20 amino acids, for immunization as free inullunogens 
(Lerner et aI., 1981; Atassi & Webster, 1983; Briand et aI., 1985). For lysozyme (Bixler et 
aI., 1985) and for the FDMV (Francis et aI., 1987b) it was found that only a selection of all 
peptides of a protein is able to generate an antibody response with the free peptide. Using 
a rather large number of peptides from various proteins selected by computer prediction 
methods, we found that only a minor proportion, ± 20%, is able to generate an anti-peptide 
response using the unconjugated peptide and in most cases, only when administered 
subcutaneously (chapter 5). McCormick et al. (1988) showed that irrespective of the T-cell 
epitope character of a peptide the response was dependent on the adjuvant, dose and timing 
as well as on the sex of the mice used. The generation of antibodies even with long peptides 
does not guaranteed the generation of anti-native protein antibodies as was shown for the 
insulin ,6-receptor. Four out of four peptides did not produce anti-native receptor antibodies 
(Pessino et aI., 1989). 
IV.2. Coupling procedures 
Both for immunization as well as for evaluation of the immune response, conjugates of 
peptide and carrier protein are needed. Since upon immunization with a conjugate, 
antibodies are also raised against the linker between peptide and carrier, resulting from the 
conjugation, or against a neo-detelminant introduced as a side product in the conjugation 
reaction, evaluation of the immune response should ideally be determined against a conjugate 
of the peptide with another carrier and a different coupling agent. Precise and conditioned 
coupling is a requirement for avoiding introduction of neD-determinants and for achieving 
controlled orientation of the peptide relative to the carrier. Amongst many homo- and hetero-
bifunctional coupling reagents, MBS, EDC and glutaraldehyde are the most appropriate ones, 
since they are relatively simple to use, each with its own advantages and limitations. 
Improved protocols for these reagents were developed by us specifically for use with peptides 
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(Zegers et aI., 1990; Deen et aI., 1990). Conjugation by MBS by means of an introduced 
cysteine residue or a protected -SH function by SAT A at one of the termini of the peptide 
is a favoured and controlled method. N-telminal conjugation is preferable because of two 
reasons. The first reason is that during synthesis the cysteine residue, which is sensitive to 
side reactions, is only exposed to possibly hatmful chemicals during its own coupling cyelus. 
The second reason is that only completed sequences, in case the nascent chain is acylated 
after incomplete coupling, contain a cysteine residue. Of course, N-terminal conjugation of 
a peptide is not always an advantage (see under orientation). Addition of a non-native 
cysteine to a sequence in general does not disturb the immullogenicity of the conjugate and 
reaction pattern of the induced antibodies. On the contrary, enhancement of immunogenicity 
of free peptides was reported in some cases after incorporation of a temlinal cysteine, 
probably by the fOiming of dipeptides (Francis et aI., 1987a). When a cysteine residue is part 
of the peptide sequence, MBS conjugation cannot be used in most cases. Then a choice 
between EDC and glutaraldehyde should be made. EDC, which introduces the peptide in at 
least two orientations (N- or C-terminally) onto the carrier, should not be used when several 
Lys, Glu or Asp residues are scattered through the peptide sequence. The same holds true 
for the use of glutaraldehyde when several lysine residues, especially consecutive residues, 
are part of the sequence. That these rules, however, are not an absolute truth, has been 
proven by anti-hAR MAbs selected by us. Care should be taken, however, for the protocols 
employed, since neo-detelminants and uncontrolled coupling are easily introduced. 
It is not easy to predict the influence of coupling procedures on the immunogenicity 
of a peptide and the recognition of native protein. Application of different conjugation 
methods simultaneously and subsequent inununization with the different conjugates is the 
most pragmatic and fastest way of achieving antibodies with a broad reaction pattern. 
Evaluation of these antibodies should point out which method leads to success. 
Poor solubility of the peptides negatively influences the efficiency of coupling. 
Synthetic peptides despite being selected from a hydrophillic sequence of a protein may show 
highly variable solubility behaviour. Peptides which do not readily dissolve in aqueous 
solution, DMSO or DMF (frequently used in coupling protocols) may be conjugated as 
described before (Gerritse et aI., 1991). In this procedure, peptides were dissolved in high 
concentrations of urea and conjugated to alkaline phosphatase, which did not prevent the 
activity of the enzyme. 
IV .3. Orientation of the peptide on the carrier 
From the experiments conducted with peptides from ",-AT, it can be concluded that the 
distal end of the coupling site is readily exposed to the immune system. The antibodies 
elicited are specific for the distal end. 
The N- or the C-terminus of a protein in general is a flexible part of the protein 
implying probably a high immunogenicity. If antibodies are desired against one of the termini 
of a protein, by means of synthetic peptides, the termini should be exposed. In other words, 
the N-terminal part of the protein should be coupled at its C-terminus and the C-terminal palt 
204 
Discllssion 
at its N-terminus (Zegers, unpublished results; Boersma et aI., 1992; Schaaper et aI., 1989; 
Briand et aI., 1992), 
Most successful for eliciting Z-variant specific antibodies, were the pep tides with the 
substitution in the centre of the sequence. Positioning the substitution site near the distal 
terminus (one residue from it) relative to the coupling site did not lead to the desired 
antibodies, The substituted amino acid probably has to be flanked with some residues in the 
synthetic peptide to mimic the stmcture in the aI-AT protein. From the experiments with the 
peptides derived from the 342 site of "I-AT, we decided to place the 264 substitution in the 
middle of all the peptides selected, With these peptides, we found that an immunodominant 
sequence, even when placed at the coupling site and thus badly presented to the immune 
system, in general, leads to antibodies against this immunodominant sequence overruling the 
presentation of the flexible distal end, 
Cyclization of a peptide through a disulphide bridge of the termini may give good 
results when the native protein contains a loop. Such a cyclic peptide and structure-constraint 
peptide mimics the stl1lcture of a loop in the native protein. Antibodies raised with cyclic 
peptides may discriminate between a linear and a cyclized peptide and recognize the native 
protein instead of a denatured protein, 
In conclusion, controlled coupling methods should be used for the conjugation of 
peptides and carriers, to avoid introduction of neo-determinants and to achieve a controlled 
orientation of the peptide relative to the carrier. The use of MBS, EDC or GA is dependent 
on the constituent amino acids, but can best be judged pragmatically, Multiple antigen 
peptides can be considered if conjugation is difficult, e,g" if the peptide is insoluble or if the 
residues involved in coupling are part of the epitope. 
V. IMMUNIZATION 
In general, a dose of 25-50 ~g peptide-carrier conjugate (carrier-based calculations) or free 
peptide lead to a proper antibody response specific for the protein, from which the peptide 
sequence was derived, in mice, A higher dose of 150-250 ~g may substantially enhance the 
fraction of the protein-reactive antibodies and can be employed in case a poor anti-protein 
antibody response is encountered. We usually immunize mice via an i.p. administration since 
the constructs often contain some aggregated material for which i. v. injection is not possible. 
Injection in the footpad stimulating the popliteal lymph node is a useful alternative, but in 
some cases only peptide specific responses were found (chapter 5), Moreover, this method 
is animal unfriendly and should be employed only in limited cases when other methods fail. 
We compared different adjuvants for stimulating peptide immunization, from which 
specol, a water in oil adjuvant, emerges as useful with a good perfOlmance: convenient to 
prepare the immunogenic mixture, minor side effects for the animal, high and persisting 
antibody responses. Titermax~, Adjuvax\ Ribisystem* and Alhydrogel* or Lipovant~ were 
compared to Freund's complete adjuvant by Bennett et al. (1992) using haptens and peptides, 
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Adjuvax\ Ribisystem-l and Alhydrogel~ or Lipovantt were compared to Freund's complete 
adjuvant by Bennett et al. (1992) using haptens and peptides. They demonstrated that 
Titennaxt led to the highest titers when anti-peptide antibody titers were compared. In most 
experiments the Ribi' adjuvant was the second best. FCA induced the highest anti-peptide 
titers but with the highest adverse effects. This was also reported by Leenaars et al. (1994). 
The persisting antibody response can be a disadvantage, since for an optimal booster effect 
the response should be at a minimum level. In our protocols, at least a four week interval 
between immunizations is taken, leading to good results. Longer intervals between these 
injections (6-12 months) proved to give high numbers of stimulated B cells beneficial in cell 
fusion procedures for obtaining monoclonal antibody secreting hybridomas. An option could 
be: assay for specific antibody responses in serum at, e.g., weekly intervals and boost only 
when the antibody response level has returned to 10-20% or less of the maximum level. 
To generate monoclonal antibodies, immunize at least 4 and at maximum 8 mice with 
a peptide conjugate. Following evaluation of the antibody response after the prime and 
booster irnnlUnization, only restimulate the mouse with the highest level of antibody 
responses for hybridoma production. Leave the other mice; these mice can be immunized at 
a later stage in case a second fusion protocol should be carried out, e.g., with an alternative 
selection procedure. Meanwhile, the antibody response in these mice will return at a 
minimum level. A strong memory-B cell response can be obtained by subsequent 
immunization. 
In our experience peptide-specific PAbs (elicited in rabbits), which are mono-specific, 
provided useful reagents for use in various immuno-assays (ELISA, Western blotting, 
inmmno-precipitation, immuno-histochemical detection and inmmllo-staining of cells) 
(Gerritse et aI., 1990 ; Van Denderen et aI., 1989; Van Laar et aI., 1989). In addition, there 
appears to be a tendency that outbred rabbits recognize a broader repertoire than we regularly 
observe in the Balblc mice. 
In conclusion, intraperitoneal immunization with 25-50 I1g of the peptide-carrier 
constlUct per mice given in a mineral oil suspension as a mild adjuvant generally leads to 
satisfying antibody responses, providing, of course, that the chosen sequence is 
immunogenic . 
VI. EVALUATION, SELECTION AND CHARACTERIZATION 
Upon immunization with synthetic peptides, the polyclonal antibody response has to be 
evaluated after each administration. Routine evaluation can be made 7 days after injection. 
As stated in section III, a booster injection can be given when the antibody level has 
decreased to a level below 20% of the peak level. Assay selection proved to be of major 
importance. Some of these are several kinds of ELISA formats, Western blot, immuno-
precipitation, immunocyto- and histochemistry. The easiest method is assaying serum samples 
in ELISA on a coating of the native protein. In addition, the response to the peptide-carrier 
construct as a control for proper immunization, the response to the peptide and the response 
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to the peptide presented as a peptide-protein constlUct made by an alternative conjugation 
method should be determined. 
It should be taken into account, however, that coating to the plastic may change the 
conformation of the protein in such a way that a denatured protein is mimicked. The 
antibodies which recognize protein coated to plastic in general also tend to recognize the 
protein applied in SDS-Western blotting procedures or in immunohistochemistry of freeze 
sections of tissue specimen. Recognition of proteins in formaldehyde treated paraffin sections 
of tissues is often hampered by the stringent fixation method. Formaldehyde modifies the 
protein to a large extent in such a way that antigenic detelminants are destroyed. Retrieval 
of the antigenic determinant by heating the sections in acid solutions, in the presence of 
heavy metal ions necessary for some proteins, is possible in some cases following selected 
procedures (Jansen et aI., 1994). Antibodies that recognize only the denatured form of the 
protein can still be useful reagents in diagnostic immuno-assays. 
Recognition of the native protein in solution is possible with competition assays: pre-
incubation of the antibodies with the native protein and subsequent transfer for incubation in 
ELISA, Western blot or immuno-chemislly (for review see Jenmlerson, 1995). With 
polyclonal antisemm, a competition assay is not always predictive for the existence of native 
protein-specific antibodies, since these antibodies, especially those with high affinity, may 
only be a smail proportion of total antibodies present (pathak at aI., 1995). With adequate 
stimulation and selection protocols, high-affinity monoclonal antibody secreting hybridomas 
can be found. 
Upon detecting antibodies of the desired specificity in the semm of immunized 
animals. the next step often will be generating hybridomas which secrete monoclonal 
antibodies. The selection procedure to screen the hybddomas eventually determines the 
specificity of the antibodies and thus can be considered as one of the major steps. The MAbs 
should preferentially be selected with the method in which the MAbs are going to be used. 
For sandwich assays. this is not always possible, since a useful capture antibody may not be 
available. Polyclonal rabbit antisera can be very useful for this aim and should be raised with 
the protein, if possible, or with a peptide derived from a different region of the protein than 
the one that is used for MAb production. Care should be taken, if the protein is used for 
eliciting PAbs. As was demonstrated (Zegers et aI., 1993), the major fraction of the PAbs 
could be directed against ioununodominant regions which also have been used for peptide 
sequences. - Peptides often are selected because of their high antigenic indices. - A step 
by step sandwich assay then fails. A solution to this problem is a pre-incubation step of the 
supernatant from the culture wells with the native protein, hereby allowing the MAb to be 
selected to form an Ag-Ab complex. Subsequently, the Ag-Ab complex is transferred to the 
well with the capture antibody. The concentration of the native protein should not exceed the 
coating concentration of the capture antibody. Sometimes it is necessary to expose betterthe 
antigenic determinant in protein, e.g., by denaturing by mild heating in the presence of {3-
mercaptoethanol. 
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In conclusion, evaluation of the reactivity pattern in the polyclonal selUm should be 
carried out after each administration, The reactivity should be assayed with the peptide, with 
the carrier, with the coupling determinant, with the native protein and with irrelevant 
peptides and proteins as negative controls. Crossreaction with the native protein should be 
carried out by competition or inhibition or sandwich assays, Only by selecting MAbs in the 
assay method that is going to be used or that is designed in such a way that it will resemble 
the ultimate assay, can specific, high-affinity antibodies be found. 
VII, USE OF T CELL DETERMINANTS 
Immunization with free hybrid peptides, i.e., which possess both a T cell determinant (TD) 
as well as a B cell determinant (BD), can be used to elicited BD-specific antibodies. The 
selection of the TD is important. The factors that play a fole in the selection were 
exhaustively discussed in chapter 8, The conjunction between the TD and BD is very 
important. A natural peptide bond (instead of chemically linkage by, e.g., MBS or GA) 
yields the most immunogenic constructs, but the efficiency of synthesis of long sequences 
decreases with length. The conjunctional site may create a new TD or BD with positive or 
negative result. Consider the MHC restriction, Elongation of a TD can have a positive 
influence due to increased stability providing that the flanking sequences contribute to 
increased helix character. Multiple copies of a TD may lead to an increase of the antibody 
response. N-terminal position of the TD in a hybrid TD-BD construct is preferred. 
Peptide-protein constructs in general are morc immunogenic than free peptides, 
probably since these constructs possess various TDs. Free peptides could be advantageous 
for effective vaccines. A useful alternative for eliciting high-titer antibodies may be the MAP 
construct provided that a TD is incorporated into the sequence, Such a MAP is advantageous 
if a sequence can only with difficulty be conjugated to a carrier because of critical residues 
which might be involved in the conjugation reaction. 
VIII. CONCLUSION 
Peptides have proven to be useful tools in the production of antibodies. Though it seems that 
immunization with peptide antigens is straightfonvard, it is a delicate process to arrive at 
useful antibodies. On the basis of two model proteins, it was demonstrated in this thesis that 
only profound control of all individual steps of the peptide strategy eventually lead to the 
appropriate antibodies. Selection of the epitope sequence and the development of the selection 
assay for screening hybridomas together with the development of the assay in which the 
antibodies are going to be used are most important and determine the result of the affinity 
and specificity of the antibodies. Careful application of the peptide strategy following the 
recommendations abstracted and discussed in this chapter has led to hAR-specific MAbs and 
MAbs specific for ",-AT and the Z-variant of ",-AT, 
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I. PEPTIDES 
I. 1. Selection of peptide sequences for synthesis 
Materials and Methods 
For practical purposes, when there are no restrictions posed by homology etc" then the antigenicity prediction as 
described by a computer program is helpful. We used the program of the Genetics Computer Group, Wisconsin 
(Devereux et ai., 1984). Terminal segments may be very useful since they loop out of the globular structure. 
Peplides arc chosen at least 15 (15-25) amino acids long. Amino acids for coupling purposes may be added at 
strategic terminal positions. The sequence is chosen such, that both ends of the peptide do nol represent a minimum 
in hydrophillicity. Peptides can be elongated either N- or C-terminally by a cysteine or arginine residue for coupling 
purposes. 
],2. Peplide synthesis 
Peptides are synthesized with a Sam II Biosearch peptide synthesizer (San Rafael, Ca, USA) using the Merrifield 
(1963) solid phase technique with I-Boc-prolected amino acids on a polystyrene resin (1 % crosslinking). Deblocking 
and cleavage for t-Boc synthesis is performed by treatment with thioanisol and hydrogen fluoride (90 min, O'C) as 
described by Bhatnager el al.(1983). Crude peptides are precipitated from ether followed by an extraction with acetic 
acid (5%). Subsequently, peptides are lyophilized and subseq~lently reduced with 10 equivalents of Illreo-
1,4,dimercapto-2,3,butanedioi, pH 8.0, 60 min at room temperature and lyophilized. 
Some of the peptides (59-66) were produced semi-manually using the Dupont RaMPS system (Dupont Medical 
Products, Biotechnology Systems U.S.A.) and Fmoc protected amino acids (Dupont, Wilmington, USA) essentially 
as descrihed elsewhere (Zegers et al. 1991a) according to the manufactorer's instruction. 
Peptide synthesis using Fmoc-amino acids is performed on a Milligen 9500 machine (MilJigen, San Rafael, CA, 
USA) using the protocol and amino acids from the manufacturer. Pepsyn-KA and PEG-PS resins (Milligen) arc uscd 
substituted with the C-terminal Fllloc-amino acid, suhstitution degree 0.1-0.2 mmol/g. OPfp-esters arc used for most 
amino acids if available. Otherwise, the Fmoc-protected amino acids (His, run, Gin, and Arg) arc activated ill situ 
using DlPCDJIHObt. Protecting groups are: Tn for Cys and His, tBu for Ser, Thr, and Tyr, OtBu for Asp and Glu, 
moe for Lys, Tmoh for Asn and Gin, Pmc for Arg. Deblocking and cleavage is performed with :t mixture of 
scavengers and trifluoroacetic acid according to the Milligell protocol. Standard 95% TFAls% phenolls% water. 
Dependent on the protecting groups used, additonal 2 % anisol andlor 2 % 1,2-ethanedithiol is used (see protocol 
Milligen). Relevant peptides containing Cys residues are reduced before purification using 10 equivalents {J-
mercaptoethano! for 30 min at 37"C and Iyophilizcd. 
1.3. Peptide purification 
The crude peptide is dissolved in a minimum amount of 5% (vlv) acetic acid. Gelfiltration is performed Oil G-Is 
Sephadex (pharmacia, Uppsala, Sweden) using 5% (v/v) acetic acid as eluent. Analysis of the fractions is assessed 
by reversed phase HPLC. A gradient ofO.l % trifluoroacetic acid in acetonitrile (15-40%) into 0. 1 % trifliloroacetic 
acid in H20 on a Beckman Ultrosphere CI8 S,Im column (4.6x250 mm) is applied. Fractions showing the same 
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homogenous peak at 214 om, are pooled. Amino acid analysis is performed essentially as described by Janssen et 
al. (1986), The proportion of available -SH groups is determined using the method described by Ellman (1959) (See 
section 1.4.3). All reagents for peptide synthesis or derivatization are HPLC quality. 
Alternatively, peptides can be purified using HPLC as described above. For purification, a column for preparative 
scale Delta Pak CIS 15 ttm (19x300mm) is used. 
1.4. Peptide derivafization 
For an introduction into various amino acids, specific chemical protection techniques, which have been developed 
for proteins but in general can be applied to peptides as well, see Atassi (1977). For the selection of proper coupling 
reactions the following rules of the thumh: a) Use preferably bi-functional reagents, b) use specific coupling 
procedures for an .1mino acid that has a low frequency in the peptide, c) aVoid amino acids that are crucial for 
recognition, d) elongate peptides with an amino acid for coupling purposes e.g. Cysteine or Arginine. 
Frequently applied reagents: Sulfo derivatives ofN-hydroxysuccinimide compounds are less susceptible to hydrolysis 
and water-soluble. In general they lead to belter conjugate yields (2-4x). Most other coupling reagents are 
hygroscopic and readily hydrolyse. Storage _20cC. First equilibrate to ambient temperature befure use. Tris, glycine 
and other amino-group containing reagents (ammonium sulphate) should be avoided. SP-protein conjugates stored 
at 4"C were not stable (Briand et al. 1985). It is advised to store all conjugates at protein concentrations> Img.ml·] 
at -20 "C. 
104.1. Biotillyiatioll (Lollg chain biotin, LCB) 
Biotin binds extremely well to avidin. However, to prevent unwanted interactions by the avidin bound, due to the 
extreme depth of the binding pocket (4-5 amino acids deep), it is best to couple biotin via a, long aliphatic chain, 
linker (Suter et al. 1986). N-hydroxysuccinimidyl-6-(biotinamido)-hexanoate (Pierce) is bound equimolar to the 
peptide. The procedure is easiest to perform while the peptide is still bound to the resin with all its protecting groups 
still in place. Coupling to the unprotected -NH2 terminal side is than easily obtained. Be sure that all protecting 
groups are removable using TFA. 
Ingredients: DMF, amylalcohol, acetic acid, diethylether, a saturated solution of phenol in water, long chain biotin, 
imidazole (10 mg LeB in 10 III imidazole). 
Procedure: The resin-peptide is washed thoroughly with DMF. Leave the resin submersed in DMF. LeB is added 
in imidazole to equimolar concentration with the peptide. Incubate overnight (room temperature). Wash with DMF. 
Subsequently wash with terLamylalcohol (2x), acetic acid (2x), terl. amylalcohol (2x), diethylether and dry in 
vacuum. With conjugated avidin the biotinylation can be monitored. Then cleave the peptide from the resin with 95% 
TFA, 5% phenol in water. Purification of pep tides according to standard procedures. 
1.4.2. 1ll1rodflCtioll of ,W/lfl!)'dryigrollps 
When peptides or proteins do not contain free -SH groups, these easily can be introduced using Traut's reagent: 
methyl-4-mercaptobutyrimidate (iminothiolane) (fraut et ai., 1973) This compound reacts preferentially with amino 
groups. On mild reduction the peptide or protein is lagged with free -SH groups. The -SH groups introduced can 
be used for coupling with a hetero-bifunctional coupling agent or they can be allowed to form -S-S- bonds (King et 
aI., 1979). 
Procedure: For the best result a 3-fold concentration of 2-iminothiolane (MW 140) over the peptide concentration 
is used. The reaction is allowed to take place in a sodium phosphate buffer (NaPi), pH 8.1. Iminothiolane is added 
dropwise to the peptide solution (5-10 mg.ml·]) in a small reaction vial and allowed to react for 1 hat roomtemp. 
Subsequently the peptide is separated from iminothiolane by gelfiltration over G-15 Sephadex (Pharmacia). (Dialysis 
membranes with low mol. weight cut off. (1 kD) give disappointing results). 
104.3. Detennillatioll of available -SH groups 
Available -SH groups can be determined using Ellmans reagent (Ellman, 1959). 
Ingredients: NaPi buffer 0,1 MpH 8.0.; 5,5'dithio-bis-(2-nitrobenzoie acid (DTNB, Ellman's reagent), 4 mg.ml-1 
in NaPi O.IM, pH 8.0.; solution of cysteine or l3-mercaptoethanol as a standard. 
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Procedure: Briefly, add 0.1 ml of the sample to 0.1 ml of the reagent solution and mix with 4.8 ml Napj pH 8,0 
buffer. After a few minutes the reaction is completed. Read absorbance at 412 nm. EIl1=L36.104cm,l.M'[ versus 
blank, 
II. COUPLING PROCEDURES 
II.I Homo bl·functional coupling 
fl.I.i. Actimted -SH 
(coupling two active -SH which are incorporated into the protein/peptide) 
Ingredients: N-succimidyl 3-(2-pyridyldithio)propionate (SPDP) solution 20-40 mM (MW 312.4; 1.56-12.5 mg.mi' 
I)in ethanol or DMSO; protein (carrier) l-lD mg.mi,1 in Napj buffer 0.1 M, pH 7.5, with 0.1 M NaCl; small 
reaction vial; sepharose 0-25 column (PD-1O, Pharmacia); acetate buffer 0.1 M, pH 4.5 with 0.1 M NaCl; 
dithiotreitol (OTT) 0.1 M; n-ethyl-maleimide 10 mM. 
Procedure: Coupling principle: protein + SPDP (10 fold excess, minimum) ~ protein with protected -SH; idem for 
peptide. On reduction of one of the 2-pyridyldisulphides with DTT, preferably the protein, the protecting groups are 
removed. Mixing the peptide-2-pyridyldisulphide with the thiolated carrier protein yields an -S-S- coupling product. 
The coupling i.e. the release of the pyridyl-2-thione can be followed spectrophotometrically ~3 =8.08.10·3M·i. cnfi. 
Allow the protein to react with SPDP under stirring in a small reaction vial for 30 min at room temperature. For 
the determination of protein concentrations speclrophotometrically, a correction factor for the 2-pyridyl disulphide 
should be taken into account (ElSD =EuD-rpyridyne-2-thione released, molair] x 5,1.101, Pharmacia methodology 
SPDP method). To transfer 10 acetate buffer and to remove excess SPDP, bring protein-2-pyridyl disulphide over 
a G-25 column (PD-IO), Reduce Ihis disulphide with D'rr (final concentration 50 mM, 30 min roomtemp.), Transfer 
to NaPi pH 7.5, 0.1 M NaCI and remove reagents over G-25 column (PD-IO, Pharmacia). Similarly the peptide is 
treated with SPDP and excess of reagents removed by HPLC-chromatography, Finally, the 2-pyridyl disulphidcd 
peptide and the thiolated protein are allowed to form a disulphide bond (Ih-overnight, room temperature), Thiolated 
protein (pH 7,0) may be stored at -20°C. Remaining free -SH groups if necessary can be blocked with n-elhyl-
maleimide (IOmM). 
II.i.2. Glutaraldehyde 
(coupling -NH22 
Ingredients: Carrier protein: 10 mg.ml· 1 in PBS; peptide: 10 mg.ml·! in water; dialysis membrane cut off 10 kD); 
glutaraldehyde (Baker's); glycine 0.2 M; PBS; small reaction vials. 
Procedure: Dialyse (4"C, overnight) carrier protein (lml) versus 0.2 % glutaraldehyde (1.6 ml) in 200 ml PBS, 
Dialyse two times versus 250 ml PBS (2 x 21t). Transfer activated carrier into reaction vial, Slowly add SP: tOO 
mol/mol carrier protein. Incubate overnight (4<'C). Then add 0.1 ml 0.2 M glycine to block all active aldehyde 
groups left (2h, roomtemp.), Dialyse extensively to PBS. Store conjugate at -20"C (Zegers et al., 1990, adapted from 
Boorsma. 1984). For the conjugation of peptides which are not readily soluble a method has been described by 
Gerritse et aI., 1991. 
Peptides sometimes are not readily soluhle in water or water solutions like borate or phosphate buffers etc. 
Alternatively DMSO or DMF can be used as a solute. 
If peptides still are not dissolved urea may be used. Recently a modification of a glutaraldehyde coupling of peptides 
to alkaline phosphatase (Zegers et aI., 1990) has been described by Gerritse et al. (1991), using 8 M urea to dissolve 
the peptides. 
Procedure: Briefly, Dialyse AP (10 mg.m!·I) against 0,2% glutaraldehyde in PBS for 16 h at 4"C. Remove excess 
glutaraldehyde by dialysation of AP against PBS, Transfer into a small reaction vial. Dissolve peptide (Img.ml· l ) 
in 8M urea pH 7.0 by stirring for 10 min at roomlemp. Remoy,;: the non-dissolved material by centrifugation. 
Solubilized peplides are mixed with the activated AP (peptide/Ap = 100/1) for 16 h at 4"C. Block remaining active 
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glutaraldehYde groups by adding 100 III 0.2 M lysine.Hel, incubate another 2h. Excess reagents are removed by 
dialysis to PBS. 
11.2. Helero-birunctional coupling 
1l.2.1. Carbodiimide EDC 
(coupling e.g. -NHlt -eDam 
Ingredients: N-methyl-imidazole 0.5 11, pH 6.0; carrier 10 IlIg.ml'! in N-methyl-imidazole; peptide 20 mg.ml'\ in 
N-methyl-imidazole; EDC (1-clhyl-3-(3-dimcthyJaminopropyl)cardodiimide hydrochloride, Pierce) 100 mg.m!'\ in 
N-mcthyl-imidazole; dialysis membrane cut off 10 kD; small reaction vials. 
Procedure: Mix carrier and peptide solution in reaction vial: SP 100 moUmol carrier (mol weight carrier 150 kD) 
for other carriers similar e.g. BSA (mol weight 60 kD): 50 mol SP/mol carrier protein. Subsequently add slowly 
(drop-wise) the EDC (MW 191.7) solution to 50 mollmol SP. Mix 30' at roomtemp. Then dialyse vs PBS overnight, 
4"C. Store at -20"C (Deeo et aI., 1990). 
1l.2.2. Maleimide/N-hydrmysliccillimide MRS 
(coupling of -SH and -NH) 
Ingredients: NaPi buffer 0.1 M, pH 7.0 (SPB); carrier protein 10 mg.ml'! in SPB; Coupling agent 01-
maleimidobenzoyl-N-hydroxysuccinimideester (MBS, mw. 314.2, Pierce) 20 mg.ml'! in dimethylformamide (DMF); 
peptide: 20 mg.ml'l in SPB; 2 small reaction vials; PD-lO column (Pharmacia). 
Procedure: Carrier solution in vial is stirred on ice. MDS is added dropwise/slowly in 3 portions with 5 minutes 
intervals to 200 mol MDS/moi carrier (mol weight 150 kD). MBS with NaPi buffer gives a precipitate. This is 
discarded by centrifugation (Eppendorf, minifuge). Activated carrier is separated from unreacted MDS via a desalting 
column (Pharmacia, PDI0). A little bit of precipitate can be discarded. The activated carrier is transferred to a clean 
reaction vial. The peptide is added to 100 mol SP/mol carrier (mol weight carrier 150 kD). Stir at roomtemp for 
1 h. Store at -20~C. 
II. 2.3. A'l.idophellylglyoxal APG 
(Arginine to Tyrosine, histidine; photoaffinitylabeling) 
Glyoxal containing compounds react selectively (at pH 7-8) with arginine residues (Ngo et ai., 1981) (for a review 
see Atassi 1977). Coupling arginine containing peptides to proteins and vice versa arginine containing proteins to 
any peptides containing tyrosine, histidine or lysine has been applied by us. 
Ingredients: SP: 5.1O-3M (± 10 mg.ml"!) in HP; APG: 1.1O-2M (1.9 mg.ml"! in borate buffer 0.1 M, pH 7.9), 
prepared and kept in the dark; UV lamp (A= 360 nm, socalled black ray 40W). NaBH4 to"1M in H20. KLH 10 
mg.ml"! in PBS. Dark glass mini-reaction vial. 
Procedure: The procedure starts in complete darkness! Incubate 0.2 ml SP with 0.2 ml ApG (for one Arg in the 
peptide; APG: ARG= 2) at 37"C for 2 h. The course of the reaction can be followed spectrophotometric ally: APG 
free has a maximum at 297 nm whereas the APG-Arg product has a maximum at 250 nUl. 0,2 011 of the reaction 
mixture is mixed with 0.2 Illi KLH solution. Mix well and place this solution in a smal petri-dish or 24 well tissue 
culture plate under the UV-lamp for 30 min. Subsequently the coupling product is reduced for stabilization with 0.4 
ml NaBH~ for 2 h on ice. Dialyse to PBS. 
1l.3. COl/pling of peptldes to enzymes 
Peptide-enzyme conjugates can be applied for detection of receptors for peptide ligands (antihodies, peptide-hormone 
receptors etc.) (Laman et ai., 1990, 1991a). In principle the methods as described for peptide coupling in general 
can be applied. In our hands GA and MBS-like reagents fulfil our criteria best. 
218 
Materials alld Methods 
III. Jl\lMUNIZATION 
111.1. Animals 
For our experimentations,femaleBALB/c mice aged 12-16 weeks were used throughout. They were kepi in macrolon 
cages under an 11 he dark/13 he light regimen at 20°C and were given acidified water (pH 3) and pelleted mouse 
food (Hope Farms, Woerden, The Netherlands) ad libitum. Fiamish Giant rabbits rondom bred (MBL-TNO, 
Rijswijk, The Netherlands) were used to elicit polyclonal anti-peptide sera. Experiments were performed under the 
auspices of the Dutch Veterinary Inspection, according to the law on Animal Experimentation. 
For the production of immunological reagents Iwo routes are mosl widely used: 1) Injection of conjugate or peptide 
together with adjuvant intraperitollcally in mice or 2) Subcutaneously on the back of rabbits or subcutaneously on 
the upper side of the feet or in the inguinal and axillary regions of the mice. In both cases serum IgG responses are 
obtained after a booster immunization. The spleen and lymphe node cells can be used for the production of Mabs. 
With subcutaneous injections the doses should best be distributed over more places (four) for better results. 
III.2 Doses 
Peptides of 15-20 amino acids are immunized in doses between 25 and 100 Ilg per mouse or 100-200 Ilg per rabbit. 
Conjugates contain a number of peptides per carrier and in general a doses range between 50 and 150 Ilg of the 
conjugate, based on the carrier content, will be sufficient. 
IU.3 Adjuvants 
m.3.i. Specol 
Water phase (9/20 v/v) including the antigen is slowly pipelted onto the oil-phase (Specol) (Bokhout et aL, 1981) 
under thorough mixing on a Vortex. The emulsion is relatively stable and can be used for administration. 
1ll.3.2. Freund's adjlll'al/t 
Using Complete Freund's Adjuvant (CFA) thorough mixing of the components (incomplete, bacteria, antigen) until 
water-in-oil and oil-in-water emulsions are obtained is necessary for good results. Mixing is easily performed when 
Iwo glass syringes are connected by a double luer-Iock. In general 45/55 v/v of antigen solution and CFA is used. 
(Caution, the mixture of CFA is a skin-irritant). 
Tn mice, 200 It! of the emulsion is administered intraperitoneally, while 50 It! per location is injected subcutaneously. 
In rabbits, 250 Iii per location is used for water-in-oil emulsions as well as for CFA. 
1ll.3.3. Alum precipitation 
Precipitates of proteins or peptide-conjugates onto alum (Aluminium-potassium-sulphate gel) act as depot 
administrations. 
Ingredients: 10% w/v solution of aluminium~potassium-sulphate in phosphate buffered saline (PBS) is prepared; 1M 
NaHC0.l (2.1 g125 011 PBS); mini-reaction vial. 
Procedure: Dissolve 100 pg of protein to 210 It! PBS. Add dropwise the NaHCOJ (90 JIi) and mix. Subsequently 
200 pI of the alum gel is added slowly under vigorous stirring (or vortexing). Leave the mixture overnight at 4°C, 
freshly prepared alum precipitates may be toxic! Mix before introduction. Use 200 Id of the mixture per mouse. 
m.3.4. Bordetella Perlussis 
Similar to mycobacteria in Freund's Complete Adjuvant, various other bacteria (mainly membrane/cell wall 
components) show adjuvant activity. For this purpose heat killed Bordetella Pertussis bacteria are frequently used. 
At the time of immunization or one day in advance 2x109 bacteria are injected inlraperitoneally in mice. For rabbits 
8x 109 bacteria are administrated subcutaneously. Do not mix Bordetella pertussis suspensions with alum precipitates 
since in that case large aggregates will develop. 
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111.4. Scheduling 
The time-course of development of serum antibody responses may in part be dependent on the type or carrier protein 
used. When KLH is applied. then in mice serum antibodies (IgG + IgM) increase gradually up to at least 21 days. 
For an estimate of responses repeated tapping of the animals al various time points (14 and 21 days) after 
immunization is advised. In rabbits taking some serum 14 days after each immunization is sufficient. Immunizations 
with peptide-carrier conjugates are given with four weeks intervals. In general after two to three subsequent 
immunizations the maximum titers are obtained. 
Best results following booster immunizations are obtained when priming titers have decreaJ;cd. However, using KLH, 
which itself has adjuvant properties, anti-carrier titers will remain high for months. Nevertheless normal 
immunization schedules can be completed. 
The timing of the immunization preceding spleen cell fusion depends on the routing: soluble antigens (conjugates) 
can be introduced intravenously three days before fusion. Less soluble antigens are given intra-peritoneally (i.p.) with 
IFA, as a water in oil emulsion or precipitated on aluminium hydroxide gel four days before an intcnded spleen cell-
fusion. Though we prefer spleen cells for fusion, for fusion of lymph nodes regional nodes are activatcd by immuniz-
ation with adjuvant (as for Lp. immunization). Mirza et al. (1987) performed fusion of Iymphe node cclls at day 14 
after primary immunization for the production of anti-insulin (5.6 kDa) MAbs. 
IV. EVALUATION OF ANTIBODY RESPONS&~ 
IV.I. ELISA 
ELISA is the most easy and rapid method for the analysis of experimental antibody reponses. In gcneral optimal 
conditions for each ELISA arc found by titration of coating and detector reagents. For regular ELlSAs we followed 
the procedure as described in detail by Haaijman et aL (1988). 
PVC-micrOliter plates (Titertek, 77-172-05 highly activated, Flow Laboratories, Irvine, U.K.) arc coated overnight 
at 4"C with 50 It! PBS containing 5pg'ml'l protein, peptide or alternatively the peptide conjugated to BSA (not used 
for immunization) with a reagent not used in the immunogen. Plates are blocked with 0.5% gelatin in PBS during 
a 30 minute incubation at room temperature. Sera are diluted in 0.1 % gelatin and 0.05% tween-20 in PBS and 
incubated for 1 h. Alkaline phosphatase conjugated to goat-anti-mouse IgG or swine-anti-rabbit Ig (Kirkcgaard and 
Perry Laboratories, MD, U.S.A.) are used. p-nitrophenyl phosphate (l mg·mt1) in 10 mM diethanolamine + 1 mM 
MgCl1 at pH 9.8 is used as substrate. After 30 min the absorbance is read at 405 nm in a Tilcrlek Multiskan reader 
(Flow Laboratories, Irvine, U.K.) against normal mouse serum or pre-immune rabbit serum responses as a blank. 
A direct ELISA is used to determine the isotype of the MAbs with specific 
rabbit-anti-mouse-immunoglobulin-subc1ass anti-sera (Miles Laboratories, Kankakee, IL, U.S.A.). 
For various special applications other coating procedures were tested and practised. 
lV.I.I. Passive coaling 
Coating of protein and pep tides ill PBS 5-10 Ilg.ml'l overnight at 4"C or 1-2 h at room temp. Peptides are best coated 
according to this procedure. If the peptides do not adhere (a conjugate is the best control) then coating at lower or 
higher pH is advised. Citrate (pH 2.5) or borate (pH 9.5) provide conditions which will solve most problems. 
IV.}.2. Gllltaraldehyde 
Antigens that do 110t adhere spontaneously to plastic surfaces can be coated actively onto glutaraldehyde pre-activated 
polystyrene plates (Nunc 2.69620). Procedure: Glutaraldehyde is diluted to 0.025% in Na2COJ (0.1 M, pH 9.0). 
The wells of 96-wells polystyrene plates are filled with 100 Id. Leave the plates wrapped in aluminium foil for 120 
min. at 56"C. After the incubation the plates are washed with water and subsequently dried with hot air in a short 
time (15 min). Then the antigen (5 Ilg protein.ml,1 in Na2COJ (0.1 M, pH 9.0) is immediately added in a volume 
of maximum lOOp I. The plates with antigen are incubated for 1-2 h at roomteillp. or at 4°C overnight. Pre-activated 
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plates cannot be siored (Klasen el al. 1983), Include proper controls since glutaraldehyde may introduce some 
background. 
IV.l Poly-L-L ysine 
Proteins or peptides which do not adhere to polyvinyJchloride plates, may adhere to poly-L-lysine. 
Procedure: Poly-L-Iysine (stock: 10 mg.nti'! in PBS) is diluted to 10 jlg.m!'] in PBS. To each well tOO III is added 
and incubated at 4"C overnight or 1-2 h at room temp .. After incubation the plates are washed in PBS (3x) and dried 
in air at room temp .. Plates can he stored at -20'C. This procedure has been shown to be useful for coating DNA 
to ELISA plates. 
lV.1A. Carbadiimide ill imidazole 
Various compounds can be coated to polystyrene plates using activation with carbodHmides. The procedure is carried 
out in imidazole (sce also EOC coupling Oeen et aI., 1990). 
Procedure: ELISA-plates are pre-coated according to the glutaraldehyde method with BSA (5 JIl.ml'I). The 
compounds to be coupled are pre-treated with carbodiimide (EOC, couples to NHl and COOH groups). For DNA: 
n ml of DNA 20 fll.ml·l + n ml EOC (0.2 M in N-methylimidazole 0.1 M, pH 6.0) is mixed and incubated for 1 
h at room temp. Of this mixture at max. 100 It! per weIl is incubated at 4"C overnight. 
IV.I.5 Fixed antigen ELISA 
Mimicking of antigens in fixed tissues can be accomplished with this coating. Antigen is coated as for standard 
procedure. Subsequently the coating is incubated with formalinlHgCL1 for 1-2 h. Longer incubation does nOllead 
to better discrimination. The plates are washed and the ELISA is developed as usual, 
Ingredients: The fixative is prepared as follows: HgCI2 (42 g) is added to a mixture of acetic acid 35 011 + aqua dest. 
595 ml + formalin 40% 70 ml. The wells are incubated with this mixture for 1-2 h. 
IV.2. Inul1ullobloUing 
Ingredients: Immobilon membrane (Millipore)j Whatman 3MM filtrationpaperj PBS; OAB (20 mg DAB + 100 Jt! 
H20 2 (30%) in 100 ml PBS + 0.05% Tween 20 (PT-buffer); 0.1 % BSA in PT-buffer. Electrophoresis in agar. 
Procedure: First agar electrophoresis is performed, ImmobiIon is washed successively in methanol, aqua dest. and 
PBS. Dress Immobilon layer over the agar electrophoresis gel. Subsequently overlay with 3 layers of wet and 7 
layers of dry fillrationpaper. Put on a glass plate and a pressure of I kg, Leave for one h. The blot is rolled up and 
put in a test tube (15 011). 5 ml PTB buffer is added to block free sites at the immobiloll membrane. Wash 2x with 
PT buffer. Apply antibody/serum appropriately diluted (5 1ll1). Incubate on a roller overnight at 4"C or 1-2 h room 
temperature. Wash 3x with PT buffer. Apply second antibody-conjugate (Peroxidase) diluted in PTB. Incubate on 
a roller as for the first antibody. Wash 3x with PT buftcr. Staining with 5-10 011 substrate solution (for DAB in 
dark), Take the blot from the incubation tube and wash for 15 min in aqua des!. Dry under filterpaper and a glass-
plate. Keep blots away from light. Store data as photonegatives (Radl et aI., 1988, Nooij et aL, 1990). 
The BioRad immunodot apparatus is a very easy for direct immunoblotting, In ELISA fOfmat the antigen is deposited 
(1 h) on a pretreated ImmobiIon sheath. The pretreatment now includes a last wash with NaHCO) (0.5M, pH 8.0). 
The antigen applied is diluted (30 Jcg.ml· l ) in the same solution. The rest of the procedure is similar as described 
for blotting. 
IV.3. Western blotting 
We use Ihe protocol and system from the Phast SystemR (Pharmacia). The sample (I or 3 Jll) containing the proteins 
are transfered onto the gel (commercially available gradient or homogenous SOS polyacrylamide gels, or native 
polyacrylamide gels). Immediately after gel electrophoresis, the protein bands are blotted for 40 minutes at 70°C 
onto pre-welted (with aqua desl.) O.l-jlm-thick cellulose-nitrate membrane (pH79j Schleicher and Schuell GmbH, 
Dassel, F,R,G,). The cellulose-nitrate membrane is developed according to the ELISA protocol, but with 
5-bromo-4-chloro-3-indolyl phosphate (Sigma), 165 flg/ml, and nitroblue tetrazolium (Sigma), 330 Jcg/m!' as 
substrate and stain, respectively. After blocking the unoccupied binding sites on the membrane, and between 
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incubations wilh antiserum, the blots are washed three limes with Tween 20, 0.5 td/ml in PBS, for 5 min. Finally, 
the blots are rinsed in distilled water and dried between tissues, 
IVA. Blotting from JEF gels 
Samples of human sera (1,11 undiluted) are transferred to the middle of an IEF gel, pH 4-6.5. We use the protocol 
and system from the Phas! SyslemR (pharmacia). Immediately after gel electrophoresis, the protein bands are blotted 
hy diffusion onto pre-wetted (with TrisfmelhanoUglycinc, pH 8.3) O.l-rm-thick cellulose-nitrate membrane (pH79; 
Schleicher and Schuell GmbH, Dassel, F.R.G.) at room temperature for at least 3 h or overnight at room 
temperature. The proteins are detected according the protocol described in section IV.3. 
IV.s. JnulluIlocylochemlslry 
Thc immunocytochemical procedure discussed in this thesis refers to frozen tissue sections. For this, tissues are taken 
from the animal or from patients and immediately immersed in liquid nitrogen. The tissues are stored at -70'C in 
airtight aluminium capsules containing a small amount of ice to prevent dehydration on prolonged storage. 
1v'5.1. Fixation techniques 
Staining techniques apply to thin cryostat sections (5-8 /tm) of frozen tissues. The sections are kept overnight in a 
sealed hox with relative high humidity, then they are air dried and stored at roOIn tempcrature in scaled boxes. over 
silicagel. Subsequently mildly fixed by submersion in acetone containing 0.02% (v/v) hydrogen peroxide (to min) 
(V .. m Rooijen and Claassen, 1986). Then sections are air dried. Using this technique especially aIllibodies remain 
in good shape and keep their antigen specificity (Claassen and Van Rooijen, 1985; Van Rooijcn et aI., 1989), 
The method was used to demonstrate the presence of HIV-l determinant specific antibodies in immunized mice. 
Laman et ai. (l99Ib) evaluated fixation inactivation methods that are applicable for situations of increased biohazard 
risks (HIV-infections), They showed that fixation in 37% (v/v) formaldehyde in PBS or in 0.5% paraformaldehyde 
(w/v) in PBS for to min at roomtemp. (Lifson et aI., 1986) are the methods of choice, combining preservation of 
antigen binding sites (Fab) and membrane antigens in tissue with good morphology. 
Alternatively, rapidly after surgery the tissue can be chilled in isopentane and stored in liquid nitrogen until use. Thin 
cryostat sections (5 11m) are air dried for 30 min and subsequently fixed in buffered 4% formalin for 10 min. Then 
immunocytochemistry can be performed. This method was used to reveal the distribution of the androgen hormone 
receptor (polyclonal anti-peptide-antibodies: Van Laar et aI., 1989; Ruizeveld-De Winter et al., 1990; Mabs: Zegers 
et ,I .. 1991,). 
Following fixations, the sections are incubated with the first antibody diluted in PBS/O.l % BSA for sufficient timc, 
1 hr RT or overnight at 4°C. The optimal dilution must be found in a pilot experiment. After washing the slides. 3 
times with PBS, the second antibody (specific for the first antibody) conjugated to an enzyme (e.g., alkaline 
phosphatase or horse radish peroxidase) is added onto the sections for 1 hr RT. After washing with PBS color 
staining with the appropriate substrate is accomplished. 
IV.S.2 Alkaline p!lOsp!wtaJe 
Ingredients & procedure: Tris.HCI 0.1 M, pH 8.5, 37~C; To 40 ml Tris-buffer 5 Illg naphthol-AS-MX phosphate 
in 250 Itl N,N-dimethylformamide is added. 10 mg fast blue BB base is suspended in 250 III 2 N Hel, add 4% 
NaNDI solution and mix for 1-2 min. This fast blue BB solution is added to the naphthol-AS solution. Finally 10 
mg levamisole in 2 Illi buffer is added to the substrate solution (inhibits endogenous AP). After mixing for 2 min 
(37"C) precipitates are filtered off. Slides are incubated vertically for )0-45 min. The reaction is stopped by 
transferring to PBS. If necessary slides can be incubated a second tillle in a fresh solution (Claassen et aI., 1986) 
lV.5.3. Horseradish peroxidase 
Ingredients & Procedure: 40 1Il1 Na-acetate (O.05M, pH 5.0). Add 16 mg 3-amino-9-ethylcarbazole (AEC) in I Illi 
N,N-dimethylformamide to the buffer. Just before use add 200 IJi 3 % HP2' Incubate slides vertically for 7-10 min. 
Stop reaction by transferring to PBS (Claassen et al. 1986) 
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Alternatively, diaminobenzidine (DAB) can be used for staining. 
Ingredients & Procedure: 40 mI Tris-HCL buffer (0.05 M, pH 7.6), dissolve 20 mg 3,3'-diaminohcnzidine-
tetrahydrochloride into the buffer. Just before use add 50 111 3 % H20 l and incubate as for AEC. Staining may be 
enhanced by incubation of the slides in 0.5% CuS04 in 0.9% NaC!. 
IV.6. lmlllulloprccipitatioll 
The response to the native androgen receptor was analyzed in an immunoprecipitation assay. Sera arc incubated at 
different dilutions for 2 h at 4"C in roller tubes with anti-mouse-lgO conjugated to agarose (Sigma). After 
centrifugation and washing of the pellet with PBS, 25 ~I of a nuclear extract from LNCaP cells (a human cell line 
of a lymph node carcinoma oflhe prostate) in which the receptor was labelled with [17a-metltyPHImethyltrienolone 
WH]R1881, a synthetic androgen, NEN-DupOflt, Dreieich, F.R.G,), is added, Subsequently 400 pi PBS is added 
and the mixture is incubated for 2 h at 4"C while rotating. After centrifugation and washing of the peliet, the sample 
is assayed for the amount of radioactivity, Values are corrected for background, 
IV.7. Sucrose gradient centrifugation 
Essentially the method described by De Boer et aL (1986) is applied, Briefly, 50 ml of (.IHJR1881-labelied nuclear 
extract (0.15 M NaCI) from LNCaP cells is incubated for 6 h at 4"C with antiserum or RPMJ 1640 culture medium 
(Flow, Irvine, U,K.) supplemented with 7,5% FeS and 1 % NMS as a control and subsequently layered on lO-30% 
sucrose gradients in the presence of 0.15 M NaCI and centrifugated for 20 h at 370000 x gat 4"C. 
IV.S. Dipstick method 
The dipstick method is carried out as a sandwich assay for detection of antigens largely according to the ELISA 
protocol. Apply 1 It! of a catching MAbs 1 mg/ml in PBS as a spot onto O.l-jtm-thick cellulose-nitrate membrane 
(BAS5; Schleicher and Schuell GmbH, Dassel, F.R.G.) in a convenient dipstick formal. For easy handling of the 
ccllulosenitrate, the membrane can be Slicked to a plastic backing. We use plate sealers as backing (Costar 3095, 
Cambridge, MA, USA), Dry the spots and block free sites with PBS/0,5 % gelatine. Immerse the dipstick in a 
solution with antigen (For ai-antitrypsin detection, a serum dilution of I :50 was made in PTG and heated for 30 min 
at 56°C for exposition of the determinant) and incubate for 1 hr on a rocking platform in a petridish or perform the 
incubation in a test tuhe in an end-over-end rotor. Wash with PBS/tween and incubate with a detecting MAb 
conjugated to .a-galactosidase for 1 hr with mixing. Perform the staining with X-Gal (5-bromo-4-chloro-3-indolyl-
galactopyranoside) substrate unlilthe colour is clearly visible and rinse the dipstick with water. Alternatively, the 
reaction can be Slopped with 0.1 M NaHCOy Dry them between tissues. 
Substrate: Stock solution A: 10 mg X-Gal in 500 It! DMF; Stock solution B: Add 500 It! 50 mM Potassium 
fcrricyanide and 500 III 50mM Potassium ferrocyanide to 7 1111 1.1 mM MgCl 2 in PBS. Both solutions can be kepi 
at -ISoC, Working solution: Mix 125 Itl of solution A with 5 ml of solution B. 
V. PRODUCTION OF MONOCLONAL ANTmODlliS 
A spleen cell suspension is prepared 4 days after a booster immunization. Spleen cells and SP210 cells in logarithmic 
growth were washed twice with serum-free RPMl 1640 (Boehringer Mannheim, Mannheim, F,R.G,), Spleen cells 
and SP2/0 cells are fused at a ratio of 5:1 in 1 m140% poly(ethylene glycol) 4000 (Merck, Darmstadt, F.R.G,) + 
5% DMSO in PBS for 1 min. The suspension is slowly diluted with 9 ml RPMI 1640 culture medium and incubated 
for 20 min at room temperature. The fused cells are carefully centrifugated, 10 min 300g and resuspended ill 
sclection medium. The fused cells (HNweli in 0,2 ml) are cultured in RrMI 1640 selection medium, containing 1 
Itg'ml'[azaserine and 0.1 mM hypoxanthine, 15% FCS, 2 mM glutamine, 0.1 mg'ml-[ streptomycin, 100 E'ml'] 
penicillin, I mM sodium pyruvate, and 5-lO-5 M fi-mercaptoethanol. After I week of culture the azaserine was 
discontinued and the Fes concentration was lowered to 10%, The culture medium is replenished 3 times a weck by 
100 /11 at a time. The hybridomas can be tested tor specific antibody production when the surface is overgrown for 
at least 30% with hybridoma cells, usually after about 10 days of culture for the fastest dividing cells, Selected cell 
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cultures are transfered to a 24-well culture plate and subsequently to a culture flask, They are collected for storage 
in liqued nitrogen as soon as possible. (A pellet of cells in logarithmic growth from a 25 eml culture flask is 
suspended in 1 m1 10% DMSO in FCS and frozen via a programmed procedure ill a a controlled rate freezer (Kryo 
10 series II, Planer Diomed, Middx, UK) below -70°C and transfered immediately to the container with Jiqued 
nitrogen). Some of the most promising clones are subc!oned althe earliest timepoint possible in culturing by limiting 
dilution at a density of 0.5 cells/well. 
Ascites production: HALB/c mice are injected intraperitoneally with O.S ml pristane (2,6,10,14-tctra-
methylpentadecane 96%, Ega-chemic, Steinheim, F,R,G,), Seven days later the mice were injected with 106 
monoclonal hybridoma cells in 0,25 ml PBS, Ascites fluid was collected under anaesthesia, 
VI. MISCELLANEOUS 
VI.l. Purification of Q:',-antitrypsln variants 
a]-AT(Z) was purified from 20 ml of plasma from a ZZ donor by use of an immuno-affinity column, Purified rabbit 
JgG directed against aj-AT (Sigma) was coupled to 5 ml of AffigelRHZ (Bio-Rad Labs., Richmond, CAl according 
to the manufacturer's protocol. The aj-AT protein bound to the column was eluted with 0, I moUL glycine buffer 
pH 3.0 and subsequently dialysed against PBS, 
VI.2. Mild denaturation of Q:']-antitrypsin 
For binding of the variant~specific MAb F43.8.1 to the M variant, it is necessary to disrupt the salt bridge between 
residues Lys (AA 342) and Glu (AA 290) for exposition of the 342 site. This can be accomplished by heating the 
serum at 56°C for 30 min, 
VI.3. Conjugation of MAb and p-Galactosldase 
(j-Galactisodase is conjugated with MBS via its Ihiol groups to the amino groups of the immunoglobulin. 
Ingredients: PBS; MAb lO mg,ml-' in PBS; MBS 20 mg,nll- j in OMF; fJ-galactosidase 10 mg.ml- j (Boehringer 
Mannheim #745731); PO-lO column (pharmacia), MgClz 1 M; (j-mercaptoethanol 1 M, 
Procedure: Add the MBS solution in three equal portions every 5 min to 1 ml MAh at ice while stirring. Use 150 
mol MUS per mol JgG. Stir for another 15 min. Separate the modified JgG from the excess MUS over a PD-IO 
column. Add slowly (j-galactosidase to the IgG-maleimide and stir for I hr at room temperature. Add MgCI2 and 
(j-mercaptoethanol, both to an end concentration of 10 mM. Store with to parts (v/v) glycerol at _20°C, 
VI.4. Conjugation of MAb and alkaline phosphatase 
Ingredients: Alkaline Phosphatase (AP) 5 mg.rnf] in PBS; MAb 2 mg.ml-\ in PBS: glutaraldehyde 0,2 % in PBS; 
glycine 0.2 M in PBS. 
Procedure: Dialyse 1 ml AP against the glutaraldehyde solution overnight at 4°C. Oialyse subsequently three times 
against PBS. Transfer the GA-activated AP to a reaction vial and add 2 Illg of the MAb in 1 IllI PBS and incubate 
overnight at 4°C. Add 0,1 ml glycine and incubate for 2 hr at room temperature. Dialyse against PBS. Store with 
2 parts (v/v) glycerol at _20°C. 
VI.S. Purification of l\lAbs "ith protein A 
Ingredients: Protein A Sepharose CL-4B column (parmacia Fine Chemicals # 17-0780-01), glycine 1,5 MI NaCI 3 
MpH 8.9; Tris-HCI 1.0 M pH 11; Phosphate (NaH2POiNa1HP04) buffers 0,1 MpH 6,0, pH7.0 and pH 8,1; 
Cilrate buffers 0.1 MpH 5,0, pH 4.5 and pH 3.0, 
Procedures: For Mouse IgGI: Equilibrate column with glycinelNaCI. Dilute cleared ascites nuid 1:1 with 
glycinelNaCI and apply slowly (0,2 ml.min; IgOl is poorly bound by protein A) over the column. Wash with 
giycine/NaCI. Eluate wilh NaPi buffer pH 6.0. Concentrate the eluate to > 1 mg.mt·] and dialyse against PBS. Store 
at -20°C. 
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For Mouse IgG2a, IgG2b and IgG3: Equilibrate column with Napj buffer pH 7.0. Apply cleared ascites fluid over 
column (0.8 ml.min). Wash with Napj pH 7,0. Eluate IgG2a with citrate buffer pH 5.0, TgG2b with Citrate buffer 
pH 4.5 and IgG3 citrate buffer pH 4.5. Immediately neutralise the fractions containing the immunoglobulin with 1.0 
M Tris-llel pH 11. Concentrate the antibodies 10 a concentration> 1 mg.nli'! and dialyse against PBS, Store at -
20 oe. 
The column should be cleaned after each run wilh citrate buffer pH 3.0 and stored in Napj pH 7.0 + NaNJ (0.1 % 
wtv). 
MA TERlALS 
Buffers and media PBS: 0,01 M phosphate buffered saline 0.15 M NaCI, pH 7.4; PT: 0.05% l\veen 20 in PBS; 
PTG: 0.1 % gelatine in PT; PBS·GEL: 0.1-0.5% gelatin in PBS; DEA: diethanol amine lOmM (Merck p.a.)+ I mM 
MgCI2, pH 9.8; N-methylimidazoIe (Aldrich, MS, 083-4, Brussel, Belgium); DMF, DMSO, TFE, amylalcohol, 
acetic acid, diethylether, TFA, ethanol and urea preferably all of p.a. quality or HPLC quality. 
Adjuvants. A water-in-oil emulsion is simply made by thorough mixing of the antigen solution in PBS with Speeol 
or span tween (the Netherlands Veterinary Jnstute, Lelystad, The Netherlands, Bokhout, 1981)_ Complete and 
incomplete Frcunds can he obtained from Difeo (inc.: 0639-60-6, com.: 06638-60-7). 
Coupling reagents, derivatization MBS (Pierce, 223310), APO, HSAB, Biotin NHS, Iminothiolane can be obtained 
from Pierce. OA: J.T.Baker; OIT: Aldrich 14,046-0; N-ethylmaleimide: Sigma (E-3876); EOC: Sigma (E-77S0). 
PDlO prepacked sephadex 025 colullls to be obtained from Pharmacia, Uppsala, Sweden. 
Antigens: KLH (Calbiochem, 374811, San Diego, Ca. U.S.A.); CGG: Sigma, 0-6516; BSA: Sigma A-9647, SI. 
Louis, MO., U.S.A.; C<'l-AT(M) was obtained from Sigma Chemical Co., St. Louis, MO. 
ELISA can be performed in polyvinyl plales (Falcon, 3911, Becton and Dickinson Labware, CA., U.S.A., or 
Titertek, 77-172-05) or polystyrene plates (NUNC, 2.69620). 
Conjugates anti-mouse, anti-goat, anti rabbit conjugates can be obtained from various suppliers: Dakopatts, Sigma 
KPL-Labs. Alkaline phosphatase can he obtained from Sigma P-6774 Type VII-T; horseradish peroxidase (PO) 
RZ~3.0 (type VI; P-8375); 
Substrates: PNPP: p-nitrophenylphosphate: Boehringer (107905); o-phenylenediamine-di-hydrochloride: OPD 
(1078054): Kodak, Rochester, USA; DAB: 3.3'-diaminobenzidine: Sigma 0-5637; X-Gal 
(5-bromo-4-chloro-3-indolyl-galactopyranoside, Boehringer Mannheim #651745) 
FITC (fluorescein ISOlhiocyanate, isomer 1) can be obtained from Nordic Immunology, Tilburg, The Netherlands. 
Human sera phenotyped for aI-antitrypsin were obtained from Dr. R.R. Franls (State University of Leiden, The 
Netherlands) and Dr. J.H. Kramps (Academic Hospital, Leiden, The Netherlands). 
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SUMMARY 
Antibodies are widely applied in immunochemical assays for the specific and sensitive 
detection of three dimensional stlUctures in or on different cell-types, microorganisms and 
solutes. Immunization of experimental animals with an immunogen (a molecule, cell, or 
microorganism) generates a polyclonal antibody response against the immunogen. These 
polyclonal antibodies react with the immunogen but may also crossreact with other structures 
resembling the immunogen. Immunization with part of the immunogen, e.g., with a surface 
protein isolated from a cell, microorganism or virus, renders the antibody response more 
specific. Also, with the advent of the hybridoma technique, monoclonal antibodies which are 
more specific and do not demonstrate unwanted crossreactions can be selected. Sometimes, 
a protein is not available for immunization for different reasons: e.g., it cannot be purified, 
or the protein is toxic, Immunization with a synthetic peptide (SP), which represents a part 
of the sequence of the protein, is an alternative to immunization with the entire protein. SP 
can elicit antibodies that crossreact with the native protein. Such synthetic peptides are also 
powerful tools for the generation of antibodies against: 
a) a protein which belongs to a protein family of which the members are homologous. 
Immunization with a unique sequence differing from the other members elicits antibodies 
which can discriminate a single protein from the rest of the family. 
b) a protein that differs in only one amino acid from another protein, e.g., variants of a 
protein, or virus mutants. Antibodies elicited with an SP that contains the sequence with 
the substitution can specifically detect the variant protein. 
c) functional domains of a protein. Immunodominant sequences from flanking domains can 
be circumvented by using an SP derived from the domain of interest. Antibodies specific 
for a domain are useful for unravelling the function of the domain. 
d) a protein which has not been isolated before, but for which the amino acid sequence can 
be derived from the DNA base sequence, 
It was the aim of the experiments described in this thesis to investigate and optimise 
the factors which playa role in the generation and evaluation of antibodies elicited with SP. 
These factors are: a) the selection of the peptide sequence; b) constmction of the inununogen, 
Peptides themselves generally are not immunogenic since they often only contain a B cell 
determinant. Coupling of a peptide to a carrier protein, which provides T cell detelminants, 
renders the peptide immunogenic. The choice of coupling chemistry and procedure, the ratio 
of peptide and carrier, and the orientation of the peptide relative to the carrier are important 
for the peptide construct; c) the immunization procedure; d) evaluation of the antibody 
response in pertinent assays; e) selection procedure of monoclonal antibodies. In chapter 1, 
these factors are introduced and discussed. 
Immunization with synthetic peptides often results in disappointment. Only if all the 
conditions, which determine the outcome of the generation of antibodies upon immunization 
with SP, are carefully chosen and applied, can strongly specific (monoclonal) antibodies be 
selected which are useful in immunochemical assays. During the process of the generation 
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and selection of antibodies using synthetic peptides, the various parameters were investigated 
and optimised which resulted in straightforward suggestions. 
Constl1lction of the immunogen is an important step in antibody generation. In chapter 
3, we describe a new and efficient conjugation method of a synthetic peptide to a carrier 
protein using glutaraldehyde. With this new method, the carrier protein is dialysed against 
a solution of glutaraldehyde. Most available € amino groups of the carrier protein will be 
modified by glutaraldehyde. The excess glutaraldehyde is removed by subsequent dialysis 
against PBS. The peptide is added to the glutaraldehyde-modified carrier protein and will 
bind to it through its amino groups. Surplus reactive glutaraldehyde groups were blocked by 
lysine. This method prevents the homopolymerization of carrier proteins and the 
homopolymerization of pep tides found in classical coupling by glutaraldehyde. Immunization 
with conjugates proved to elicit peptide-specific antibodies which were crossreactive with the 
native protein. 
The human androgen receptor (hAR) is a member of the steroid receptor family. 
These steroid receptors are very homologous to each other. The steroid receptors consist of 
three functional domains: the N-terminal part which is involved in the regulation of gene 
transcription, a DNA-binding domain and a steroid-binding domain at the C-tenninus. 
Domain-specific antibodies are helpful for research purposes. The antibodies can be helpful 
for immuno-affinity purification of the hAR, for investigation of the AR stmcture, 
distribution and its physico-chemical properties, for immuno-histochemicallocalization of the 
receptor, and for monitoring AR expression during endocrine therapy for prostatic cancer. 
Immunization with the hAR is not possible since the hAR has not been isolated, but the 
cDNA sequence has been elucidated. Therefore, immunization with SP is the only 
alternative. This method has additional advantages. \Vith SP immunization, domain-specific 
sequences can be selected and sequences homologous with other steroid receptors can be 
avoided. Since the antigenic delerminants of the hAR were not known, putative continuous 
epitopes were selected on the basis of theoretical considerations. The selection of the epitopes 
and the subsequent generation of polyclonal and monoclonal antibodies are described in 
chapter 4. The selected monoclonal antibodies were bAR-specific, not crossreactive with 
other steroid receptors (oestrogen, progesterone and glucocorticoid receptor), domain 
specific, not interfering with hormone and DNA binding, and could be used in multiple 
immunochemical assays. 
Human O:'t-antitrypsin is a serum protease inhibitor which mainly inhibits neutrophil 
elastase in the lungs. Nowadays more than 70 different isoforms of the protease inhibitor are 
known, most of them being point mutations in the DNA sequence leading to amino acid 
substitutions. Severe Q:',-antitrypsin deficiency results from a single amino acid substitution 
(Glu342_Lys) in the molecule which causes (Xl-antitrypsin accumulation in the liver where it 
is synthesized. The change of charge from negative to positive in the Z molecule (the normal 
protein is designated as M) induces an alteration in the three-dimensional stlUcture of the Z 
variant protein which, as a consequence, also shows reduced activity. Homozygous carriers 
with the Z type substitution (Glul42~Lys) are at risk of developing lung emphysema at a 
relatively young age. Heterozygous carriers with the SZ phenotype may also be at risk. Early 
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detection of such carriers offers the possibility of prescribing lifestyle measures, which delay 
the disease, Replacement therapy with (recombinant) "I-antitlypsin can be given to such 
individuals. Presently applied methods for detection of variants are not suitable for routine 
screening since they are difficult to interpret. 
Generation of antibodies specific for the Z and S variant cannot be achieved by 
immunization with the variant proteins. Also, for these variant proteins, immunization with 
SP proved to be the only alternative, In part II (chapters 5-7), we describe the generation of 
variant specific antibodies. In doing this, we have investigated the influence of the length of 
the peptide, the position of the substitution site in the selected peptide sequence, the 
construction of the immunogen regarding the coupling chemistry and the orientation of the 
peptide relative to the carrier protein, the route of immunization, the immunization schedule, 
the selection method of the monoclonal antibodies, and the pretreatment of the protein. 
Simple assays, which can distinguish between the Z variant and the normal M protein, based 
on monoclonal antibodies. have been developed. Both homozygous and heterozygous carriers 
for the Piz gene can be detected, 
Most peptide sequences only contain a B cell determinant and do not contain a T cell 
determinant. For memOlY B cell responses, both T cells and B cells have to be activated, 
This can only be accomplished by making an immunogenic construct that contains both a T 
cell and a B cell determinant. Usually, such a construct is made by coupling an SP, which 
contains the B cell determinant, to a carrier protein. which contains one or multiple T cell 
determinants, In part III, the use of single selected T cell determinants in a construct with 
a B cell determinant is described, The use of a single T cell epitope can have advantages 
over the use of a carrier protein. Immunodominance resulting from the carrier protein could 
be circumvented. To produce antibodies against weakly immunogenic regions of a protein, 
a construct of that weakly immunogenic region combined with a T cell determinant will be 
usefuL For synthetic vaccines, it is a requirement that the vaccine construct contains T cell 
determinants, in addition to B cell detelminants, derived from the pathogen. The immune 
systems will mount a memory response to both the B and the T cell epitope, Challenge with 
the pathogen will lead to a prompt response, Chapter 8 gives a broad overview of the 
existing literature on this topic. Literature consensus guidelines for the use of T cell epitopes 
are: a) The T cell epitope should be selected in functional assay with cells from the animal 
species or from human origin for which the inul1unization is meant; b) attention should be 
paid to the conjunctional sites of a T and a B cell detelminant, since new T cell determinants 
may arise with a positive or negative result; c) elongation of a strict T cell determinant may 
have a positive effect if the flanking sequences are chosen with the result that increased 
stability of a helix structure emerges; d) a light preference is given for the N-terminal 
position of a T cell determinant in a construct, but testing of all possible combinations is still 
the best approach in designing inununogenlc constructs; e) multiple copies of a T cell 
determinant may lead to an increase of the antibody response; f) linkage of the deterulinants 
by peptide bonds is preferable to other chemical linkers; and g) covalent coupling of T and 
B cell detelminants is a requirement for inducing a high level of antibodies with a high 
affinity towards the B cell determinant. 
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The last point of the aforementioned guidelines for the use of T cell determinants in 
peptide constructs, point g), was the subject of conflict in literature. Some investigators 
reported the generation of B cell determinant-specific antibodies with co-immunization of a 
T cell and a B cell determinant without a covalent bond between these two. However, these 
authors aU used the same T cell determinant. We showed in chapter 9, that, in general, 
covalent linkage between a T and a B cell determinant is essential for generation of a 
bonafide memory (IgG) response. 
In chapter 10, we investigated the role of T cell determinants in multiple antigenic 
peptides, a new format of peptide immunogens. A multiple antigenic peptide consists of a 
branch of coupled lysine residues (through a and, amino groups) to which the selected 
peptide sequences can be synthesized. Branches with four or eight peptide sequences are most 
frequently used. These multiple antigen peptides appear to be highly immunogenic and were 
described in literature as applicable to every B cell determinant. We showed that 
incorporation of a T cell determinant is a requirement for strong and native protein-specific 
antibody responses. 
In chapter 11, the main results from the different studies are discussed. Guidelines 
emerging from the different studies are given for the successful generation of antibodies 
using SP. The main points are: 
a) Selectioll of the sequellce. Choose a sequence of 15 to 25 amino acids. Avoid "difficult 
sequences" to synthesize. Choose the terminal sequences to containhydrophillic residues. 
Avoid homology with other proteins by search in data bases. Place the epitope in the 
middle of the sequence or at the distal end of the coupling site. Search for antigenic 
sequences with the aid of computer prediction programs. 
b) Construction of the immunogen. Apply controlled coupling methods for the conjugation 
of peptides and carrier proteins as described in this thesis. Use MBS, EDC or GA 
coupling dependent on the incorporated amino acids. Avoid coupling through amino 
acids when they are part of the epitope. Coupling through the N-terminus is preferable 
with an additional cysteine incorporated. Multiple antigen peptides can be considered if 
conjugation is difficult, e.g., if the peptide is insoluble or if the residues involved in 
coupling are part of the epitope. 
c) Immunization. Intraperitoneal immunization with 25-50 J,tg of the peptide-carrier 
construct in a mineral oil as adjuvant leads to good results. For high-affinity antibodies, 
boost only after the level of antibodies has decreased below 20% of the highest level 
reached. 
d) Evaillation of the antibody response. Evaluation of the reactivity pattern in the polyclonal 
semm should be carried out after each administration. Assay for reactivity with the 
peptide sequence, with the carrier protein, with the coupling determinant and with the 
native protein. Cross reaction with the native protein should be carried out by competition 
or inhibition or sandwich assays of the antibodies with the native protein. Sandwich 
assays are only possible if a catching antibody is available from another animal than the 
one generating the antibodies to be assayed. 
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e) Selection ojmolloc!onal antibodies. Selection of the hybridomas is best performed in the 
assay that is going to be used for the eventual diagnostic assay. First screening on 
peptides can be done for cost-effective reasons. 
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SAMENVATTING 
Antilichamen worden op grote schaal toegepast in immuno-chemische detectiemethoden. In 
deze technieken kunnen antilichamen specifiek en gevoelig drie-dimensionale structuren 
(antigenen) detecteren die kunnen worden aangetroffen in of op verschillende ceUypen, 
micro-organismen en in oplossing, Immunisatie van proefdieren met een immunogeen (dat 
kan bijvoorbeeld een moleeuul, een eel of een micro-organisme zijn) genereert een 
polyclonale antilichaam respons tegen dat immllnogeen. Polyclonale antilichamen herkennen 
verschillende delen van hetzelfde antigeen doordat ze gemaakt worden door verschillende B 
lymfocyten. Deze polyc1onale antiliehamen reageren met het immunogeen, maar kunnen ook 
kruisreageren met andere structuren die gelijkenis vertonen met het gebruikte immunogeen, 
Immunisatie met een deet van het immunogeen, dat specifiek is voor b,v, een oppervlakte-
eiwit gelsoleerd van een eel, een miero-organisme of een virus, beperkt de kruisreaktiviteit. 
Door de komst van de hybridoma techniek, kunnen monoclonale antilichamen gemaakt 
worden. Deze monoc1onale antiliehamen zijn afkomstig van nakomelingen van cen B 
Iymfocyt die onsterfelijk is gemaakt door fusie met een myeloma cel. De hybride eel blijft 
zich delen en produeeert steeds dezelfde soort antiIiehamen. De monoclonale antilichamen, 
die zeer specifiek reageren met het inununogeen zander ongewenste kmisreaktie met andere 
structuren, kunnen door een gesehikte selectiemethode toe te passen, worden gevonden. Soms 
is het niet mogelijk om met een eiwit te inununiseren omdat het niet voorhanden is, b. v. 
omdat het niet gezuiverd kan worden of omdat het eiwit zelf toxisch is. Immunisatie met een 
synthetisch peptide (SP), dat een representatief dee I van het eiwit vertegenwoordigt, is een 
alternatief vaal' immunisatie met het gehele eiwit. Een SP kan antilichamen opwekken die 
kmisreageren met het eiwit waarvan het SP is afgeleid. Zulke synthetische peptiden zijn ook 
belangrijke hulpmiddelen om antilichamen op te wekken tegen: 
a) een eiwit dat tot een eiwit-familie behoort waatVan de !eden homoloog zijn. Immurusatie 
met een unieke sequentie, specifiek voor een der Ieden, genereert antilichamen die een 
enkel eiwit van de rest van de familie kunnen onderscheiden. 
b) een eiwit dat slechts in een aminozuur afwijkt van een ander eiwit, b.v. varianten van 
een eiwit of virusmutanten. AntHichamen, die zijn opgewekt met de sequentie die de 
substitutie bevat, kunnen gebmikt worden om specifiek het variant eiwit te detecteren. 
c) funetionele domeinen van een eiwit. Immunodominante sequenties die aanwezig zijn in 
omringende domeinen kunnen worden omzeild door een SP te gebruiken dat afkomstig 
is uit het gewenste domein. De antilichamen die specifiek een domein herkennen, zijn 
zeer bmikbaar om de functie van een domein te bestuderen, 
d) een eiwit dat nag niet eerder is gelsoleerd, maar waarvan de aminozuur voIgorde kan 
worden voorspeld uit de DNA base volgorde. 
Verschillende factoren spelen een 1'01 bij het opwekken van de antilichamen met SP 
en bij de karakterisering van de antiIichamen. Het doel van de experimenten die beschreven 
zijn in dit proefschrift was om deze factoren te onderzoeken en te optimafiseren. Deze 
factoren zijn: a) de selectie van de peptide sequentie; b) de constmctie van het immunogeen. 
Peptiden zijn zelf over het algemeen niet immunogeen daar ze slechts een B eel epitoop 
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bevauen. Koppeling van een SP aan een dragereiwit dat T cel epitopen bevat, maakt het SP 
immunogeen. De keuze van de koppelingschemie, de verhouding tussen SP en dragereiwit 
en de orientatie van het SP 1.0. v. het dragereiwit zijn belangrijk voor de immunogeniciteit 
van het peptideconstruct; c) de immunisatieprocedure; d) de evaluatie van de antilichaam 
respons in de geschikte testmethoden; e) de selectieprocedure van de monoclonale 
antilichamen. In hoofdstuk 1 worden deze factoren ge'introduceerd en bediscussieerd. 
Inununisatie met SP mondt vaak uit in teleurstelling in die zin dat het niet die antilichamen 
oplevert die bruikbaar zijn voor detectie van natieve eiwitten. Aileen als aan aBe 
voorwaarden, die bij het vinden van de gewenste antilichamen belangrijk zijn, wordt voldaan, 
kunnen specifieke (monoclonale) antilichamen worden geselecteerd die bruikbaar zijn in de 
beoogde immunochemische detectie methoden. Gedurende het proces van het opwekken en 
selecteren van de antilichamen m.b.v. SP, werden de verschillende parameters onderzocht 
en bijgesteld. Dit onderzoek heeft geresulteerd in duidelijke randvoorwaarden voor de 
toepassing van SP als immunogenen. 
De constructie van het immunogeen is een belangrijke stap in het gehele proces. In 
hoofdstuk 3 beschrijven we een nieuwe, efficiente en handzame koppelingsmethode om een 
SP aan een dragereiwit te koppelen met behulp van glutaaraldehyde. In deze methode wordt 
het dragereiwit eerst gedialyseerd tegen verdund glutaaraldehyde. De meeste van de 
beschikbare E-aminogroepen worden hierbij gemodificeerd door glutaaraldehyde. De 
overmaat glutaaraldehyde wordt verwijderd door het gemodificeerde dragereiwit vervolgens 
te dialyseren tegen PBS. Het peptide wordt dan toegevoegd en zal via zijn aminogroepen 
binden aan het dragereiwil. Overgebleven reaktieve glutaaraldehyde groepen op het 
dragereiwit worden geblokkeerd met lysine. Deze methode verhindert de hOl1lopolymerisatie 
van dragereiwit moleculen en de homopolYl1lerisatie van peptiden zoals die worden gevonden 
bij de klassieke eenstaps glutaaraldehyde koppeling. Immunisatie met conjugaten die met deze 
nieuwe koppelingsmethode zijn gemaakt hebben peptide-specifieke antilichamen opgewekt 
die ook kruisreageerden met het natieve eiwit (waarvan het SP was afgeleid). 
De humane androgeen receptor (hAR) is een lid van de steroid receptor familie. Deze 
steroid receptoren zijn onderling in hoge mate hOl1loloog. De steroid receptoren bestaan uit 
drie functionele domeinen: het N-terminale deel dat betrokken is bij de regulatie van 
gentranscriptie, eeo DNA-bindend domein en een steroid-bindend domein aan de C-terminus 
gelegen. Domein-specifieke antilichamen zijn bruikbaar voal' research doeleinden en 
diagnostiek. Deze antilichamen kunnen o.a. gebruikt worden voor de affiniteits-zuivering van 
de hAR, voor het onderzoeken van de hAR stlUctuur en zijn physico-chemise he 
eigenschappen, voor de inununo-histochemische localisering van de receptor, en voor het 
monitoren van de hAR expressie tijdens endocriene therapie bij prostaatkanker. Bij de 
aanvang van deze studie was immunisatie met de hAR niet mogelijk daar de hAR, ondanks 
vele pogingen, nog niet gelsoleerd was. Wei was de cDNA sequentie opgehelderd. Daarom 
leek immunisatie met SP het enige alternatief. Deze methode biedt belangrijke voordelen. 
Domein-specifieke sequenties kunnen worden geselecteerd en sequenties die hOlllOloog zijn 
met sequenties van de andere steroid receptoren kunnen worden vermeden. Daar de antigene 
determinanten voor de hAR niet bekend waren, werden mogelijke epitopen geselecteerd op 
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basis van theoretische beschouwingen. De selectie van de epitopen en de generatie van poly-
en monoclonale antilichamen worden beschreven in hoofdstuk 4. De geselecteerde 
monoclonale antilichamen zijn specifiek voor de hAR en kmisreageerden niet met andere 
steroid (oestrogeen, progesteron en glucocorticoid) receptoren. Ze zijn domein-specifiek en 
interfereren niet met hormoon en DNA binding, en ze kUIll1en worden gebruikt in 
verschillende immuno-chemische testen. 
Humaan cxl-antitrypsine is een proteaseremmer in serum die hoofdzakelijk neutrofiel 
elastase in de longen remt. Tegenwoordig zijn er meer dan 70 verschillende isovormen 
bekend. De meeste isovormen zijn puntmutaties in het DNA die resulteren in substitutie van 
een eukel aminozuur in het eiwit. Een enkele aminozuur substitutie (GluJ42 - Lys) in het 
molecuul veroorzaakt cxl-antitrypsine accumulatie in de lever waar het wordt gesynthetiseerd. 
De verandering van lading van negatief naar positief in het Z molecuul (het normale eiwit 
wordt als M aangeduid) induceert een verandering in de drie-dimensionale stmctuur van het 
Z variante eiwit dat, als gevolg hiervan, cen gercduceerde activiteit vertoont. Ernstige 0'1-
antitrypsine deficientie is hiervan het gevolg. Homozygote dragers met substitutie in het Z 
type (GIll'" ~ Lys) ontwikkelen op jonge leeftijd longemfyseem. Heterozygote dragers van 
het SZ fenotype lopen ook dat risico. Vroegtijdige deteetie van zulke dragers biedt de 
mogeJijkheid om leefregels voor te sehrijven die de ziekte kunnen uitstellen. Oak toedienen 
van (recombinant) cxl-antitrypsine kan als therapie worden gegeven aan deze individuen. 
Huidige detcctiemethoden voor het opsporen van varianten zijn niet bmikbaar voor routine 
screening daar ze moeilijk interpreteerbaar zijn. 
Het opwekken van antilichamen, die specifiek de M, Z en de S varianten kunnen 
onderscheiden, is niet mogelijk door immunisatie met het gehele eiwit. Ook voor deze 
variante eiwitten, is immunisatie met SP het enige alternatief. In deel II (hoofdstukken 5-7) 
wordt het generen van variant-specifieke antilichamen beschreven. Daarbij is de invloed van 
de !engte van het peptide onderzoeht, de positie van de substitutieplaats in de gekozen peptide 
sequent ie, de constructie van het inununogcen m.b.t. de koppelingschemie en de orH::ntatie 
van het peptide t.o.v. het dragereiwit, de immunisatieroute, het immunisatieschema, de 
selectiemethode van de monoclonale antilichamen, en de voorbehandeling van het O'r 
antitrypsine in serum. Eenvoudig uit te voeren testen die gebaseerd zijn op monoclonale 
antilichamen en die de Z variant kunnen onderscheiden van het norma Ie M eiwit, zijn 
ontwikkeld. Zowel homozygote als heterozygote dragers van het Piz gen kunnen worden 
gedeteeteerd. 
De meeste peptide sequenties bevatten aileen een B cel determinant en geen T eel 
determinant. Om geheugen B eel responsen te verkrijgen is het noodzakeJijk dat zowel B als 
T cellen worden geactiveerd. Dit kan aileen worden bereikt door te immuniseren met een 
inununogeen construct dat zowel een B als een T eel determinant bevat. Gewoonlijk wordt 
zo'n construct gemaakt door cen SP, dat een B cel determinant be vat, te koppelen aan een 
dragereiwit dat meestal meer dan een T eel determinant bevat. In deel 1II wordt het gebruik 
van losse T cel epitopen en een B eel epitoop in een construct beschreven. Het gebruik van 
een enkele T eel epitoop kan voordelen hebben boven het gebruik van een dragereiwit. Zo 
kan immunodominantie van B cel epitopen afkomstig van het dragereiwit worden vermeden. 
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Dus, om antilichamen op te wekken tegen zwak immunogene regionen van een eiwit zal een 
construct, gemaakt met een sequentie uit dat zwak immunogene deet gecombineerd met een 
T cel epitoop, blUikbaar blijken. Voar synthetische vaccins is het een vereiste dat het 
vaecinconstruet T eel determinanten naast B cel determinanten bevat die beiden afkomstig 
zijn van hetzelfde pathogeen. Na vaccinatie met dat construct, zal het immuunsysteem een 
geheugen respons opbouwen tegen de B en de T cel epitoop. Infectie met het pathogeen zal 
dan leiden tot een snelle en adequate respons. 
Hoofdstuk 8 geef! een breed overzicht van de bestaande literatum over T cel epitopen. Vit 
de literanlUr zijn richtlijnen opgesteld over het gebruik van T cel epitopen. Deze zijll: a) De 
T eel epitoop moet geselecteerd worden middels een funetionele testmethode m.b.v. cellen 
die afkomstig zijn van het dier of van de mens waarvoor de immunisatie bestemd is; b) aan 
de aansluiting van de epitopen moet aandacht worden gesehonken daar nieuwe T cel epitopen 
op die plaats kunnen ontstaan met een positief of negatief resultaat ais gevolg; c) verlenging 
van een strikte T cel epitoop kan een positief effect hebben als de flankerellde sequenties 
dusdanig worden gekozen dat er een stabiliserende werking van uitgaat op de helix structuur; 
d) een lichte voorkeur wordt gegeven aan de plaatsing van een T cel determinant aan de N-
terminus, maat· het uittesten van aHe mogelijke eombinaties is nag steeds de beste benadering 
bij het ontwerpen van een construct; e) aanwezigheid van verschillende kopieen van een T 
cel detenninant kan tot een toename leiden van de antilichaam respons; f) de verbinding van 
de determinanten door een peptide band verdient de voorkeur boven de verbinding via andere 
chemisehe sehakels; en g) een eovalente koppeling van de T en de B eel determinant is een 
vereiste voor het induceren van geheugen antiliehaam (IgG) respons. Zo worden antilichamen 
met een hoge titer en een hoge affiniteit Yoor de B eel determinant opgewekt. 
Over het laatste punt van de bovengenoemde richtlijnen voor het gebruik van T eel 
determinanten in peptide eonstrueten (punt g) bestaat diseussie in de Iiteratuur. Sommige 
onderzoekers rapporteerden dat het opwekken van antilichamen die specifiek de B eei 
determinant herkennen, kan plaatsvinden door eo-immunisatie van een T en een B eel 
determinant zonder een covalente band tussen deze determinanten. Deze onderzoekers 
gebruikten echter allemaal dezelfde T cel determinant. Wij laten in hoofdstuk 9 zien dat een 
covalente band tussen de T en de B eel determinant noodzakelijk is VOOI' het opwekken van 
een bonafide geheugen (lgG) respons VOOf door ons geseiekteerde detenninanten. 
In hoofdstuk 10 hebben we de rol van T eel determinanten onderzocht in 'meervoudig 
antigene peptiden' (MAP), een nieuwe peptideconstlUctie. Een MAP bestaat uit een 
vertakking van aan eikaar gekoppelde Iysines (via Oi en E amino groepen) waaraan het 
geselecteerde peptide kan worden gesynthetiseerd. Vertakkingen met 4 of 8 peptide 
sequenties worden het meest gebruikt. Deze MAPs blijken erg immunogeen te zijn en werden 
in de literatuur besehreven als toepasbaar voar iedere B eel determinant. Wij Heten zien dat 
de T onafhankelijkheid niet algemeen is en dat dus ineorporatie van een T eel determinant 
in de MAP noodzakelijk is voor een sterke antilichaamrespons gericht tegen het natieve eiwit 
waarVan het peptide is afgeleid. 
In hoofdstuk 11 worden de belangrijkste resultaten uit de verschillende studies 
bediscussieerd. Richtlijnen, die konden worden gedistilleerd uit de onderzoeken, voor het 
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succesvol opwekken van antilichamen met behulp van SP, zijn opgesteld. De belangrijkste 
zijn: 
a) Seleetie vall de sequelltie, Kies een sequentie van 15 tot 25 aminozuren, Vermijd 
"moeilijk" te synthetizeren sequenties, Kies de uiteinden zodanig dat ze hydrofiele 
residuen bevatten, Vennijd homologie met andere eiwitten door te zoeken in data 
bestanden. Plaats de epitoop in het midden van de sequentie of aan het andere eind van 
de koppelingsplaats. Selecteer antigene sequenties m.b. v. computer voorspellings 
programma's, 
b COlls/ruetie van Itet immunogeell. Pas gecontroieerde koppelingsmethoden toe voor de 
conjugatie van peptiden en dragereiwiUen. Gebruik MBS, EDC of GA koppeling 
afbankelijk van de gei'ncorporeerde aminozuren. Vermijd koppeling d.m. v. een 
aminozuur als dit dee I uitmaakt van de epitoop. 
c) immunisatie, Intraperitoneaie immunisatie van muizen met 25-50 p.g van het peptide-
dragereiwit construct in cen minerale olie als adjuvans leidt tot goede resuitaten, Herhaal 
de immunisatie pas nadat het niveau aan antilichamen weer is gedaald tot minder dan 
20% van het piekniveau om antilichamen te verkrijgen met hoge affiniteit. 
d) Evaluatie van de immuunrespons, Evaluatie van het reactiviteitspatroon van de 
antilichamen in polyclonaal serum moet worden uitgevoerd na iedere toediening van het 
immunogeen. Test op reaktiviteit tegen het peptide, tegen het dragereiwit, tegen de 
koppelingsdetelminant en tegen het natieve eiwit. Test op kruisreaktie met het natieve 
eiwit; dit moet worden uitgevoerd door competitieve, remmings of sandwich testen van 
de antHichamen met het natieve eiwit. Sandwich testen zijn aileen mogeJijk als een 
invangend antilichaam van een andere diersoort beschikbaar is dan van de diersoort 
waarin de antilichamen die getest moeten worden gegenereerd zijn. 
e) Selectie vall de mOlloe/ollale allfilichamell. Selectie van de hybridomas kan het best 
worden uitgevoerd in de test die uiteindelijk als diagnostische test gebruikt gaat worden. 
Een eerste screening kan met peptiden worden uitgevoerd uit overwegingen van 
kostenbesparing. 
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Nu het manuscript hier voor me ligt en ik tClUgkijk op de peri ode die het experimenteren, 
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Wim Boersma, jij bent er bijna vanaf de eerste peptide synthesen bij betrokken geweest. Bij 
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afstuderen, naar mij toekwamen (naar dat kleine kantoortje in gebouw 77), om te zeggen dat 
ik maar cens Inoest gaan promoveren, Ik heb me wei eens afgevraagd waarvoor ik me dat 
op de hais gehaald heb. Maar nu kan ik tevreden temgkijken. Deze promotie heb ik aanjullie 
samen te dank en. 
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veel plezier denk ik ook temg aan de pauzes die we in de tuin konden doorbrengen tijdens 
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collega's uit Rotterdam. Hoe jullie door gezamenlijke inspanningen van de verschillende 
vakgroepen een synergie bereiken met als weerslag hiervan publikaties in belangrijke 
tijdschriften, kan voor ons een voorbeeld zijn. Bedankt Albert Brinkmann, Coos van Laar, 
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Coos Ruizeveld de Winter, Cor Berrevoets, Eppo Mulder, Jan Trapman, Patrick Janssen, 
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